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Abstract 
Cardiopulmonary exercise testing (CPX) is established for the investigation of cardiac disease. In patients with 
heart failure multiple variables have shown prognostic benefit, although peak      remains the most widely used. 
It is accepted that peak      is affected by respiratory disease as well, and may be highly susceptible to influence 
from respiratory disease coexistent with cardiac disease. I propose an alternative variable will show significantly 
greater specificity for cardiovascular disease when compared to peak      (and other variables) and aim to 
identify this “ideal” variable through the investigation of patients undergoing isolated cardiac interventions. 
Patients were recruited to the following groups: undergone/going cardiac resynchronisation therapy (CRT); 
heart failure; mitral valve surgery; COPD or mixed disease. Each patient underwent echocardiography, 
pulmonary function tests and blood sampling. They then performed (after an initial familiarisation CPX) a 
baseline CPX. In patients undergoing intervention (CRT and mitral surgery) they underwent another CPX 2-3 
months after intervention, and a further CPX at 6 months in the mitral valve group.  
I assessed the following characteristics to aid in finding an ideal variable: ability to discriminate between heart 
and lung disease; high reproducibility; relation to exercise capacity and disease severity; and appropriate 
changes with physiological interventions. 
ROC curve analysis showed that breathing reserve, OUES and double product had the greatest areas under curve 
when differentiating COPD from heart failure. OUES also showed excellent test-retest reproducibility and was 
strongly correlated to disease severity. Following mitral surgery OUES fell less at 2 months than peak     ; 
OUES may therefore be influenced to a lesser degree by muscular maladaptation post-surgery. 
The ideal cardiopulmonary exercise test variable for cardiac patients has yet to be described. OUES appears to 
show discriminating properties between heart and lung, is reproducible and is less influenced by peripheral 
changes when compared to peak     . 
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1.1 Heart Failure and Exercise Intolerance 
Chronic heart failure (CHF) is a common condition typically caused by a weakness or stiffness of the heart 
muscle. It is a difficult disease entity to fully define; despite numerous attempts, all with their own merits, none 
have been able to encapsulate all points. The current definition used within the UK’s National Heart Failure 
Audit 2010-11 states: 
“Heart failure is a complex syndrome that can result from any structural or functional cardiac 
disorder that impairs the ability of the heart to function as a pump to support the circulation in 
the normal physiological range. The syndrome of heart failure is characterised by symptoms 
such as breathlessness and fatigue, and signs such as fluid retention.” 
CHF is correctly felt to be a syndrome, rather than a disease per se and is characterised by exercise intolerance 
and exertional dyspnoea. Aetiology of heart failure is varied; this heterogeneity includes ischaemic heart 
disease, cardiomyopathy, valvular disease, and arrhythmias. Heart failure is amongst the commonest chronic 
diseases in Westernised countries and within the UK affects more than 1% of the population (UK National Heart 
Failure Audit 2011). Heart disease overall accounts for more deaths than any other (UK Office of National 
Statistics, WHO website) with heart failure accounting for a large proportion of these deaths.  
There are a number of pathophysiological abnormalities in heart failure. It is characterised by  low cardiac 
output, or an inability to raise cardiac output appropriately during times of increased demand; an increase in 
intra-cardiac pressures, usually in an attempt to maintain cardiac output, at the expense of increased proximal 
pressures in vascular beds such as the lungs or peripheries leading to symptoms of oedema; and increased 
neurohormonal activation with systemic consequences that are as yet not fully understood but include increased 
sympathetic activation, activation of the renin-angiotension-aldosterone system, abnormal endothelin activity 
and a chronic inflammatory response. 
CHF is not only common but leads to significant morbidity and mortality. Hospitalisations are frequent, long 
(median 9 days in the UK National Heart Failure Audit 2010-11) and associated with a high mortality rate (33% 
during or soon after admission). Exercise limitation is a frequent principal presenting complaint of patients 
admitted to hospital with CHF in the UK, but in the ambulant outpatient population with heart failure is likely to 
be even more common as the main symptom. It has a significant impact on quality of life. 
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The degree of exercise intolerance has been shown to be a key determinant of prognosis in an ambulant 
population with CHF in numerous studies using multiple measures of exercise capacity such as the New York 
Heart Association (NYHA) functional classification, 6 minute walk test and cardiopulmonary exercise testing. 
NYHA classification was established in 1928 with a significant re-clarification in 1964. It suffers from poor 
reproducibility (Goldman et al 1981, Raphael et al 2007) and is generally within studies a non-predictor or, at 
best, a weak univariate predictor of prognosis in CHF (Willens et al 1987, Van den Broek et al 1992, Cowie et 
al 2000, Hobbs et al 2007). Since the introduction of objective measures of exercise capacity it rarely maintains 
significance in most multivariate analyses (Likoff et al 1987, Cohn et al 1993). The 6 minute walk test (6MWT) 
is a simple clinical test, potentially less subjective than NYHA classification, and can be done with minimal 
equipment. However it is at best a weak indicator of prognosis (Roul et al 1998) with only the most limited 
patients (6 minute walk distance <300m) showing a correlation to prognosis. It does not appear to provide 
complementary prognostic data beyond formal exercise testing and NYHA classification (Opasich et al 2001, 
Sharma et al 2001). In contrast to NYHA classification and the 6WMT, formal exercise testing with gas 
analysis, known as cardiopulmonary exercise testing (CPX) has shown in dozens of studies strong univariate 
and multivariate power in determining the prognosis of patients with CHF. The extensive literature on CPX in 
CHF prognosis will be discussed later alongside description of commonly measured CPX variables. However, 
of clinical relevance to heart failure physicians, is that objective variables of exercise capacity, as measured by 
CPX, are key determinants for the identification of appropriate patients for heart transplantation and often 
supersede measures of cardiac morphological impairment.  
However we define and measure it, exercise intolerance in CHF is common with undeniable importance to 
prognosis but the physiological abnormalities behind exercise intolerance in CHF remain poorly understood. It 
is not as simple as low cardiac output during exercise; the poor correlation of the haemodynamic disorder to 
exercise capacity has long been established (Wilson et al 1983, Szlachcic et al 1985, Cohn et al 1993, Wilson et 
al 1995). First and foremost, CHF must be seen as a multisystem disease, with common interactions between the 
heart and the lungs, skeletal muscle, peripheral vasculature, neurohormonal systems and the kidneys. The 
skeletal muscles and lungs deserve special mention in their interaction with the heart in patients with CHF. 
These 3 organ systems, which are stressed and measured during CPX, interact together, with typical 
abnormalities in all, rather than just the heart, in patients with CHF (Figure 1.1). 
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Figure 1.1: A conceptualisation of the interaction between the heart, lungs and muscles in CHF. The 
interaction of all 3 leads to reduced exercise capacity. 
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1.2 Skeletal muscle in CHF and the link between cardiac function and exercise 
capacity 
There is substantial evidence that the degree of cardiac abnormality does not correlate strongly with exercise 
capacity. In 1981 Franciosa et al showed that, in patients with CHF, non-invasive measurements of cardiac 
function at rest did not correlate to total treadmill time. Following 5 weeks of randomisation to placebo or 
vasodilator therapy, patients increased their treadmill time by, on average, 1.5 minutes, without a significant 
change in measures of left ventricular (LV) function, and no correlation between the improvement in exercise 
capacity and degree of change of LV variables. 
We find greater agreement between abnormalities of invasive haemodynamics and exercise capacity, but a large 
degree of unexplained heterogeneity still remains. In a study of 27 patients with CHF Szlachcic et al showed 
that of all resting invasive measurements, only capillary wedge pressure correlated to exercise capacity (as 
defined by peak oxygen consumption which will be discussed extensively later) (Szlachcic et al 1985). Of 
variables on exercise, only cardiac index (cardiac output indexed to body surface area (BSA)) and peak heart 
rate correlated to exercise capacity, and heart rate was the only variable where the change from rest to exercise 
correlated to exercise capacity. Values obtained during exercise, rest and the degree of change from rest to 
exercise for stroke volume (indexed for BSA), systemic and pulmonary vascular resistance, left ventricular 
stroke work (indexed for BSA) and left and right ejection fractions did not correlate to exercise capacity. Wilson 
et al showed that in patients with reduced exercise capacity awaiting heart transplant, there was no difference in 
exercise capacity when patients were grouped according to the degree of cardiac output response and/or elevated 
wedge pressure (Wilson et al 1995). In another study the initiation of vasodilators led to improvements in 
exercise capacity, and improvements in invasive haemodynamics, but these two improvements were not 
correlated (Massie et al 1981). Separately the use of dobutamine was able to substantially increase cardiac index 
in one study, but improvements in oxygen consumption were modest without improvements in treadmill time 
(Maskin et al 1983). Cardiac index at peak exercise, measured non-invasively,  correlates to oxygen 
consumption (Shelton et al 2010, Hummel et al 2012) but whilst being lower in patients with heart failure than 
in healthy adults, rises during equivalent exercise by the same amount (Shelton et al 2010). This suggests that 
cardiac output does not limit exercise, at least at submaximal levels. In agreement with this is a study by 
Esposito et al, which showed that peak oxygen consumption during maximal cycle exercise was 33% lower in 
patients with CHF compared to healthy controls. During single leg knee extension (when the required cardiac 
output will be much lower than required for cycle exercise, freeing the heart from its role as limiter) oxygen 
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consumption was also lower than in healthy controls (Esposito et al 2010). If cardiac output was the only 
limiting factor then we would also expect that at peak exercise oxygen consumption could not increase further, 
but Jondeau et al showed that the addition of arm crank exercise to cycling increased this significantly in 
patients with severe CHF, but not healthy controls, suggesting that prior to the addition of arm crank exercise 
the leg muscles had reached a maximum, beyond which they cannot extract more oxygen even if more is made 
available, but the addition of a further muscle group (the arms) did allow further cardiac output (Jondeau et al 
1992). 
Positive interventions to the heart which acutely improve haemodynamics therefore do not appear to rapidly 
improve exercise capacity. However the reverse is not true. When patients with left ventricular assist device 
(LVAD) implantation for severe left ventricular dysfunction have their LVAD support reduced (by decreasing 
the pump speed) there is an immediate reduction in cardiac output and exercise capacity (Jakovljevic et al 2010, 
Noor et al 2012). 
If cardiac output and other measures of cardiac function are only loosely related to oxygen consumption as a 
marker of exercise capacity in CHF, then maybe alternatively the haemodynamic abnormalities are strongly 
related to the degree of breathlessness, and this, rather than oxygen, limits exercise capacity. The cause of the 
increased sensation of breathlessness in CHF was, for a long time, believed to be increased ventilation to 
perfusion mismatch, so that, even if for any given activity oxygen consumption was the same as for healthy 
adults, ventilation to both consume this oxygen and eliminate carbon dioxide was higher. Perhaps one of the 
first suggestions that organs beyond the heart were associated in the abnormal ventilatory response to exercise 
was observed in a study by Fink et al which looked at the relationship between minute ventilation (   ) and 
carbon dioxide (     ) production. Wedge pressure correlated weakly with the  
 
        relationship at rest, and 
not at all at peak exercise. Wedge pressure was then deliberately reduced through the use of prazosin or 
dobutamine; in neither group did the           relationship significantly improve (Fink et al 1986). Substantial 
work over the past two decades has gone on to elucidate more about the cause of breathlessness in heart failure. 
In a study by Wensel et al an increase in dead space, which will be affected by abnormal ventilation: perfusion 
mismatch, correlated with the relationship between carbon dioxide (CO2) and ventilation, but in addition an 
independent mechanism, the depression of arterial CO2, correlated more closely (Wensel et al 2004). It was 
therefore proposed that there is a strong drive to ventilation outside of the lungs. An explanation was that lactate 
may be this stimulus, however blood lactate levels did not correlate with the arterial CO2 levels (paradoxically 
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the patients with the lowest CO2 values also had the lowest hydrogen ion concentration). Interestingly it was 
shown, in the patients with the most abnormal ventilation to CO2 relationship that a pronounced rise in systemic 
lactate levels occurred during recovery. Again the relationship with arterial CO2 behaved in a paradoxical 
manner; the increased hydrogen ions should have stimulated a respiratory compensation and a reduction in 
arterial CO2, but the opposite occurred (Wensel et al 2005).  
All this evidence therefore suggests a situation where cardiac haemodynamics are abnormal at rest and on 
exercise, but the degree of abnormality does not appear to relate closely to the severity of exercise limitation, 
although perhaps cardiac index and wedge pressure are more tightly related to exercise capacity than other 
variables. Cardiac output is reduced but can improve with intervention; however this does not generally restore 
exercise capacity, at least not immediately. Finally ventilation: perfusion mismatch arising from abnormal 
pulmonary vasoregulation and blood flow distribution only explains some of the increased ventilation and 
symptoms of breathlessness found in patients with CHF. Despite changes within the lung, arterial blood leaving 
the heart is generally fully oxygenated, and so it is to the muscle that we look to explain the reductions in 
exercise capacity. 
The skeletal muscle is commonly altered in CHF (Clark et al 1996) and the cause of this “myopathy of heart 
failure” is multifactorial; including deconditioning through underuse, the toxic accumulation of neurohormonal 
substances, the systemic inflammatory response, and possibly iatrogenic causes such as statins and the well-
meaning, but ultimately harmful, medical discouragement of exercise.  
Total muscle mass is typically reduced (Mancini et al 1992) and there are characteristic structural alterations 
such as a switch in muscle fibre type. In a study by Mancini et al, type IIb fibres were found as a greater 
percentage of total muscle fibres in patients with CHF. Type IIb fibres are glycolytic and much less fatigue 
resistant than the type I oxidative fibres. Oxygen consumption inversely correlated with the percentage of type 
IIb fibres (r= -0.81), and positively correlated with the percentage of type I fibres (r= 0.68) (Mancini et al 1989). 
Other findings include fibre atrophy (Lipkin et al 1988), decreased mitochondrial density (Drexler et al 1992, 
Esposito et al 2010) and abnormal enzyme activity (Mancini et al 1989, Sullivan et al 1990, Ralston et al 1991, 
Drexler et al 1992, Okita et al 1998). There is conflict regarding the changes within the capillary density of the 
muscle, with Esposito et al and Mancini et al finding a trend to increased capillary density. Sullivan et al 
showed that capillaries per fibre were reduced although density based on cross-sectional area was normal. 
Overall it appears likely that the area of muscle supplied by each capillary is largely unchanged, but other 
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factors, such as sympathetic activation, probably restrict flow. The consequences of these changes are a 
reduction in muscular peak power (Lipkin et al 1988) and early fatigability (Wilson et al 1996). The muscles of 
patients with CHF are unique in that they display signs of oxygen supply and demand limitation. Athletes 
typically display signs of oxygen supply limitation; that is the introduction of hyperoxia improves oxygen 
consumption at the muscle (Knight et al 1993), whereas sedentary individuals are oxygen demand limited; the 
addition of oxygen does not increase oxygen consumption further (Cardus et al 1998). Patients with CHF show 
improvements in oxygen consumption at the muscle with oxygen therapy, suggesting a degree of supply 
limitation, but even with 100% oxygen, they still do not match healthy adults in normoxia (Esposito et al 2010). 
This has been described as a reduction in both the convective (delivery of oxygen within the larger vessels) and 
diffusive (ability of the muscles to extract the delivered oxygen) capabilities of the muscle.  
The muscle may also give us the answer to the “non-respiratory” portion of the high ventilatory levels seen in 
CHF, which appears to be caused by an autonomic ventilatory response activated by signals from exercising 
muscles – the ergoreflex. This has been shown to increase ventilatory drive in patients compared with healthy 
controls during similar levels of exercise (Piepoli et al 1996, Scott et al 2002). The addition of sodium 
bicarbonate (which will reduce acidosis) but not a glycogen free diet (which will reduce lactate) can abrogate 
this reflex, suggesting that it is principally driven by high intramuscular hydrogen ion concentration (Scott et al 
2002). This may therefore allow us to reconcile some of the paradoxical findings by Wensel et al. In patients 
with CHF, high intramuscular concentrations of hydrogen ions drives ventilation through the ergoreflex, this 
lowers arterial CO2. Possibly through reduced tissue blood flow, venous efflux is reduced during exercise, so 
that the increased hydrogen ion concentration is not measured in the blood. On recovery these ions spill over 
into the blood, reducing the ergoreflex but giving the impression of a systemic acidosis. 
As further support in the argument for the central role of the muscle in CHF, exercise rehabilitation, and muscle 
strengthening have been shown to increase indices of muscle function and, in tandem, exercise capacity and 
prognosis. Critically prognosis is improved, as shown by a meta-analysis of 9 studies utilising exercise 
rehabilitation programmes (Piepoli et al 2004). However this doesn’t give direct evidence that the muscle is 
central to CHF, as whole body exercise could be improving the cardiac haemodynamics of the patients and 
therefore prognosis. Following an 8 week training program consisting only of knee extension exercises 
(deliberately designed to avoid stressing, and thereby strengthening the cardiovascular system), Esposito et al 
showed that peak oxygen consumption could increase to levels seen in matched sedentary controls, despite 
significantly lower values pre-programme (Esposito et al 2011). Cardiac output was not significantly altered, 
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but the convective and diffusive components of oxygen delivery to the muscles both increased. It has also been 
postulated that the main benefits of exercise training would be to improve the efficiency and comfort of 
submaximal activity rather than measures of maximal exercise capacity; submaximal exercise is after all more 
representative of day-to-day activity. Following 6 months of a cycle exercise programme patients significantly 
improved their maximal oxygen consumption by approximately 10% (unlike controls with CHF who did not 
undertake regular exercise and showed no improvements in maximal oxygen consumption). However more 
impressive were the improvements in variables based on the oxygen kinetics of submaximal exercise during 
constant work rate testing, with changes of nearer 20% seen (Mezzani et al 2012); these improvements are 
believed to reflect improved symptomatology. 
In conclusion skeletal muscular abnormalities in CHF probably explain the heterogeneity in exercise capacity 
previously unexplained by markers of cardiac function. Structural, metabolic and neural changes lead to reduced 
convective and diffusive components of oxygen delivery to the muscle, an increased drive to ventilation (and 
therefore breathlessness) and exercise training, even when only directed at small muscle groups, improves 
exercise capacity without necessarily improving cardiac function. 
 
1.3 The interaction of heart and lungs in CHF 
CHF commonly affects the lungs, not just through an increase in interstitial fluid, but with easily identifiable, 
objective abnormalities such as restrictive defects, airway obstruction, diffusion abnormalities and inspiratory 
muscle weakness (Hosenpud et al 1990, Naum et al 1992, Dimopoulou et al 1998, Hughes et al 1999, Daganou 
et al 1999).  
Left atrial pressure in heart failure is almost always elevated, if not at rest, on exercise, causing pulmonary 
vascular congestion. Initially, to limit the onset of interstitial oedema, lymphatic drainage is able to compensate, 
however once lymphatic clearance is maximal (this often occurs early due to systemic venous pressure 
elevation) interstitial oedema intervenes. With chronic elevations in pulmonary pressures, protective 
mechanisms occur. Within the pulmonary vasculature these lead to medial and intimal thickening, which affects 
perfusion of the alveoli, and in the capillary endothelium structural changes reduce microvascular permeability; 
these limit the transfer of oxygen and carbon dioxide, the key role of the lungs (Chua et al 1995). 
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On spirometry the commonest abnormality seen is a reduction in vital capacity – a restrictive pattern. Less 
commonly an obstructive pattern is noted. The latter phenomenon is more commonly seen during an acute 
decompensation of heart failure, rather than the stable chronic state. 
 
1.4 Lung disease is common in CHF 
Heart disease and respiratory disease, exemplified by CHF and chronic obstructive pulmonary disease (COPD) 
respectively, are very common within the UK. Furthermore respiratory disease often coexists with 
cardiovascular disease (Rutten et al 2005, Mascarenhas et al 2008, Iversen et al 2008, Hawkins et al 2010). In a 
recent study the prevalence of COPD in an out-patient cohort with CHF was 39.2% (Mascarenhas et al 2008). 
Similarly approximately 30% of patients with stable COPD have unrecognised heart failure (Rutten et al 2005). 
Within the UK this prevalence of coexistence appears to be rising (19.8% of heart failure patients had coexistent 
COPD in 1999, rising to 23.8% in 2004 (Hawkins et al 2010)). The reason for the high coexistence rates may 
relate to certain undesirable risk factors, principally smoking.  
When both conditions coexist, management of either condition may be compromised by the presence of the 
other. A common problem encountered is the reluctance of physicians to initiate beta-blockers – drugs proven to 
significantly reduce mortality in CHF (CIBIS investigators and Committees 1994, MERIT-HF Study Group 
1999, Packer et al 2002) – in the presence of COPD; this despite plenty of evidence to show safety in this 
patient group (Gottlieb et al 1998, Chen et al 2001, Salpeter et al 2002, Kotlyar et al 2002, Sirak et al 2004). In 
one study of CHF patients only 22% with a diagnosis of COPD received beta-blockers, and mortality, over an 
average of just under 2 years, was 17% compared with 31% for the remainder of patients not treated with beta-
blockers (Staszewsky et al 2007). In a large retrospective analysis of 200,000 patients following a myocardial 
infarction, only 22.1% (compared with 34.3% of the total cohort) of patients with COPD received beta-blocker. 
Mortality was 16.8% at 2 years in those prescribed beta-blockers compared with 27.8% if they were not 
(Gottlieb et al 1998). However, given that beta-blockers may not benefit survival in patients with severe COPD 
(Chen et al 2001), these results may simply reflect a more severely affected spectrum of patients in the non-beta 
blocked groups. Randomised trials will be required to answer the question definitively. 
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1.5 The respiratory patient with exercise intolerance or dyspnoea 
It is estimated that two thirds of patients presenting with exertional limitation or chronic dyspnoea have a 
cardiac or pulmonary cause for the symptoms and as described above these two groups of diseases commonly 
coexist.  
Pulmonary disease commonly presents with dyspnoea as the predominant symptom. Chronic Obstructive 
Pulmonary Disease (COPD), asthma, interstitial lung disease, chest wall disease (including muscular 
abnormalities of the chest wall muscles or diaphragm) are amongst the most common diseases. With the 
exception of asthma, these diseases are all generally progressive, leading to deterioration in symptoms including 
dyspnoea. There is a strong environmental cause linked in many patients.  
COPD is one of the most common chronic diseases in Westernised cultures with a proposed 6.9% prevalence of 
mild COPD in adults in the USA aged between 25-75 years (Mannino et al 2000). It is characterised by airflow 
limitation, which unlike asthma, is not fully reversible. This is usually progressive with an abnormal 
inflammatory response of the lungs. It can be viewed as a combination of chronic bronchitis, a clinical diagnosis 
defined by the presence of a chronic productive cough for 3 months in subsequent years; and emphysema, a 
pathological diagnosis with airspace dilatation of the distal bronchial tree (American Thoracic Society/European 
Respiratory Society Standards for the Diagnosis and Management of Patients with COPD 2004). Currently 
diagnosis is made using a combination of typical symptoms (chronic dyspnoea, cough, sputum production), 
appropriate environmental exposures (principally cigarette smoking) and appropriate spirometric findings 
(forced expiration in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio of <0.7) (GOLD 2011) or more rarely 
in the presence of an inherited disease predisposing to COPD (e.g. α-1 antitrypsin deficiency). Use of 
spirometry alone would lead to an over-diagnosis - a normal FEV1, with supranormal FVC resulting in a low 
ratio, is not uncommon. In these cases a lack of symptoms and exposure risks limits the chance of a 
misdiagnosis. Whilst COPD is a disease of the respiratory parenchyma and airways it often has effects beyond 
the lungs. There are consequences for both sides of the heart (Barr et al 2010), and importantly the musculature 
(Donaldson et al 2012) which we will discuss in detail. There are also multi-organ consequences of the 
treatment, for example osteoporosis and myopathy with recurrent steroid use. Hence COPD, whilst identified as 
the most common, chronic progressive respiratory disease, should not be thought of as purely a disease of the 
lungs.  
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1.6 The muscle in COPD 
Similarly to heart failure, COPD is a multiorgan disease with consequences to the musculature as well as the 
lungs. In CHF it is generally the peripheral muscles such as the calves and quadriceps that have been 
investigated. In COPD patients the ventilatory muscles such as the diaphragm also deserve special mention. 
COPD behaves similarly to CHF, in that there is a reduction in strength of the peripheral muscles (Man et al 
2003, Man et al 2005), with early fatigability (Mador et al 2003, Allaire et al 2004). There is a shift in fibre 
type, away from oxidative type I fibres, towards the glycolytic type II fibres (Jobin et al 1998). Capillary density 
reduces (Jobin et al 1998) and there are reductions in the enzyme activity involved in aerobic activity within the 
muscle (Maltais et al 1996). Conversely the diaphragmatic muscle is able to increase its force generating 
capabilities (Similowski et al 1991), with a shift towards type 1 fibres (Levine et al 1997). This likely represents 
the continued training exposure of the high ventilatory demand of COPD, and gives evidence that muscular 
training, as it does for CHF, can abrogate some of the abnormalities found. Again, in a similar fashion to CHF, 
the degree of peripheral muscular dysfunction correlates relatively poorly to resting determination (spirometry) 
of COPD severity (Gosker et al 2003, Seymour et al 2010). 
 
Therefore, for physicians treating patients presenting with exertional limitation, a difficulty with diagnosis, 
follow-up and management can exist; COPD and CHF are common, frequently overlap, and can lead to 
consequences within the other organ system. Diagnosis alone may be challenging, but in patients with 
coexistence of these two conditions it is very difficult to elucidate the relative contribution of each to the 
symptoms of dyspnoea and exercise intolerance. Importantly both conditions can lead to similar changes in 
skeletal muscle which will exacerbate symptoms of exercise limitation.  
Cardiopulmonary exercise testing has the potential to elucidate the degree of exercise limitation and identify 
principal limiting physiology in a patient, but it is unclear at present if a variable exists for either organ system 
that can quantitate the degree of specific organ dysfunction. It is the aim of this thesis to discover if such a 
variable on CPX exists. I will first discuss how CPX works, followed by the aims of the thesis and potential 
candidates for “ideal variables”. 
. 
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1.7 Cardiopulmonary exercise testing, the requirement for oxygen and the role of 
the heart, lungs, vasculature and muscles in performing exercise 
Gas exchange is the principal role of the heart and lungs. Cardiopulmonary exercise testing is a clinical test 
involving exercising an individual whilst making real-time measurements of their ventilation, and the 
concentrations of oxygen and carbon dioxide within the ventilation allowing us to calculate gas exchange in 
incredible detail. In order to understand CPX, an understanding of the physiological processes of gas exchange 
within the body, and how they go wrong in disease, is necessary. 
 
Oxygen (O2) is required by all metabolic tissues, without this life could not exist. The consequence of this 
oxidative metabolism is the production of carbon dioxide (CO2) as a waste product. Although it is a continuous 
cycle, we will view it as starting with an inspiration; negative pressure is generated within the chest cavity and 
air travels from the mouth down the airways and into the alveoli of the lungs. Assuming normal atmospheric 
concentrations of O2 and no significant left to right shunting within the heart, there will then exist a 
concentration gradient across the alveolar surface to the pulmonary capillaries, across which O2 will diffuse, to 
bind to the metalloprotein haemoglobin, raising blood oxygen levels. Blood passes to the left side of the heart 
where rhythmic contractions eject a volume of blood approximately once a second. This blood travels down 
arteries, then arterioles to target organs. Here the blood vessels, now called capillaries, get smaller and densely 
infiltrate the tissue to allow easy diffusion of oxygen, again down a concentration gradient, into metabolising 
cells. Along with glucose (or alternative energy sources such as protein or fat), this oxygen is involved in the 
production of finite packets of chemical energy known as adenosine triphosphate (ATP) from adenosine 
diphosphate (ADP) and inorganic phosphates (Pi), which allow the tissue to perform its actions. In the process 
of the conversion of an energy source and O2 to ATP, termed cellular respiration, carbon dioxide and water are 
produced as waste products. When glucose is the principal energy source the conversion is as below: 
C6H12O6 + 6O2   6CO2 + 6H20 
 
There are 3 principal parts to cellular respiration, through which ATP is produced (Figure 1.2); firstly 
glycolysis, which is not oxygen dependent, takes the raw glucose and produces intermediate metabolites, one of 
which, pyruvate, then passes into the second part, the Kreb’s cycle, with the production of some ATP, carbon 
dioxide and further intermediate metabolites. Finally many of these intermediates enter the electron transport 
36 ADP 
+ 36 Pi 
36 ATP 
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chain, which in the presence of oxygen produces the majority of the 36 ATP units. This process is termed 
aerobic respiration.  
 
 
 
 
 
Figure 1.2: The intracellular production of energy, CO2 and water from carbohydrate and O2. Within the 
cytosol glucose is converted to pyruvate with the production of the intermediate NADH+H
+
. Pyruvate crosses 
the mitochondrial membrane where it enters the Kreb’s cycle, producing further NADH+H+ and CO2. The 
NADH+H
+
 is then oxidised to produce water and ATP. The original NAD is regenerated. 
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Parts 2 and 3 are dependent on each other and oxygen; but when oxygen supply cannot keep up with demand the 
intermediates (NADH + H
+
) quickly build up limiting further energy production. In contrast glycolysis produces 
metabolites which, in the absence of sufficient oxygen, can build up within the cytosol of the cell without 
stopping further glycolysis. This allows a small production of energy (3 ATP units compared to 36 in the 
presence of oxygen) and so is only used by the tissue as a short-term solution, firstly because it is highly 
inefficient (only 8.1% of each glucose molecule’s potential energy is utilised) and secondly because this 
intermediate is necessarily converted to lactate, an acidic by-product, which impairs cellular activity as it builds 
up; this process is called anaerobic respiration. The lactate allows the regeneration of NAD, a necessary 
intermediate in glycolysis. 
Fortunately when the conditions are improved and adequate oxygen supply resumes (typically following the 
cessation of exercise) this formation of lactate can be reversed, with these metabolites entering the Kreb’s cycle 
and allowing the generation of the full quota of potential energy. The production of lactate forms a central part 
of the analysis of gas exchange.  
Following cellular respiration carbon dioxide is produced as a waste product. This is found in higher 
concentrations in the metabolic tissue than the blood vessels bringing blood to the tissue so CO2 diffuses in the 
opposite direction to O2, into the blood. This blood then returns to the heart, and thereon to the lungs. In contrast 
to the transfer of oxygen, CO2 is in greater concentration in the blood of the capillary bed of the lungs than the 
alveolar air, so moves out into the air, in the opposite direction to the oxygen transfer. By generating positive 
intra-thoracic pressures, expiration occurs, expelling this air (now lower in O2 and filled with CO2) into the 
atmosphere, allowing the cycle to start again.  
Exercise intolerance can occur with a defect in any, or many, of these processes described above. Abnormalities 
within the lungs will lead to an inability to ventilate sufficiently at an earlier point during activity, typically 
resulting in a build up of CO2. Oxygen delivery to the muscles can remain relatively normal and cessation of 
exercise is typically a consequence of a mechanical inability to ventilate further at higher rates/volumes, with a 
perception of respiratory difficulty even if physiological reserve exists. However as described above, the lungs 
are not in isolation in respiratory disease, there are often associated problems with the heart and circulation, 
limiting the ability to distribute blood around the body; within the muscles, so that capillary density may be 
reduced, leading to a lower relative supply of O2; and potentially changes within the blood itself. 
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In heart failure a primary abnormality is reduced oxygen delivery to the muscles. At rest oxygen consumption 
may appear normal, but a reduced cardiac output requires compensation with increased oxygen extraction 
(Shelton et al 2010). During exercise the cardiac output increasingly fails to increase appropriately to deliver 
blood to exercising muscles, requiring even greater oxygen extraction from the muscle. Oxygen extraction 
cannot go above a certain threshold, approximately 80%, so earlier than expected the Kreb’s cycle and electron 
transport chain are starved of oxygen. Glycolysis however can continue to produce some energy for exercise. 
One of the intermediates, NAD, is required to help produce ATP, but builds up in its reduced form, NADH + H
+
 
in the absence of adequate oxygen. This NADH + H
+
 can be oxidised back to NAD by the reduction of pyruvate 
to lactate, however the build-up of the acidic lactate, can have unwanted consequences. This generally impairs 
the ability of the muscle to perform work and is almost always perceived as painful or discomforting, leading to 
early exercise cessation, although it also has beneficial properties such as shifting the haemoglobin dissociation 
curve to the right (the Bohr effect) facilitating the unloading of further oxygen stores within the blood.  
Isolated problems within the muscle will also lead to symptoms of exercise intolerance. This may be anatomical, 
with a reduction in the motor units of the muscle (which can even be seen after a long period of relative 
sedentary behaviour) or a mismatch of perfusing capillaries to muscle; or metabolic, usually with an inherited 
problem with glycolysis, the Kreb’s cycle, the electron transport chain, or another metabolic pathway required 
to supplement and complement them. Mitochondrial myopathies are probably much more common than either 
believed or diagnosed (Flaherty et al 2001). There may be a problem with the arterial or venous vessels used to 
supply blood to, or remove blood from, the muscles respectively, such as peripheral vascular disease. Blood 
may also have limitations to its oxygen transport capacity, as seen with anaemia and certain 
haemoglobinopathies.  
CPX allows a way, through measuring the uptake of O2 and excretion of CO2 at the mouth, of understanding 
how all these processes perform, and how they can go wrong in disease.  
Measurements of oxygen uptake (    ) are central to CPX and this uptake measured at the lungs is believed to 
equal the consumption of oxygen at the tissues (    ), and therefore the term oxygen consumption, whilst 
scientifically incorrect, is often used; they will be used interchangeably within this manuscript. In an equal 
(albeit opposite) way      , the elimination of carbon dioxide by the lungs, is calculated and reflects the 
production of CO2 at the muscles. However, although oxygen uptake/consumption is increased in only one 
manner - the aerobic conversion of fuel to ATP for energy - carbon dioxide elimination/ production occurs in 3 
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main ways; as a end-product of the conversion of fuel and oxygen for energy, to buffer the build-up of hydrogen 
ions from lactate production, and as respiratory compensation for the metabolic acidosis caused when hydrogen 
ion (from the lactate) build-up overwhelms local bicarbonate buffering capacity.  
 As exercise increases in intensity, oxygen uptake and carbon dioxide elimination increase, the latter at a 
progressively faster rate than the former. When exercise stops, although no new work is being done, there is an 
oxygen deficit to be replaced, so      drops towards baseline over a few minutes. Lactate in the muscle is re-
integrated into the Kreb’s cycle, and from there the electron transport chain, to form energy aerobically, and 
replenish cellular stores for future exercise.      takes much longer to return to normal because of the acidosis.  
 
1.8 Common CPX Variables in the diagnosis and assessment of dyspnoea 
Patients commonly complain of exercise intolerance, exercise fatigue or breathlessness on exercise. History and 
examination alone commonly fails to find a diagnosis (Pratter et al 1989, DePaso et al 1991). This is principally 
because the descriptions of the symptoms are themselves of limited diagnostic value as they vary minimally 
between diseases. Common clinical tests to identify the aetiology include pulmonary function, chest 
radiography, blood chemistry and haematology, electrocardiography (ECG) and echocardiography. But as 
described earlier, the use of spirometry to identify respiratory disease may be flawed by the common prevalence 
of abnormalities on spirometry in patients with cardiac disease. Likewise echocardiographic abnormalities can 
occur in patients with respiratory disease. A possible distinguisher between cardiac and respiratory disease is B-
type natriuretic peptide (BNP), secreted by cardiomyocytes, which rises in heart failure. However patients with 
stable, compensated heart failure may normalise their BNP and in patients with COPD, elevations in BNP have 
been shown (Ando et al 1996). 
Given that the symptoms are typically present on exercise and not at rest, it makes sense that to differentiate the 
cause of exercise limitation, exercise should be utilised.  CPX generates a number of variables that can be useful 
both in identifying the presence of true exercise intolerance and the cause of exercise limitation. Once a 
diagnosis is made CPX is invaluable in determining the prognosis of common cardiac and respiratory diseases. 
This is important because both CHF and COPD have significant prognostic implications. There are 2 well 
quoted statistics for patients with CHF; 1 year mortality is 50% following an admission, and secondly it carries 
a worse prognosis than many cancers. Whilst these facts were identified prior to current therapeutic options, 
CHF still causes significant mortality. In the UK in 2008/9, following a hospital admission with a diagnosis of 
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heart failure, in-hospital mortality was 12%, and a further 22% of patients died during follow-up (average 158 
days) (Cleland et al 2011), giving a predicted total 1 year mortality >40%. These are similar values to those seen 
at the end of the last century where 1 year mortality in UK patients diagnosed with heart failure (either as an 
admission or through out-patient services) was 38% (Cowie et al 2000). When population screening is used to 
identify patients with heart failure (rather than wait for presentation to health services) prognosis is better but 
still significantly reduced compared with healthy adults; a 5 year mortality rate of >40% was found in one UK 
study (Hobbs et al 2007) and 41% in a Dutch study (Mosterd et al 2001). 
COPD has an overall better prognosis than CHF. Following admission for COPD, 1 year mortality was 22% 
(Almagro et al 2002). Another study showed a median survival of 3.1 years (Incalzi et al 1997). Despite these 
differences in prognosis CPX has excellent utility for determining prognosis in both (Mancini et al 1991, Cohn 
et al 1993, Hiraga et al 2003, Oga et al 2003, Cote et al 2007).  
 
1.8.1 Peak     / 
 
  Max 
Oxygen uptake (practically synonymous with oxygen consumption) is the principal measurement of CPX. It 
increases throughout incremental exercise, and around the termination of exercise, when exercise is at its most 
intense,      will be at its highest. This highest value is termed the peak  
 
  . Peak  
 
   is the most commonly 
described CPX variable.  
     max is often used synonymously with peak  
 
  . It is the highest attainable  
 
   for the patient, and when 
effort is truly maximal on an exercise test it will equal the peak     . However because it is difficult to confirm 
maximal effort and therefore the attainment of      max, especially in patients rather than athletes, peak  
 
   is 
preferentially used. 
Peak     can give us a surrogate for maximal cardiac output, with  
 
   and cardiac output related via the Fick 
Principle. This may explain why peak      has shown a great ability to determine prognosis in heart failure, 
which is largely thought of as a disease of reduced cardiac output. Peak     has been the most widely-used and 
accepted variable for the assessment of prognosis in patients with CHF and there have been numerous studies 
validating its ability to determine prognosis (Szlachcic et al 1985, Likoff et al 1987, Mancini et al 1991, Van 
den Broek et al 1992, Cohn et al 1993, Cohen-Solal et al 1997). However peak      falls in most disease states 
so is not useful when trying to discriminate causes of exercise intolerance. It is a strong prognostic marker in 
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respiratory disease as well (Oga et al 2003, Cote et al 2007) but what is interesting is that the relationship 
between prognosis of these two disease groups and peak     differs vastly. Considering exercise capacity, COPD 
mortality remains markedly lower than similarly limited patients with CHF. In a cohort with COPD (mean age 
of 67 years and a mean peak      of 10.8 mL/min/kg) the 12 month mortality was only 4% (Cote et al 2007). A 
comparable study in CHF with a similar peak      (mean 11.0 mL/min/kg) showed a 10-fold greater mortality 
(40%) over the same period despite a mean age 10 years younger (Szlachcic et al 1985) although it must be 
noted that 2 decades of time separate these two studies. In patients with both conditions it appears to be the heart 
failure that drives the prognosis as shown in a study by Mascarenhas et al where patients with CHF and 
concurrent mild to moderate COPD (GOLD stages 1 and 2) had a similar prognosis compared to those patients 
with CHF alone (Mascarenhas et al 2008). 
 
1.8.2 Anaerobic/ Lactate threshold 
As described above there comes a point in incremental exercise when oxygen supply cannot meet demand , 
pyruvate is reduced to lactate leading to the oxidation of NADH + H
+
, to allow the regeneration of NAD for 
further energy generation. Lactate liberates hydrogen ions (it is acidic) and an increase in circulating levels 
prompts changes in ventilatory patterns. It is typically identified on cardiopulmonary exercise testing when there 
is a change in the relationship between CO2 and O2 and is termed the anaerobic or lactate threshold. The merits 
of various ways of identifying it will be discussed in the methods.  It is believed that the early onset of anaerobic 
metabolism is a specific sign of heart failure (Nery et al 1983, Weber et al 1984, Hansen et al 1984) and it may 
be a stronger prognostic marker in this population than peak      (Gitt et al 2002). 
 
1.8.3 Ventilatory equivalents 
An important concept in gas analysis is the relationship between ventilation and either the oxygen uptake or, 
much more commonly, the carbon dioxide elimination. We will focus on the latter here. This is generally 
described as the efficiency of ventilation to eliminate carbon dioxide. This          relationship can be described 
throughout exercise, or at certain pre-specified points. One of the commonest forms is the           slope. Lower 
values are better. 
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Throughout the majority of exercise     and       are linearly related and it is the slope of this relationship, 
during the linear portion, that typically constitutes the           slope (Figure 1.3).  As exercise continues the 
relationship deviates from linearity as ventilation increases disproportionately at high intensities. 
 
 
 
Figure 1.3: Minute ventilation and carbon dioxide elimination rise together during incremental exercise. 
Initially this is linear and the slope of this relationship is termed the          slope (22.68 in this example). 
Towards the end of exercise the buffering systems of bicarbonate are overwhelmed and respiratory 
compensation (by reducing arterial CO2) for the metabolic acidosis occurs, decoupling the previously tight     to 
      relationship. 
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Alternatively the          relationship can be calculated instantaneously; this is termed the  
 
       ratio and is 
measured at a number of points, such as the anaerobic threshold, or its lowest point. These are almost always 
very similar values, and similar to the          slope. Heart failure patients exhibit an elevated  
 
        
relationship for reasons well described above; increased ventilation: perfusion mismatch, and primary 
hyperventilation during exercise leading to a lower arterial CO2 partial pressure. Whilst the severity of this 
“ventilatory inefficiency” relates to peak     , it gives us additional information regarding the pathophysiology 
of the patient beyond maximal exercise capacity. This may help explain why these measures largely outperform 
peak     when assessing for prognosis in heart failure (Chua et al 1997, Robbins et al 1999, Gitt et al 2002, 
Davies et al 2006). Because ventilatory equivalents are influenced by ventilation: perfusion mismatch, which is 
common in respiratory disease, abnormal equivalents may also seen in respiratory disease, so may not be useful 
when discriminating these 2 common conditions. 
 
1.8.4 Breathing reserve 
Our lungs have a theoretical maximum ventilation which they can attain; this differs from person to person and 
changes over time. An estimate of this maximum voluntary ventilation (MVV) is possible for each patient and, 
from this, the percentage remaining, which is termed the breathing reserve (BR). Typically healthy adults have a 
BR >30%, i.e. at peak exercise their lungs have used less than 70% of their potential- it is other organs that limit 
exercise. With lung disease the maximum voluntary ventilation is reduced and so for any given level of 
ventilation (and therefore exercise) the breathing reserve is reduced. When reaching low levels of breathing 
reserve during exercise, i.e. lungs working at or near maximum, breathing becomes mechanically limiting and 
intolerable. It has been suggested that breathing reserve can be used to differentiate patients limited by their 
lungs (where it will be low) from patients with CHF or other conditions (where it will be normal) (Milani et al 
2004). The breathing reserve at the anaerobic threshold may be more discriminant than at peak exercise (Medoff 
et al 1998). 
 
1.8.5 Oxygen efficiency 
When oxygen uptake is plotted against     the resulting relationship is curvilinear, and so is less commonly 
described than the largely linear           relationship. However the relationship between  
 
   and  
 
  has been 
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described in 2 ways. Firstly when     is logarithmically transformed the resultant plot is linear and is termed the 
Oxygen Uptake Efficiency Slope (OUES) (Baba et al 1996) (Figure 1.4). 
More recently the use of the highest value of the ratio of     : 
 
  has been explored, this has been termed the 
oxygen uptake efficiency plateau (OUEP) (Sun et al 2012).  
These variables are typically used for the assessment of prognosis in CHF (Davies et al 2006, Sun et al 2012) 
where they appear to be superior to peak      and  
 
        slope, but our experience with their use in respiratory 
disease is limited. 
 
1.8.6 Oxygen Uptake: Work Rate relationship 
As muscular work increases, oxygen uptake increases linearly in tandem. There is a slight lag in oxygen uptake, 
resulting in an oxygen deficit but generally the relationship of the two is linear. In previous studies this linear 
relationship has been shown to vary minimally in healthy adults, with negligible influence from patient 
characteristics such as height, weight, age and gender. CHF, but not respiratory disease, has been shown to 
reduce the slope of this relationship, and it may therefore be beneficial to help discriminate between a primary 
cardiac or respiratory abnormality in a breathless patient (Hansen et al 1987). Its use in identifying prognosis is 
less well established than for peak     ,  
 
       relationship and the OUES. 
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Figure 1.4: Graphical representation of how OUES is calculated. A plot of oxygen consumption against 
minute ventilation shows a curvilinear relationship. When minute ventilation is logarithmically transformed it 
assumes a linear relationship and the OUES is the gradient of the slope of the regression line through this data. 
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1.8.7 An algorithm approach 
So there exist a number of potential variables which may reflect cardiac physiology. However rather than using 
any single variable described above, an algorithm has been proposed utilising these variables to aid in diagnosis 
in a patient who presents with exercise intolerance and/or breathlessness on exertion (Figure 1.5). 
It can be seen that 3 of the variables I have described are used together in this algorithm: peak     , the anaerobic 
threshold and the breathing reserve. In a patient with respiratory and cardiac disease the approaches described 
above cannot identify the relative contribution of each disease to the patient’s exercise limitation. If this patient 
were to be followed up serially, whilst we could identify a deterioration in overall function using peak     , we 
could not identify whether this came about through a change in their heart or lungs. 
  
Therefore CPX can distinguish cardiac from respiratory disease, but not easily through the use of a single 
variable. If a single variable exists can it quantitate cardiac dysfunction? Certain variables show a greater 
prognostic potential in heart failure than others; does this relate to their greater specificity for cardiac disease 
over respiratory disease. 
 
These questions form the basis for this thesis. Can we identify, for patients with cardiac disease, a variable in 
CPX that is largely independent of respiratory disease (one of commonest co-morbidities) with a predictable 
linear course that can be used to measure the degree of cardiac limitation? 
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Figure 1.5: Flow Chart for the differential diagnosis of exertional dyspnoea. Neuberg et al. 
Cardiopulmonary exercise testing. The clinical value of gas exchange data. Arch Intern Med 1988; 
148(10):2221-6. Reproduced with Permission. 
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1.9 Aims 
The aim of this thesis is to identify a single variable on cardiopulmonary exercise testing that can differentiate 
cardiac from respiratory limitation, and that can quantitatively identify the impact of cardiovascular disease on 
the patient’s exercise capacity. 
We will call this the “Ideal” variable although I do not suggest that it will necessarily behave perfectly, merely 
that it will have greater specificity and sensitivity to cardiac disease and changes in cardiac function over other 
variables. In a patient undergoing regular follow-up for a known cardiac condition this “Ideal” variable would 
be the best for serial assessment of their cardiac condition, and would be largely independent of changes in co-
morbidities, especially respiratory disease. 
An “Ideal” variable would have the following characteristics:  
1. Be significantly different between various pathophysiological groups (i.e. cardiac vs respiratory) so can 
be used to identify, in a patient with exercise limitation, the principal limiting physiology. This 
specificity is the key determinant of an “Ideal” variable. 
2. Have good test-retest reproducibility. Our aim is to identify a variable that can be measured serially to 
identify subtle changes in cardiac function; a poorly reproducible variable will not be able to perform 
this function. 
3. Change predictably and appropriately over time with deterioration/ improvement in the relevant organ 
system. Specifically our “Ideal” variable will reflect improvements in cardiac physiology and 
haemodynamics and so when the heart is intervened upon, assuming this intervention is successfully 
positive, our variable should improve appropriately. 
4. Closely relate to an accepted measure of exercise capacity (e.g. peak     ) or symptoms (NYHA class, 
BNP) at baseline in patients with cardiac limitation. The variable should therefore be a continuous 
variable where the magnitude directly relates to the severity of disease limitation. An inherent 
assumption of this statement is that peak     is not specific, and will be abnormal in both cardiac and 
respiratory patients. Should the variable closely relate to peak     in the cardiac but not in the 
respiratory patients this is further evidence for its specificity. The relationship with peak      and other 
markers of disease will not be expected to relate as closely following intervention. This is because we 
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know, as described earlier, that exercise capacity may not normalise quickly after intervention despite 
immediate changes to cardiac haemodynamics. The “Ideal” variable should improve quickly, as it more 
directly reflects the cardiac function. As time passes the close relation between peak      and the 
“Ideal” variable should improve again as the whole body takes time to respond to the improved 
haemodynamics with changes in muscle function, lung function and vascular physiology. 
5. Remain unchanged over time with deterioration/ improvement in other organ systems. This will not be 
directly tested within the experimental setting of the thesis, put previous and future work will be 
discussed. 
 
Initially, to confirm the proof of concept, 2 data sets will be examined. Firstly on a retrospective cohort of 
patients with clinical heart failure, referred for treadmill CPX tests at St Mary’s Hospital between 2003-2007, I 
will show the differential effect of spirometric measures on CPX variables. Secondly I have collaborated with 
the investigators of the Study of Health in Pomerania, a large population study in over 1200 adults undergoing a 
single bicycle CPX test. Using this data I will show the influence of certain demographic variables (such as 
smoking) and spirometric measures on CPX variables within healthy adults as well as define normal limits for 
some of the less typically used variables. 
 
In the main study for this thesis I will prospectively recruit patients with respiratory disease, and patients with 
cardiac disease undergoing interventions aimed at improving cardiac haemodynamics. The directed comparison 
of these 2 groups (prior to intervention) will be used to investigate criteria 1. Each patient will undergo 2 
exercise tests at baseline; the comparison of these 2 tests will be used to investigate criteria 2. Criteria 3 will be 
investigated comparing the exercise tests before and after intervention in the cardiac patients. Criteria 4 will be 
investigated by comparing measures of disease severity such as symptoms and symptom scores, overall exercise 
capacity, BNP, and resting echocardiographic and spirometric abnormalities to the CPX variables, both at 
baseline, and comparing to the change following intervention. 
 
  
49 
 
2.0 Methods & Materials 
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2.1 Overview 
The overall aim of this study is to better identify ideal variables for the serial follow-up of patients with 
cardiovascular disease by cardiopulmonary exercise testing (CPX). The 2 central components to this are an 
Observational study and an Interventional study. Both of these arms involve the recruitment of patients with 2 
common cardiovascular diseases; chronic heart failure (CHF) and mitral valve disease (to include mitral 
regurgitation (MR) and mitral stenosis (MS)). For the purposes of the Interventional arm, patients were awaiting 
either the implantation of cardiac resynchronisation therapy (CRT) for CHF, or surgical correction of mitral 
disease. For the Observational study these cardiovascular patients were compared with patients diagnosed with a 
common respiratory disease; chronic obstructive pulmonary disease (COPD). All patients recruited underwent 
testing to ensure their diagnosis was correct and alternative diagnoses did not coexist. These methods included 
echocardiography and lung function testing with spirometry, lung volume subdivisions and gas transfer. These 
methods will be discussed in detail later. As abnormal renal function and anaemia can affect ventilation, venous 
blood sampling was performed on one day of testing to allow for consideration of these factors on analysis. 
All patients then underwent 2 baseline CPX tests on a bicycle ergometer, and this will be discussed in detail 
later. 
 
2.2 Patient Identification and Recruitment  
Ethics: South East London Research Ethics Committee (REC) Ref 10/H0805/36. Documents from the Ethical 
committee are included in appendix 2. 
Starting date following ethical approval was 29
th
 September 2010. The following groups of patients were 
recruited by the methods outlined in each.  
 
2.2.1 Mitral valve disease 
Mitral regurgitation is a common clinical condition, typically detected through cardiac auscultation and later 
confirmed via echocardiography. It exists on a spectrum, and is generally believed not to limit exercise capacity 
until of severe magnitude.  Whilst causes are manifold, two typical situations exist. Firstly there is organic 
mitral regurgitation, usually involving leaflet prolapse, where one or both of the anterior and posterior valve 
leaflets do not correctly coapt, leading to regurgitation of blood into the left atrium, often during late systole. 
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There is typically a structural problem with the mitral valve apparatus as well as the leaflets (which often have 
redundant tissue). It is often amenable to surgical repair and found in younger, otherwise healthy individuals. 
This was the group that we largely recruited from. The second commonest current cause in the UK is ischaemic 
MR. Generally the valve is normal, but changes in ventricular geometry or papillary muscle dysfunction lead to 
incomplete closure at the end of diastole. This is often termed functional ischaemic mitral regurgitation and 
often does not respond well to surgical correction (because the principal problem is with the ventricle, not the 
valve). Another cause is secondary to infective endocarditis.
At our institution (Imperial College Healthcare NHS Trust – ICHNT) mitral valve surgery is performed in 
house by 2 experienced surgeons. Following identification of a patient with MR, a cardiologist from our 
instituition or another local trust without in house surgical expertise, will review the patient and severity of 
their MR, and if deemed appropriate will be referred to an individual surgeon, or the surgical team via the 
multi-disciplinary Joint Cardiovascular Cardiology Meeting at Hammersmith Hospital. Guidance for the need 
for surgical intervention is based on international guidelines as shown below (Figure 2.1). 
Due to our local high success rate of early reparative surgery, many patients are operated in the presymptomatic 
period prior to the onset of LV dysfunction (Class IIa indication). Once surgery has been agreed between the 
cardiologist, cardiothoracic surgeon, and importantly the patient, they are placed on an outpatient waiting list, 
with wait times of typically a few weeks. The patient may be identified for my study at any point along the 
decision making process, but this typically occurs by the cardiologist (where the cardiologist is also involved in 
the research study) or once on the surgical wait list. The 2 surgeons were involved in the study, and aided with 
recruitment. 
Mitral stenosis (MS) is a rarer condition within the UK. It is almost always a consequence of rheumatic heart 
disease. Surgery is encouraged in symptomatic patients with a reduced valve area (<1.5cm
2
) , unfavourable 
valve structure for percutaneous balloon mital commissurotomy and no contraindications to surgery. It presents 
with symptoms similar to mitral regurgitaiton but reparative surgery is much less successful and replacement is 
typically required. 
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      Figure 2.1: European Society of Cardiology guidance 2012 for treatment of organic mitral regurgitation.
  
53 
 
2.2.2 Heart failure 
Patients with CHF were recruited from 3 main areas. Firstly, and so that overall recruitment could be optimised 
for both the Observational and Interventional arms of the study, patients awaiting CRT for heart failure were 
recruited. The role of CRT and the indications for implantation will be explained in detail elsewhere. A member 
of the heart failure or electrophysiology team was involved in decisions regarding CRT and, after discussion 
with the patient, they were placed on a waiting list for CRT. Either following identification from the referring 
cardiologist or from the CRT waiting list, patients for the study were highlighted. The second cohort within the 
CHF group were patients with pre-existing CRT. These were typically identified from the pacing clinic, where I 
was clinically involved. However to maximise numbers of appropriate individuals for recruitment, a second 
London based hospital trust (Royal Brompton & Harefield NHS Foundation Trust) was involved. Ethical 
approval for the identification and recruitment of patients was granted by the South East London Research and 
Ethics Committee. Patients were recruited by the cardiology team at this trust and referred to our study team for 
further information and potential inclusion in the study. Finally because more patients with heart failure were 
required for the Observational study than the Interventional study a number of patients without CRT were 
recruited. These patients were under the care of the routine Heart Failure Clinic at the St Mary’s hospital site of 
ICHNT, and a community cardiology site at Maida Vale. Both myself and other members of the research team 
were members of these clinics, routinely involved in the care and identification of these patients. 
 
2.2.3 COPD  
Patients with COPD were only recruited from ICHNT. Involvement of the respiratory clinic and a principal 
consultant chest physician occurred regularly. Patients with symptomatic COPD were identified by members of 
this clinic and, after agreement with the patient, details were passed to me. A number of stable COPD patients 
were also reviewed by the pulmonary rehabilitation team, and so meetings between myself and this group 
occurred regularly.  
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2.2.4 Inclusion and exclusion criteria 
The principal inclusion criteria were as below: 
1. Patients with symptomatic left ventricular systolic dysfunction. Ideally patients either had or were 
awaiting the implantation of CRT. Left ventricular systolic dysfunction was defined as a left ventricular 
ejection fraction (LVEF) < 50%. Cut-offs of normality for LVEF are debatable; multiple previous heart 
failure studies used an LVEF < 40% as an inclusion criteria, but more recent guidelines define systolic 
impairment as an LVEF ≤ 54% (Lang et al 2006). Studies of patients with preserved ejection fraction 
have traditionally used 45% or 50%, results from the CHARM study show that LVEF is a strong 
predictor of outcome below 45%, but above this there was no correlation (Solomon et al 2005). 50% 
has been proposed as a reasonable cut-off (Mahadevan et al 2008) and I believe this has a reasonable 
degree of specificity without compromising sensitivity. Patients must have been symptomatic, either 
with exercise intolerance or breathlessness on exertion, but were allowed to be stable with minimal 
symptoms at enrolment, as it is well established that asymptomatic patients with left ventricular 
dysfunction typically still have a reduction in exercise capacity (LeJemtel et al 1994, Mahon et al 
2000).  
2. Patients with mitral valve disease awaiting mitral valve surgery. Mitral regurgitation or stenosis must 
have been severe, and ideally reparative surgery (not replacement) was considered as the first line 
surgical option. Mitral stenosis is not usually amenable to repair, so a valve replacement was not a 
contraindication. No limits were placed upon symptom status or ventricular function. 
3. Symptomatic COPD or a condition with symptoms of COPD (e.g. bronchiectasis) with obstructive 
spirometry. COPD must have been at least mild, and ideally moderate or above; moderate corresponds 
to GOLD stage 2 (FEV1:FVC <0.70, FEV1 50-80% predicted and typical symptoms of breathlessness 
on exertion, cough and sputum production). 
4. A mixed cardiac and pulmonary disease group. Patients with known left ventricular or mitral valve 
disease awaiting surgery with concomitant COPD of at least GOLD stage 2 (FEV1:FVC <0.70, FEV1 
50-80% predicted and typical symptoms of breathlessness on exertion, cough and sputum production). 
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The principal exclusion criteria included: 
 Inability to perform exercise and/or significant neurological or musculoskeletal limitation 
 Renal impairment (eGFR <30 as calculated by the Modified Diet in Renal Disease formula), as severe 
renal dysfunction can affect ventilatory variables. 
 Symptomatic coronary disease, or significant ischaemia noted on cardiopulmonary exercise test.  
 Recent (recovery within <1month) decompensation of their underlying cardiac or respiratory disorder. 
 Anaemia (Hb <11). 
 Significant obesity (BMI >40) which could lead to limitation independent of the cardiovascular or 
respiratory condition. 
 Poor echocardiographic windows so that an assessment of left ventricular function and presence of 
significant valvular pathology cannot be reliably determined. 
 Inability to perform spirometry. 
 Inability to consent/make decisions (lack of competence) 
 Vulnerable adult/current detainee in prison/elsewhere. 
 Inability to complete all the investigations at the time intervals agreed in the protocol. 
 Permanent Pacemaker unless in the biventricular pacemaker group in the Interventional Study. 
 Atrial fibrillation if within the COPD group (this arrhythmia was allowed in the cardiac groups and 
mixed group because of the very high incidence). 
 Uncontrolled hypertension. 
 Untreated life threatening arrhythmia. 
 Recent surgery (within 10 weeks). 
 All standard absolute contra-indications to exercise testing. 
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2.3 Equipment and Testing 
 
2.3.1 Cardiopulmonary exercise testing 
2.3.1.1 Overview of exercise testing and terminology 
Every cardiopulmonary exercise test was performed on a COSMED Quark CPET System (COSMED S.r.l. 
Rome, Italy). This employs a 28mm diameter bidirectional flow turbine for the measurement of flow, and a 
<1mm diameter sampling line to deliver expired gases to the Quark unit. This measures oxygen concentrations 
using a paramagnetic analyzer with a response time <130 ms. Carbon dioxide concentrations are measured using 
a digital infrared analyzer with a response time <100 ms. Recent American Heart Association (AHA) guidance 
into CPX testing was adhered to (Balady et al 2010). During testing breath-by-breath measurements through the 
turbine are recorded, giving a real-time view of gas exchange. Both inspiratory and expiratory flow volumes can 
be measured, this is tidal volume (VT). The time delay between the onset of a given expiration and the preceding 
one is also measured, allowing respiratory frequency (Rf) in minutes
-1
 to be calculated. The product of VT and Rf 
is the minute ventilation (   ), which is the volume of air expired within one minute (measured in litres/min). 
The two other main variables measured breath-by-breath are the uptake of oxygen (    ), and elimination of 
carbon dioxide (     ). As described in Chapter 1 these are ventilatory surrogates for the consumption of oxygen 
(    ) and production of carbon dioxide ( 
 
   ) in the tissues (during exercise this is almost entirely the 
exercising skeletal muscle). In simple terms they are measured by calculating the product of the concentration of 
oxygen difference between expired air and room air and the expiration volume (and similarly for CO2). In 
reality, because oxygen concentration in expired air changes throughout each breath, more complex techniques 
using integration are used.  
As described earlier, CO2 is the product of cellular respiration. When glucose is the fuel the ratio of CO2 to O2 is 
1:1, however this ratio is different when the fuel source contains fats or proteins as shown below: 
Glucose: C6H12O6 + 6O2 → 6CO2 + 6H2O       The ratio here is 6:6 or 1.00 
Fat: C16H32O2 + 23O2 → 16CO2 + 16H2O     The ratio here is 16:23 or 0.696 
Protein: C72H112N18O22S + 77O2 → 63CO2 + 38H2O + SO3 + 9CO(NH2)2        The ratio here is 63:77 or 0.818 
These are just typical examples for fats and proteins. This ratio of CO2:O2 is termed the Respiratory Quotient or 
RQ. At rest the RQ lies below 1 as a combination of glucose, fats and protein make up the fuel source. As 
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exercise starts a greater percentage used is glucose (the preferential substrate of skeletal muscle) so this RQ will 
rise. 
The RQ at the muscle can be seen to be a ratio that must be <1, as no energy source produces more CO2 than it 
consumes O2. However we cannot measure RQ at the muscle, only a surrogate at the mouth. The      : 
 
   ratio 
measured is termed the respiratory exchange ratio (RER). At rest and low levels of exercise it resembles the 
RQ, although typically the action of measuring it elicits some hyperventilation of the patient, with an excess of 
CO2 elimination, raising the RER above the RQ. This hyperventilation usually settles during very early in 
exercise, so that the RER falls to a baseline level somewhere around 0.75. As exercise continues the RER slowly 
climbs as proportionally more glucose is used by the skeletal muscle. As described in Chapter 1 when aerobic 
exercise can no longer keep up with demand, anaerobic metabolism starts with the production of lactate and 
hydrogen ions, which is initially buffered by CO2 production. This CO2 is expired with a rise in the RER. As 
lactate production increases and hydrogen ion concentration rises there is a second method of compensation, 
hyperventilation, with the result of resetting arterial CO2 concentration at a lower level; this is respiratory 
compensation. If exercise is allowed to progress to this stage, these last 2 processes will almost always allow the 
RER to climb above 1; values of 1.2-1.4 at peak exercise are suggestive of near maximal effort. 
With this understanding of these key measurements in exercise testing in place detailed description of the many 
variables I measured, and how they were measured, can be made. 
 
2.3.1.2 Calibration 
The Quark CPET system was calibrated prior to each patient’s exercise test. Two forms of calibration were 
performed. 
Firstly calibration of gas analysis was performed (Figure 2.2). The sampling line was connected to the Quark 
device and a two-point calibration involved the controlled introduction of two gases down the sampling line was 
performed. The first gas was air, to allow for correct calibration of the current atmospheric conditions. The 
second gas was from a premixed cylinder of 16% O2 and 5% CO2 (approximately the concentrations in expired 
air). This allowed the calibration of both O2 and CO2 within the normal physiological range. Abnormalities in 
calibration allowed identification of problems that could have led to inaccurate gas analysis during CPX.  
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Secondly calibration of turbine flow was performed using a 3L syringe. This was attached to the turbine and 12 
full emptying and filling manoeuvres of the syringe were performed. Acceptable turbine calibration involved 
obtaining values within the accepted limits of normality, as shown below for a typical patient (Figure 2.3). 
No tests were performed unless both successful calibrations had occurred. 
 
 
 
 
 
 
Figure 2.2: Calibration of the Gas Analyzer Results Table. This involved a two-point calibration with room 
air and a 16:5 mixture of 16% oxygen and 5% carbon dioxide (to roughly simulate expired air). The oxygen 
analyzer and carbon dioxide analyzer were both calibrated during this test, and the presence of an abnormality 
was shown with a red highlighted figure within the results table; this prompted the operator to look for, identify, 
and correct a problem, and re-calibrate before starting the exercise test. 
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Figure 2.3: Calibration of turbine flow. A 3L calibration syringe (COSMED, Italy) was attached to the turbine, and 12 full emptying and filling manoeuvres to simulate 
expiration and inspiration were performed. The box to the left shows each individual manoeuvre, before successful calibration is shown on the right. 
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2.3.1.3 Ergometer and test set-up 
I performed each CPX test as principal operator.  
Each test was performed on an Ergoselect 100, bicycle ergometer (Ergoline GmbH, Bitz, Baden-Württemberg, 
Germany) (Figure 2.4). This is a computer-controlled electronic ergometer capable to eliciting work rates of up 
to 999 watts, independent of pedal speed within the range 30-130 revolutions per minute (rpm). 
Another operator was present for safety. 
Bicycle ergometry rather than treadmill was chosen for its principal advantages; work rate can be measured, 
upper-body movement and therefore artefact is reduced, and it is safer than treadmill exercise. Work rate 
measurement was particularly important as it is necessary for the calculation of an important variable, the 
oxygen uptake: work rate relationship. Limitations of bicycle over treadmill testing include a lower muscle mass 
utilised (typically reflected in lower peak oxygen uptake) and more technically challenging in those unused to 
cycling. 
Each patient had the ergometer adjusted to allow for optimal pedalling comfort. Following sitting on the 
ergometer the seat height was adjusted so that the patient’s legs were slightly bent at the knee (typical angle 10-
15%) as recommended, and the feet secured using the Velcro foot straps. The handlebars were also adjusted 
towards or away from the patient as required. A few pedal turns were encouraged to ensure a comfortable 
pedalling position. 
The Quark CPET turbine was fitted to the patient using a silicon mask with quick-release headgear straps (Hans 
Rudolph Inc, Shawnee, KS, USA). A tight seal was attempted for each patient by the use of a range of sizes of 
masks, and confirmed with an attempted moderately forced expiration against a blocked turbine (air could be 
heard escaping in the event of a poor seal, and the patient was able to make a maximal expiration). A poor seal 
led to further attempts to ensure optimal positioning to eliminate/minimise mask leak. 
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Figure 2.4: Ergoselect bicycle ergometer. Seat height and handlebar position were adjustable for patient 
comfort. There is a panel at the front, visible only to the operator, displaying work rate, time and cadence. 
Another panel to the rear of this, visible to the patient, only displays the cadence.
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Prior to exercise testing, baseline spirometry was performed for each patient through the turbine, using the 
manufacturer’s software System (PFT Suite, COSMED S.r.l. Rome, Italy) (Figure 2.5). I described each 
manoeuvre with 3 parts: firstly a gentle expiration through an open mouth; immediately into a full, controlled 
inspiration; and finally, without a pause, a maximal forced expiration until a plateau in expiration had occurred 
(patients were encouraged to expire for at least 6 seconds). This was repeated until an accurate reproducible 
effort was achieved. The main role of this spirometry was for safety rather than diagnosis. Spirometry 
performed at the time of full lung function tests was defined as the patients’ formal results (discussed later). The 
measurement of an FEV1 prior to exercise testing allowed for breath by breath evaluation of ventilation during 
exercise to identify when a patient was approaching a possible respiratory maxima (described in detail later). 
A 12 lead ECG was attached to the patient with the standard configuration of the 10 electrodes (Figure 2.6). The 
limb electrodes were, when necessary, moved if the pedalling motion led to noise artefact. 
Continuous 12 lead ECG monitoring occurred throughout the test (Stress PC ECG Application, Version 5.0.522, 
COSMED S.r.l. Rome, Italy). The ECG monitoring also performed the action of measuring and transmitting 
heart rate data to the gas exchange analysis software (PFT Ergo, COSMED S.r.l. Rome, Italy).  
Continuous arterial oxygen saturations were measured through one of two non-invasive mechanisms; either a 
finger or an earlobe pulse oximeter. These measure the change in absorbance of two different wavelengths of 
light passed through either the finger or earlobe to a photodetector on the other side. They exclude interference 
from non-pulsatile sources such as venous blood and fat.  
Finally a non-invasive blood pressure cuff was attached to the right arm of each subject. Blood pressure was 
measured manually by one of the operators using a sphygmomanometer and stethoscope with the arm in the 
fully extended position after removal from the ergometer handlebars. Both systolic and diastolic blood pressure 
readings were recorded at rest. A blood pressure of >200/100mmHg at rest led to cancellation of the test and 
recommendation of a review with a physician. 
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Figure 2.5: Software visualisation of spirometry. The curve on the left is a flow-volume curve with expiration 
above the x-axis. The maximum values for volume and flow as well as the pattern can be distinguished. In the 
right hand plot volume in plotted against time. A plateau in volume can be seen to occur indicating full 
expiration. 
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Figure 2.6: Positioning of ECG electrodes on the subject’s chest. A traditional 12 lead ECG positioning was 
used with 4 limbs electrodes and 6 chest electrodes.
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2.3.1.4 Testing 
Each subject underwent at least two CPX tests on the bicycle. Each was given instructions on how to perform 
the test, following which each test started with 3 minutes of complete rest once I was happy the patient was in a 
true resting state (     approximately 3.5 mL/min/kg, RER 0.70-0.85). The patient was advised not to talk 
(during this and any subsequent stage of the test) unless necessary (for example if they were experiencing pain). 
Following this 3 minutes I prompted the patient to begin cycling at a cadence of 55-64 rpm. This cadence (ideal 
for the ergometer to control work rate) was visible to the patient and the operators and gentle encouragement 
was given to ensure this cadence was achieved and sustained. The patient continued to cycle, initially through a 
3 minute “unloaded” phase where the cycle did not offer resistance. In keeping with most hospital based 
ergometers, this did not have a flywheel, so was not fully unloaded. However the energy requirements to turn 
the pedals at zero watts is low and so the term unloaded will be used throughout the thesis. Following on from 
this initial 3 minutes of exercise, the ergometer started to increase load. The patient was prompted that it would 
get more strenuous to pedal but they should not alter their approach (i.e. a cadence of 55-64 was maintained 
throughout). The work rate continued to increase at a linear rate determined prior to the test, in increments of 
12-15 seconds. Encouragement was given to the patient regularly to ensure they exercised as close to their 
maximum as possible. 
Blood pressure was measured manually, in the same manner as pre-test, at least every 3 minutes, and as close to 
peak exercise as possible, an exercise reading of >240/120 led to immediate cessation of the test.  
The operators continuously monitored both the ECG and the principal gas analysis variables in real time to 
identify any problems early and avoid any adverse clinical events. Standard criteria for cessation of a test were 
adhered to (Balady et al 2010). Unless an arrhythmia was present the exercise test was not stopped due to heart 
rate, and values over 100% predicted by the patient’s age were allowed.  
Unless an abnormal clinical finding occurring during testing (i.e. arrhythmia, ischaemic ECG changes, 
respiratory distress) prompted me to stop the test, the patient was in control of when to stop, however an 
inability to maintain a cadence of at least 50rpm despite encouragement did lead me to advise that a maximum 
had been achieved. 
Following cessation of the test the patient entered an active recovery phase. The work rate on the bike reverted 
to zero immediately, and the patient, following a few seconds rest, was encouraged to begin cycling again, this 
time at whatever cadence they felt comfortable at. The purpose of active recovery was to allow for continued 
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flow of blood through the exercising muscles but at a rate below the anaerobic threshold, to washout the 
metabolites such as lactate to reduce muscular discomfort later; and secondly to allow for a slower, more 
controlled fall in blood pressure. Gas analysis was measured for 5 minutes of recovery, at which point the test 
was stopped and the patient disconnected (unless variables such as ECG, heart rate, BP required a longer period 
of monitoring for safety purposes). 
Each patient’s first test was performed on a 10 watts/minute ramp. This, following the 3 minute unloaded 
section, increased work rate of the ergometer by 2 watts every 12 seconds, or 10 watts per minute, linearly. 
The purpose of the first test was two-fold: 
1. To familiarise the patient with the test. CPX and cycling are not commonly performed and it has been 
suggested that there may be a learning effect to this test. A study on the effect of familiarisation showed a 
significant 0.8mL/min/kg increase in peak     on test 2 in heart failure patients on treadmill exercise 
(Elborn et al 1990). These results were in conflict with a reproducibility sub-study of the HF-ACTION 
trial, where 88% of patients exercised on the treadmill, and the remainder on the bicycle, which did not 
show a familiarisation effect between tests 1 and 2 for patients with CHF in peak     (Bensimhon et al 
2008). However, in this study other variables, such as exercise time,          slope, peak HR and peak 
RER did show improvements in the second test. Peak     was similarly unchanged between serial 
treadmill tests in a further study (Russell et al 1998), although exercise time was prolonged in the second 
test compared to the first, which was interpreted by the authors to show evidence of a learning effect for 
greater efficiency on the treadmill without increases in oxygen consumption. Marburger et al and Meyer 
et al also showed no significant differences between test 1 and test 2, however all of the patients in these 
studies had either previously undergone CPX, or were given a practice test prior to the first recorded test 
(Meyer et al 1997, Marburger et al 1998). The discrepancies noted between these studies are difficult to 
explain. The original study by Elborn et al was small, and much earlier than the others, perhaps at a time 
when familiarity with treadmills per se was uncommon, especially amongst a group with an average age 
of 69. It may be possible therefore that it was not a lack of familiarisation with CPX so much as a lack of 
familiarisation with walking on a treadmill. This hypothesis would be difficult to confirm without the 
authors having specifically asked the study subjects their experience with treadmills.  
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What is relatively uncertain is whether the familiarity effect applies to bicycle ergometry. Bensimhon et 
al did not report whether a difference in the reproducibility results between the 88% on the treadmill and 
the 12% on the bicycle existed or not. Because the impact on cycle exercise is less well known it was felt 
that a familiarisation test would be beneficial to the current study. 
2. To identify the optimal protocol. It is largely accepted (although this advice appears to be largely 
experiential rather than evidence-based) that exercise tests should aim for maximal effort to be obtained 
by approximately 10 minutes (Balady et al 2010). Significantly longer tests are believed to lead to undue 
fatigue and boredom and may lead to cessation prior to a physiological maximum. Shorter tests may lead 
to a lack of data and difficulty measuring certain variables such as the anaerobic threshold. Every 
patient’s first test was performed with incremental work of 10W/minute. This was found in practice to be 
a common appropriate protocol for many patients, and had the mathematical advantage that the number 
of minutes performed signified the incremental protocol required to perform 10 minutes of work (e.g. a 
patient pedals for 15 minutes achieving 150watts; the ideal protocol for him would be 150W/10 minutes 
= 15W/min, which was the time achieved). Protocols of 6, 8, 10, 12, 15 and 20W were felt to be 
sufficient to allow for the spectrum of exercise capacities. Where a patient’s ideal protocol lay between 
two of these values the upper protocol was chosen, as it is generally believed that a slightly shorter, more 
intense ramp is superior to a longer one. 
The second test was conducted identically to the first test, except that the incremental section may have been at 
a different increase in work rate, i.e. 6, 8, 12, 15 or 20 rather than 10.  
The second test was performed at least 2 hours after the first test to allow for recovery. In some patients these 
two tests were performed on different days (either due to fatigue or time constraints) but these patients were not 
chosen randomly, so in some analyses this as a potential confounding variable will be considered. 
 
2.3.1.5 Data analysis and key variables 
Each test was performed using the same software package (Quark CPET, COSMED) with identical default 
settings of measurement. Following each test’s cessation the data was outputted in two formats, firstly an .xpo 
file, to be used for analysis within the software, and an .xls format for further analysis within the spreadsheet 
package Excel (Microsoft Corporation). All analysis was performed in Excel. An example patient’s data is 
included in Appendix 1 (Chapter 12) to show graphically how it was handled. The data were recorded breath-
68 
 
by-breath, so that for every test there were many rows of data (typically between 200-400 rows). There were 
multiple variables generated as well displayed as columns, some directly measured such as oxygen uptake (      
and minute ventilation (   ), and others derived from multiple variables. No averaging was performed initially. 
Initially for each test the row numbers were identified that corresponded to the four stages of the exercise test; 
rest, unloaded cycling, incremental exercise and recovery. This allowed calculation of certain variables to only 
contain information within a certain portion of the test, for example if incremental exercise occurred between 
rows 100-300, then the OUES was calculated using only data between and including these two rows. 
Peak     , peak minute ventilation ( 
 
 ), peak respiratory frequency (Rf) and peak O2 pulse, were all calculated in 
the same manner. The pre-determined limits for peak exercise variables were 20 second averages within the 
final minute of exercise and including 10 seconds of recovery. Rolling sequential averages were manually 
calculated starting 40 seconds before cessation of exercise to include all breaths within the preceding 20 second 
period as displayed in Figure 2.7. I have no knowledge of an identified ideal average time span within the 
literature; there will be a compromise between high precision but high variability with very short averaging 
intervals (or no average at all) with the low precision but low variability with very long intervals. Guidelines 
suggest averaging of data between 20-30 seconds (Balady et al 2010). I arbitrarily chose 20 seconds with rolling 
averages largely based on clinical experience of how exercise data is reported. Although there is some evidence 
that in heart failure delayed attainment of peak exercise ventilatory variables may occur up to 45 seconds after 
the end of exercise (Cohen-Solal et al 1997), practically this is not yet part of clinical guidance, and certain CPX 
software only allow for detection of peak variables during exercise itself.  
The raw data was also assessed to ensure that there were no spurious readings. Peak     was defined as the 
highest 20 second rolling average of     measurements throughout the final minute of exercise.  
 
  and Rf in 
analysis were the highest 20 second rolling average of     and Rf measurements throughout the final minute of 
exercise. The oxygen, or O2, pulse is defined as the     / heart rate. As  
 
         cardiac output, so the O2 pulse is 
to stroke volume. It is the product of stroke volume and [CaO2 – CvO2] (where [CaO2 – CvO2] equals the 
oxygen content difference between the arterial and venous blood) and is often considered as a surrogate for 
stroke volume (because oxygen extraction at the muscle is said to be similar between adults, in my opinion a 
false assumption). I measured the O2 pulse on a breath-by-breath basis, and then recorded the highest 20 second 
rolling average of measurements throughout the final minute of exercise (i.e. it was not the ratio of peak      to 
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peak heart rate). Unfortunately a limitation of the ECG software I use was that heart rate was not always 
accurately measured in the presence of a broad QRS complex or pacing spikes. In patients where heart rate 
measurement was unreliable, the O2 pulse was not calculated to avoid error.  
Maximal voluntary ventilation (MVV), is the predicted maximum ventilation in a minute for a given patient. 
When directly measured the patient is encouraged to ventilate as hard and fast as they can for a set period of 
time (often 12 seconds) and the corresponding total volume then corrected for one minute; this is an 
uncomfortable manoeuvre and technically challenging. Alternatively a patient is asked to perform a forced 
expiration as described in section 2.3.1.3. The volume expired within the first second (FEV1) is multiplied by a 
coefficient (I used 40) to allow an indirect calculation for the MVV (Campbell 1982, Hansen et al 1984). For 
example a patient with an FEV1 of 2.5L will have an MVV of 100L/min. The formula to calculate the indirect 
MVV for my patients was therefore:  MVV=FEV1 x 40. 
Knowing the MVV allows you to calculate the breathing reserve (BR), which shows the remaining potential for 
the lung to increase ventilation. It is typically greater than 30% in healthy adults, which means that the lungs 
still have 30% of their ventilatory potential remaining, showing the redundancy that exists within our lungs to 
perform exercise. They are not the organ maximally stressed upon typical exercise.  
The BR was calculated using the following formula: BR = 100 x (MVV –   ) / MVV 
For safety during the test the FEV1 measured during spirometry performed immediately prior to the test was 
used (this automatically calculated and displayed BR on a breath by breath basis to allow the operator to view). 
However for the purposes of the analyses the FEV1 obtained at the time of full lung function tests was used 
(discussed in section 2.3.3). 
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Figure 2.7: How peak data was manually averaged in Excel.  Data from the final 40 seconds of exercise and 
the first 10 seconds of recovery have a rolling average of the preceding 20 seconds (as can be seen being 
calculated for one 20 second interval in the top panel) for each breath during this time period. The highest 20 
second average for     , minute ventilation, breathing reserve, respiratory frequency and O2 pulse are 
highlighted. 
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The final variable calculated using averaged raw data was the oxygen uptake efficiency plateau (OUEP) which 
was in the original paper describing it defined it as the highest 90 second average of the       
 
  ratio (Sun et al 
2011). In line with this study, which showed the strong predictive value of OUEP in the prognosis of heart 
failure patients, I also defined the OUEP as the highest 90 second average. OUEP was plotted for each patient 
against time so that a region of interest where the OUEP was highest could be identified, and the peak value 
(and that it was correctly averaged over 90 seconds) could be ensured manually. 
Following on from the identification of these peak variables, all strictly defined in their calculation to eliminate 
observer bias/error, I calculated the only 2 variables in each test that were assessed subjectively. These were the 
anaerobic threshold, and the ventilatory compensation point. As discussed within Chapter 1, exercise can be 
divided into phases based on the responses to the production and elimination of lactate. The first stage, aerobic 
exercise, is a period where lactate does not form (or more correctly only at a very low basal level, easily 
managed by the body). Following this, as exercise becomes more intense, lactate production increases, but the 
hydrogen ions produced are buffered by bicarbonate within the system, yielding an increase in carbon dioxide. 
This is the second phase, anaerobic isocapnic buffering, and the anaerobic threshold (AT) delineates this phase 
from the aerobic phase. With increasing intensity of exercise the bicarbonate in the system is overwhelmed, 
ventilation must then increase relative to carbon dioxide to bring about a respiratory alkalosis to compensate for 
the metabolic acidosis and maintain body pH as close to physiologic neutral (7.35) as possible. This is the third 
phase, or respiratory compensation, and the ventilatory compensation point (VCP) delineates this from the 
second phase. The ventilatory mechanisms that occur at these two thresholds are too complex to discuss in detail 
here, but put simply the AT is the point at which oxygen consumption and ventilation become “decoupled” but 
carbon dioxide production and ventilation remain tightly coupled. This can be viewed graphically as an increase 
in the      / 
 
   ratio (the RER), a rise in the  
 
       ratio without a concomitant rise in the  
 
       ratio, and a 
plateau in the end-tidal CO2 with increasing end-tidal O2 partial pressures. However the commonest clinical 
method for identifying the AT is to use the V-slope method (Beaver et al 1986), which displays the oxygen 
uptake (x-axis) against the carbon dioxide elimination (y-axis). It should assume the appearance of two straight 
lines, with the left-most line < 45º (i.e.      rising faster than  
 
   ) and the right-most line > 45º (i.e.  
 
    rising 
faster than     ). This is graphically represented in Figure 2.8 where the gradients of the 2 lines can best be 
observed easily with the addition of a line of identity (y=x-c). The intercept of these two lines is the AT.  
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Figure 2.8: The identification of the     at the anaerobic threshold. 2 subjects are demonstrated (left and 
right).      is plotted against  
 
    with a line of identity (y=x-c). The data should closely approximate 2 lines, 
one with a gradient < 45% (flatter than the line of identity) and one > 45% (steeper than the line of identity). 
The overlap point is the     at the anaerobic threshold. The patient on the right (C &D) managed a maximal test 
so his      starts to trend vertically at the end, where further increases in  
 
   do not occur but continued 
increases in       does. This data should be ignored as can be seen in plot D (red line ignores highest points). 
  
A
C
D
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The      at this value can be directly measured from this plot, and the corresponding breath identified for all 
further variables dependent on the AT. Practically however, I feel that the AT identification can only be 
strengthened by the inclusion of the graphs of the RER against time, ventilatory equivalents against time, and 
the end-tidal partial pressures against time. The equivalent 3 plots from the second patient in Figure 2.8 are 
shown in Figure 2.9. 
Measurements made at the anaerobic threshold include the     , the  
 
       ratio, RER and end-tidal CO2 (these 
variables will be discussed in detail below). 
In clinical medicine this first threshold in changing ventilatory patterns, the AT, is the most important in helping 
us to delineate disease aetiology and severity. However should exercise continue for long enough, lactate 
production causes a significant drop in blood pH, beyond the bicarbonate system’s ability to buffer, which as 
described above causes the lungs to hyperventilate, in order to reduce arterial CO2 concentration (PaCO2), and 
compensate for the metabolic acidosis with a respiratory alkalosis. This second threshold is termed the 
ventilatory compensation point or VCP; at this point the linear relationship between     and       is lost. Whilst 
in clinical medicine the occurrence of this second threshold is largely irrelevant, one important clinical variable 
does require its identification. The slope of the minute ventilation to carbon dioxide elimination relationship, the 
         slope, is traditionally agreed to be measured using data only from the linear portion of the slope (Figure 
1.3). This therefore only applies to the portion of the relationship prior to the VCP. I identified for each patient if 
the VCP occurred, and if so, at which time point (Figure 2.10), to aid in the accurate measurement of the 
         slope. 
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Figure 2.9: Identification of the anaerobic threshold using 3 supplementary plots. The plot on the left shows the ventilatory equivalents, the          ratio (red) and the 
         ratio (blue) against time. The middle plot shows the respiratory exchange ratio against time. The final plot shows the end-tidal CO2 (blue) and end-tidal O2 (red) 
against time. The AT (indicated by the vertical dashed line) can be seen to occur at a time when: the          ratio either reaches a plateau with further decreases in the 
         ratio, or rises with a plateau in  
 
       ; there is a consistent steep rise in RER with time; and end-tidal CO2 reaches a plateau with further increases in the end-tidal 
O2. The dotted lines in these plots all correspond to the AT identified in this patient in Figure 2.8. All of these conditions may not be met at the same time point in each 
patient due to other factors that may impact ventilation (for example anxiety) so some interpretation is necessary along with the V-slope method to allow for an accurate 
estimation of the time point and oxygen uptake at the AT.  
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Figure 2.10: Identifying the Ventilatory compensation point (VCP). The VCP occurs when the lactic acidosis overwhelms the local buffering capacity of bicarbonate, 
potentially leading to acidaemia. This requires hyperventilation with respect to      , to elicit a “respiratory compensatory alkalosis” and maintain pH close to the 
physiological range. This leads to a lowering of the arterial CO2 set point. Graphically the VCP occurs when the          ratio starts to increase towards the end of exercise, as 
shown in the first plot at 810 seconds, and when     and      lose their tight linear relationship, as shown in the second plot with a  
 
   of approximately 3L/min. The 
traditional measurement of the          slope will be calculated as the slope of the line of best fit in the right hand plot through the linear portion of the curve, i.e. with data 
after the VCP ignored. 
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A potentially important feature of the AT and VCP as variables in this analysis is that they are the only variables 
where subjective decision-making from the operator is necessary. Hence they may be more susceptible to bias 
than other markers, which may influence their reproducibility. 
I will now discuss how I calculated the variables of the     to      relationship. The first measure is the            
          slope as just discussed, which was calculated in 2 ways. As shown in Figure 2.10,  
 
  can be plotted 
against      . Firstly the line of best fit using least squares regression is plotted within Excel for data starting at 
the onset of unloaded exercise and ending at the VCP; the slope of this line is defined in my analyses as the 
         slope, or slope 1. Secondly the same method is used but including all data from unloaded exercise until 
the end of incremental exercise, i.e. ignoring the VCP, I termed this the full slope, or slope 2. There has been 
some data suggesting that calculating the slope using all data points, rather than censoring at the VCP, has 
greater prognostic power compared with limiting data to the linear portion (Ingle et al 2007), although a 
conflicting study showed no difference in prognostic ability when the data included progressively shorter blocks 
of data from the same exercise test (Arena et al 2003). Conceptually the evidence from Ingle et al is difficult to 
explain; in healthy adults, ventilation post-VCP (which is an uncommon occurrence in patients with heart failure 
and COPD) is uncomfortable and often leads to prompt cessation of the test. Greater time spent in this phase 
will mean a proportionally greater contribution to the slope from this non-linear segment which will increase the 
magnitude of the slope. Therefore subjects who push themselves harder and go further into anaerobic 
metabolism in the test will appear to be “less fit” by virtue of having a steeper slope than if they had stopped 
earlier (this makes it the only variable where values worsen as exercise continues in healthy adults). Differences 
in protocol may also affect this slope to a greater degree than the slope measured sub-VCP, as they may alter the 
proportional time spent in this ventilatory compensation phase of exercise. Therefore physiologically, the 
inclusion of data post-VCP does not make sense when calculating the slope. However, it is possible that patients 
with heart failure who display a non linear portion to the          slope have a different physiological 
mechanism than healthy adults to explain these ventilatory patterns. I therefore felt it would be appropriate to 
calculate both slopes separately and allow independent analysis of both. 
The ratio of             was also calculated, at 3 time points. Firstly at the anaerobic threshold and secondly, the 
ventilatory compensation point, when they occurred. These values were taken as the instantaneous ratios at the 
time points identified as previously described. Thirdly the lowest             ratio during the test was also 
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determined; this is termed the          at nadir. This was, simply, the lowest instantaneous ratio at any time point 
during unloaded and incremental exercise. 
The respiratory exchange ratio (RER) was described briefly earlier and is the instantaneous ratio of        
 
   per 
breath.      alone is rarely described during CPX but through this ratio we are able to see the impact of exercise 
on the metabolic systems. At rest it should almost equal the RQ, with fluctuations relating to the variable nature 
of ventilation. At complete rest ventilation normally matches demand, but with awareness (the presence of a 
facemask or mouthpiece often impacts on this) this tight relationship may be lost with short periods of relative 
hyperventilation. However as exercise starts RER settles to match RQ, and ventilation adopts a more regulated 
pattern, before it slowly starts to rise (as skeletal muscle metabolises an increasing proportion of carbohydrate 
over fats and proteins). At the onset of anaerobic metabolism the RER rises more rapidly (although the rate of 
this increase is highly variable and dependent on the duration of the exercise) as excess CO2 is produced from 
buffering, and then later as more hyperventilation expels yet more CO2. Typically RER should reach its highest 
values at peak exercise (although recovery values are typically even higher). For this study I determined the 
RER at 3 time points. Firstly all values during the 3 minute rest period were assessed for the lowest value; this 
was chosen to represent resting RER. Although there are criticisms of picking a single value in this way, there 
are also conceptual concerns with averaging RER. It is very common during a rest period for subjects to 
hyperventilate (a totally flat RER profile never occurs), and therefore an average of the RER over these 3 
minutes will be falsely elevated. The counter argument is that the RER will fall to levels lower than equilibrium 
after a period of hyperventilation (as CO2 stores require replenishment, and CO2 elimination reduces relative to 
O2 uptake at the mouth). However this phenomenon appears to be less pronounced than the elevation in RER 
with hyperventilation, so whilst not a perfect measure, I feel it is reflecting resting muscle respiratory quotient 
(RQ) the closest. Secondly RER was recorded instantaneously at the AT (as previously described). Finally the 
RER was recorded at peak exercise, as the final RER value before the patient stopped exercising. 
Gas analysis measures concentrations of oxygen and carbon dioxide in expired gas throughout the whole 
expiration. Values for      and  
 
    therefore use an average of the whole expiration. There is, however, benefit 
to looking only at the final instant before inspiration as well – this is termed end-tidal. The final portion of 
expired gas has been within the lung the longest and has had the greatest time to equilibrate with the pulmonary 
capillary system. The end-tidal partial pressure of oxygen and carbon dioxide in expired gases closely resembles 
the partial pressures within the arterial system and so is a potential surrogate for arterial values minimising the 
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requirement for invasive arterial blood sampling. This has a number of unique uses. Probably the most relevant 
is the identification of hyper or hypoventilation. Hyperventilation leads to loss of CO2 from the blood stream, so 
arterial PaCO2 (partial pressure of CO2 in the artery) and PETCO2 (end-tidal partial pressure of CO2 in the 
expired gas) are both lower than anticipated. The opposite happens in patients who relatively hypoventilate (can 
be seen in obesity). End-tidal partial pressures are also of use in the diagnosis of intra-cardiac shunts (Barron et 
al 2012) with a mirror image to the typical response indicative of a right-to-left shunt. The main limitation of 
end-tidal partial pressures is that they are only a surrogate for arterial values. The close relationship between 
these values and the corresponding arterial values (typically +2 to – 4mmHg) can be lost in patients with 
respiratory disease and/or ventilation: perfusion mismatch. In these cases (invariably the patients in which we 
wish to use them) they must be interpreted cautiously. Whilst arterial measurement of O2 and CO2 are more 
accurate, they are time consuming, cannot be done in real-time and are invasive. End-tidal values are calculated 
routinely with each breath, and can act as a safe, surrogate for arterial values, so long as their limitations are 
respected. For each CPX test values of end-tidal CO2 (PETCO2) and end-tidal O2 (PETO2) were measured breath-
by-breath. The only measurement recorded for data analysis was the PETCO2 at the anaerobic threshold. This 
typically represents the highest value and a plateau in PETCO2. 
Heart rate was recorded by the software continuously, but was recorded for analysis every 3 minutes. Resting 
heart rate was the average of all values within the 3 minute rest period. All other values were single, non-
averaged, values on the 3 minute intervals (or the closest reading to this). Blood pressure was recorded as close 
to every 3 minute interval as possible and recorded alongside this time point (so for example if blood pressure 
was being taken between 8:40 and 9:10 it would be recorded as the BP at 9:00). A peak blood pressure was 
recorded alongside peak heart rate, and the product of the systolic blood pressure and the heart rate at this point 
was calculated as the Double Product (DP). The circulatory power was defined as the product of the peak      
(highest 20 second average as described earlier) and the peak systolic blood pressure.  
Exercise duration including the 3 minutes of unloaded cycling and maximal work rate (in watts) were also 
recorded, along with the subjects’ principal symptom for stopping the test. 
Finally 3 other slopes were measured. Firstly the oxygen uptake efficiency slope (OUES), which was defined as 
the slope of the line of best fit when     is plotted against log10 minute ventilation (logarithmic transformation of  
    leads to a close linear relationship with     ) (Baba et al 1996). There remains a point of contention as to the 
units of OUES. Some believe it unitless, others L per 10-fold increase in minute ventilation. I largely favour the 
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latter, however it is an unruly unit for tabular and diagrammatic data, so will largely be referred to with no units. 
The OUES was calculated in Excel using least squares regression utilising data within incremental data only. A 
proposed strength of the OUES is its resilience to foreshortening of data; we therefore further calculated the 
OUES using data between 25-75% of incremental exercise, 0-50%, 0-70% and 0-90%; these periods of exercise 
foreshortening have commonly been used in studies before. To calculate the time points 25, 50, 70, 75 and 90% 
a chart for each test was constructed as shown in Figure 2.11. 
 
 
 
Figure 2.11: How submaximal OUES limits were constructed. PE indicates peak exercise time in seconds. 
360 seconds (total time for rest and unloaded exercise) was subtracted and then the 25
th
, 50
th
, 70
th
, 75
th
 and 90
th
 
percentiles of this “incremental exercise time” were calculated. 360 seconds was then added to these percentile 
times so that the corresponding time within the whole exercise test for each percentile was found. The 
corresponding row for that time point within the excel sheet was then identified for each of the 5 percentiles. 
OUES25-75 was then calculated as the slope of data between rows a and d, OUES50 was calculated as the slope 
of data between onset of incremental exercise and row b, OUES70 between onset of incremental exercise and 
row c and OUES90 between onset of incremental exercise and row e.  
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The next slope to be calculated was the oxygen uptake-work rate slope (        slope).  
 
   rises linearly with 
work, and the slope of this relationship approximates 10 mL/min O2/Watt in healthy subjects (Wasserman et al 
1975, Hansen et al 1984). It was calculated as the slope of the line of best fit (using least squares regression) in 
Excel when      in mL/min (y-axis) is plotted against work rate in watts (x-axis). I arbitrarily chose to measure 
the slope including data from 10W upwards. Work rates below 10W were not subjectively distinguishable from 
unloaded cycling when subjects were asked (Chapter 5 goes into this in more detail), and so data prior to this 
time point was ignored. The effect of the delay from the onset of incremental exercise to the start of measuring 
the slope (termed the physiologic time constant) has been previously examined (Hansen et al 1987) with the 
recommendation that the slope is not measured until at least 35 seconds of incremental exercise has passed. My 
choice of 10W was loosely based upon this recommendation. 
Finally we calculated the heart rate – oxygen uptake slope (       slope) as the slope of the line of best fit (by 
least squares regression) in Excel when heart rate in bpm (y-axis) is plotted against      in mL/min (x-axis) using 
data from incremental exercise only. The y intercept for this line of best fit was also recorded.  
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2.3.2 Echocardiography 
Each study subject for the Observational and Interventional studies underwent transthoracic echocardiography. 
This was for the purpose of identifying severity of left ventricular dysfunction or mitral regurgitation in the 
cardiac groups, and ensuring there was no undiagnosed structural cardiac disease in the respiratory group. 
For each patient the IE33 imaging system was used (Philips, Amsterdam, The Netherlands). A S5-1 probe, with 
a 1-5 MHz extended operating frequency range, was used for all cases, and all echocardiographic studies were 
conducted by me in keeping with the British Society of Echocardiography guidelines (Chambers et al 2010). A 
three lead ECG (corresponding to leads I, II and III) was attached to each patient. Main gain settings were 
optimised for endocardial border delineation. Each subject underwent the same echocardiographic study, 
however echocardiography is highly dependent on subject characteristics and not every view and measurement 
was possible in every patient. Principal measurements (highlighted later) were performed in triplicate and a 
mean of these 3 values recorded. 
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2.3.2.1 Views 
Standard echocardiographic views were attempted in every patient. These are shown below: 
Parasternal long axis (PLAX) – Probe placed on the 
left sternal edge pointing towards the right 
shoulder. The left ventricular dimensions can be 
measured here.  
 
 
Right ventricular outflow –Probe is tilted superiorly 
to see the pulmonary valve and pulmonary artery. 
 
Tricuspid inflow view –Probe tilted inferiorly to 
view the tricuspid valve, right atrium and right 
ventricle. Tricuspid regurgitation can be measured 
here. 
 
 
Parasternal short axis (PSAX) – From PLAX the 
probe is rotated 90º, then tilted to different levels. 
 
 
Apical 4 Chamber (A4C) – Probe is placed where the 
cardiac apex is located, pointing superiorly. Both 
ventricles and atria can be seen in this view. 
 
 
Apical long-axis (A2C) – Probe is rotated 
approximately 60º anticlockwise from A4C to see the 
left ventricle and atrium in another plane. 
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Other views included:
Apical 5 Chamber (A5C) – Probe is tilted anteriorly from A4C to open up the left ventricular outflow tract (the 
so-called 5
th
 chamber). 
Apical 3 Chamber (A3C) – Probe is rotated approximately a further 30º anticlockwise from A2C to see the 
ventricle in a further plane. 
Subcostal 4 Chamber view – Probe is placed on the abdomen looking superiorly to the heart. Intra-atrial septum 
visualised well in this view. 
Subcostal IVC view – The probe is rotated to view the IVC as it passes through the liver to the right atrium. 
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2.3.2.2 Two-Dimensional measurements 
Left ventricular dimensions – In the PLAX view the septum, internal diameter of the left ventricle and the 
posterior wall were measured at the level of the mitral valve tips in both diastole and systole (i.e. at the maximal 
and minimal sizes for internal diameter). Fractional shortening was then calculated as the difference between 
internal diameter in systole and diastole divided by the diameter in diastole. 
Left ventricular volumes and areas – In the A4C and A2C views the endocardium was traced at the end of 
diastole and maximal systole to measure volume and area (Figure 2.12). A technique called Simpson’s biplane 
method calculated volumes based on the assumption of small disks stacked. 
Left atrial dimensions – The left atrial diameter was measured in the PLAX view at the beginning of diastole. 
Left atrial area was measured in the A4C view along with left atrial length, also at the beginning of diastole, to 
calculate left atrial volume. 
Right ventricular dimensions – In the A4C view the right ventricular dimensions were measured at the level of 
the tricuspid annulus, at the level of the papillary muscles and the length from apex to tricuspid at the end of 
diastole.  
Right atrial dimensions – Right atrial area was measured at the beginning of diastole in the A4C view along with 
atrial length, to allow for the calculation of right atrial volume. 
Left ventricular outflow dimensions – 3 measurements were made at the beginning of systole; the left 
ventricular outflow tract (LVOT) diameter, aortic valve annulus diameter and the sinus of Valsalva diameter. 
These measurements were all made in the PLAX view with zoom focused on the left ventricular outflow region. 
TAPSE – The tricuspid annular plane systolic excursion is a simple measure of right ventricular systolic 
function. In the A4C view a single one-dimensional view down through the right ventricle and the lateral 
tricuspid annulus is imaged against time. This is termed M-mode echocardiography, and was one of the original 
modalities. The movement towards or away from the transducer for points along a single line can be measured. 
When correctly aligned the annulus of the tricuspid valve can be seen to move towards the transducer in systole. 
The distance moved relates to systolic function, with values over 1.6 cm considered normal. 
Inferior vena cava (IVC) – This is imaged in the subcostal view. The IVC was viewed throughout at least 1 full 
respiratory cycle for assessment of inspiratory collapse. The diameter of the IVC was measured at its maximum 
and minimum, corresponding to expiration and inspiration. 
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Figure 2.12: Measurement of ventricular volumes using the Simpson’s method. The endomyocardial border is traced around at end-diastole (left) and end-systole (right). 
Using a model based on a series of stacked disks the volume within the cavity is calculated. Because the left ventricle is not symmetrical (i.e. the same width in all planes) it 
is recommended that this process is also performed in a plane perpendicular to this one, such as the A2C view. This Simpson’s biplane method will combine these two views 
to calculate the end-diastolic and end-systolic volumes, and from them an ejection fraction. 
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2.3.2.3 Standard Doppler measurements 
Doppler echocardiography uses the Doppler principle to identify blood flow, and the direction and velocities of 
this within the heart. The Doppler effect describes how the wavelength or frequency of a wave is altered when 
there is relative motion between the source/receiver of the wave (these are the same for echocardiography), and 
the wave reflector (red blood cells). The change in frequency (or wavelength) is termed the Doppler shift and 
relates to blood flow velocity in the following way, termed the Doppler equation:  
 
    
        
 
 
 
Measuring the velocities of blood is important as it allows us to calculate the difference in pressure between two 
locations within the heart. Through the Simplified Bernoulli equation pressure difference between two locations 
relates to the velocity of blood passing between them in the following way: Δ Pressure = 4 x (Velocity)2 
Doppler derived measurements included: 
Transmitral filling pattern – Blood typically fills the left ventricle during diastole from the left atrium in 2 
movements, an initial passive filling denoted as the E wave, and atrial contraction denoted as the A wave. A 
sample volume is placed at the tips of the mitral leaflets in the A4C and pulsed wave Doppler displays the 
Doppler signals coming from this area of interest to measure the E and A waves. The time taken for the E wave 
to return to the baseline, the deceleration time, was also recorded (Figure 2.13). 
Aortic valve flow – Continuous wave Doppler of the LVOT is sampled in the A4C view. Unlike Pulsed wave 
Doppler, Continuous wave Doppler samples all points along a line allowing for identification of maximum 
velocity, but without identifying where that maximal velocity has originated from (range ambiguity). This 
generates an aortic flow pattern. Maximal and mean velocities (and therefore pressure gradients) can be 
measured. By tracing around the signal a velocity-time integral is measured. This is the distance that blood 
passes in one cycle, and when multiplied by the cross-sectional area of the structure, a volume of blood passing 
that point per cycle is calculated. A similar flow profile is measured using Pulsed wave Doppler with the sample 
volume placed in the left ventricular outflow tract (LVOT), proximal to the aortic valve. The two profiles along 
with the LVOT diameter measured in the PLAX view allow for calculation of the aortic valve area. 
Where Δf = change of frequency; ft = transducer 
frequency; V = velocity of blood flow (unknown),     
Ɵ = incident angle between the beam and direction of 
blood flow; and c = velocity of sound in soft tissue 
(assumed to be 1540 m/s). 
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Figure 2.13: Transmitral filling pattern. Following optimisation of the signal to ensure a clean spectral trace, the pattern of two distinct waves can be seen, both moving 
towards the subject’s cardiac apex (transducer position in the A4C view). The E wave occurs following systole. The A wave occurs shortly before the following systolic 
phase. The peak velocities of both waves are measured and displayed on the image. The line of descent of the E wave is drawn to the baseline to measure the deceleration 
time. 
88 
 
Pulmonary valve flow – Pulsed wave Doppler of the right ventricular outflow tract (similar to the LVOT Pulsed 
wave Doppler) is viewed in the PSAX or the right ventricular outflow tract view of the PLAX view. The VTI 
can be measured, and specific to this profile, the time from onset to peak velocity is measured. This is termed 
the Pulmonary Acceleration Time and values <100 ms have been shown to identify patients with elevated 
pulmonary pressures. 
Mitral and Tricuspid regurgitation – Small, physiological quantities of regurgitation through these 2 valves is 
not uncommon. A continuous wave Doppler signal can be identified which measures the pressure difference 
between the ventricle and the atrium in systole. If atrial pressure is known this allows calculation of the 
ventricular pressure. This is principally used to calculated pulmonary pressure (working with the assumption 
that right ventricular systolic pressure equals pulmonary systolic pressure is the absence of pulmonary stenosis 
which is a very rare condition). IVC vessel calibre and respiratory variation predicts right atrial pressure, so 
together with tricuspid regurgitation velocity, pulmonary artery systolic pressure can be accurately estimated. 
 
2.3.2.4 Tissue Doppler measurements (TDI) 
In the same way that Doppler can measure blood velocities, it can also measure the velocity of tissue. Filters are 
introduced to exclude high velocities seen with blood so that only the lower velocity tissue is seen. Using pulsed 
wave Doppler, we can see movement of the myocardium throughout the cardiac cycle, however it is highly 
dependent on the quality of the echocardiographic view of the region of interest. The TDI measurements 
typically obtained are: e’, a’, s’ waves at the lateral and septal walls – These 3 waves are measured with the 
sample volume of the Pulsed wave Doppler placed on the lateral and septal aspects of the mitral annulus in the 
A4C view. The e’ and a’ waves correspond to the timings seen with the transmitral filling pattern, and are 
directed away from the transducer. The s’ wave corresponds to systolic motion, and is towards the transducer 
(Figure 2.14). 
Right ventricular S’ – Similarly to the left ventricle, the sample volume is placed over the lateral tricuspid 
annulus to view movement of the right ventricle. Only the S’ wave is of significant interest when interrogating 
the right ventricle, it represents systolic function of the RV and is towards the transducer. 
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Figure 2.14: Tissue Doppler imaging of the septal wall at the mitral annulus. The e’(*), a’(‡) and s’(†) 
waves can be seen throughout the cardiac cycle and correspond to early passive diastolic filling, late diastolic 
filling from atrial contraction and systolic contraction respectively. 
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2.3.2.5 Specific measurements for mitral regurgitation 
Traditionally the determination of MR severity has largely been a qualitative exercise, where the operator views 
the size and turbulent nature of a regurgitant jet, the strength of the regurgitant signal relative to the forward 
signal, and the impact on the LV and LA. More recently semi-quantitative and quantitative methods for severity 
determination have become popular, including jet area: left atrial area ratio, vena contracta width, and the 
proximal isovelocity surface area (PISA) technique. For jet area measurements the atria and the regurgitant jet at 
its maximum are traced to give two corresponding area measurements. The vena contracta is the narrowest 
diameter of the regurgitant jet as it passes through the mitral valve.  
In contrast to these simple measurements the Proximal Isovelocity Surface Area (PISA) method, first described 
for MR over 20 years ago (Recusani et al 1991), is a complex calculation requiring multiple measurements. 
How PISA calculates mitral regurgitant volumes, fractions and the regurgitant orifice area is well described 
elsewhere (Simpson et al 1995) and uses the principles of the continuity equation and conservation of mass. 
Flow has been noted to accelerate towards a regurgitant orifice, a so-called convergence zone, and has the 
appearance of a hemisphere. The diameter of this hemisphere and the velocity of blood at its outer limits (which 
is the velocity at which the echocardiogram cannot distinguish direction of flow – the aliasing velocity - and is 
clearly shown on the display) allows for calculation of the flow rate (Figure 2.15). The flow rate through the 
regurgitant orifice must be the same (conservation of mass), thus generating the formula: 
 
                      
 
 
 
If the VTI of the regurgitant jet is also calculated then regurgitant volume can be calculated: 
                 
 
Finally if the LVOT VTI and diameter were measured then the regurgitant fraction (proportion of blood ejected 
from the left ventricle that goes “backwards”) can be calculated: 
Where RV = regurgitant volume, and VTIRJ = VTI of 
the regurgitant jet. 
Where 2πr2 = surface area of the hemispheric shell,    
r = diameter of this shell; VN = velocity at the radius 
of the shell, the aliasing velocity; EROA = effective 
regurgitant orifice area (unknown) and Vmax = 
maximal velocity of regurgitant blood through the 
mitral valve measured by Continuous wave Doppler. 
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Severity of mitral regurgitation as assessed by these mechanisms was graded as per the British Society of 
Echocardiography guidelines. 
 
 
 
Figure 2.15: The calculation of mitral regurgitation severity via the PISA method. The baseline of the 
colour Doppler scale is moved in the direction of the regurgitant jet. The resultant low velocity (seen circled on 
the right) allows aliasing of the colour jet proximal to the valve (on the ventricular side as seen here in the A4C 
view). A hemisphere is seen where there is a clear distinct edge of colour aliasing (yellow into blue). The 
distance from the valve tips to the edge of this hemisphere is measured (upper circle). Along with knowledge of 
the mitral regurgitant VTI and LV forward stroke volume (calculated using the LVOT VTI and diameter) 
regurgitant volume, fraction and effective regurgitant orifice area can all be calculated. 
 
  
Where SVLVOT = stroke volume through the LVOT 
and is calculated using the VTI and diameter. 
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2.3.2.6 Specific measurements for mitral stenosis 
2 measurements, proven to correlate to orifice area in mitral stenosis were measured. The VTI of the transmitral 
flow in the A4C view was measured using continuous wave Doppler (similar to the measurement of the E and A 
waves). This gives a mean pressure gradient, which increases with worsening stenosis. The pressure half time 
(PHT) of the slope of the E wave of this Doppler also accurately estimates mitral valve area via the following 
equation: mitral valve area = 220/ PHT. 
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2.3.3 Pulmonary function tests 
Full lung function testing was performed on the Spiro Air (Medisoft, Sorinnes, Belgium), and included 
spirometry, diffusion and full lung subdivisions. These tests were all performed by an experienced and trained 
respiratory physiologist at St Mary’s Hospital Chest and Allergy Clinic. Following machine calibration 3 groups 
of tests were performed on each patient: Spirometry, full lung subdivisions and diffusion capacity. 
 
2.3.3.1 Calibration 
At the beginning of every day, and after every change of pneumotachograph, calibration was performed on the 
equipment. Similarly to the CPX machine and software, flow is calibrated using a 3L syringe. Secondly the 
carbon monoxide-helium analyser performs an automatic calibration, measuring a known concentration of both 
these gases found in a standardised cylinder, and then using as a second reference gas, air (where the 
concentration of both these gases will be zero). 
 
2.3.3.2 Spirometry  
Flow is measured using a pneumotachograph, and volume measured by true volume displacement. This 
measures a pressure difference across a multitude of small bore tubes which act to control resistance and direct 
flow in a laminar manner, so that the resulting pressure difference can be used to calculate flow (and therefore 
volume) using the Hagen-Poiseuille formula: 
   
      
      
 
The variables recorded during spirometry include the Forced Expiratory Volume in 1 second (FEV1), Forced 
Vital Capacity (FVC), the ratio of these two variables (FEV1:FVC ratio), the Peak Expiratory Flow rate (PEFR), 
and the Maximum Expiratory Flow when 50% of the FVC has been exhaled (MEF50). 
 
2.3.3.3 Full lung subdivisions  
The closed circuit helium (He) dilution method (with CO2 absorption and O2 compensation) is used to measure 
subdivisions. Following a short period of stable tidal volume breathing, the subject is connected via the 
spirometer through the closed circuit which contains a known concentration and volume of helium. This reaches 
Where P = pressure drop, r = radius of the tube,     
η = viscosity, and l = length of the tube. 
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equilibrium within the lungs (and does not cross the alveolar membranes) and settles at a new concentration 
allowing calculation of the lung volumes by the following equation: 
    
      
  
     
 
Initially the subject continues to breathe to their tidal volume and the concentration can be measured at the point 
of a normal expiration (functional residual capacity, FRC). Maximal inspiratory and expiratory efforts then 
allow calculation of total lung capacity (TLC) and residual volume. The full breakdown of lung volumes is 
shown in Figure 2.16. 
 
2.3.3.4 Diffusion capacity 
The diffusion capacity or transfer factor of the lung for carbon monoxide (DLCO or TLCO) is a measure of how 
well oxygen passes from the alveoli into the blood. DLCO and alveolar volume (VA) were measured using the 
single breath helium trace gas method. The subject is attached to a bag collection system and after stable tidal 
breathing occurs, they are told to take a maximal slow expiration. At this point the test gas is introduced and the 
subject takes a rapid inhalation to reach, as near as possible, TLC, at which point they hold their breath for 10 
seconds. The gaseous mixture is Helium (14%), carbon monoxide (0.28%), oxygen (21%), and the remainder 
nitrogen. The 10 second pause allows for the carbon monoxide (but not the helium which is termed the tracer 
gas and is used to measure VA) to move from the alveoli into the blood. On exhaling, the first 500mL of gas is 
discarded (the washout volume) as this constitutes gas that was present in the airways, and was not in contact 
with the blood. The following volume of gas is termed the sample volume and from this the DLCO is measured. 
 Following measurement of the DLCO it is corrected in 2 ways: firstly for haemoglobin, which was measured on 
every patient using a capillary blood sample and the HemoCue Hb 201+ analyzer (HemoCue, Dronfield, UK). 
Secondly, as it is determined by the surface area of the alveolar membranes (VA) it is corrected for this to give 
the transfer coefficient (KCO) (KCO = DLCO/VA).  
Each patient underwent full lung function testing as described above on recruitment to the study. For patients 
undergoing mitral valve surgery, the tests were repeated at reassessment following the surgery, to identify any 
changes that may have been caused by the process of surgery. Alternatively the reduction in pulmonary artery 
pressures following correction of a regurgitant mitral valve may actually improved lung mechanics.   
Where SD = subdivision, C1 = Initial He 
concentration, C2 = Final He concentration, 
and V1 = volume of gas in the spirometer. 
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Figure 2.16: The subdivisions of the lung. Most of these subdivisions can be measured using simple spirometry, however RV, FRC and TLC require more advanced tests, 
such as the helium dilution method. 
 
 
96 
 
2.3.4 Venous blood sampling 
Each patient underwent sampling of their venous blood on recruitment to the study, and also on the second visit 
for patients after mitral valve surgery and CRT insertion. I performed all the venous blood sampling for the 
study. 
Following application of a tourniquet to the upper left arm, a visible/palpable vein, typically in the antecubital 
fossa, was cleaned with a sterile alcohol swab. Then using an aseptic technique a sterile needle attached to a 
Vacutainer holder (BD Medical, Franklin Lakes, New Jersey, USA) was passed into the chosen vein. 3 vials of 
blood were then sequentially introduced into the Vacutainer and 2-5mL of blood was used to fill each. The vials 
collected were: 
 2x Lavender top – EDTA coated tubes to prevent blood clotting, used for whole blood haematology 
determinations including haemoglobin concentration, white cell concentration and platelet concentration. The 
second EDTA tube was used to measure B-type natriuretic peptide (BNP). BNP is an amino acid secreted by the 
heart in response to chamber stretch, and regulates body salt and water composition. It is a sensitive marker of 
heart failure, being elevated in patients with decompensation, and to a lesser extent in patients with stable heart 
failure with a moderate inverse relationship to echocardiographic indices of ventricular dysfunction (Cowie et al 
2002, Atisha et al 2004). 
1x Gold top – Clot activator and gel for serum separation, used for biochemistry determinations. The specific 
biochemical recordings made included: creatinine, urea, sodium, potassium, bicarbonate, bilirubin, albumin, 
alanine transaminase and alkaline phosphatase. 
Most of these blood tests have normal ranges that do not differ with patient demographics, but for creatinine, 
age, gender and race can influence the normal values. Estimated glomerular filtration rate (eGFR) can be 
calculated using creatinine and these 3 variables via the Modification of Diet in Renal Disease (MDRD) 
formula, which I performed in each patient. 
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3.0 Retrospective Pilot analysis – the differential 
influence of spirometry on CPX variables 
  
98 
 
3.1 Abstract 
 
Heart failure and ventilatory disease often coexist and both cause abnormalities in cardiopulmonary exercise test 
variables. I analysed the relative reliance of peak     , the  
 
   at the anaerobic threshold (AT), the  
 
         
slope and the Oxygen Uptake Efficiency Slope (OUES), upon measures of abnormal respiratory function. 
The data of 168 patients (median age 65, IQR 22-87) with clinical heart failure who underwent treadmill CPX 
testing with spirometry and echocardiography were retrospectively analysed. 43 patients had heart failure with 
preserved ejection fraction. 
 Median peak     was 16.8 mL/min/kg (IQR 12.0-21.1),  
 
   at the AT 11.1 (6.9-14.0),  
 
       slope 44.0 (36.4-
55.7), OUES 1.38 L/min/10-fold increase in     (0.97-1.83), and FEV1 1.78 L (1.43-2.30).  
FEV1 was significantly related to peak      (3.2 mL/min/kg difference between above- and below-median 
percentage of predicted FEV1), with a weak relationship to     at the AT. FEV1 was not related to the  
 
        
slope or OUES. When patients were separated into normal, obstructive, restrictive or mixed patterns of 
spirometry peak      was the only CPX variable to significantly differ between groups. 
Although it is the pre-eminent variable for cardiac dysfunction on CPX testing, peak     is very sensitive to 
abnormalities in spirometry, and is highly dependent on FEV1. In contrast          slope and OUES do not show 
any relation to FEV1. It is possible that the accepted greater prognostic power of          slope and OUES, over 
peak     , may be in part due to a greater specificity for the impact of cardiac- rather than ventilatory- 
dysfunction on exercise capacity. This pilot data shows proof of concept that various CPX variables appear to be 
differentially affected by respiratory disease. 
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3.2 Introduction 
Cardiopulmonary exercise testing (CPX) is an excellent test for distinguishing cardiac from respiratory 
limitation, but in a patient with both aetiologies of disease it can be difficult to evaluate the relative 
contributions from both the cardiovascular and respiratory systems. Both cardiovascular and respiratory diseases 
are common, and commonly coexist (Mascarenhas et al 2008). Abnormal exercise physiology is a central 
feature of chronic heart failure (CHF) perhaps more so than with respiratory disease, but in both groups 
quantifying exercise capacity is a vital step in risk stratification and estimation of prognosis; CPX is the gold 
standard investigation to assess exercise capacity. 
Within a population with CHF many CPX variables have shown the ability to accurately predict prognosis 
(Mancini et al 1991, Cohn et al 1993, Chua et al 1997, Robbins et al 1999, Francis et al 2000, Gitt et al 2002, 
Davies et al 2006), but peak oxygen consumption (peak     ) remains the measure of exercise physiology most 
widely accepted despite newer measures of the abnormal physiological response to exercise appearing to have 
greater prognostic power (Chua et al 1997, Robbins et al 1999, Francis et al 2000, Gitt et al 2002, Davies et al 
2006).  
It is unclear why certain variables perform more strongly than others, but peak     can be limited by its 
dependence on maximal effort. Peak     is calculated using data from the last portion of exercise; the assessment 
of cardiovascular function in CHF patients by peak      may be confounded if a secondary ventilatory restriction 
becomes the major limiter as peak     is approached, i.e. the peak  
 
  in this instance does not reflect the impact 
to exercise capacity from their cardiac limitation.  
Variables that have shown increased prognostic power over peak     include the  
 
       relationship (Chua et al 
1997, Robbins et al 1999, Gitt et al 2002), the oxygen uptake efficiency slope (OUES) (Davies et al 2006) and 
the anaerobic threshold (Gitt et al 2002). A strength of these 3 variables is their greater independence from the 
degree of effort when compared to peak     . In principle they may also be more independent of abnormal 
respiratory function, since respiratory limitation typically leads to an early peak in      but not necessarily with 
an abnormality in physiology in the lead up to this point. 
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In this retrospective pilot study I examine how abnormal respiratory function impacts on certain CPX variables 
in a group of patients with CHF. If ventilatory abnormalities differentially relate to various variables on CPX 
testing then this may explain the differences in prognostic power, and gives further evidence for the validity of 
the thesis concept that a CPX variable exists which is specific for cardiac dysfunction. 
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3.3 Methods 
3.3.1 Subjects 
All patients undergoing CPX with spirometry and echocardiography as part of outpatient assessment for CHF at 
St Mary’s Hospital, between July 2003 and June 2007, had their raw data analysed retrospectively. The patients 
had been referred to the heart failure clinic based on an appropriate history of exercise intolerance or peripheral 
or pulmonary oedema and it was not necessary to have a reduced left ventricular ejection fraction to be 
diagnosed with clinical heart failure. CPX was performed for assessment of functional capacity. 
Echocardiography was performed on all patients at St Mary’s Hospital. Patients with abnormal spirometry were 
not excluded.  
 
3.3.2 Cardiopulmonary exercise testing 
Patients underwent exercise testing on a motorised treadmill in an air-conditioned room after familiarisation 
with the equipment. Spirometry and gas analysis was performed using the Medical Graphics CardioCP2 which 
was calibrated before each test (Medical Graphics UK Limited, Gloucester, UK). Percentage predicted values 
for forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were calculated by the 
spirometer. Breathing reserve (BR) was calculated retrospectively using the formula BR=100 x (MVV-
   )/MVV (%), where MVV was maximal voluntary ventilation, calculated as 40 x FEV1 and     was the minute 
ventilation at peak exercise. They exercised to symptom-limited exhaustion using a smoothed modified Bruce 
protocol
 
(Scott et al 2001). Peak exercise oxygen consumption was measured in mL/min/kg (except when 
graphically presented alongside OUES where absolute values in L/min are shown) and defined as the highest 30 
second average during the last 60 seconds of exercise, and          slope and oxygen uptake efficiency slope 
were measured across the full duration of exercise.     at the AT was calculated using the V-Slope method. 
 
3.3.3 Echocardiographic assessment of left ventricular function 
All patients had undergone a routine transthoracic echocardiogram using conventional 2-dimensional grey scale 
and Doppler techniques. Patients were imaged using a S5-1, 3.5 MHz transducer (Model 7500, Philips Medical 
Systems, Andover, Massachusetts, USA). Where possible systolic function assessment was performed using the 
Simpson’s modified ellipsoid method to compute the end-diastolic and end-systolic volumes in both apical 4-
chamber and 2-chamber orthogonal imaging planes. In some patients the Simpson’s method was not possible to 
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measure left ventricular systolic function; in these instances fractional shortening as measured in the parasternal 
long axis was used.  
 
3.3.4 Statistical analysis 
Statistical analysis was performed using Stata version 11.1 for Windows (StataCorp LP, College Station, 
Texas). Patient demographics and CPX variables were assessed for normality using the Shapiro-Wilk test. If an 
individual variable was found to be non-normally distributed, a logarithmic transformation of the data was 
performed and used if it then displayed a normal distribution. If this logarithmic transformation did not render 
the data normally distributed, the original data was used and non-parametric tests employed where possible. 
To assess for the relationship between different CPX variables pairwise correlation coefficients were calculated. 
Groups were compared using ANOVA for parametric data and Wilcoxon rank test and Kruskal-Wallis test for 
non-parametric data. The Kruskal-Wallis test is a non-parametric equivalent to one-way analysis of variance; it 
is like the Mann-Whitney test where the number of groups ≥ 3, however it is still appropriate when there are 
only 2 groups. Linear regression was used when a continuous variable was assessed for its impact on another 
continuous variable.  
A p value of < 0.05 was considered statistically significant throughout. 
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3.4 Results 
3.4.1 Patient characteristics 
From 481 patients undergoing CPX during the period between July 2003 and June 2007, 168 patients had 
undergone echocardiography with ejection fraction estimation, and cardiopulmonary exercise testing with FEV1, 
FVC, peak     ,  
 
       slope, OUES and  
 
  at the AT measurements. No patient was limited by ischaemia. 
These 168 patients make up the study cohort. 
Age, weight (but not height), body mass index (BMI) and body surface area (BSA) were not normally 
distributed but the data was not rendered normal by logarithmic transformation. The median age of the study 
group was 65 years (range 22-87). 126 (75%) were male.   
The mean height was 169.8 ± 9.0 cm. Median weight was 76.9 kg (range 46-183.3), BSA was 1.89 m
2
 (range 
1.46-2.98) and BMI was 27.3 kg/m
2
 (range 16.9-49.7). 
Mean ejection fraction (EF) was measured in 101 patients and was 38.5 ± 15.8%. In the remaining 67 patients 
the fractional shortening (FS) was 21.9 ± 9.2%. 74.4 % of patients had systolic impairment as defined by an EF 
< 55% or, in the absence of a measureable EF, an FS < 25%. Therefore 25.6% of patients had heart failure with 
preserved ejection fraction. The aetiology of heart failure was IHD in 49.4% (44 patients had undergone 
previous coronary artery bypass surgery), dilated cardiomyopathy in 33.9%, valvular disease in 7.1%, 
hypertension in 5.4%, and other/unknown in 4.2%. NYHA status was Class I in 23%, Class II in 50%, Class III 
in 20% and not documented in 6%.  
25.6% of patients had a low FEV1:FVC ratio suggestive of obstructive airways disease. However because I 
wasn’t specifying the type of respiratory disease, FEV1 was chosen as the discriminating variable of lung 
function, as it will be reduced in both obstructive and restrictive disorders. 59.5% of patients had a reduced 
FEV1 as defined by < 70% of predicted values. 50 patients had low saturations (SaO2 < 95%) either at rest or 
during exercise, of which 26 had a fall of at least 5%. Echocardiographic, CPX and spirometry measures are 
shown in Table 3.1. Echocardiographic variables were normally distributed so are displayed as mean ± SD. CPX 
and spirometry measures were not normally distributed so are shown as median, interquartile range. In 2 
patients an AT was not determined. 
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Variable Mean/ Median ± SD/ 25
th
-75
th
 
percentiles 
Left ventricular diastolic dimension (mm) 54.4 ± 9.3 
Left ventricular systolic dimension (mm) 43.4 ± 11.1 
Resting ejection fraction (%) 38.5 ± 15.8 
Heart rate (bpm) Resting  79 63-88 
Peak 136 115-156 
Systolic BP (mmHg) Resting 120 110-140 
Peak 150 130-180 
Diastolic BP (mmHg) 
 
Resting 80 70-80 
Peak 80 70-80 
RER Resting 0.76 0.69-0.83 
Peak 0.98 0.86-1.06 
Peak      (mL/min/kg) 16.8 12-21.1 
Percentage predicted peak      (%) 60.8 45.5-74.4 
         slope 44 36.4-55.7 
    at the AT (mL/min/kg) 11.1 6.9-14 
OUES (L/min/10-fold ventilation increase) 1.38 0.97-1.83 
FVC (L) 2.36 1.85-2.96 
Percentage Predicted FVC (%) 65.1 51.9-75.8 
FEV1 (L) 1.78 1.43-2.30 
Percentage Predicted FEV1 (%) 65.8 50.4-79.6 
Quotient FEV1/FVC (%) 81.0 69.0-88.4 
Breathing Reserve (%) 22.0 7.5-39.6 
 
Table 3.1: Baseline characteristics. Echocardiographic, spirometric and cardiopulmonary exercise test 
variables in 168 patients with chronic heart failure. Results are presented as mean ± SD, or median (IQR). 
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3.4.2 Relationship between exercise variables 
Peak     ,  
 
       slope, OUES,  
 
  at the AT and BR were all assessed by pairwise correlation. These variables 
all correlated with one another, with the exception of peak      and BR, and  
 
       slope and BR. The 
correlation coefficients (r) for four of these pairs are shown in Figure 3.1. 
 
3.4.3 Effect of ventilatory measures on CPX variables 
The influence of FEV1 as a continuous variable, when divided into 2 groups based on the median value, and the 
pattern of respiratory disease (none, obstructive spirometry, restrictive spirometry and mixed spirometry) on 
peak     , OUES,  
 
       slope and the  
 
  at the AT were all assessed. On linear regression the percentage of 
predicted FEV1 is related to peak     (R
2
=0.11, p<0.001) and to a lesser extent the     at the AT (R
2
=0.04, 
p<0.01), but not to the          slope (R
2
=0.02, p=0.07) or the OUES (R
2
=0.02, p=0.09). 
The study population was then divided at the median value of the percentage of predicted FEV1 (65.8%) into 2 
groups. Peak      differed significantly between the groups (Kruskal-Wallis; χ
2
=9.3, p=0.002) with a median 
peak      of 14.5 mL/min/kg in the group with lower FEV1, and a median of 17.7 mL/min/kg with the higher 
FEV1, an 18% reduction in the former group.     at the AT (Kruskal-Wallis; χ
2
=3.2, p=0.07),          slope 
(Kruskal-Wallis; χ2=0.39, p=0.53) and OUES (Kruskal-Wallis; χ2=1.58, p=0.21) were not significantly different 
between the patients with the lowest and highest predicted FEV1 (Figure 3.2).  
Finally the group was divided into four groups: The first group “normal spirometry” included patients with 
percentage of predicted FVC > 70% and FEV1:FVC ratio > 70% (n=43); the second group, “obstructive”, had a 
ratio < 70%, and percentage of predicted FVC > 70% (n=19); the third group, “restrictive”, had a ratio > 70% 
and percentage of predicted FVC < 70% (n=82); and the final group,  “mixed”, had a ratio < 70% and 
percentage of predicted FVC < 70% (n=24). Peak      differed significantly between the groups (Kruskal-
Wallis; χ2=11.3, p=0.01).     at the AT (Kruskal-Wallis; χ
2
=3.1, p=0.37),          slope (Kruskal-Wallis; 
χ2=1.28, p=0.74) and OUES (Kruskal-Wallis; χ2=1.97, p=0.58) were not significantly different between the four 
groups. The median peak     was 18.3, 17.6, 15.9 and 12.8 mL/min/kg in the 4 groups respectively (Figure 3.3). 
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Figure 3.1: Correlation between the 4 CPX variables; peak      (L/min), OUES (L/min/10-fold increase in 
ventilation),          slope, and  
 
  at the AT (L/min). The correlation coefficient for each pair is shown on 
each plot. 
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3.4.4 Impact of ventilatory measures on CPX variables in patients not limited by lungs 
A breathing reserve of ≥ 30% is typically believed to indicate a test that is not limited by the lungs. 67 patients 
had a BR ≥ 30% and within this group the percentage of predicted FEV1 remained related to peak      (R
2
=0.15, 
p=0.001) and to the     at the AT (R
2
=0.10, p=0.01), but not to the          slope (R
2
=0.03, p=0.19) or the 
OUES (R
2
=0.06, p=0.05). 
 
3.4.5 Effect of ejection fraction on CPX variables 
Similarly to the analyses with percentage of predicted FEV1, the study population was divided into 2 groups 
based on left ventricular systolic function in 2 ways. Firstly I divided into normal ejection fraction (heart failure 
with preserved ejection fraction (HF-PEF)) and abnormal (heart failure with reduced ejection fraction (HF-
REF)) with a cut-off for normality of ≥ 55%. Where an ejection fraction was not directly measured it was 
calculated using Teichholz formula from the internal dimensions in the parasternal long axis view. 125 patients 
had a reduced EF and 43 a preserved EF. There were no significant differences in peak      (Kruskal-Wallis; 
χ2=1.9, p=0.66),     at the AT (Kruskal-Wallis; χ
2
=0.63, p=0.43),          slope (Kruskal-Wallis; χ
2
=2.6, 
p=0.11) or OUES (Kruskal-Wallis; χ2=0.03, p=0.87) between these 2 groups. 
Secondly I divided into 2 groups by median EF (42.5%). There were no significant differences in peak      
(Kruskal-Wallis; χ2=3.2, p=0.07),     at the AT (Kruskal-Wallis; χ
2
=1.9, p=0.17) or OUES (Kruskal-Wallis; 
χ2=2.1, p=0.15) between these 2 groups (Figure 3.2). However          slope showed a borderline significant 
difference, with higher values in the group with the lower EF (Kruskal-Wallis; χ2=4.2, p=0.04). 
To assess if EF as a marker of heart failure severity was confounded in this analysis by the presence of patients 
with HF-PEF, the relation between EF and the 4 CPX variables was assessed only in patients with a reduced EF. 
On linear regression ejection fraction is not related to any of the 4 variables (peak      (R
2
=0.02, p=0.14);     at 
the AT (R
2
=0.02, p=0.11);          slope (R
2
=0.00, p=0.88); OUES (R
2
=0.01, p=0.41)).
 
  
108 
 
 
 
 
Figure 3.2: Box and whisker plot of the impact of FEV1 (divided into 2 groups by median percent 
predicted (65.8%)) and ejection fraction (divided into 2 groups by median (42.5%)) on the four CPX 
variables. The whiskers represent the lowest data point within 1.5 IQR of the 25
th
 and 75
th
 percentiles. Kruskal-
Wallis statistic and p values are shown for each comparison. 
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Figure 3.3: Box and whisker plot of the impact of spirometric abnormalities on the four CPX variables 
when patients are divided into normal, obstructive, restrictive or mixed pattern. The whiskers represent the 
lowest data point within 1.5 IQR of the 25
th
 and 75
th
 percentiles. Kruskal-Wallis statistic and p values are shown 
for each comparison. See text for definitions of the four groups. 
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3.5 Discussion 
In this pilot study, to help establish a proof of concept for the thesis, I took a retrospective cohort of patients 
with a diagnosis of heart failure (independent of echocardiographic evidence of a low ejection fraction) and 
assessed the impact of spirometric abnormalities on 4 commonly reported CPX variables; peak     , the  
 
        
slope, the     at the anaerobic threshold and the OUES. Peak  
 
  , and to a lesser extent  
 
  at the AT, related to 
respiratory abnormalities as measured by spirometry, whereas          slope and OUES did not. None of the 
variables related closely to ejection fraction. 
 
3.5.1 The relation of CPX variables to one another 
It is an important concept and central to the hypothesis of the thesis, that CPX variables behave differently from 
one another and are not just different ways of portraying the same information. If they all closely predicted one 
another it is unlikely any single variable could outperform the rest when assessing for either prognostic purposes 
or disease discrimination. Within this pilot cohort OUES and peak      were the most closely correlated (r=0.77) 
suggesting that the value of either could be reasonably predicted from the value of the other one. The           
slope was the least closely correlated to the other 3 variables. The OUES is known to correlate closely to peak 
     in healthy adults with correlation coefficients ≥ 0.79 (Baba et al 1996, Hollenberg et al 2000, Pichon et al 
2002, Van Laethem et al 2009, Williamson et al 2012), and in heart failure with correlation coefficients ≥ 0.80 
(Van Laethem et al 2005, Davies et al 2006, Straburzyńska-Migaj et al 2010). In patients with heart failure the 
correlation of OUES to the anaerobic threshold and          slope are not as close as with peak  
 
   (Davies et al 
2006, Straburzyńska-Migaj et al 2010). Within one study of healthy individuals the AT showed a closer 
correlation to peak      than OUES (Van Laethem et al 2005). Our results are similar to those seen in these 
studies, peak     , AT and OUES are reasonably well correlated; with  
 
       slope to a lesser extent. It is 
important that these variables relate to one another, but also important that they do not relate too closely. As 
shown by Pichon et al 2002, the OUES cannot be reliably used to predict peak      from submaximal data 
despite a close correlation. Whilst this might be seen as a limitation to using OUES in an athletic cohort (where 
arguably only peak     / 
 
   max, and to a lesser extent AT, are relevant) it may well be a strength in clinical 
medicine. The presence of a correlation with peak      suggests that the magnitude of the variable may be 
important and relates to disease severity, whilst the lack of a perfect correlation shows that there may be extra 
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information regarding the physiological response to exercise shown by the AT,          slope and OUES beyond 
what we can gain from the peak     . May this extra information relate to the heart or lungs, or another organ? 
 
3.5.2 The impact of spirometric abnormalities on CPX 
Within our pilot study, however respiratory abnormalities were identified, peak     was significantly affected. It 
showed a relatively strong relation (R
2
=0.11) to percentage of predicted FEV1, was significantly lower in 
patients with the lowest percentage of predicted FEV1 when divided into 2 groups, and significantly affected by 
the grouping  into normal spirometry and obstructive, restrictive and mixed patterns. In contrast the           
slope and OUES were not affected by spirometric abnormalities, and the AT was weakly related (R
2
=0.04) to 
percentage of predicted FEV1 but not when the patients were separated according to their FEV1 or into disease 
patterns. This differential effect of respiratory physiology on CPX variables may explain some of the 
heterogeneity between them regarding their correlation to one another, to their prognostic power and potentially 
to their discriminatory power. But do these results mean that peak      is more sensitive to respiratory disease? 
Spirometric abnormalities are very common in patients with CHF (Hosenpud et al 1990, Naum et al 1992, 
Dimopoulou et al 1998, Hughes et al 1999, Daganou et al 1999), especially an isolated restrictive defect which 
was seen in almost half of the patients in this study. Abnormal spirometry within this cohort may be a sign of 
more significant heart failure, and therefore the lower peak     seen when patients are separated according to 
their FEV1 relates to their more severe heart failure, and is therefore actually more significantly correlated to 
cardiac function than     at the AT,  
 
       slope or OUES. However the relation between peak  
 
  and 
spirometry in patients who do not appear to be limited by their lungs is evidence against this hypothesis. A cut-
off of 30% for the breathing reserve has typically been used to identify patients who are limited by their lungs 
versus another organ. Whilst heart failure patients have abnormalities within their lungs that impair both 
maximal voluntary ventilation and ventilatory efficiency, the cardiac limitation still generally halts exercise with 
a significant breathing reserve remaining. Therefore we can say that for heart failure patients with or without a 
respiratory limitation to exercise (as evidenced by a BR cut-off of 30%) there remains a strongly significant 
relationship between peak      and percentage of predicted FEV1. Peak  
 
  , in contrast to  
 
  at the AT, OUES 
and          slope, is affected by the added presence of respiratory abnormalities to CHF. 
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3.5.3 The impact of ejection fraction on CPX variables 
It has long been established that resting markers of cardiac dysfunction such as ejection fraction relate poorly to 
exercise capacity (Szlachcic et al 1985, Cohn et al 1993). My data agrees with these previous studies; peak     , 
OUES and     at the AT do not relate and  
 
       slope shows a borderline significance between 2 groups when 
separated by median EF. There are also no significant differences in the 4 variables between patients with 
clinical heart failure and preserved ejection fraction, and those with reduced ejection fraction. When excluding 
patients with preserved ejection fraction, and analysing EF as a continuous variable, there remains no 
relationship between EF and any of the 4 variables. 
 
3.5.4 Clinical implications of these results 
In a general population, often with a combination of respiratory and cardiac disease, it is, from a multitude of 
CPX variables, typically peak      that is used to make clinical decisions. However our interpretation of peak 
     is based upon information extrapolated from studies with very different populations. The patients in the 
studies which support peak      as the principal prognostic variable have typically been a highly selected group 
referred to specialist centres for evaluation of severe CHF and assessment for potential heart transplantation. 
These patients were invariably young, with a mean age of 50 years in the landmark paper on the role of 
measuring peak      in heart transplant candidates (Mancini et al 1991). The patients were less likely to have 
coexisting respiratory disease because of these younger ages and because there was a higher prevalence of 
idiopathic dilated cardiomyopathy (DCM) than that seen typically in clinical practice. Patients with an 
ischaemic cause of CHF are much more likely to have non-desirable risk factors, such as smoking, that would 
increase the prevalence of coexistent lung disease in this group. In young patients with idiopathic DCM, peak 
     is an accurate measure of functional capacity and prognosis. However, does this apply to a more typical 
hospital heart failure population, with the greater likelihood of co-morbidities? 
Generally prognosis is significantly worse in patients with cardiovascular disease than respiratory disease at 
similar levels of functional impairment, as discussed in Chapter 1. The addition of mild to moderate COPD does 
not alter prognosis in CHF (Mascarenhas et al 2008), yet it should depress exercise capacity. Any CPX variable 
influenced by both heart and lung disease may have its ability to predict prognosis attenuated by its sensitivity to 
respiratory abnormalities. In our mixed population with cardiac and respiratory abnormalities peak      was 
significantly affected by FEV1. 
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Therefore I suggest that peak      is not an ideal variable when assessing a general population with heart failure. 
Its sensitivity to respiratory abnormalities means that its ability to detect changes in exercise capacity relating 
specifically to cardiac limitation, and in determining the impact of cardiac disease on prognosis is only strong 
for selected patients with normal respiratory function; an uncommon finding. 
Other variables may better reflect cardiac physiology in all patients, because they are relatively unaffected by 
respiratory disease. 
 
3.5.5 Implications for the thesis 
The aim of this pilot data was to show a proof of concept for the thesis. Peak      is known to be reduced in 
respiratory and cardiac disease, and so it is unlikely that it can be used to specifically follow changes in cardiac 
over respiratory function. This pilot data confirms the strong association between respiratory abnormalities and 
peak      and shows that other variables do not display this association. Therefore the hypothesis that an ideal 
variable on CPX exists, that can distinguish cardiac from respiratory limitation and track changes in cardiac 
function, seems valid. The prospective study aims to confirm the results seen here and extend them to identify if 
a variable does exist that is minimally influenced by respiratory physiology and strongly influenced by cardiac 
physiology. 
 
3.5.6 Limitations 
This pilot data collection is purely retrospective; prospective data collection is needed to confirm the findings. 
Because I was not involved in the exercise tests or echocardiography I cannot vouch for the validity of the 
original datasets. Certain results suggest that spirometry may have been poorly performed in some patients, with 
extremely low breathing reserves noted. 27 patients had negative breathing reserves with 16 having values under 
minus 10%. In these cases the MVV must therefore be spuriously low, due to an under-representative FEV1 on 
spirometry. The direct measure of MVV (patient voluntarily ventilates at their maximum for 12 seconds) is not 
routinely performed in clinical medicine and is quite uncomfortable; the indirect method (FEV1 x 40) is 
therefore generally preferred, although this can be susceptible to error through poor spirometric technique. It is 
likely however that my outliers do not affect the results too significantly. It is known that poorly measured 
independent variables will reduce the power of statistical relationships between them and the dependent 
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variable; therefore the relationship with peak      will probably be even stronger in a cohort with highly 
reproducible spirometry through more accurate testing, than the already statistically significant values I show 
here. 
All patients were referred for cardiopulmonary exercise testing and an echocardiogram based on functional 
limitation and clinical CHF, but not all patients show echocardiographic evidence of left ventricular systolic 
dysfunction, as measured by ejection fraction. The majority of these patients will have heart failure with 
preserved ejection fraction. The diagnosis of heart failure has been made by an experienced cardiologist, but it is 
possible that a small proportion of these patients will not in fact have cardiac disease. I have used ejection 
fraction as the measure of cardiac function, although it is recognised, and I accept, that EF is not the best 
measure of severity of cardiac failure. However EF is easily measurable, widely recognised, and in general it is 
accepted that a lower EF identifies patients with more impairment in their systolic function. Within this 
retrospective cohort EF was readily available. There is also a suggestion that many patients in this analysis did 
not perform maximal tests. The low peak RER (median 0.98, IQR 0.86-1.06) from these patients, lower than 
values seen in patients in previous CHF studies, is likely to be explained by the cohort, i.e. real world patients 
with multiple co-morbidities. The values seen in this analysis lie somewhere between pure CHF (RER= 1.1 in a 
study by Davies et al 2006) and pure COPD (RER= 0.82 in a study by O’Donnell et al 1992). In reality 
submaximal tests are common and should not invalidate the results of the test or this analysis. 
Finally it must be remembered that all these tests were treadmill exercise. Although this isn’t a limitation to this 
analysis, the prospective study will investigate bicycle ergometer testing and potential differences in results 
between these 2 forms of exercise may be possible. 
 
3.5.7 Conclusions 
Peak     , OUES, the  
 
       slope and  
 
  at the AT were all differentially influenced by respiratory function, 
as identified by spirometric findings, prior to CPX testing in a typical out-patient CHF population. Peak      
related closely to FEV1 and was significantly different between groups when patients are categorised by pattern 
of respiratory disease. Even in patients unlimited by their respiratory function (as defined by a normal BR ≥ 
30%) peak      was still related to FEV1. In contrast OUES and  
 
       slope, and on most analyses  
 
  at the 
AT, were not related to FEV1 or disease grouping. Although these 4 variables correlate reasonably closely to 
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one another it is possible that the lack of complete agreement between them is, in some part, due to the 
differential effect of cardiac and respiratory pathophysiology on each variable. 
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4.0 Study of Health in Pomerania - Physiology of 
oxygen uptake kinetics 
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4.1 Abstract 
 
Cardiopulmonary exercise testing (CPX) allows for assessment of cardiac and respiratory limitation, but is often 
affected by patient effort. Indices of oxygen kinetics, including the Oxygen Uptake Efficiency Slope (OUES), 
oxygen uptake to work rate slope (        slope) and the heart rate to oxygen uptake slope (    
 
   slope) 
are relatively independent of effort but it is unknown how much they are affected by patient characteristics. 
They may be more resistant to confounding from respiratory abnormalities than traditional variables identified 
at peak exercise. 
1708 volunteers from the population-based Study of Health in Pomerania (SHIP) underwent an incremental 
bicycle exercise protocol. In each, markers of oxygen kinetics were calculated throughout exercise only (rest 
and recovery excluded). Participants with structural heart disease, echocardiographic or lung function pathology 
were excluded. The final study sample consisted of 577 males and 625 females. Age, height, weight, smoking, 
and beta-blockers were analysed for their influencing power in each sex. Reference equations for each variable 
were determined by quantile regression analysis.  
Age, gender, height, weight, FEV1 (but not percent predicted FEV1) and other variables of lung function 
strongly related to OUES and OUES/kg (although height related to OUES/kg much less strongly than to 
OUES). Smoking was weakly related to OUES in males only.         slope was minimally affected by age, 
gender, weight and FEV1. Gender, height, weight and beta-blocker use, and smoking status, were related to the  
        slope whilst age was only related in females and spirometry in males. 
Markers of oxygen kinetics are differentially affected by age, gender, height, weight, lung function, beta-blocker 
use and smoking status. This allows the generation of unique reference equations for these variables, which aid 
physicians when exercise effort may be submaximal. 
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4.2 Introduction 
Understanding why CPX variables change, and to varying degrees in each variable, both between and within 
patients is difficult. Humans are complex organisms and whilst we have excellent mechanisms designed to 
maintain homeostasis there are still marked differences between any two heart beats or two breaths. Largely 
through the identification of reference equations for the principal CPX variables previous researchers have 
identified factors that contribute to the between-patient variation. Within this chapter I will aim to expand this 
understanding, to look at factors influencing some of the lesser described CPX variables; those involved in 
oxygen kinetics. In Chapter 5 I will then look closely at factors contributing to the within-patient variation of 
many variables. 
Variables of oxygen kinetics differ from peak      in that they assess the change in  
 
   in relation to different 
denominators throughout exercise, rather than focus only on a specific portion, for example peak exercise. 
Variables measured at peak exercise ignore all the potential data gathered during the minutes preceding this, 
which may be extremely valuable. It is believed that variables of oxygen kinetics relate to cardiovascular 
function, the delivery and utilisation of oxygen for which an adequately functioning heart and circulatory system 
is key. Early examples of these variables included tau, otherwise called the time constant, which described, 
through an exponential function, the time taken for      to plateau after the beginning of exercise. However this 
required a constant work rate exercise test and these are largely no longer performed, certainly not in clinical 
medicine where incremental tests are now standard. A potential estimation of tau, measurable on an incremental 
test is possible using the oxygen uptake to work rate (       ) relationship. This is the slope describing the 
generally linear relationship between oxygen uptake and work rate in Watts. Even with an initial unloaded 
period, there is still a time lag before      starts to rise following the start of the incremental exercise portion, 
and this appears to correlate to tau. However it is the gradient of this slope that has become the principal 
measure described from this relationship. The         slope appears to show a certain degree of specificity 
for cardiovascular dysfunction, and varies little between healthy adults, regardless of age, height and weight 
(Hansen et al 1987).  
If, instead of work rate, we plot the change in       against minute ventilation ( 
 
 ) we find an exponential 
relationship. In 1996 it was first shown that logarithmic transformation of     describes a linear relationship; the 
oxygen uptake efficiency slope (OUES) was created (Baba et al 1996). The slope of this relationship is largely 
unchanged when data is shortened in patients with heart failure (Van Laethem et al 2005), it appears to be 
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highly predictive of prognosis in heart failure (Davies et al 2006) and may, like the         slope, signal 
some specificity for cardiac dysfunction. 
Finally we can view the change in      against heart rate. At peak exercise the instantaneous relationship of these 
two variables is commonly described as the O2 pulse. As peak      can be considered a surrogate for cardiac 
output so too can the O2 pulse be considered a surrogate for stroke volume. But peak exercise variables fail to 
appreciate how they have evolved during the test, and are highly reliant on patients performing until truly 
symptom limited. When plotting heart rate (y axis) against      (x axis) the relationship rises roughly linearly. 
The regression line of this relationship will be steeper (greater change in heart rate relative to     ) in conditions 
where stroke volume or oxygen extraction are limited, for example valvular regurgitation or peripheral 
myopathy (Flaherty et al 2001) and shallower (lesser change in heart rate relative to     ) in conditions where 
heart rate is constrained, for example conducting system disease leading to chronotropic incompetence or the 
use of beta-blockers. 
All 3 of these variables have the potential to give us more information than we currently extract when we limit 
our focus on the final few seconds before test termination. They may be crucial in patients unable to exercise to 
a cardiorespiratory maxima because of an alternative limiting condition, for example an orthopaedic complaint. 
Despite the potential benefits of routinely reporting these variables they are largely under-researched compared 
with other CPX variables such as peak     , the  
 
        slope, the O2 pulse and the anaerobic threshold. 
Before variables can be used for diagnosis and management decisions in patients, it is vital to understand how 
they behave in health, and to identify factors that may confound a variable. Large scale population cohort 
studies give us an excellent way to identify how variables behave in health and typically, because recruitment is 
randomised, results are less susceptible to bias. 
The Study of Health in Pomerania (SHIP) is a large population cohort study of healthy volunteers and recently 
published results on the influence of factors such as age, gender, body size, smoking and beta-blockade on some 
of the more commonly used CPX variables such as peak     (Gläser et al 2010). It generated contemporary 
predictive equations for a European population, and, unlike many previous studies, also provided the normal 
distribution of data across a wide age range and genders so that limits of health and normality could be 
appreciated.  
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Collaboration between my department and the authors of SHIP has allowed me a unique opportunity to 
investigate the oxygen kinetics of over one thousand largely healthy volunteers from a typical European 
population. My aim within this Chapter is to identify the impact of factors, such as age, gender, body size, 
respiratory function, smoking and beta-blockade, on these variables of oxygen kinetics - OUES, the         
slope and the        - as well as generate predictive equations, both a measure of the average and range of 
normality. A further aim of this study is to investigate the reproducibility of OUES and the         slope 
following cropping of data prior to exercise termination, to mimic foreshortened exercise, and therefore to 
assess the statement that they are more robust measures than peak variables. 
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4.3 Methods 
4.3.1 Study population 
The Study of Health in Pomerania (SHIP) is a large cross-sectional, population-based survey in a region in the 
north-east of Germany. It recruited volunteers as study participants. The overall design and objectives of SHIP 
are well described (John et al 2001, Völzke et al 2010). Following reunification, it was noted that residents of 
former East Germany had worse health outcomes than those from former West Germany; this study was 
initiated to help explain these differences.  
212 157 inhabitants were living in the region at the time of the study start date, a random selection of these 
residents were identified from the population registration offices (this captures all German inhabitants). A two-
stage cluster sampling method was adopted from the World Health Organization (WHO) Monitoring 
Cardiovascular Disease Project in Augsburg, Germany. A representative sample, comprising 7 008 adults aged 
20–79 yrs with 292 persons of each sex in each of the twelve 5-yr age strata, was identified. Following removal 
of migrated or deceased people the net sample consisted of 6 267 eligible subjects. 4 310 individuals 
participated in the baseline study of SHIP (SHIP-0), with data collection between October 1997 and March 
2001. A 5-yr follow-up examination was performed (SHIP-1) between March 2003 until July 2006, which then 
comprised 3 300 subjects aged 25–85 yrs (the remainder had migrated, were deceased or were non-responding). 
Of those, 1708 individuals (834 males and 874 females) volunteered for a standardised progressive cycle 
incremental exercise test.  
The study was funded by the Community Medicine Net of the University of Greifswald. The study conformed 
to the principles of the Declaration of Helsinki as reflected by an a priori approval of the Ethics Committee of 
the University of Greifswald (Greifswald, Germany) and all participants gave written informed consent. 
Aside from CPX a number of other investigations and questionnaires were performed on participants at either of 
these time points or a third time point - SHIP-2 (between 2008-12). My analysis is limited to socio-demographic 
information and CPX results. 
 
4.3.2 Pre-exercise diagnostics and exclusion criteria 
Socio-demographic and behavioural characteristics, smoking status, and medical histories, were assessed using 
computer assisted interviews, administered by trained and certified staff. The previous history of diseases was 
based on self-reported physician’s diagnosis. The definition of cardiopulmonary disorders was based on self-
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reported physician’s diagnosis, use of specific medication, electro- or echocardiographical pathological findings, 
and lung function abnormalities measured by spirometry and body plethysmography. Normal lung function was 
defined according to the recommendations of the European Coal and Steel Community (Quanjer et al 1993).  
Information regarding participants underlying cardiopulmonary disorders was not released to me; however a list 
of participants felt to have an underlying contributory cause to exercise intolerance was supplied (without 
specific causes). 
External observers regularly participated in certification procedures to facilitate comparability between SHIP 
and other population-based studies. Data collection was monitored by a Data Safety and Monitoring Committee 
(Greifswald). 
Height and weight were measured for the calculation of the body mass index (BMI; body weight in kg divided 
by square of height in metres). Full lung function tests were performed at rest using a body plethysmograph 
equipped with a pneumotachograph (VIASYS Healthcare, Jaeger, Hoechberg, Germany). A minimum of three 
lung function manoeuvres were performed to obtain at least two acceptable readings. 
 
4.3.3 Exercise testing 
CPX variables were analysed breath-by-breath using a VIASYS Healthcare system (Oxycon Pro, Rudolph’s 
mask, JAEGER/VIASYS Healthcare system; Hoechberg, Germany). Prior to each test, the equipment was 
calibrated in standard fashion with reference gas and volume calibration. A single symptom-limited exercise test 
was performed using the same ergometer model as used for my Observational and Interventional studies 
(Ergoselect 100; Ergoline, Bitz, Germany). The protocol, which differed from the one described in my methods 
section and was not individualised, was modified from Jones et al with a stepwise increase in work load of 16 
W/min, following unloaded cycling (Jones et al 1985). Each test was preceded by a resting period of ≥ 3 min to 
reach steady-state conditions. The test was continuously monitored by a physician. All tests were continued as 
symptom-limited (volitional exertion, dyspnoea or fatigue) unless the participant developed chest pain or ECG 
abnormalities. Participants were encouraged to reach maximal exhaustion prior to starting; during exercise no 
further motivation was given. A standard 12-lead ECG was obtained at rest, at every minute during exercise, 
and for ≥ 5 min during recovery; blood pressure was measured with a standard cuff sphygmomanometer. 
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Measures of     (L/min), tidal volume (VT; in litres),      and  
 
    (both mL/min) were acquired on a breath-by-
breath basis and averaged over 10-second intervals. 
 
4.3.4 CPX data analysis 
Peak     ,  
 
   at the AT, O2 pulse,  
 
        slope and ratios at rest and at the AT, and end-tidal CO2 measures 
were all previously calculated by the SHIP authors. 
Participant data (10 second averages) was made available to me for post-hoc calculations of further variables. 
These calculations included OUES,         slope and     
 
   slope, which were conducted using Matlab 
(Mathworks, Natick, Mass, USA) using only data points during exercise (unless otherwise described). OUES is 
defined as the slope of the regression line when      (mL/min) (y-axis) is plotted against log10 minute ventilation 
(x-axis). Similarly the         slope is defined as the slope of the regression line when  
 
   (mL/min) (y-axis) 
is plotted against work load (Watts) (x-axis). Finally the         slope is defined as the slope of the regression 
line when heart rate (bpm) (y-axis) is plotted against      (mL/min) (x-axis).  
 
4.3.5 Test foreshortening 
OUES and the         slope were further analysed so that a number of pre-specified data ranges within 
exercise were used to assess for the within-test reproducibility of these variables and their susceptibility to 
foreshortened exercise. Participants were grouped by their final workload achieved and the OUES for different 
data ranges compared by pairwise correlation within each group. Different ranges of foreshortened exercise 
were therefore not compared against different groups of participants which would affect the results (for 
example, the OUES calculated using data between 20-68W was compared against the OUES calculated from 
20-196W, but only in participants achieving exactly 196W - if all participants were used then the larger numbers 
in the 20-68W cohort would include more exercise-limited people with typically lower OUES values). For the  
        slope the average  
 
   at each workload was calculated and the slope calculated using this data from 
the start of exercise up until various points (52W, 100W, 148W, 196W and 244W) for 3 groups of participants 
based on their final workloads (100-116W, 148-164W, 196-212W and 244-276W) to view how foreshortening 
of data affects the slope. 
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4.3.6 Statistical analysis 
Age, height, weight and BMI and lung function variables were assessed as continuous variables using regression 
analysis. The cohort was further divided into 5 age ranges; 25-34, 35-44, 45-54, 55-64, > 64 years and into 2 
BMI groups with the cut-off at 25 kg/m
2
 for graphical and tabular representation of the data only. Furthermore 
because the impact of age on CPX variables may not behave linearly at the extremes, polynomial regression was 
used to visually assess this. ANOVA was used for categorical potential confounders such as gender, smoking 
and beta-blocker use. To construct median, 5th and 95th percentile predictive equations, quantile regression was 
used. Quantile regression uses data within prespecified quantiles to draw regression lines. Its strength is that 
outliers do not influence the results; in this respect it is similar to linear regression in the way that the median is 
similar to the mean. Based on the results of the regression analysis for each variable individually, age, gender, 
height and weight, beta-blocker use and smoking status (graded as current or non-smoker – former smokers are 
graded with non-smokers) and FEV1 could be included as co-variates in the model (in a similar manner to the 
complementary reference ranges published for peak     , anaerobic threshold and O2 pulse). Each variable is 
only added to the regression equation for each variable individually if it showed a significant contribution in the 
simple univariate analyses. OUES and OUES/kg were interrogated with the same model.  
Furthermore, for OUES, the current predictive equations, once identified, were compared to those previously 
published (Hollenberg et al 2000, Sun et al 2012) using the median participant within 3 height, age and BMI 
brackets for males and females. 
A p value of <0.05 is considered significant throughout. 
 
.  
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4.4 Results 
4.4.1 Baseline characteristics 
Following exclusions (prior to my involvement with the data) there remained a population of 1203 participants. 
These participants were not deemed to have a cardiopulmonary condition likely to limit exercise. They could be 
considered “healthy adults”, although exclusion did not mandate the absence of every chronic disease; the 
phrase “general population” is probably more appropriate. Hypertension, for example, was not a reason for 
exclusion. From these 1203 a single participant did not have raw data of sufficient quality to perform 
calculations of OUES,         slope and     
 
   slope. This left a final study population of 1202. 
625 of these participants were female, 577 male. Within males the age range was 25-84 years, and within 
females 25-80 years. Median height was 170 cm (range 145-197 cm) and weight was 76 kg (range 42-150 kg). 
Table 4.1 shows demographic data by age and gender. 
159 males and 160 females were current smokers. 39 males and 54 females were taking regular beta-blockers.  
 
4.4.2 Influence of demographics on CPX 
Gender was a significant determinant of OUES (by ANOVA, R
2
=0.38, p<0.0001), OUES/kg (R
2
=0.11, 
p<0.0001), and        slope (R
2
=0.30, p<0.0001), with a significant but weaker interaction with         
slope (R
2
=0.04, p<0.0001). Further determinants were thereafter assessed for males and females separately.  The 
strength of the relationship between each determinant and each variable is shown in Table 4.2. 
In both males and females, age was strongly inversely related to OUES and OUES/kg. The         slope was 
only weakly, though significantly, related to age; in males this is a positive relationship and in females an 
inverse relationship. The        slope was not related to age in males, and had a weak, albeit significant, 
relation to age in females. It can be seen in Figure 4.1 that the relationship of peak      and OUES with age 
remains linear throughout the majority of adult life (approximately 30-70 years of age) but outside of this range 
these variables behave in a less linear fashion. However given the linear portion of these plots is the age range 
where the majority of our patients are drawn from, and that polynomial equations are complex in clinical 
practice to understand and use, linear regression was used for reference range distribution. 
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 Final 1202 participants 
Age 
(years) 
Subjects  
(n) 
BMI  
(kg/m
2
) 
Smokers 
(%) 
Beta-
blockers 
(%) 
Peak      
(mL/min/kg) 
25-34 170     
M 79 25.7 ± 3.2 41.8 0 34.5 ± 6.3 
F 91 24.3 ± 4.8 35.1 1.1 28.1 ± 6.2 
35-44 307     
M 154 26.8 ± 3.5 31.2 1.9 32.2 ± 7.0 
F 153 24.8 ± 4.0 38.6 1.3 26.1 ± 5.0 
45-54 286     
M 129 27.8 ± 3.7 35.9 3.9 28.4 ± 6.4 
F 157 27.2 ± 5.2 25.4 7.0 22.8 ± 4.1 
55-64 257     
M 117 27.6 ± 3.4 19.7 8.5 27.5 ± 5.6 
F 140 27.6 ± 4.6 15.7 11.4 22.0 ± 3.9 
≥ 65 183     
M 99 27.7 ± 4.5 9.1 21.2 23.7 ± 5.4 
F 84 26.9 ± 4.1 8.3 28.6 19.7 ± 3.6 
Total 1202     
M 577 27.2 ± 3.8 27.6 6.8 29.3 ± 7.1 
F 625 26.3 ± 4.8 25.6 8.6 23.8 ± 5.3 
 
Table 4.1: Baseline characteristics of the 1202 participants undergoing CPX testing with 
measurement of oxygen kinetic variables. Participants are grouped by gender and 10-year 
age deciles. For peak      and BMI data are displayed as mean ± SD. 
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Height had a strong, positive relationship to OUES in males and females but, although remaining significant, the 
strength of this relationship was weaker when OUES was corrected for weight. The         slope was not 
significantly related to height. The        slope was weakly, inversely related to height in both males and 
females. Weight was strongly positively related to OUES in males and females, and strongly, but inversely, 
related to OUES/kg, The         slope was weakly related to weight in both genders. The     
 
  slope 
was strongly, inversely related to weight in males and females. Weight, when categorised by BMI, related, by 
ANOVA, to all 4 variables. 
Importantly BMI did not relate as strongly to any of the 4 variables as height and weight as co-variates, and the 
addition of BMI to a simple model of height and weight did not increase the predictive power of the model (i.e. 
no change in R
2
) suggesting that height and weight, but not BMI should be used in the more complex regression 
models. BMI was weakly but significantly related to the        , and strongly inversely related to the 
       slope. 
The impact of gender, age (divided into decades) and body size (divided into 2 groups, 25≤ BMI >25 kg/m2) can 
be viewed in Figures 4.2-4.5. 
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Figure 4.1: The distribution of peak      and OUES with age fit a polynomial distribution. The line represents the median, with 95% confidence 
intervals in grey. Throughout the majority of adult life the relationship between these variables and age is linear. In adults before 30 and after 70 years 
of age, the relationship deviates from this linearity. 
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  OUES  OUES/kg          Slope      
 
  Slope 
Determinant 
 Strength of 
relationship (R
2
) 
p-value 
 Strength of 
relationship (R
2
) 
p-value 
 Strength of 
relationship (R
2
) 
p-value 
 Strength of 
relationship (R
2
) 
p-value 
M 
Age (yrs)  (-) 0.17 <0.001  (-) 0.13 <0.001  (-) 0.02 0.001  0.00 0.66 
Height (cm)  0.18 <0.001  0.01 0.003  0.00 0.77  (-) 0.06 <0.001 
Weight (kg)  0.12 <0.001  (-) 0.09 <0.001  0.01 0.046  (-) 0.23 <0.001 
BMI (kg/ m
2
)  0.02 <0.001  (-) 0.16 <0.001  0.01 0.032  (-) 0.17 <0.001 
F 
Age (yrs)  (-) 0.12 <0.001  (-) 0.18 <0.001  0.02 0.001  (-) 0.02 <0.001 
Height (cm)  0.14 <0.001  0.02 0.001  0.00 0.37  (-) 0.02 <0.001 
Weight (kg)  0.10 <0.001  (-) 0.20 <0.001  0.01 0.015  (-) 0.21 <0.001 
BMI (kg/ m
2
)  0.03 <0.001  (-) 0.27 <0.001  0.01 0.003  (-) 0.17 <0.001 
 
Table 4.2: The influence of age, height, weight and BMI on the four variables of oxygen kinetics in both males and females. The R
2
 value indicates the rough 
contribution of a determinant to the variability of that variable. A p <0.05 indicates statistical significance. The R
2
 value was calculated using linear regression analysis. R
2
 
values with a preceding (-) indicate a significant inverse relationship (i.e. an increase in the magnitude of a continuous determinant causes a reduction in the variable). 
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Figure 4.2: Reference ranges for OUES for males and females with relation to age and subdivided 
according to body mass index (BMI) groups             BMI ≤ 25kg/m2,             BMI > 25kg/m2. Lower lines 
represent the 5
th
 percentiles, centre lines the medians and upper lines the 95
th
 percentiles. 
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Figure 4.3: Reference ranges for OUES/kg for males and females with relation to age and subdivided 
according to body mass index (BMI) groups             BMI ≤ 25kg/m2,             BMI > 25kg/m2. Lower lines 
represent the 5
th
 percentiles, centre lines the medians and upper lines the 95
th
 percentiles. 
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Figure 4.4: Reference ranges for         slope for males and females with relation to age and 
subdivided according to body mass index (BMI) groups             BMI ≤ 25kg/m2,             BMI > 25kg/m2. 
Lower lines represent the 5
th
 percentiles, centre lines the medians and upper lines the 95
th
 percentiles. 
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Figure 4.5: Reference ranges fo        slope for males and females with relation to age and 
subdivided according to body mass index (BMI) groups             BMI ≤ 25kg/m2,             BMI > 25kg/m2. 
Lower lines represent the 5
th
 percentiles, centre lines the medians and upper lines the 95
th
 percentiles. 
 
  
134 
 
4.4.3 Influence of respiratory variables and smoking on CPX 
The separate influence of FEV1, FVC, the FEV1:FVC ratio and KCO on males and females can be seen in Table 
4.3. Whilst a number of the interactions reached statistical significance it can be seen that only a few had a 
reasonable strength of relationship (i.e. R
2
 value). Whilst the         slope was related to most of the 
measures in males and females it can be seen that this relationship was weak for all. The        slope was 
related to FEV1 and FVC, but only in males, and these relationships were very weak. 
OUES and OUES/kg were both related to FEV1 and FVC, but not the ratio of the two. These relationships were 
stronger for OUES than for OUES/kg. Generally a much stronger relationship was also noted in males than 
females. A multivariate regression model including age, height and weight showed that in males both OUES and 
OUES/kg remained related to FEV1, FVC and KCO (p<0.001 for all). However for females neither of the CPX 
variables related to FEV1, FVC or KCO. Because it is difficult to identify the contribution to a regression model 
from one co-variate over another, the percent of predicted FEV1 was also calculated. OUES related significantly 
but weakly in males (R
2
=0.02, p=0.002) and not in females (R
2
=0.00, p=0.19). 
Furthermore the R
2
 values for the variables of oxygen kinetics were compared against the R
2
 values for other 
variables. Peak      had, for both males and females, a higher R2 value for both measures of FEV1 (R
2
=0.34 & 
0.21 respectively), FVC (R
2
=0.34 & 0.21 respectively), and KCO (R
2
=0.21 & 0.06 respectively) than OUES. 
Similarly peak     /kg had higher R
2
 values than OUES/kg. In the same multivariate model used above there 
was a significant relationship between peak      and FEV1 and FVC in both males and females. The  
 
         
slope and      at the AT both were significantly related to FEV1, FVC, and KCO, although the R
2
 values were 
lower than for both peak      and OUES.  
Smoking did not relate to OUES/kg,         or the     
 
  slope, and had a weak inverse relationship with 
OUES in males (R
2
=0.01, p=0.01) and a weak positive relationship with females (R
2
=0.01, p=0.01).  
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  OUES  OUES/kg          Slope      
 
   Slope 
Determinant 
 Strength of 
relationship (R
2
) 
p-value 
 Strength of 
relationship (R
2
) 
p-value 
 Strength of 
relationship (R
2
) 
p-value 
 Strength of 
relationship (R
2
) 
p-value 
M 
FEV1 
 0.22 <0.001  0.12 <0.001  0.03 <0.001  (-) 0.01 0.031 
FVC  0.22 0.002  0.12 <0.001  0.02 0.003  (-) 0.01 0.008 
FEV1:FVC 
 0.01 0.006  0.01 0.054  0.02 0.001  0.00 0.39 
KCO 
 0.16 <0.001  0.07 <0.001  0.05 <0.001  0.01 0.057 
F 
FEV1 
 0.12 <0.001  0.09 <0.001  (-) 0.01 0.003  0.01 0.054 
FVC  0.12 <0.001  0.08 <0.001  (-) 0.01 0.002  0.00 0.16 
FEV1:FVC 
 0.00 0.18  0.00 0.22  0.00 0.73  0.00 0.10 
KCO 
 0.05 <0.001  0.01 0.046  (-) 0.01 0.019  0.00 0.34 
 
Table 4.3: The influence of four respiratory variables on the four variables of oxygen kinetics in both males and females. The R
2
 value indicates the rough contribution 
of a determinant to the variability of that variable. A p <0.05 indicates statistical significance. The R
2
 value was calculated using linear regression analysis. R
2
 values with a 
preceding (-) indicate a significant inverse relationship (i.e. an increase in the magnitude of a continuous determinant causes a reduction in the variable). 
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4.4.4 Influence of beta-blockade on CPX variables 
Age, height and weight were all significantly different between those who did and didn’t take beta-blockers; on 
average regular beta-blocker users were older (mean difference 13.8 years, p<0.001), shorter (mean difference 
3.7cm, p<0.001) and heavier (mean difference 3.9 kg, p=0.01). Therefore the effect of beta-blockade on the 
CPX variables was performed in a multivariate model with these co-variates.  
As shown in Table 4.4, beta-blocker use did not significantly reduce OUES, OUES/kg or the         slope in 
males, although there were borderline significant reductions in OUES and OUES/kg in females. The use of beta-
blockers significantly reduced the        slope in both males and females. 
 
4.4.5 Reference distribution 
Using quantile regression reference distributions for median predicted and prespecified percentiles can be 
calculated. I chose the 5
th
 and 95
th
 percentiles to delineate the upper and lower limits of normality. The effect of 
age, gender, height, weight, beta blocker use, current smoking, and FEV1 on the predictive equations for these 
four variables can be seen in Table 4.5. 
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 Males 
 
Females 
 
 Mean difference 
(95% CI) 
SE P 
 
Mean difference 
(95% CI) 
SE P 
OUES  -127.3 (-346, 92) 111.5 0.25 
 
-128 (-242, -14) 58.3 0.028 
OUES/kg  -1.12 (-3.8, 1.5) 1.34 0.41 
 
-1.71 (-3.4, -0.1) 0.84 0.043 
        Slope  -0.12 (-0.59, 0.36) 0.24 0.63 
 
-0.17 (-0.53, 0.2) 0.19 0.38 
       Slope  -0.004 (-0.008, -0.001) 0.00 0.016 
 
-0.005 (-0.009, -0.001) 0.00 0.024 
 
Table 4.4: Multivariate regression analysis adjusted for age, height and weight in males and females for the effect of 
taking beta-blockers on CPX variables. 
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  Percentile Value Equation 
Variable  Females 
OUES  5
th
 1272.9 -727 -6.98A +11.82H +6.56W -47.65bb-10.65cs +15.29f 
  50
th
 1876.3 -182.4 -8.89A +10.12H +10.51W -117.65bb-21.45cs +40.31f 
  95
th
 2613.6 36.5 -18.47A +15.55H +12.63W -317.24bb-91.98cs +13.47f 
OUES/kg  5
th
 18.22 13.8 -0.14A +0.16H-0.16W -0.19bb-0.64cs-0.34f 
  50
th
 26.65 23.1 -0.16A +0.16H-0.2W -1.77bb-0.13cs-0.06f 
  95
th
 38.62 33.5 -0.23A +0.19H-0.29W -2.11bb-0.4cs +1.3f 
        Slope  5
th
 7.66 7.28 -0.01A +0.02W-0.04f 
  50
th
 9.47 8.82+0.01A +0.01W-0.1f 
  95
th
 11.3 10.61+0.02A +0.01W-0.23f 
       Slope  5
th
 0.0320 0.0897 -0.0001A -0.0002H-0.0004W -0.0021bb +0.0027f 
  50
th
 0.0544 0.1327 -0.0001A -0.0003H-0.0004W -0.0042bb +0.0027f 
  95
th
 0.0796 0.2279 +0.0001A -0.0008H-0.0005W -0.01bb +0.0038f 
 
  Males 
OUES  5
th
 1783.5 54.7 -9.82A +4.42H +11.74W -227bb-169cs +180.72f 
  50
th
 2703.5 907.7 -11.51A +5.67H +8.62W -49.99bb-214.53cs +172.97f 
  95
th
 3951.4 -2380 -13.97A +34.48H +9.54W -251.11bb-523.24cs +-0.47f 
OUES/kg  5
th
 21.82 21.44 -0.13A +0.07H-0.11W -2.4bb-1.88cs +1.6f 
  50
th
 31.43 43.12 -0.14A +0.05H-0.23W -0.57bb-2.68cs +2f 
  95
th
 46.88 18.25 -0.14A +0.34H-0.37W -2.96bb-6.1cs +1.38f 
        Slope  5
th
 8.06 9.31 -0.02A-0.01W +0.17f 
  50
th
 10.06 9.63 -0.01A +0.01W +0.07f 
  95
th
 11.47 9.98 -0.003A +0.01W +0.17f 
       Slope  5
th
 0.0236 0.0686 -0.0001A -0.0001H-0.0002W -0.0016bb +0.0004f 
  50
th
 0.0368 0.0743 -0.0001A -0.0003W -0.0039bb-0.0006f 
  95
th
 0.0548 0.0795 -0.0001A +0.00023H-0.0005W -0.002bb-0.0051f 
 
 Table 4.5: Predictive equations of reference ranges for 5
th
, 50
th
 and 95
th
 percentiles derived from age (A) 
in years, height (H) in cm, weight (W) in kg, and FEV1 (f) in L. Beta blocker intake (bb) is coded as ‘0’ for 
no and ‘1’ for yes. Current smoking (cs) is coded as ‘0’ for no and ‘1’ for yes. The values show the average 
magnitude of each variable at the 3 percentiles. 
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4.4.6 Comparison with previous predictive equations for OUES 
There are no standardised references ranges for        slope or  
 
      slope. However for OUES 
previous reference equations have been published (Hollenberg et al 2000, Sun et al 2012). For 3 heights, 3 BMI 
values and 3 ages the median male and female participants were identified. The age, height, weight and FEV1 
were entered into my predictive equations from Table 4.5 and the predictive equations from these 2 studies. The 
results were plotted as a percentage of the values identified from Table 4.5 (Figure 4.6). Sun et al 2012 can be 
seen to under-predict considerably compared to both other ranges with shorter, older and heavier individuals. 
Hollenberg et al over-predicts in the younger, and then under-predicts in the older participants compared to my 
data. 
 
4.4.7 Impact of foreshortened exercise on OUES  
Alongside the full OUES, calculated using all exercise data, OUES was also calculated from 9 different sub-
maximal ranges. I cropped progressively from the whole exercise duration to shorter durations removing ever 
increasing periods at the end of exercise. Because each participant underwent an identical bicycle protocol 
periods of data cropping were denoted by Watts achieved. The data was cropped sequentially from full exercise, 
from 292W downwards, then 244W, 196W, 148W, 116W, 100W, 84W, 68W, and finally 52W downwards. 
Figure 4.7 shows how this cropping affects the OUES in three groups: those achieving 116W but then stopping; 
those achieving 196W but then stopping; and those achieving 292W but then stopping, as a percentage of OUES 
measured using full data. For comparison the      at these points, as a percentage of peak  
 
  , was also 
calculated and shown in Figure 4.7. Table 4.6 shows the pairwise correlation coefficient for each different crop 
against 7 others. Almost all cropped data correlated to all other crops with the exception of the 20-292W crop. 
This only contained a small number of participants and a value that significantly correlated to the full value was 
obtained so long as a work rate of at least 148 was achieved (144W below maximum).  
140 
 
 
 
 
Figure 4.6: Comparison of my new reference equations with 2 pre-existing reference ranges. Hollenberg et al 2000 is shown with crosses and Sun et al 2012 with 
open circles. 3 different heights (varied between males and females because of the height distribution within these groups), 3 different BMIs and 3 different ages were 
arbitrarily chosen and the median participant within the SHIP population meeting that criterion (i.e. male 190cm) was identified. The predicted OUES for that person was 
calculated using all 3 predictive equations with comparison for Hollenberg et al and Sun et al made against those in Table 4.5. 
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Figure 4.7: The effect of data cropping on OUES and peak     . Participants data was measured from the beginning of exercise until one of nine different work rates 
(dots) with the OUES calculated in the typical way. Both OUES and      are plotted as percentages of the value obtained using the full data for 3 groups of participants based 
on their final work rate. Data foreshortening affects peak      to a greater degree than OUES. In participants achieving the lower peak work rates (116W) foreshortening 
affects OUES less than in those with higher maximum work rates (292W). 
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 20-84 20-100 20-116 20-148 20-196 20-244 20-292 Full 
OUES 
20-100 0.9518* 1       
20-116 0.9128* 0.9821* 1      
20-148 0.7990* 0.8947* 0.9422* 1     
20-196 0.6555* 0.8000* 0.8514* 0.9043* 1    
20-244 0.5804* 0.6409* 0.6754* 0.7705* 0.8454* 1   
20-292 0.3776 0.3749 0.3728 0.5576* 0.8705* 0.9719* 1  
Full OUES 0.7888* 0.8443* 0.8826* 0.8981* 0.9212* 0.9807* 0.9954* 1 
 
Table 4.6: Correlation coefficient values for comparison of each pair of foreshortened OUES readings, 
calculated for all data present for the range stated. For example the value is 0.9518 when comparing OUES 
calculated from data between 20 to 100W, versus OUES calculated using data from 20 to 84W in the same 
participants, i.e. those attaining at least 100W. Full OUES is the OUES calculated for each participant using 
their full exercise data, i.e. no foreshortening. Starred values indicate a statistically significant correlation. 
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4.4.8 Impact of foreshortened exercise on the        slope 
In a similar manner the data was then grouped into four cohorts based on final achieved work rate (100-116W, 
148-164W, 196-212W and 244-276W), and      plotted against work rate for each of these groups based on 
cropping the data at the lower limits of each of these groups. These arbitrary groups roughly corresponded to 
each quartile, but all participants within each quartile were not included because each group needed to contain a 
small range of maximum work rates achieved for consistency. So participants with final work rates between 
these 4 group’s ranges were excluded from this analysis. 
It can be seen that cropping the data from the top causes small decreases in the slope for the 2 groups where 
greater work rates were achieved (Figure 4.8A). However for the 2 lower final work rate groups there was 
actually an increase in the         slope as the data is cropped. Figure 4.8B displays the mean  
 
   at each 
work rate for each of these same four groups. It can be seen that for any given work rate the      is higher in the 
groups achieving higher maximum work rates but the change in      over time remains similar. There does not 
appear to be a clear point of change on any of the four lines away from a linear relationship. 
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Figure 4.8A: Multiple mean         slopes were calculated from all the participants within four groups; those achieving a maximum of 100-116W, those 
achieving 148-164W, those achieving 196-212W and those achieving 244-276W. These slopes were calculated using data from start of exercise to 5 different final cut-off 
points. For example the grey column in the left most set is the         slope calculated from the beginning of exercise to the final second of 52W only in participants 
stopping at between 244-276W.  
Figure 4.8B:      was then plotted against work rate for all participants within these same four groups. It can be seen that the slope does not deviate from linearity and 
is similar between different work rates attained. 
 
A B 
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4.5 Discussion 
As shown in Chapter 3, OUES and           slope are less affected by spirometry in a group of patients with 
heart failure. Here I demonstrate, for OUES and other important cardiopulmonary exercise test variables 
focusing on the kinetics of oxygen uptake, how they are affected by demographic characteristics and lung 
function in a general healthy population as well as generate a set of contemporary predictive equations based on 
quantile regression.  
 
4.5.1 Study of Health in Pomerania 
SHIP is a large ongoing population cohort study, in the North-East of Germany, established to answer some of 
the differences in health equality between areas of Germany. Although the study found higher rates of obesity, 
hypertension and left ventricular hypertrophy than the national rates within Germany (John et al 2001, Völzke et 
al 2010), because Germany typically has better indices of health than the European average (WHO Global 
Infobase 2013),  it could be considered that this population is relatively representative of northern Europe. A 
random sample from over 200 000 inhabitants was drawn, of which almost 2000, aged 25-84, returned at 5 years 
and underwent CPX. A final study population of 1203 was identified, without significant cardiopulmonary 
disease. The participants may not have been fully healthy, in that certain chronic diseases, for example 
hypertension, were not excluded. Hypertension is so common within a general population (especially in older 
life) I felt it was important to retain these participants. Previous publications from these 1203 participants looked 
at the impact of individual characteristics on peak     , O2 pulse,  
 
   at the AT, and the  
 
        slope and ratio 
(Koch et al 2009, Gläser et al 2010). All variables were influenced by age, height, weight and gender. Current 
male smokers showed a significant impact on all variables as well, although in females only the          ratio 
was worse in smokers. Importantly they showed that for peak     ,  
 
   at the AT, and the  
 
        ratio, a strong 
linear trend of worsening values with increasing pack year histories of smoking (Gläser et al 2010). 
I show similar results, with OUES (and OUES/kg) related to height and weight and inversely related to age, as 
has been shown before (Hollenberg et al 2000). The         slope was largely unrelated to any of these 
variables. The         slope was affected by gender, and significantly inversely related to weight. It was 
largely unrelated to age, with a weak inverse relationship to height. Smoking only weakly related to OUES, and 
in different directions in males and females, and did not relate to the other variables. FEV1, FVC and KCO appear 
to relate to OUES and OUES/kg more strongly in males than females. Much of this appears to be due to the 
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dependent impact of age, height and weight on both lung function and OUES. Peak      appears more strongly 
related to spirometric variables than OUES. Finally beta-blockade largely only affected the        slope, 
unsurprisingly in an inverse manner. 
 
4.5.2 Predictive equations 
Predictive equations and values for cardiopulmonary exercise variables are necessary in order to establish 
normality for patients. Previous predictive equations should be revisited as populations change. As CPX 
availability has grown, the number of commonly reported variables has also expanded. In many cases predictive 
values are either based on small cohort studies or on studies where participants recruited may not necessarily be 
representative of the whole population. Also many predictive equations focus largely on a measure of average 
without demonstrating the boundaries of normality. Within a clinical population it is expected that well over 
50% of tested individuals will have values below the mean, therefore a measure of the spread of normality is 
more important than the average. I have used quantile regression because this allows the calculation of the 5th 
and 95th percentiles without any effect from significant outliers beyond these boundaries. This is similar to the 
advantages seen by using the median over the mean as a measure of the average, which I have also used as the 
single “average” measure for each variable. I believe these predictive equations (and the ones for peak      from 
Gläser et al 2010) are highly representative of a general European population, and I will therefore be using them 
throughout the rest of the thesis.  
Another interesting result from this data is the relationship between age and CPX variables. Whilst a linear 
relationship can be fitted to almost any set of data, this does not mean that the relationship is truly linear. 
Polynomial regression will fit linearly if that best describes the data, but otherwise will form as a complex 
function of the 2 axes. We can see in Figure 4.1 that for most of adult life OUES, like peak      , declines 
linearly with age. However this decline becomes less pronounced after about 70 years, and we can also see a 
plateau around 30-35 years of age. This is important when using these predictive equations, as certainly below 
25 years they will be unreliable. I would suggest the possible entry of age 30 into the predictive equations for 
anyone younger than this (to avoid over-predicted misrepresentative reference ranges). 
 I will now look at the results of the interaction between demographic factors on each of the variables in turn, as 
well as this impact on the predictive equations. 
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4.5.3 Oxygen uptake efficiency slope 
It has largely been accepted that OUES is an effort-independent variable (Baba et al 1996); this makes it useful 
for patients undergoing clinical exercise testing who may stop prematurely due to reasons beyond their heart or 
lungs, for example orthopaedic constraints. However, just like peak      ,   
 
    at the AT and  
 
         slope, 
participant characteristics such as age, gender, height and weight significantly influence the result. This means 
that OUES, as an absolute value, has limitations to its use, and should, therefore, wherever possible be corrected 
by predictive equations. What is interesting is the influence of lung function on OUES. Smoking affected OUES 
but with a very weak relationship in males, and in females was associated with an improvement in OUES. 
Spirometry unsurprisingly related strongly to OUES in a general population, because they both are strongly 
related to age, height and weight. When corrected for these factors using predictive equations for FEV1, OUES 
remained related to FEV1 in males but not females, and the strength of this relationship was very weak. OUES 
was less strongly related to all spirometric variables than peak      , which supports the results found in patients 
with heart failure as described in Chapter 3. 
Until recently only a single set of adult predictive equations have been published for OUES (Hollenberg et al 
2000), with 2 significant limitations. Firstly the adults were aged 53 years and above. Secondly, similarly to 
many other published reference equations, average values rather than normal ranges are shown. To generate 
their predictive equations, the effect of age on OUES was extrapolated backwards from 53 years, which may not 
make it reliable for younger patients. The difference between this predictive equation and mine can be seen 
graphically in Figure 4.6 (crosses). I have calculated, for the median person within three age, height and BMI 
groups, the predicted OUES based on both sets of equations. Unsurprisingly Hollenberg’s reference ranges 
appear to over-predict the average value in younger adults. However there are no consistent trends in how height 
and BMI influence the differences between these 2 equations; these two equations show a relative amount of 
agreement. Very recently a further set of predictive equations has been published from the USA (Sun et al 
2012). Using this predictive equation shows startling differences at the extremes of height and age, more 
noticeable in females than males. It is difficult to reconcile these differences, but I feel that the equations from 
Sun et al markedly under-estimate predicted OUES, rather than mine over-estimate. For example for both an 
average female of 150cm height, and an average female aged 70 years (using average age, weight and FEV1 of 
females of 150cm height, and average height, weight and FEV1 of females of 70 years of age from within the 
SHIP’s large population to generate a predicted values) an OUES of only 0.8 L/10-fold increase in     are 
predicted from Sun et al; predicted values disproportionately lower than other groups and males. 
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I have also generated the predictive equation for OUES when adjusted for weight in kilograms. Correction for 
weight is easier than for body surface area (BSA) or BMI; these both require calculations and are less popularly 
performed in busy clinical practice. Correcting for weight allows for comparison with peak        which 
everyone typically describes in a weight adjusted (per kilogram) manner. Higher average values of peak        in 
mL/min are seen in heavier individuals, however when adjusted for weight peak        in mL/min/kg is generally 
lower. The same pattern is seen with OUES (Figures 4.2 and 4.3). By viewing OUES as both absolute and 
weight adjusted values we may be able to reduce the limitations that either value has when used alone.  
Whilst it is believed that OUES is resistant to foreshortened exercise, and so is, therefore, an effort-independent 
variable, I show that foreshortening of exercise by cropping the data at a number of arbitrary points can affect 
results (Figure 4.7). The reliability of OUES despite foreshortening has been shown in numerous studies (Baba 
et al 1999, Hollenberg et al 2000, Van Laethem et al 2005) and whilst my data largely agrees, in the most fit 
individuals (those achieving at least 200W) variation can be seen. Reassuringly when data including at least 
66% of final intensity is included, an OUES value within 10% of the overall is achieved. It is unlikely that a 
participant capable of achieving almost 300W would voluntarily stop prior to 200W for example. In people 
achieving lower final intensities (arguably the group in which foreshortening of data is most likely) the variation 
seen with cropping is even less noticeable. These volunteers will have exercise capacities similar to patients 
with heart failure, which supports the previous data showing no significant effect from submaximal data in heart 
failure patients (Van Laethem et al 2005). My data therefore provides further evidence to the argument that, 
whilst not completely effort-independent, OUES is an excellent variable in its robustness to foreshortened 
exercise. 
 
4.5.4 Oxygen uptake to work rate relationship 
The slope of the linear relationship between work rate (Watts) against       (mL/min) is believed to reflect 
aerobic work efficiency, and oxygen delivery and utilisation at the muscle. It is therefore believed to be 
primarily influenced by cardiac rather than respiratory function. Previous cohort studies identified almost 
identical average values of 10 mL/min/Watt in healthy controls with a standard deviation of 0.7-1.0          
mL/min/Watt (Wasserman et al 1975, Hansen et al 1984, Hansen et al 1987). A reduced slope has been reported 
in patients with heart failure, peripheral vascular disease and myopathies. In contrast, extremely fit cyclists have 
been found to have an increased slope of 11.5 mL/min Watt (Riley et al 1996). However one of these previous 
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studies only examined males, and, as can be seen from Figure 4.5, females appear to have a slightly lower 
median value. In the SHIP cohort age does not appear to affect median values of the slope, however there does 
appear to be a divergence of values in the older age groups. Unsurprisingly BMI doesn’t have much effect on 
the slope; it has long been established that obesity displaces the       -work rate relationship upwards without 
altering the slope (Wasserman et al 1975, Hansen et al 1984, Hansen et al 1987). Despite having generated a 
predictive equation there are conceptual concerns to generating a predicted value for a variable like this. Unlike 
a linear variable, such as peak        and OUES, the  
 
      slope corrected as a percentage of predicted 
would be less meaningful as a value of 5 is not half as good as 10, and 20 is not twice as good. Figure 4.5 would 
be best employed to place a patient’s value on the graph and ensure it lies within the 5th and 50th percentile lines 
to be reassured about normalcy. 
Amongst participants achieving higher final work rates there is a small but clear reduction in the slope as the 
data is cropped from the top (Figure 4.8). In contrast the         relationship in those achieving lower 
intensities did not noticeably differ when cropped. It is conceivable that in stronger, larger individuals a 
minimum work rate exists below which it still requires the same amount of energy to turn the pedals, i.e.        
remains similar from unloaded through to 20-40W, beyond which the normal increment of ~10 mL/min/W takes 
over. This would have the effect of reducing the slope as proportionally more of the data came from this plateau 
section. The reduced slope seen in foreshortened data from fitter individuals does argue against one of the 
explanations given for the low slope in heart failure patients; the proportional increase from anaerobically 
derived energy sources at all time points compared with healthy adults. If this was true we would still expect to 
see this pattern in healthy individuals following the anaerobic threshold, albeit to a lesser degree than heart 
failure patients, and arguably the group we would see this pattern in most would be fit individuals, who are able 
to push themselves further into anaerobic metabolism than sedentary individuals. In fit individuals we see a 
slight increase in the slope as exercise continues, suggesting that, certainly within this group, anaerobic sources 
do not replace, merely supplement, aerobic sources; the delivery of 10 mL/min/W of oxygen continues well into 
high intensity exercise. A confounding factor is that fit individuals are more likely to use accessory muscle 
groups towards peak exercise, which might necessitate an increase in energy requirements per increment of 
work rate. This phenomenon is less likely to occur in sedentary individuals and those with heart failure. 
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4.5.5 Heart rate to oxygen uptake relationship 
There are 3 main factors influencing oxygen uptake; heart rate, stroke volume and oxygen extraction at the 
muscle. The former two factors comprise cardiac output. Many conditions can affect any number of these 
factors so it can be useful for the exercise physiologist to assess the individual interaction between them. 
Typically we use the relationship of       / heart rate, the O2 pulse. Peak muscular oxygen extraction is believed 
to be near equal in all adults under standard conditions, therefore the O2 pulse, which is the product of oxygen 
extraction and stroke volume, can be used as a surrogate for stroke volume. However this has a similar 
limitation to peak     , namely that sub-maximal effort will fail to produce a true reflection of peak exercise 
stroke volume. An alternative is the heart rate –      relationship or slope, where heart rate is plotted on the y 
axis, and        on the x axis, with the slope of the regression line calculated by least squares. A similar variable, 
the heart rate response (HRR) which is equal to (HRpeak – HRrest)/ (    peak –  
 
  rest), has occasionally been 
described in other studies utilising CPX. My measure of the slope of the regression line of HR versus        will 
incorporate all data points, whilst the HRR only utilises the peak and rest instantaneous data. I therefore believe 
it may be more robust (resting values are especially susceptible to error) and may be more easily calculable from 
modern CPX software packages where the measurement of a regression slope requires a single click. I also 
believe there may be multiple clinical utilities of this variable. A healthy adult stopping prematurely through 
non-cardiac limitation will display a normal slope - both maximum heart rate and peak        are similarly 
reduced from predicted maxima - and this makes it, in these cases, a more useful variable than the O2 pulse to 
reassure there is a normal response. In patients with heart failure the slope may either be elevated (when cardiac 
conduction is maintained) or decreased (when there is associated chronotropic incompetence). The latter is more 
commonly seen, especially in the modern era of beta-blockade. In a group of patients with mitochondrial 
myopathies, proven on biopsy, Flaherty et al showed the HRR to be universally above 50, perhaps reflecting an 
increased dependency of oxygen uptake on heart rate to compensate for reduced oxygen extraction at the muscle 
(Flaherty et al 2001). This would reflect a         slope of 0.050.  
Amongst the SHIP population markedly higher median values in the         slope were noted in females 
compared to males, with little variation attributed to age. The slope was reduced in heavier individuals, 
paradoxically suggesting lower heart rates throughout exercise. Height did not strongly affect this slope. 
Unsurprisingly the use of beta-blockers reduced the slope in males and females. Importantly a         slope 
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of 0.05, equivalent to a HRR of 50 which is believed to be helpful in the diagnosis of mitochondrial myopathies, 
would be considered a healthy, normal finding based upon my findings especially in females.  
 
4.5.6 Limitations 
It is widely accepted that exercise testing should employ individualized protocols, so that exercise duration 
ranges from 8-12 minutes (Balady et al 2010). All participants in the SHIP study were assessed using the same 
protocol and it is currently unknown how an exercise test lasting significantly less than 8 or more than 12 
minutes may affect the OUES, the         slope or the     
 
  slope. Simply cropping the data does not 
reproduce the differences from short, medium and long duration tests. 156 participants did not achieve 8 
minutes; 135 participants achieved over 12 minutes. Within Chapter 5 I will look into the effect of test duration 
on CPX variables. However although this could be considered a limitation, for an exercise physiology 
laboratory or research study where individualised protocols are not practical, adherence to a 16W/min protocol 
will still allow these reference equations to be applicable. Whenever possible I believe individualised protocols 
should be performed. 
As described earlier within this section these participants were not entirely representative of an overall German 
population, with greater levels of obesity and hypertension within Pomerania than the rest of Germany. 
Therefore it is possible that they are not reflective of a general European population. However this criticism 
could be levelled at all reference range studies; it isn’t practical for each country or geographical region to 
produce their own predictive equations.  
Participants who don’t deem themselves fit enough would be less likely to volunteer for the exercise study, 
leading to a selection bias. This is likely to be an ever increasing problem as volunteer age increases. However it 
has been shown in a previous publication that the CPX population was largely similar to the general SHIP 
cohort of over 4000 participants with the only differences less hypertensive people and less smokers represented 
in the CPX group (Koch et al 2009). 
I included ex-smokers with non-smokers. It could be argued that they should be included with current smokers, 
however I feel that the main impact on exercise testing from smoking will be a reduction in oxygen carrying 
capacity in the blood due to increased carbon monoxide. This is removed from the blood within 48 hours of 
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smoking, and so would not limit ex-smokers. The long-term detriment of smoking to lung function would be 
captured on the full lung function tests and so would not require consideration. 
Finally prior to my involvement with the data, certain conditions had been selected for which participants from 
the original 1708 were excluded, leaving the remainder which was considered a cohort of healthy adults. It 
could be argued that certain conditions I elected to keep in, smoking, hypertension and obesity, could be 
considered disease states and should not therefore be involved in the identification of reference ranges. However 
these are common patient attributes that we see regularly in clinical practice and so I felt it was important to 
include them. 
 
4.5.7 Conclusions 
CPX variables such as the OUES,         slope and     
 
   slope have not been investigated to the same 
extent as variables such as peak        so questions remain as to how they are influenced in a typical population. 
Within this chapter I have shown how age, height, weight and gender interact to affect these variables and from 
these interactions generate predictive equations for an average value and 5
th
 to 95
th
 percentiles.  
OUES, whilst affected by lung function, compares favourably to peak        in that it is less affected by resting 
spirometry and is more resistant to data-foreshortening.         slope and the     
 
  slope are largely 
unrelated to lung function, although the         slope is related to beta-blocker use. 
  
153 
 
5.0 Reproducibility/ Repeatability 
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5.1 Abstract 
 
Cardiopulmonary exercise testing (CPX) has been shown to have good reproducibility. However the test-retest 
reliability for multiple CPX variables has not been compared in a single study and the influence of different 
diseases and study conditions on test-retest reliability has not been examined. I show different measures of test-
retest reliability for multiple CPX variables and compare them by category of cardiac or respiratory disease. 
Patients from the Observational study underwent two CPX tests as part of the study protocol. Separately eight 
healthy adults underwent four CPX tests, two on an individualised appropriate ramp, one on a very steep ramp 
and one on a shallow ramp. Comparison of between patient/participant intraclass correlation coefficients (ICC) 
and coefficients of variation between the two tests were calculated. Analysis of variance was used to calculate 
the influence of potential confounders on test-retest reliability.  
Variables such as peak      (ICC 0.95; CI 0.94-0.97), OUES (ICC 0.93; 0.90-0.95), O2 pulse (ICC 0.96; 0.94-
0.97) and the          ratio at the nadir (ICC 0.92; 0.89-0.95) all showed excellent test-retest reliability, with 
within-subject coefficients of variation <0.12 in the patient study. Oxygen uptake at the anaerobic threshold 
(ICC 0.84; 0.78-0.89) and the           slope (ICC 0.88; 0.79-0.93) still showed good test-retest reliability, 
although significantly weaker than for peak     . Overall test-retest reliability was similar in the healthy adults. 
A change in ramp protocol affected the reliability of the peak work load and         slope, but did not 
significantly affect the majority of CPX variables. 
CPX shows high test-retest reliability; certain variables such as peak      and OUES outperform others. These 
results identify which variables are most suitable for serial testing of patients with 3 common disease aetiologies 
owing to their superior reproducibility. 
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5.2 Introduction 
Any test for a chronic feature of a patient should, in principle, give the same value every time it is conducted. 
The more alike two results conducted on the same specimen are, the more reproducible they are said to be. The 
correct definition of reproducibility relates to the degree of agreement between measurements or observations 
on the same specimen/ patient in different locations by different people. In clinical medicine and research true 
reproducibility is rarely assessed. Typically the criteria of one or both of different locations and different 
operators are not met; when this occurs it should correctly be termed repeatability, rather than reproducibility. 
However repeatability can be considered an important component of reproducibility. 
There are many factors affecting a test’s reproducibility, broadly broken down into 2 groups; random error, 
which includes within-patient biological and temporal variations and operator/reporter variability: and 
systematic error, which includes phenomena which causes the result to be consistently under or over-estimated 
within a particular individual, in exercise testing examples would be fatigue or familiarisation. This second part 
is sometimes called bias or trueness as it relates to the ability of the test to identify the patient’s true result; any 
consistent deviation is bias. The magnitude of the random error every time a test is conducted cannot be 
predicted but it is possible to understand the likely spread of random error so that the final result can be reported 
with intervals of confidence. Both random and systematic errors are assessed with repeatability studies. For the 
purposes of this introduction I will largely use the term reproducibility, as this is the term typically used by 
authors publishing in this area, even if their studies actually report repeatability. The results I show within this 
chapter are however repeatability, not true reproducibility, data. 
Cardiopulmonary exercise testing (CPX) has had its reproducibility assessed in a number of studies (Elborn et al 
1990, Lehmann et al 1996, Marburger et al 1998, Skinner et al 1999, Hansen et al 2004, Bensimhon et al 2008, 
Keteyian et al 2010).  Each of these studies looked at only a single aetiology of disease (or healthy adults). 
The precision of modern hardware at measuring the principal non-derived gas-exchange variables such as 
oxygen consumption (    ) and carbon dioxide production ( 
 
   ) is quoted to be around 0.01-0.03%, and for 
flow variables such as tidal volume (VT) and respiratory frequency (Rf) around 1-3% (Balady et al 2010). The 
majority of derived variables are now calculated using computer software, minimising interpretation error. 
Therefore the majority of variation between two tests in the same patient will be temporal and biological 
variation in the patient and technical imperfections such as mask leak. This variation is largely what is measured 
in these reproducibility studies. 
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A key study into reproducibility was the HERITAGE family study (Skinner et al 1999) which, due to its study 
design, probably is the most accurate study at determining true reproducibility as a subgroup of their participants 
were assessed at each of 4 recruitment sites to look for the influence of different locations and different 
operators. Coefficients of variation (CoV) and intraclass correlation coefficients (ICC) for peak      did not 
differ when within site repeatability was compared with between site reproducibility. The total numbers of 390 
healthy individuals makes it one of the largest reproducibility studies to date. 
Prior to this, Elborn et al had, in a small group of patients with heart failure, shown evidence of a learning effect 
on the treadmill, with a consistent bias between the first two tests. When comparing tests 2 and 3 there was not a 
significant difference. Exercise time was 20% higher and peak      was 17% higher in the second test compared 
with the first (Elborn et al 1990). Bensimhon et al tried, on multivariate analysis, to find factors that altered the 
reproducibility of peak     . The strongest predictor of a change in peak  
 
   on the second test was a low peak 
     on the first test. Reproducibility also appears to be relatively unchanged when looking at a more elderly 
population with heart failure (Marburger et al 1998) and when patients with severe heart failure are tested 
(Meyer et al 1997). 
Largely the above studies have focused on a small number of cardiopulmonary variables, namely peak     , peak 
     ,  
 
   at the AT, peak RER, blood pressure and heart rate. A study by Keteyian et al was perhaps unique in 
its broad approach to evaluating a number of variables for reproducibility, although somewhat strangely many 
variables were only assessed in a subgroup of study individuals, which would not allow for a visual qualitative 
comparison of the CoV between variables. Often following the introduction of a new variable into the CPX 
vocabulary, studies will report the reproducibility or repeatability of this variable, but often fail to compare with 
all other established variables in a methodological and statistical manner (Hollenberg et al 2000, Van Laetham 
2009, Jakovljevic et al 2012). What remains unknown is whether a group of variables are consistently and 
significantly better or worse than others in reproducibility. 
Another problem with quotations for reproducibility statistics in medicine is that studies often perform under the 
most optimal conditions. They take optimal patients and have experts in the field performing the tests. This is 
not the picture seen in day-to-day clinical practice. In CPX research studies participants are tested on standard 
protocols, yet in clinical practice protocols are often not standardised within an institution, let alone between 
institutes. Within the 11 studies described above, 10 used a standard protocol for all patients with no deviation. 
It is established that to obtain optimal results for your patient an individualised protocol, aiming for maximal 
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exercise within 8-12 minutes, should be employed (Balady et al 2010). The only study that appears to have 
definitively looked into the effect of test duration, did so on only 5 healthy adult males (Buchfuhrer et al 1983). 
Only a single study (Agostoni et al 2005) has investigated the effect of work rate protocol on exercise test 
variables, and only in patients with heart failure. Peak      and the  
 
      slope were lower in the shortest, 
steepest ramp protocol. However the reproducibility of various variables were not directly, statistically 
compared between their 3 levels of protocol difficulty. I do not believe a similar experiment has been published 
in healthy controls, and certainly there is no established data as to the contributing nature of protocol difficulty 
on a broad range of CPX variables. 
Another problem is that research studies often adhere to strict policies that are rarely enforced in routine clinical 
practice, for example the fasting state. Many of the previously reported reproducibility studies utilised baseline 
data for an interventional study. In these cases it is appropriate to optimise and standardise testing conditions, to 
minimise biological variation and allow a true interventional effect to be seen. But it is highly likely with the 
increased use of CPX in research (often without direct input from CPX experts) that controlled, optimal 
conditions will be less rigorously adhered to. “True” or “day-to-day” reproducibility is yet to be described. In 
research a familiarisation test may be warranted, but to minimise time disruption it may need to be performed on 
the same day as the second test; none of the studies described above examined the role of inter-test interval on 
reproducibility. 
Therefore I believe a number of questions remain regarding the reproducibility of CPX variables: 
• What is the test-retest reliability of all commonly used CPX variables? 
• How do the test-retest reliabilities of each variable compare with one another in the same study? 
• Do the test-retest reliabilities perform similarly under typical clinical conditions when comparing 
to studies employing ideal research conditions? 
• Does disease aetiology affect reproducibility? 
• How does protocol affect reproducibility of the test? 
• How does inter-test interval affect reproducibility? 
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There is an assumption that measurements of slopes, including the          slope and OUES, are more 
reproducible than instantaneous or averaged data variables such as peak      or  
 
        ratio, largely due to their 
relative independence from effort. However this issue has not been examined by formal statistical techniques. 
Measurement of the gradient of a slope is susceptible to variation, which may therefore affect reproducibility, if 
the start and finish of the data used to construct the slope are not standardised. There still remains doubt as to 
where many CPX slopes should be measured. For example the          slope should include exercise data up to, 
but not beyond, the ventilatory compensation point (the point in incremental exercise where the relationship 
between minute ventilation and carbon dioxide elimination becomes decoupled due to the metabolic acidosis 
secondary to lactate build-up). Recently evidence has suggested that measuring the slope using all data points 
increases its prognostic power in patients with heart failure (Ingle et al 2007) when compared to measuring only 
until the VCP. Could this be influenced by the subjectivity of VCP identification? Unlike most other CPX 
variables, the VCP requires subjective identification from the operator. Therefore it is possible that the slope up 
to the VCP has poor reproducibility because the identification of the VCP is difficult? Using healthy adult data 
and a sample from the heart failure, mitral valve surgery and COPD patients I will show graphically how the 
slopes may change when data is foreshortened to different degrees. There also remains a question as to when 
slope measurements should start? In cycle exercise an unloaded period of exercise typically occurs. This may be 
of different lengths of time between centres (although 3 minutes is a typical value used) but depending on how 
long a patient manages to cycle in the incremental phase, the proportional contribution of this unloaded section 
will vary from test to test, which may affect the value of the slope. 
Within this study I performed 2 baseline tests on each patient. The initial test protocol was 3 minutes of 
unloaded cycling following 3 minutes of rest, and then a ramp of 10 watts per minute until exhaustion, and had 
two main aims: to act as familiarisation for the patient; and to identify the optimal protocol for their second test. 
Based on the peak work rate achieved on a 10W/min protocol, an appropriate protocol aiming to deliver 8-10 
minutes of incremental cycling was chosen for the second test. As stated earlier, based predominantly on a small 
study (Buchfuhrer et al 1983) 10 minutes allows enough time for accurate data acquisition, whilst minimising 
fatigue. Most patients underwent this second test on the same day as the first after at least 2 hours of recovery, 
others on a separate day. The design of the study therefore allows the calculation of, for typical patients with 
COPD, heart failure and mitral regurgitation, the test-retest reliability of multiple CPX variables, and assessment 
of the influence of different disease aetiologies, protocol changes and inter-test time interval on the test-retest 
reliability. 
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Separate to the principal study I also recruited a group of healthy adults, who underwent four CPX tests to allow 
the test-retest reliability of variables in healthy adults to be shown and to act as a baseline for our protocol. 
Similar to the study by Agostoni et al (which was in heart failure patients) participants performed one test with a 
ramp that would be considered too hard, one test with a ramp considered too easy and two tests with a ramp 
considered appropriate. The aim of this test was to compare, within a healthy population, the test-retest 
reliability of multiple variables under the conditions of an identical protocol (the two appropriate tests) versus 
the conditions of significantly different ramp protocols. 
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5.3 Methods 
5.3.1 Study 1 – Healthy controls 
A group of eight healthy participants was recruited, all employees of either Imperial College, or Imperial 
College Healthcare NHS Trust. These participants had no chronic cardiorespiratory disease, were of normal 
weight and did not smoke. They included some (n=3) with high levels of physical fitness (but no elite athletes) 
and some more sedentary individuals (n=5). They each undertook four CPX tests, none on the same day. 
Wherever possible I tried to perform each individual’s tests at a similar time of the day. Based on the 
participants’ described exercise capacity, an average protocol aimed at delivering maximal effort around 8-12 
minutes was agreed upon, a further protocol was then designed aiming for maximal effort in approximately 6 
minutes, and a further protocol aiming for maximal effort in approximately 15 minutes. Two tests were 
performed using the middle protocol (8-12 minutes). Test 4 was always one of these tests. Tests 1 to 3 were a 
random order of a too hard protocol, a too easy protocol and an appropriate protocol. Henceforth these will be 
referred to as steep, shallow and standard ramps respectively.  
The tests were performed on an Ergoselect 100 bicycle ergometer (Ergoline GmbH, Bitz, Baden-Württemberg, 
Germany) in an air-conditioned room after familiarisation with the equipment. Participants were encouraged to 
abstain from caffeinated products. The fasting state was not adhered to, but only small meals were encouraged, 
remote from testing. Spirometry and exercise testing was performed using COSMED Quark CPX System 
(COSMED S.r.l. Rome, Italy) which was calibrated before each test in the same manner as for the principal 
cohort study. They were asked to refrain from talking throughout the test, unless clinically required. Gas 
exchange was monitored breath-by-breath. The protocol resembled that of the main study cohort: 3 minutes 
resting; 3 minutes unloaded cycling without any resistance from the cycle ergometer; a steady ramp protocol 
specific to the participant and which test they were performing; and 3 minutes of recovery. The ramp protocol, 
in the same manner as the patient cohort, increased in small increments every 10-15 seconds, rather than larger 
increments every minute. The participants were asked to soundlessly indicate when they felt the resistance of the 
pedals. Although they were not blinded to the length of the unloaded portion (3 minutes) no clock was visible to 
help influence their decision. The work rate on the bike was only visible to the operator (me), not to the 
participants.  
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5.3.2 Study 2 - The Observational cohort 
The full methodology for the recruitment and testing of patients is described in the Methods Chapter. As part of 
the study design each patient undertook two CPX tests prior to any intervention. The first test acted both as 
familiarisation and to identify an optimal protocol for test 2. Therefore when comparing tests 1 and 2 they were 
not always on the same protocol. The change in protocol and its influence on reproducibility will be assessed as 
described in the statistics section. Many patients in the Observational cohort also underwent an intervention. 
These results are not included in the reproducibility analysis. Patients with prior CRT implantation undertook 3 
tests: the familiarisation test with their CRT settings unadjusted as for the other groups; a further test with their 
CRT settings unadjusted on the patient’s optimal protocol; and another test with the CRT function of their 
pacemaker disabled (but basic pacing and defibrillator functions were not adjusted). These final two tests were 
performed on the same protocol as decided from the familiarisation test and were performed in a random order. 
These 3 tests were spread out over 2 visits, largely with the familiarisation test on visit 1, and the two 
subsequent tests in a random order on another day. In the same manner as for all other patients, at least 2 hours 
separated the 2 tests performed on the same day. For the purposes of the reproducibility analyses the 2 tests with 
the CRT settings unadjusted will be compared. Where the second of these 2 tests was performed on a separate 
day to the familiarisation test, but 2 hours after the test with CRT settings disabled (whose data is not considered 
in the reproducibility analysis), it will still be considered as being on the same day, as the principal aim of this 
analysis is to determine the role of fatigue on reproducibility. 
 
5.3.3 Statistical Analysis 
Statistical analysis was performed using Stata version 11.1 for Windows (StataCorp LP, College Station, 
Texas). All patient characteristics and CPX variables were assessed for normal distribution using Shapiro-Wilk 
test. Because of the problems with analysing multiple variables, and no a priori hypotheses regarding which 
variables may behave normally or non-normally, a Sidak correction was employed (β = 1 – (1 – α)1/n) where β 
equals the p value for significance, and n equals the number of variables (correctly variables that are related for 
example peak      and peak  
 
  /kg count as 1). For those variables showing a non-normal distribution only if 
logarithmic transformation significantly normalised distribution was this transformation used. For all other non-
normal distributions the raw value was used in non-parametric analyses when necessary. 
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Because there were only 8 participants within study 1, non-parametric tests were used throughout where 
necessary. 
To assess for differences between 2 tests in the healthy cohort Wilcoxon rank tests were used, and between both 
pre-intervention tests in the patient cohort, paired t-tests were employed for parametric data, and Wilcoxon rank 
tests for non-parametric data. In the healthy cohort the steep and shallow ramps were compared against the first 
standard ramp (to minimise any potential confounding from a learning effect). 
Data were examined using Bland Altman plots (Bland et al 1986) and the mean difference and standard 
deviation of the difference (SDD) between pairs of tests was calculated. A within-subject coefficient of variation 
(CoV) was calculated as the ratio of the SDD and the mean value of the test variable. This gives a convenient 
measure of the absolute reliability. CoV measurements performed this way are typically applicable for most 
data, even non-parametric data, as it is the distribution of the residuals that concerns us, not the distribution of 
the original data. Residuals are typically normally distributed. However I also present for the main study CoV 
values  calculated using logarithmic transformation of the data (and identify in which variables this method has 
been used) with an exponential correction back at the end for any variable that displays residuals that diverge as 
the magnitude of the mean value increases, i.e. the residual is proportional to the mean. These logarithmic CoV 
are calculated via the following equation (where x1 and x2 are the values for each variable on test 1 and test 2 
respectively):  
   
  
                 
  
 
Bootstrapped intraclass correlation coefficients (ICC) were also calculated for the pooled group and each 
individual disease category, to give a measure of relative reliability. In the simplest terms the ICC is a ratio of 
the within-patient variance to the whole group variance, and as a ratio of 2 variances is a unit-less value. This 
allows, even if 2 variables have different units of measurement, a comparison of 2 ICC values. 95% confidence 
intervals of each ICC were calculated by bootstrapping and a z-score of Fisher transformation was calculated 
with p values for direct comparison of some of the more important variables’ ICCs within the patient cohort (the 
numbers were too small in the healthy cohort to render this reliable). Excellent reliability was defined as ICC 
>0.90, good reliability 0.7-0.89, and moderate reliability 0.4-0.69 (as standard). Reliability was also calculated 
with regards to comparison to peak     , i.e. better, worse or similar reliability to peak  
 
  . ICC calculations 
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always used raw data, not logarithmically transformed data, even when previously stated the variable was non-
normally distributed. 
I analysed for 6 potential confounders to reproducibility that differed between patients; age (separated into 
above and below median), gender, weight status (BMI above or below 25), aetiology of disease,  whether the 2 
tests were performed on the same day (inter-test interval) and finally, whether the ramp protocol was steeper, 
shallower or the same as the original protocol. I constructed repeated measures mixed linear models using an 
interaction term between test and potential confounder. A significant interaction term (p<0.05) identified that 
the difference in a variable between tests 1 and 2 was influenced by that confounder. The presence of a 
significant interaction term however does not identify the direction of the affect on reproducibility (improving or 
reducing it). Therefore oneway analysis of variance was also used, with the differences between the tests as the 
dependent variable. Because disease aetiology is an important potential confounder, ICC and SDD/mean values 
were produced for each variable within each disease category. 
Within the healthy cohort only ramp protocol was assessed for its potential role as a confounder. 
A p value <0.05 was considered statistically significant throughout. 
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5.4 Results 
5.4.1 Study 1 - Participant and test characteristics 
Eight healthy participants undertook four CPX tests each. The healthy adults included two females and six 
males, median age 25 (range 22-43). The characteristics of the participants are shown in Table 5.1. None of the 
participants were smokers. Spirometry was normal with a percentage of predicted FEV1 105.7% (IQR 87.6 – 
111.8%) and percentage of predicted FVC 114.4% (IQR 97.4 – 136.1%). 
The steep ramp protocol was designed to elicit an exercise time of approximately 6 minutes. For one participant 
the protocol was more challenging than expected (exercise time 04:49 minutes) and another not challenging 
enough (exercise time 08:25 minutes) but all others lay between 05:39-07:28 minutes. On the shallow ramp 
protocol an exercise time of approximately 15 minutes was the target. 2 participants were significantly short of 
this target at 12:03 and 12:53 minutes. On the standard protocol, aiming for an exercise time of 8-12 minutes, 
one participant stopped earlier than this (06:58 minutes) and one participant beyond this exercise time (12:23 
minutes). These were the same participants who were significantly shorter and longer respectively on the steep 
ramp. 
 
5.4.2 Study 1 – Identification of intensity onset 
From these 32 tests, on 30 occasions the participant remembered to indicate when they detected an increase in 
work rate. The work rate first detected ranged from 9-35 W with a mean value of 22.4 ± 7.2 W (Figure 5.1). The 
intensity of the protocol did not significantly affect when the participant detected the increasing work rate 
(p=0.41 by ANOVA for the 3 groups of test intensity, p=0.61 by linear regression of ramp used in W/min). 
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Participant no. Gender 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
Considered 
Athletic? 
Steep ramp  
(W/min) and ET 
(min:sec) 
Shallow ramp 
(W/min) and ET 
(min:sec) 
Standard ramp 
(W/min) and ET 
(min:sec) 
1 Male 28 183 77 22.99 No 40W/ 06:29 10W/ 18:48 25W/ 09:34 
2 Male 25 175 75 24.49 Yes 50W/ 07:28 15W/ 20:44 30W/ 11:34 
3 Male 24 178 68 21.46 Yes 50W/ 06:44 15W/ 16:44 25W/ 10:34 
4 Female 25 162 45 17.15 No 25W/ 04:49 8W/ 12:03 15W/ 06:58 
5 Male 22 168 68 24.09 No 40W/ 07:13 15W/ 13:58 25W/ 10:13 
6 Male 22 178 70 22.09 No 40W/ 05:39 15W/ 12:53 25W/ 08:39 
7 Female 28 168 56 19.84 Yes 30W/ 08:25 12W/ 18:25 20W/ 12:23 
8 Male 43 185 69 20.16 No 50W/ 07:08 16W/ 18:59 30W/ 10:44 
 
Table 5.1: Baseline characteristics for eight healthy adults undertaking four CPX tests. The final 3 columns show the watt per minute 
increase during the incremental portion of the exercise test for each of the 3 levels of difficulty, as well as the exercise time (ET) achieved in 
each test. The exercise time for the standard protocol shown was the first time it was performed in each participant. Considered athletic? was 
the participant’s opinion of their own level of fitness, being athletic meant they considered themselves of above average fitness. 
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Figure 5.1: Distribution of work rate in an incremental test when participant perception of increasing 
intensity is first noticed by the participant. 
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5.4.3 Study 1 – Repeatability of 2 identical CPX tests 
 When comparing the difference between the 2 standard tests only peak minute ventilation and PETCO2 at the 
AT showed a borderline significant difference between these 2 tests. Although there was no significant 
difference in peak      between these 2 tests, if we just consider the 3/8 participants who undertook the standard 
protocol first there was a mean increase of 3.1 mL/min/kg between this first and final test. In comparison for the 
5/8 participants where the first standard protocol was performed on test 2 or 3 the mean increase was 0.14 
mL/min/kg. Although the numbers are too small to draw firm conclusions this could be evidence of a learning 
effect within this group. In conflict with this hypothesis are the results shown in Figure 5.2. This shows the 
mean peak      by the order of the tests performed. Test 1 displayed lower mean values when compared to tests 
2 and 4 but it was test 3 which had the lowest mean peak     . There were no significant differences in peak  
 
   
between any pairs of tests in test order (p>0.05 Wilcoxon rank test for all 6 pairs, i.e. test 1 vs test 2, test 1 vs 
test 3 etc). 
Table 5.2 shows the main measures of test-retest reliability between the 2 standard tests. Peak     , in mL/min, 
mL/min/kg and as a percentage of predicted, showed good repeatability as evidenced by ICC values ≥ 0.93 and 
CoV < 0.07. Most other gas exchange variables showed an intermediate degree of repeatability                (0.80≤ 
ICC <0.91; 0.10≤ CoV <0.20). Some variables such as the           slope showed a good reliability using CoV, 
but poor ICC values, whilst the OUES/kg showed a good ICC but slightly weaker CoV. Using the whole data 
(rather than ending the slope at the VCP) did not improve test-retest reliability measures of the           slope; 
both ICC and CoV were worse, although this difference was not statistically significant. 
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Figure 5.2: Median and interquartile range for peak      (mL/min/kg) by test order. Tests 1 and 3 show 
the lowest median values, which is not suggestive of a learning effect. There was no significant difference 
between any pairs of these values. The whiskers represent the lowest data point within 1.5 IQR of the 25
th
 and 
75
th
 percentiles. 
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Overall 
mean (Test 
1 and 2) 
Mean difference 
(and 95% LOAs) 
Standard 
deviation of 
difference (SDD) CoV ICC (and 95% CI) 
Peak      (mL/min) 2858 88 (-292, 468) 193.8 0.068 0.96 (0.48, 1.00) 
Peak      (mL/min/kg) 42.9 1.23 (-4.49, 6.96) 2.92 0.068 0.93 (0.51, 0.99) 
% predicted Peak      107 2.61 (-10.95, 16.18) 6.92 0.065 0.95 (0.70, 0.99) 
AT (mL/min) 1758 -39 (-528, 450) 249.6 0.142 0.90 (0.58, 0.98) 
AT (% of pred peak     ) 66.0 -2.69 (-23.9, 18.52) 10.82 0.164 0.87 (0.61, 0.96) 
OUES 2.91 -0.05 (-0.73, 0.63) 0.35 0.120 0.78 (0.21, 0.96) 
OUES/kg 44.2 -1.09 (-11.7, 9.6) 5.44 0.123 -0.93 (-0.97, -0.85) 
OUES 25-75 2.92 0.13 (-0.64, 0.9) 0.39 0.135 0.77 (0.08, 0.96) 
OUES 50 2.81 -0.31 (-1.21, 0.58) 0.46 0.162 0.81 (0.47, 0.94) 
OUES 70 2.94 -0.18 (-1.02, 0.66) 0.43 0.146 0.85 (0.48, 0.96) 
OUES 90 2.95 -0.07 (-0.77, 0.62) 0.35 0.120 0.81 (0.26, 0.96) 
OUEP 44.8 -1.4 (-7.86, 5.06) 3.30 0.074 0.82 (0.32, 0.96) 
O2 Pulse 16.8 0.12 (-3.59, 3.82) 1.89 0.113 0.89 (0.52, 0.98) 
         slope 1 24.3 -0.42 (-3.26, 2.42) 1.45 0.060 0.70 (-0.01, 0.94) 
          slope 2 27.7 1.3 (-3.81, 6.41) 2.61 0.094 0.62 (0.14, 0.87) 
          ratio nadir 24.5 0.45 (-2.28, 3.17) 1.39 0.057 0.83 (0.41, 0.96) 
         ratio at AT 26.1 0.73 (-1.43, 2.88) 1.10 0.042 0.86 (0.61, 0.95) 
RER at peak 1.24 0.02 (-0.16, 0.19) 0.09 0.073 0.59 (-0.02, 0.88) 
PETCO2 at AT * 43.5 -1 (-3.57, 1.57) 1.31 0.030 0.86 (0.38, 0.97) 
HR at peak 175 2.88 (-16.28, 22.03) 9.78 0.056 0.14 (-0.45, 0.65) 
Rf 37.7 1.39 (-4.72, 7.51) 3.12 0.083 0.68 (0.22, 0.89) 
Peak     * 108 9.83 (-12.96, 32.62) 11.63 0.108 0.90 (0.65, 0.97) 
        Slope 9.72 0.04 (-0.93, 1.01) 0.49 0.051 0.78 (0.12, 0.96) 
Maximum Wattage 254 8.38 (-12.97, 29.72) 10.89 0.043 0.98 (0.84, 1.00) 
         Slope 0.04 0 (-0.01, 0.02) 0.01 0.178 0.83 (0.63, 0.93) 
         Intercept 56.7 -6.8 (-38.65, 25.05) 16.25 0.286 0.23 (-0.53, 0.78) 
Duration (s) 613 17 (-36, 70) 27 0.044 0.95 (0.71, 0.99) 
 
Table 5.2: The mean value, mean difference, standard deviation, standard deviation of the difference and 
the bootstrapped intraclass correlation coefficient with confidence interval when comparing the two 
standard tests undertaken by 8 healthy volunteers. Slope 1 refers to the slope calculated up until the VCP. 
Slope 2 refers to the slope calculated with all exercise data. CoV is the coefficient of variation and equals the 
SDD/mean. ICC is the intraclass correlation coefficient, calculated using bootstrapping measures. LOA = limits 
of agreement. CI = confidence intervals. * p<0.05 for difference between tests 
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5.4.4 Study 1 – Repeatability of CPX tests using different ramp protocols 
Table 5.3 shows the mean difference between the first standard protocol and either the steep or shallow ramp 
protocols for each of the CPX variables. When comparing the standard and steep protocols only 3 variables 
were affected by the change in protocol, peak RER (p=0.025), peak work rate (p=0.01) and the         slope 
(p=0.01). When the shallow protocol was compared to the standard protocol the respiratory frequency at peak 
exercise (p=0.049), peak work rate (p=0.01) and the         slope (p=0.02) were affected by a change in 
protocol. 
Table 5.3 also shows how the 2 measures of test-retest reliability, ICC and CoV performed. On the steep 
protocol heart rate data was poorly recorded in one participant, the 4 variables utilising heart rate are therefore 
calculated from 7, not 8 participants. Peak     , OUES, OUES/kg and O2 pulse showed good test-retest 
reliability on both measurements. The AT and OUEP performed slightly less well. Peak heart rate, the    
      intercept, and the  
 
      slope performed poorly when measuring the ICC. The  
 
      slope had, 
however, a good CoV, reflecting the small amounts of variance relative to the magnitude of the variable. The 
        slope was significantly less reliable when comparing the steep/standard protocols with the 2 standard 
protocols (ICC 0.02 vs 0.78, p=0.02). 
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Mean difference 
steep vs       
standard (95% 
LOAs) 
CoV for 
steep vs 
standard 
ICC (and 95% CI) 
for steep vs 
standard 
Mean difference 
shallow vs 
standard (95% 
LOAs) 
CoV for 
shallow vs 
standard 
ICC (and 95% CI) 
for shallow vs 
standard 
Peak      (mL/min) -86.2 (-555, 383) 0.086 0.92 (0.53, 0.99) -42.4 (-583, 498) 0.099 0.91 (0.42, 0.99) 
Peak      (mL/min/kg) -1.29 (-8.38, 5.8) 0.087 0.88 (0.64, 0.96) -0.61 (-8.47, 7.25) 0.096 0.93 (0.5, 0.99) 
% predicted Peak      -3.69 (-21.52, 14.14) 0.088  0.91 (0.76, 0.97) -1.76 (-20.86, 17.34) 0.093 0.91 (0.67, 0.98) 
AT (mL/min) -85 (-583, 413) 0.146 0.87 (0.55, 0.97) 10 (-648, 669) 0.189 0.82 (0.43, 0.95) 
AT (% of pred max) -3.59 (-24.38, 17.19) 0.162  0.85 (0.65, 0.94) -0.82 (-29.08, 27.44) 0.215 0.75 (0.43, 0.9) 
OUES 0.07 (-0.48, 0.62) 0.094 0.88 (0.31, 0.99) -0.1 (-0.53, 0.34) 0.077 0.91 (0.55, 0.99) 
OUES/kg 1.02 (-7.08, 9.13) 0.091 0.87 (0.34, 0.98) -1.68 (-8.49, 5.13) 0.078 0.87 (0.55, 0.97) 
OUES 25-75 0.15 (-0.82, 1.13) 0.170 0.69 (-0.03, 0.94) 0.1 (-0.68, 0.89) 0.138 0.81 (0.33, 0.96) 
OUES 50 0.2 (-0.99, 1.39) 0.198 0.65 (0.41, 0.8) -0.36 (-1.61, 0.89) 0.229 0.64 (-0.02, 0.91) 
OUES 70 0.13 (-0.91, 1.17) 0.172 0.71 (0.26, 0.91) -0.24 (-1.23, 0.76) 0.174 0.73 (0.3, 0.91) 
OUES 90 0.14 (-0.51, 0.8) 0.109 0.84 (0.18, 0.98) -0.08 (-0.63, 0.46) 0.094 0.88 (0.48, 0.98) 
OUEP -0.97 (-8.45, 6.52) 0.085 0.81 (0.33, 0.96) -2.48 (-10, 5.03) 0.087 0.77 (0.05, 0.96) 
O2 Pulse 0.23 (-2.01, 2.48) 0.068 0.97 (0.83, 1) -0.66 (-3.78, 2.46) 0.097 0.94 (0.21, 1) 
         slope 1 -0.83 (-4.28, 2.61) 0.073 0.56 (-0.26, 0.91) 0.13 (-2.77, 3.03) 0.060 0.81 (0.44, 0.94) 
          slope 2 -1.11 (-4.33, 2.11) 0.062 0.78 (0.26, 0.95) 1.76 (-2.4, 5.91) 0.076 0.61 (-0.2, 0.92) 
          ratio nadir -0.15 (-3.47, 3.17) 0.070 0.73 (0.09, 0.94) 0.13 (-2.21, 2.48) 0.049 0.9 (0.52, 0.98) 
         ratio at AT -0.52 (-3.33, 2.3) 0.056 0.79 (-0.21, 0.98) 0.51 (-4, 5.02) 0.088 0.65 (-0.01, 0.91) 
RER at peak * 0.05 (-0.03, 0.12) 0.029 0.86 (0.54, 0.96) -0.06 (-0.23, 0.11) 0.071 0.55 (0.03, 0.84) 
PETCO2 at AT 0.5 (-3.56, 4.56) 0.047 0.77 (0.2, 0.95) 0.38 (-5.64, 6.39) 0.069 0.62 (-0.05, 0.91) 
HR at peak -3.6 (-19.9, 12.7) 0.048 0.38 (-0.52, 0.88) 2.6 (-12.7, 18) 0.045 0.74 (0.44, 0.9) 
Rf † -0.41 (-5.88, 5.06) 0.076 0.78 (0.48, 0.91) 3.61 (-4.05, 11.28) 0.101 0.48 (0.15, 0.71) 
Peak     -2.68 (-31.2, 25.84) 0.143 0.89 (0.62, 0.97) 4.24 (-27.78, 36.25) 0.155 0.85 (0.58, 0.95) 
        Slope *† -1.05 (-1.77, -0.32) 0.040 0.02 (-0.55, 0.58) 0.69 (-0.58, 1.96) 0.064 0.47 (0.12, 0.71) 
Maximum Wattage *† 28.5 (-14.9, 71.9) 0.084 0.87 (0.43, 0.98) -27.38 (-58.1, 3.4) 0.066 0.87 (0.46, 0.97) 
        Slope -0.001 (-0.01, 0.01) 0.160 0.86 (0.59, 0.95) 0.004 (-0.01, 0.02) 0.215 0.78 (0.3, 0.94) 
        Intercept 1.84 (-37.6, 41.27)  0.327  0.06 (-0.35, 0.44) -3.27 (-42.91, 36.36) 0.346 0.07 (-0.47, 0.58) 
 
Table 5.3: The mean difference, standard deviation of the difference: mean ratio and the bootstrapped 
intraclass correlation coefficient with confidence interval when comparing the first standard test to either the 
steep or shallow tests undertaken by 8 healthy volunteers (a negative difference indicates that the steep or 
shallow protocol had lower values than the standard test). Slope 1 refers to the slope calculated up until the VCP. 
Slope 2 refers to the slope calculated with all exercise data. LOA = limits of agreement. CI = confidence intervals. * 
p<0.05 for steep vs standard mean value, † p<0.05 for shallow vs standard mean value. 
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5.4.5 Study 2 – Patient and test characteristics 
100 patients were recruited into the Observational study to identify an ideal variable on CPX to distinguish 
between cardiac and respiratory limitation. These patients all underwent 2 baseline CPX tests. The details of 
these 100 patients, and exclusion criteria of 4 patients will be discussed in Chapter 6. From the 96 patients 
deemed appropriate for the study, 3 did not have acceptable data from 2 tests although they had completed the 
study protocol. The reproducibility statistics are based on the final 93. 
Of these 93 patients (70 male); 24 had a primary diagnosis of COPD, 43 a primary diagnosis of heart failure and 
the remaining 26 mitral valve disease requiring surgery. Some patients had a secondary problem (for example 
COPD is not uncommon in my heart failure cohort and some of the mitral regurgitation patients had impaired 
left ventricular systolic function). The reproducibility analysis will be based on their primary diagnosis only. 
The patient characteristics of the total group and by disease category are shown in Table 5.4. 18 from 26 patients 
with mitral regurgitation were symptomatic. 
On analysis of CPX variables, OUES/kg, both measures of the          slope, all measures of the  
 
       ratio, 
resting heart rate, arterial oxygen saturations, breathing reserve at the AT and peak, and t the        slope all 
showed a significantly non-normal distribution (p<0.0026 by Shapiro-Wilk test). All measures of the           
relationship were made marginally more normally distributed by logarithmic transformation, but resting heart 
rate was the only variable which became significantly more normally distributed following logarithmic 
transformation. 
On analysis of first test exercise times there was a non-significant trend to shorter times within the COPD group 
and longer times within the mitral group. The protocol chosen for test 2 reflected this difference in test 1 time, 
with a non-significant trend to the highest average protocol chosen in the MV group and lowest in the COPD 
group. Figure 5.3 shows the proportion of ramp protocols chosen for test 2. 84 from 93 patients had an 
identifiable anaerobic threshold. Only 28 patients reached and exceeded a VCP. 
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 Mean ± SD/ 
Median (IQR) 
All 
Mean ± SD/ 
Median (IQR) 
COPD (n=24) 
Mean ± SD/ 
Median (IQR)  
CHF (n=43) 
Mean ± SD/ 
Median (IQR) 
MV (n=26) 
Age (yrs) 65.2 ± 10.9  66.6 ± 9.5  66.6 ± 11.1  61.7 ± 11.3  
Male (n, %) 70, 75.3% 16, 66.7% 38, 88.4% 16, 61.5% 
Height (cm) 170.1 ± 10.0 166.8 ± 7.8 171.3 ± 9.2 171.2 ± 12.3 
Weight (kg) 77.6 ± 15.8 72.0 ± 16.1 82.7 ± 15.5 74.4 ± 13.8 
BMI (kg/m
2
) 26.7 ± 4.4 25.8 ± 4.6 28.1 ± 4.1 25.3 ± 4.0 
Diabetics (n, %) 10, 10.7% 1, 4.2% 8, 18.6% 1, 3.8% 
Current smokers (n, %) 12, 12.9% 5, 20.8% 7, 16.3% 0, 0% 
Hypertensive (n, %) 40, 43.0% 10, 41.7% 19, 44.2% 11, 42.3% 
BNP (pg/mL) 86 (37, 203) 36 (14, 52) 118 (85, 286) 85 (43, 222) 
FVC (L) 3.29 (2.59, 3.94) 2.75 (2.34, 3.18) 3.59 (3.01, 4.31) 3.29 (2.75, 3.88) 
FVC (% predicted) 97.2 ± 23.0 88.3 ± 26.4 100.1 ± 18.0 100.5 ± 25.8 
FEV1 (L) 2.21 ± 0.89 1.32 ± 0.50 2.52 ± 0.73 2.50 ± 0.87 
FEV1 (% predicted) 79.6 ± 25.7 52.8 ± 19.8 89.7 ± 20.2 87.7 ± 21.4 
FEV1:FVC ratio 67.2 (55.9, 74.0) 46.2 (38.2, 56.2) 71.1 (62.7, 77.0) 68.6 (65.1, 75.1) 
DLCO (mL/min/mmHg) 5.97 ± 2.11 4.89 ± 1.92 6.19 ± 1.94 6.61 ± 2.25 
Ramp protocol (W/min) 11.4 ± 3.3 10.5 ± 2.8 11.3 ± 2.9 12.3 ± 4.0 
  Resting heart rate (bpm) 78.1 ± 14.3 85.5 ± 16.8 72.0 ± 11.2  81.3 ± 12.8 
Peak      (mL/min/kg) 17.2 ± 4.2 17.4 ± 4.2 16.3 ± 3.6 18.6 ± 5.0 
% Predicted Peak      73.9 ± 17.0 75.6 ± 18.6 71.0 ± 14.4 77.2 ± 19.1 
AT (% Predicted     ) 53.7 ± 13.3 56.3 ± 12.5 51.7 ± 12.9 55.2 ± 14.5 
 
 
Table 5.4: Patient characteristics overall and for each of the 3 disease categories, chronic obstructive 
pulmonary disease (COPD), chronic heart failure (CHF) and mitral valve disease (MV). Data are displayed 
as mean ± SD for normally distributed variables and median (IQR) for non- normally distributed variables. 
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Figure 5.3: Proportion of each ramp protocol chosen for test 2 based on 
the results of test 1. 
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5.4.6 Study 2 – Difference between test 1 and 2 
Table 5.5 shows the mean values for test 1 and test 2 for 35 CPX variables. The mean within-patient difference 
was calculated and shown along with the 95% limits of agreement of the difference. This allows clinicians, 
when comparing two exercise tests in the same patient, to see if the magnitude of change lies outside of this 
range, thereby indicating the likely presence of a significant deterioration or improvement (rather than inherent 
variation).  
The Bland-Altman plots for 9 of the most commonly used variables are shown in Figure 5.4. Bland-Altman 
plots are still appropriate when performed on non-parametric data so no log transformations were done for the 
basic plots. Peak      and  
 
   at the AT showed a significant relationship between the residuals and magnitude 
of the mean values (p<0.05 by Bradley-Blackwood F statistic). For peak      there was a significant decrease in 
the difference between tests (test 2 minus test 1) as peak      increased, so that for the patients with the greatest 
peak      there was on average a slight decline from test 1 to test 2. For  
 
   at the AT this relationship is in the 
opposite direction. This is reflected in the Bland-Altman plots for these 2 variables with non-horizontal limits of 
agreement.  
All measures of peak      showed a significant mean increase between tests 1 and 2 (+24 mL/min, p=0.046;       
+0.35 mL/min/kg, p=0.024; +1.6%, p=0.017). The     at the AT also showed a significant mean increase 
between tests 1 and 2 (+47 mL/min, p<0.001; +2.8%, p<0.001). PETCO2 at the AT (-0.63 mmHg, p=0.02), 
breathing reserve at the AT (-1.5%, p=0.02 by Wilcoxon rank-test), breathing reserve at peak (-1.9%, p=0.02 by 
Wilcoxon rank-test), peak minute ventilation (+2 L/min, p=0.02), peak respiratory frequency (+1.7 breaths per 
minute, p=0.001), peak heart rate (+3.5 bpm, p<0.01) and double product (+ 671 mmHg bpm, p=0.03) also 
showed significant differences between test 1 and test 2 respectively. All measures of the OUES, the OUEP, O2 
pulse, measures of the          relationship, the  
 
      slope and the measures of the     
 
  relationship 
did not display a systematic difference from test 1 to test 2. 
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Overall mean 
(Test 1 and 2) 
Mean difference (and 
95% LOAs) SDD CoV ICC (and 95% CI) 
Peak      (mL/min) † 1314.2 24 (-200.2, 248.3) 114.4 0.09 0.95 (0.94, 0.97) 
Peak      (mL/min/kg) † 17.07 0.35 (-2.52, 3.22) 1.46 0.09 0.94 (0.92, 0.96) 
% predicted peak      † 73.1 1.6 (-10.7, 13.9) 6.3 0.09 0.93 (0.89, 0.95) 
AT (mL/min) † 938.1 47.4 (-194.9, 289.8) 123.6 0.13 0.84 (0.78, 0.89) 
AT (% of pred     ) † 52.3 2.8 (-9.7, 15.3) 6.4 0.12 0.86 (0.79, 0.90) 
OUES 1.65 0.01 (-0.41, 0.43) 0.21 0.13 0.93 (0.90, 0.95) 
OUES/kg 21.5 0.07 (-5.32, 5.46) 2.75 0.13 0.92 (0.88, 0.95) 
OUES 25-75 1.64 0.06 (-0.64, 0.75) 0.35 0.22 0.76 (0.63, 0.86) 
OUES 50 1.58 0.04 (-0.63, 0.72) 0.34 0.22 0.79 (0.71, 0.86) 
OUES 70 1.66 0.04 (-0.6, 0.69) 0.33 0.20 0.81 (0.71, 0.88) 
OUES 90 1.67 0.01 (-0.54, 0.57) 0.28 0.17 0.87 (0.79, 0.92) 
OUEP 33.2 0.23 (-3.99, 4.45) 2.2 0.06 0.91 (0.87, 0.94) 
O2 pulse (mL/bpm) 10.95 0.01 (-1.68, 1.7) 0.86 0.06* 0.96 (0.94, 0.97) 
         slope 1 35.1 0.34 (-7.47, 8.15) 4.0 0.08* 0.88 (0.79, 0.93) 
          slope 2 37.2 0.58 (-7.87, 9.02) 4.3 0.07* 0.88 (0.81, 0.93) 
          ratio nadir 33.6 0.42 (-3.61, 4.44) 2.1 0.05* 0.92 (0.89, 0.95) 
         ratio at AT 35.7 0.35 (-6.25, 6.94) 3.4 0.06* 0.84 (0.71, 0.92) 
         ratio at VCP 35.7 0.3 (-11.18, 11.78) 5.9 0.05* 0.93 (0.81, 0.98) 
RER at rest 0.79 -0.01 (-0.15, 0.14) 0.07 0.09 0.25 (0.03, 0.45) 
RER at AT 0.87 -0.01 (-0.11, 0.1) 0.05 0.06 0.49 (0.28, 0.65) 
RER at peak 1.09 0 (-0.13, 0.14) 0.07 0.06 0.82 (0.74, 0.88) 
PETCO2 at AT (mmHg) † 35.6 -0.63 (-5.27, 4.01) 2.4 0.07 0.83 (0.74, 0.89) 
HR at rest (bpm) 938.1 1.65 (-14.03, 17.32) 8.0 0.10 0.83 (0.74, 0.89) 
HR at peak (bpm) † 122.6 3.54 (-16.55, 23.63) 10.2 0.08 0.91 (0.86, 0.94) 
DP (mmHg bpm) † 20194 671 (-4987, 6328) 2887 0.14 0.90 (0.83, 0.94) 
Circ power (mmHg mL/min) 216409 4823 (-55098, 64743) 30572 0.14 0.93 (0.90, 0.96) 
O2 saturations at rest (%) 97.7 0.15 (-3.79, 4.09) 2.0 0.02 0.60 (0.31, 0.79) 
O2 saturations at peak (%) 96.5 0.09 (-3.9, 4.08) 2.0 0.02 0.80 (0.64, 0.89) 
BR at AT (%) † 64.4 -1.5 (-19.4, 15.55) 5.7 0.09 0.93 (0.87, 0.96) 
BR at peak (%) † 32.0 -1.92 (-7.64, 11.02) 8.9 0.28 0.92 (0.86, 0.95) 
Rf † 35.4 1.69 (-7.64, 11.02) 4.8 0.13 0.76 (0.58, 0.87) 
Peak     (L/min) † 54.8 2 (-13.29, 17.28) 7.8 0.10* 0.89 (0.83, 0.94) 
        Slope 8.67 0.23 (-2.65, 3.11) 1.5 0.17 0.70 (0.51, 0.82) 
Peak work rate (W) † 92.2 5.08 (-12.12, 22.27) 8.8 0.10 0.95 (0.93, 0.97) 
        Slope 0.05 0.002 (-0.029, 0.033) 0.0 0.29 0.87 (0.74, 0.93) 
        Intercept 54.61 0.07 (-24.44, 24.58) 12.5 0.23 0.79 (0.70, 0.86) 
 
Table 5.5: Test-retest reliability of the full cohort. Coefficients of variation calculated via logarithmic 
transformation of the raw data for variables (starred) where residuals are non-normally distributed.  
† p<0.05 for significant difference between tests 1 and 2. For abbreviations see text. 
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Figure 5.4: Bland-Altman plots of 9 important CPX variables. To maximise viewing of the data points axes 
are deliberately minimally labelled. The x-axis of each plot is the mean values of tests 1 and 2, with the y-axis 
the difference between the 2 tests. The 9 variables are peak      (mL/min),  
 
   at the AT (mL/min),  
 
  
      slope, OUES (L/min/10-fold increase in  
 
 ), OUEP,           ratio at nadir, O2 pulse (mL/beat), breathing 
reserve at the AT (%) and         slope (mL/min/W). 
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5.4.7 Study 2 – Test-retest reliability of various CPX variables 
In a similar manner to the healthy cohort, the ICC and SDD/mean (as a simple measure of the coefficient of 
variation) were calculated for the patient cohort. Separately the coefficients of variation were calculated using 
the logarithmic transformation of the raw values for each variable that showed dispersion of the residuals with 
increasing magnitude, as noted on the Bland-Altman plots of O2 pulse,           slopes and ratios and minute 
ventilation. For these variables the logarithmic coefficients of variation are shown, rather than the SDD/mean 
coefficient of variation, but these are equivalent. These measures are all shown in Table 5.5. The confidence 
interval for each variable’s ICC allows a visual comparison of two ICC values to assess for a significantly 
stronger test-retest reliability in one variable over another. 
It can be seen for gas exchange variables that peak     , OUES measured using the full data and weight adjusted, 
OUEP, the O2 pulse, peak circulatory power, and the           ratio at the VCP and nadir, and breathing reserve 
at the AT and peak all had excellent test-retest reliability as defined by an ICC ≥0.90. Despite small differences 
in the ICC values and noticeable overlap in the CIs, only circulatory power, O2 pulse and the breathing reserve 
at AT were not significantly weaker than peak     . Double product, peak watts and heart rate also showed high 
test-retest reliability. Gas exchange variables with only fair or moderate test-retest reliability (0.2 ≤ICC ≤0.69) 
included RER at rest and the AT and resting arterial O2 saturations. All other measures including the 
foreshortened OUES data,      at the AT, the  
 
        slope and  
 
        ratio at the AT, the  
 
      slope, 
and the         relationship showed good test-retest reliability (0.7 ≤ICC <0.89).  
The           ratio measured at nadir was significantly more reproducible than both the ratio measured at the 
anaerobic threshold (p=0.002) and the PETCO2 (p=0.001) at the anaerobic threshold. The slopes of the            
          relationship using full data or only data up to the VCP showed similar test-retest reliability, and these 
slopes did not have significantly lower ICC values than the           ratio measured at nadir. 
OUES had significantly better test-retest reliability than the OUES measured using foreshortened data from the 
25-75
th
 percentiles, 0-50
th
 percentiles, 0-70
th
 percentiles and 0-90
th
 percentiles. OUES was similar to OUEP 
(p=0.45). 
When assessing reproducibility using coefficients of variation peak     , OUEP, O2 pulse, the  
 
        ratio at 
the VCP, AT and nadir, both measures of the           slope, and the PETCO2 at the AT all had excellent test-
retest reliability (CoV <0.10). OUES, OUES/kg, DP and peak circulatory power had slightly worse values for 
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CoV (0.13, 0.13, 0.14 and 0.14 respectively). The breathing reserve at peak, the          relationship and 
foreshortened OUES measures had poor coefficients of variation (>0.20). The biggest discrepancies between 
CoV and ICC values can be seen with the arterial oxygen saturations, which at both rest and peak showed 
excellent CoV values (0.02) but poor ICC values (0.60 and 0.80 respectively). The BR also displayed some 
disparities; at anaerobic threshold it had excellent CoV and ICC, whilst at peak, despite a similar ICC, the CoV 
was vastly different. This probably can be explained by the nature of CoV which cannot manage negative 
numbers (10 patients had a negative BR one either test 1, 2 or both). 
 
5.4.8 Study 2 - Determinants of test-retest reliability 
6 factors (age, gender, BMI, disease category, change in ramp protocol from test 1 to 2, and tests on the same or 
different days) were assessed for their potential to influence the test-retest reliability of CPX variables in 2 
ways: firstly through a mixed regression model looking for an interaction between the factor and condition (a 
significant interaction implies that the potential determinant influences the difference between 2 tests, i.e. its 
repeatability); and secondly by comparing the confidence limits of ICCs calculated for each group. Only the 
principal CPX variables were assessed in this way to avoid achieving statistical significance because of multiple 
measures. Table 5.6 shows the influence of disease category on mean test-retest difference, CoV and ICC. 
Determinants could affect in one of 2 ways, by affecting the mean difference between 2 tests, or by affecting the 
between-test variance. 
Gender affected reproducibility minimally. The          slope had a significantly lower ICC in females (0.71 vs 
0.93 compared to males p=0.002) and females exhibited a greater mean difference in heart rate between tests at 
both rest and peak exercise, with non-significantly worse ICCs. 
Age (divided into 2 groups by median age) only affected the repeatability of the         slope, with a 
significantly lower ICC (0.46) in older patients compared with younger (0.86) (p = 0.0001). 
A BMI above 25 led to significantly poorer repeatability of the OUES (ICC 0.90 vs 0.96 against BMI ≤ 25, 
p=0.02),          ratio at nadir and AT (ICC 0.88 vs 0.96, p=0.005; 0.88 vs 0.96, p=0.005 respectively), and 
breathing reserve at the AT (ICC 0.77 vs 0.91, p=0.005). Double product and peak heart rate were more 
reproducible in heavier individuals. Comparing mean differences, the          ratio at nadir,  
 
      slope 
and resting heart rate all fell from test 1 to 2 in patients of normal weight, but rose in those where BMI >25. 
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When comparing reliability between disease categories, the      at AT had a non-significant but slightly weaker 
reliability in the CHF group than the COPD group and it can be seen that there was a much greater difference 
between tests in the mitral group than the COPD group. There was a significantly improved reliability of the 
OUES in patients with mitral valve disease (p=0.01) over the other 2 conditions, however ICC was 0.88 or 
above in all 3 groups. Category of disease influenced the reliability of the           ratio at nadir and at AT with 
better ICC values and smaller mean differences in the COPD and mitral groups compared to the CHF group. 
Patients with mitral valve disease had a larger mean difference in resting and peak heart rate between tests, but 
the ICC was not different between groups, whilst the         slope was significantly less reliable in the 
COPD group. 
There was a significant interaction between test and inter-test interval for      at the AT, with similar ICC values 
but a much greater mean difference in patients performing the tests on the same day (+69 mL/min vs -70 
mL/min). There was almost no mean difference in O2 pulse when tests were performed on the same day (-0.1 
mL/beat), with a large increase on different days (+0.5 mL/beat), and significantly worse ICC values when 
measured on different days compared to the same day (ICC 0.85 vs 0.96, p=0.03). Patients undergoing the tests 
on the same day had a greater mean difference in heart rate, both at rest and peak, but ICCs were not 
significantly different. The         slope was significantly less reliable when measured on different days 
compared to the same day (ICC 0.37 vs 0.76, p=0.03). 
Ramp protocol affected a number of variables’ reliability. O2 pulse was significantly less reliable in patients 
remaining on the 10W protocol compared to moving to either a shallower (p=0.0007) or steeper (p=0.03) 
protocol; the           slope was less reliable in the patients moving to a shallower protocol, with the best ICC in 
the group moving to a steeper protocol. There were changes to the between test mean difference of double 
product, circulatory power, maximum watts and the         slope; the latter showing similar changes to those 
seen in Study 1 in healthy individuals (mean 0.13 mL/min/W decrease in slope in those moving to steeper 
protocols, and a mean 0.63 mL/min/W increase in slope in shallower protocols), with similar ICC values in 
patients on similar or harder protocols, but a significantly worse ICC in those requiring easier protocols. Peak 
heart rate and the         slope displayed the strongest ICCs in patients moving to the steeper protocols and 
the worst in those remaining on the 10W protocol. 
Overall the test-retest reliability of most variables was largely resistant to these 6 potential determinants. Age 
and gender affected reproducibility minimally; whilst weight affected the ICCs for a few variables, generally 
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with gas exchange variables worsening, albeit to a small degree, in the heavier individuals. Inter-test interval did 
not affect the majority of variable’s ICCs. The two determinants that made the most difference are disease 
category and ramp protocol. However within disease category there was no single disease that consistently 
outperformed the others; whereas for ramp protocol it was largely the patients moving to the steepest ramp that 
displayed the strongest test-retest reliability.  
Peak     , OUEP and to a lesser extent the O2 pulse and OUES were largely unaffected. Conversely the  
 
   
   slope was affected by 4 of the 6 determinants. 
 
5.4.9 Changes in slopes throughout testing 
I have plotted sparkline plots of the OUES,           slope and  
 
      slope for 8 healthy individuals, 8 
randomly chosen patients with heart failure and 8 randomly chosen patients with COPD, to examine the 
statement that slopes are reproducible because they do not change as the test evolves. This is a qualitative view 
only; it may be of interest but does not lend itself to statistical techniques. Sparkline plots do not have labelled 
axes. The x-axis in all plots represents time, but scales will differ between plots. The y-axes are the three slopes 
calculated using data only until that time point, therefore the value at the right-most point of the plot represents 
the final value and everything before that ever-decreasing foreshortened data (Figure 5.5). The           slope 
plots utilises data throughout exercise and so we would expect the slope to rise towards the end of exercise if the 
ventilatory compensation point is reached and passed. 
We can see that OUES was largely planar for a significant proportion of latter exercise. In a couple of patients 
with COPD it appeared to be slightly rising at termination of exercise, this pattern was not seen in the CHF 
patients. 
For the         slope it was interesting to see that no slopes appear to decline towards the end of the test, 
generally they were planar with some of the COPD patients experiencing a rise.  
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COPD (n=24) 
 
CHF  (n=43) 
 
MV (n=26) 
 
 
Mean 
Mean diff 
(+LOA) 
SDD/ 
mean 
ICC 
 
Mean 
Mean diff 
(+LOA) 
SDD/ 
mean 
ICC 
 
Mean 
Mean diff  
(+LOA) 
SDD/ 
mean 
ICC 
Peak     (mL/min)  1220 23.9 (-230, 278) 0.11 0.91 (0.85, 0.95)  1329 23.5 (-186, 233) 0.08 0.95 (0.91, 0.98)  1378 25 (-203, 253) 0.08 0.97 (0.95, 0.98) 
Peak     (mL/min/kg)  17.3 0.33 (-3.46, 4.11) 0.11 0.88 (0.79, 0.94)  16.1 0.33 (-1.89, 2.55) 0.07 0.95 (0.91, 0.97)  18.4 0.39 (-2.57, 3.36) 0.08 0.95 (0.91, 0.97) 
     at AT (mL/min)  892 15 (-174, 204) 0.11 0.88 (0.74, 0.95)  955 30.5 (-212, 273) 0.13 0.81 (0.68, 0.89)  932 94.7 (-158, 347) 0.14 0.85 (0.75, 0.91) 
OUES (L/min/10-fold    )  1.93 0 (-0.56, 0.56) 0.15 0.88 (0.79, 0.93)  1.55 0.01 (-0.38, 0.41) 0.13 0.9 (0.83, 0.95)  1.55 -0.01 (-0.32, 0.31) 0.10 0.97 (0.93, 0.99) 
OUEP  31.7 0.74 (-3.25, 4.72) 0.06 0.93 (0.87, 0.96)  33.0 -0.19 (-4.4, 4.03) 0.07 0.9 (0.83, 0.94)  34.8 0.45 (-3.9, 4.8) 0.06 0.87 (0.74, 0.94) 
O2 Pulse (mL/beat)  9.98 0.03 (-1.56, 1.63) 0.08 0.92 (0.82, 0.96)  12.20 0.2 (-1.6, 2) 0.08 0.95 (0.91, 0.97)  10.23 -0.25 (-1.8, 1.3) 0.08 0.97 (0.93, 0.98) 
          slope  33.2 -0.61 (-9.12, 7.91) 0.13 0.86 (0.75, 0.92)  36.0 0.98 (-6.75, 8.71) 0.11 0.84 (0.55, 0.95)  35.2 0.15 (-7, 7.29) 0.10 0.91 (0.83, 0.95) 
          ratio nadir  34.5 -0.43 (-4.66, 3.79) 0.06 0.95 (0.91, 0.98)  33.7 0.84 (-3.45, 5.12) 0.06 0.87 (0.79, 0.92)  32.6 0.5 (-2.41, 3.42) 0.05 0.94 (0.83, 0.98) 
          ratio at AT  36.7 -0.98 (-7.91, 5.96) 0.10 0.88 (0.7, 0.96)  35.9 0.92 (-6.51, 8.34) 0.11 0.78 (0.52, 0.91)  34.7 0.24 (-4.09, 4.56) 0.06 0.91 (0.74, 0.97) 
RER at peak  1.01 -0.01 (-0.13, 0.11) 0.06 0.84 (0.72, 0.91)  1.11 -0.01 (-0.14, 0.13) 0.06 0.79 (0.62, 0.89)  1.13 0.03 (-0.12, 0.17) 0.06 0.7 (0.43, 0.85) 
HR at rest (bpm)  84.7 1.54 (-13.8, 16.9) 0.09 0.85 (0.67, 0.94)  71.6 0.86 (-13.8, 15.5) 0.10 0.77 (0.61, 0.87)  79.8 3.04 (-14.7, 20.8) 0.11 0.75 (0.39, 0.91) 
HR at peak (bpm)  125 1.67 (-19, 22.4) 0.08 0.83 (0.58, 0.93)  111 1.95 (-15.2, 19.1) 0.08 0.92 (0.86, 0.95)  139 7.88 (-14.3, 30.1) 0.08 0.87 (0.66, 0.95) 
DP (mmHg bpm)  22442 951 (-4963, 6864) 0.13 0.86 (0.67, 0.94)  16995 616 (-3965, 5197) 0.14 0.88 (0.79, 0.94)  23288 500 (-6536, 7536) 0.15 0.87 (0.64, 0.96) 
Circulatory Power (mmHg 
mL/min) 
 
218478 
9786 (-49792, 
69365) 
0.14 0.9 (0.8, 0.95) 
 
201970 
6327 (-43799, 
56453) 
0.13 0.93 (0.87, 0.97) 
 
237822 
-2189 (-75546, 
71167) 
0.16 0.95 (0.87, 0.98) 
BR at AT  49.5 0.66 (-9.43, 10.74) 0.10 0.91 (0.79, 0.96)    68.2 -1.85 (-13.64, 9.95)  0.09 0.89 (0.68, 0.96)  70.6 -2.32 (-11.34, 6.71) 0.07 0.89 (0.76, 0.96) 
Breathing Reserve (%)  10.0 0.1 (-20.8, 21) 1.07 0.86 (0.68, 0.94)  40.3 -2.14 (-18, 13.7) 0.20 0.89 (0.75, 0.95)  38.8 -3.43 (-20, 13.1) 0.22 0.84 (0.65, 0.93) 
         slope (mL/min/W) 9.35 0.24 (-2.76, 3.23) 0.16 0.61 (0.15, 0.85)  8.51 0.45 (-2.55, 3.45) 0.18 0.67 (0.32, 0.86)  8.32 -0.15 (-2.65, 2.35) 0.15 0.76 (0.54, 0.89) 
Maximum Wattage (W)  80 2 (-18.6, 22.6) 0.13 0.92 (0.84, 0.96)  93 4.81 (-8.7, 18.3) 0.07 0.95 (0.93, 0.97)  103 8.35 (-9.4, 26.1) 0.09 0.96 (0.91, 0.98) 
        slope  0.05 0 (-0.03, 0.03) 0.30 0.64 (0.14, 0.88)  0.05 0 (-0.02, 0.02) 0.27 0.87 (0.79, 0.92)  0.07 0.01 (-0.03, 0.04) 0.30 0.87 (0.64, 0.96) 
 
Table 5.6: Test-retest reliability measurements between disease categories for selected variables. Mean value, mean between-test difference, standard deviation of the 
difference (SDD) as a ratio of the mean, and intraclass correlation coefficients (ICC) for patients divided into 3 groups by their primary aetiology: COPD; chronic heart 
failure (CHF); and mitral valve disease (MV). LOA = limits of agreement. For other abbreviations see text.
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Figure 5.5: Sparkline plots for the change in OUES,           slope, and  
 
      slope in 24 
participants over time. Data from 8 healthy participants, 8 patients with CHF and 8 patients with COPD were 
analysed. The x-axis on all is time, although this will differ between each test they are all scaled differently. Y-
axes are the 3 slopes as they evolve over time, using data measured from the start of the test to each 
instantaneous point. 
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5.5 Discussion 
Cardiopulmonary exercise testing is regarded to have an excellent degree of reproducibility, as assessed in 
multiple studies (Elborn et al 1990, Lehmann et al 1996, Marburger et al 1998, Skinner et al 1999, Hansen et al 
2004, Bensimhon et al 2008, Keteyian et al 2010). Previous studies have largely focussed on CPX as a whole, 
rather than comparing variables to identify differences in repeatability between them, and also if any other 
factors can influence the repeatability. Another problem with quotations for reproducibility statistics in medicine 
is that studies often perform under the most optimal conditions. They take optimal patients and have experts in 
the field performing the tests. This is not the picture seen in day-to-day clinical practice.  
Here I show multiple measures of the test-retest reliability of multiple CPX variables performed under typical  
clinical conditions, and how they compare to one another in a population with 3 forms of cardiorespiratory 
disease, and in a separate healthy population. I also show how age, gender, weight, disease category and test-
retest interval influence these results in the patient population, and importantly how changing the ramp protocol 
influences reliability in both the patients and healthy adults. 
 
5.5.1 Test-retest reliability and the measures of reproducibility 
The large patient group (93 patients) showed excellent test-retest reliability for peak     , OUES measured using 
the full data and weight adjusted, OUEP, the O2 pulse, peak circulatory power, the            ratio at the VCP 
and nadir, and breathing reserve at the AT and peak. However only the ICCs for peak circulatory power, O2 
pulse and the breathing reserve at the AT, were not significantly worse than peak     . Within the healthy adult 
study, when comparing each participant’s 2 standard tests, the ICCs are generally weaker than for the patient 
population, with the exception of peak     ,  
 
  at the AT and the  
 
      slope. This may just reflect a much 
smaller cohort (n=8). It has been suggested that slopes will have a greater test-retest reliability when compared 
to peak values as they are resistant to differences in effort. My findings would largely dispute this concept. Peak 
     and O2 pulse are the most reliable of gas analysis variables. Whilst OUES had similar ICC and CoV values, 
the           slope and the  
 
      slope had significantly worse values, than peak  
 
  . This is most 
noticeable for the         slope with an ICC of only 0.70 despite the components, peak  
 
   and maximum 
work rate, both being individually very reliable. For the main variables these measures of reproducibility are 
very similar to those seen in the previously described trials, performed under optimal research conditions. 
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The concept of reproducibility is a difficult one and no method is without limitations. Let us consider the ICC. It 
is a function of the within-patient variance and the total group variance. There are a couple of significant 
problems with this. Firstly its magnitude is dependent on the variance of the whole group, but that is not what 
we as clinicians find relevant; it is only the within-patient variance that we are interested in. The magnitude of 
an ICC can be increased by increasing the variance of the population studied, i.e. by choosing a more 
heterogeneous group. This is quite relevant in CPX testing as variables such as peak      will have a wide range 
of values (for example the range of peak      within our patients was 546.5 mL/min – 2248.9 mL/min, a more 
than 4-fold increase). It is not that this incorrectly inflates the ICC in variables like peak     , but it must be 
considered when comparing variables whose magnitudes may not behave similarly to one another. An example 
of this is PETCO2 at the AT, which within the same population had a range of 22-50 mmHg, much smaller than 
that of peak     . A potential way to overcome this limitation is to use a measure that does not involve the whole 
group variance. Coefficients of variation, which I display here alongside the ICC for each variable, are a 
function of the ratio of within-subject standard deviation to the mean of the whole group. This standardises the 
between patient variance but is influenced heavily by the mean value chosen. A commonly described example 
of a problem with CoV is when a temperature measuring device is tested for reliability. Temperature measured 
in Kelvin or Celsius will show identical variance but because they exist on very different scales the CoV 
measurements will be vastly different. Hence CoV measurements are generally only applicable to variables that 
range from zero upwards in a linear fashion without negative values. Breathing reserve in our analysis will be 
highly susceptible to anomalous CoV measurements as the mean is unrepresentative because it is influenced by 
a number of negative values; this will artificially worsen CoV. In contrast to this, variables that display a clinical 
range an order of magnitude below their values will display artificially good CoV measurements. An example 
of this is arterial oxygen saturations, which rarely fall below 90% before a test is stopped, hence there exists a 
possible clinical range of only 0-10 readings, but where mean values will be approximately 10 times this. 
Therefore both ICC and CoV must be viewed together, and the limitations of both considered for each variable 
separately. 
The second problem with ICC, and also a problem for CoV, is that the within-patient variance can be relatively 
unaffected by systematic bias between two tests, i.e. a persistent effect where a second test is higher or lower 
than the first. ICCs were developed to compare 2 or more tests where the values are interchangeable, i.e. test 1 
could be test 2 and vice versa. This may not be the case with clinical exercise testing which may display an 
ordering effect; this may be familiarisation, which I will discuss later, or fatigue. The presence of a systematic 
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bias may not influence the ICC but will certainly influence a clinician’s interpretation of 2 sequential tests, 
therefore knowledge of the mean difference between two tests (and the limits of agreement) is vital to determine 
if a patient’s clinical situation has altered. What is helpful about ICC measurements is that they are non-scalar, 
i.e. they are comparable between any unit of measurement. This allows a comparison of two ICC values, which 
I have performed in this analysis in the form of a z-score of Fisher transformation. 
 
5.5.2 The difference between 2 tests – A familiarisation effect? 
It was proposed many years ago that CPX results can be improved upon on subsequent tests (Elborn et al 1990). 
A substantial difference on treadmill testing existed between tests 1 and 2, with a much smaller difference on 
subsequent tests. This has been termed a learning effect, but has largely not been reproduced to the same degree 
in any study since. Russell et al suggested that the increase in exercise time found by Elborn et al was largely 
due to improved efficiency of walking, as they also found evidence of an increase between tests 1 and 2 (but not 
2 and 3) in exercise time, but unlike Elborn et al, they found no significant change in peak      (Russell et al 
1998). Similarly Bensimhon et al showed a mean increase in exercise time between tests 1 and 2, without a 
concomitant increase in peak      (Bensimhon et al 2008). I show that there was a significant increase in peak 
     between tests 1 and 2, however this had a mean value of approximately 24 mL/min, only about 2.5% of the 
peak values, suggesting that whilst it is statistically significant, it doesn’t appear to be clinically relevant.      at 
the AT also shows a significant bias with statistically significantly higher values on test 2, whilst measures of 
the breathing reserve show the opposite, with significantly lower values on test 2; the magnitude of this 
systematic bias remains small. So these results largely disagree with the original findings by Elborn et al which 
showed a very large learning effect. A small, clinically non-relevant learning effect is apparent for peak     , AT 
and breathing reserve.  
 
5.5.3 The effect of potential determinants on test-retest reliability 
Almost all previous studies of reproducibility have failed to assess factors that may influence the 
reproducibility. Bensimhon et al attempted to answer this question using multivariate analysis. A low peak      
on test 1 predicted a larger change on test 2; however this could just represent regression to the mean. Other 
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factors analysed did not affect the reproducibility (as defined as a change in peak     ) and included site 
experience, gender, symptom status, ethnicity and cause of heart failure. 
I assessed within the patient study, 6 potential determinants for their influence on test-retest reliability. One 
potential problem with this analysis is the problem with multiple testing. For almost 20 variables, for 6 
determinants, p values were calculated. There was no a priori hypothesis for which variables and determinants 
should be affected so a correction factor should be employed. This would lead to a p value for significance of 
0.0026. None of the ICC measurements were that significantly different between groups, therefore all the 
significant differences described in the results section must be interpreted with caution. 
Almost all variables’ repeatabilities appeared unaffected by gender and age. Heavier patients had reduced 
repeatability of a handful of variables but the absolute difference in ICC was not large. Almost all variables’ 
repeatabilities were unaffected if the 2 tests were performed on different days compared to the same day 
suggesting fatigue does not play a role in repeatability. Disease categorisation affected test-retest measures of a 
few variables including the     at the AT, the OUES,  
 
        ratio at nadir and AT, resting and peak heart rate 
and the         slope. However one disease category did not consistently show an improved or reduced 
reliability over the other two, suggesting that these differences may largely be down to random variation. 
 
5.5.4 The effect of a change in ramp protocol on test-retest reliability 
The final determinant, a change in ramp protocol, is especially relevant and therefore warrants specific 
discussion. The other 5 determinants (age, gender, weight, type of disease, and inter-test interval) cannot be 
altered by the physician performing serial tests; their influence on test-retest reliability is unavoidable. However 
chosen protocol may have the potential to significantly alter results.  
Separate to the patient study, a healthy cohort of adults was specifically tested to assess for the influence of a 
change in ramp protocol on test-retest reliability. Maximum work load and         slope were significantly 
affected by both a shallower and steeper ramp compared to the standard ramp. The         slope had much 
lower ICC measurements in the standard vs steeper group (ICC=0.02) and standard vs shallower group (ICC= 
0.47) than the comparison of two standard tests (ICC=0.78), although only when comparing the former with 2 
standard tests is this difference in ICC significant. The magnitude of the slope decreased in steeper protocols in 
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all participants by an average of 1.05, and rose in shallower protocols in 7 of the 8 participants by an average of 
0.69. This pattern was also seen in the patient study.  
A study (Agostoni et al 2005) has investigated the effect of work rate protocol on exercise test variables and 
tested heart failure patients using bicycle ergometry at 3 levels of difficulty (individualised to the patient 
following an initial test). When testing patients to maximum within 5 minutes, peak      and the  
 
      slope 
were lower than at 10 and 15 minutes. The shallowest ramp protocol (cessation at 15 minutes) had a higher 
        slope than 10 minutes with a similar peak  
 
  . It was postulated that these results may represent the 
delay in oxygen kinetics displayed by heart failure patients. O2 consumption at the muscles and the 
corresponding oxygen uptake at the lungs occur later than in healthy controls; this lag means that the measured 
     at any given work rate on an incremental protocol represents the oxygen requirement of a preceding level of 
the ramp. The faster the ramp, the greater the difference that exists between the     we measure and the  
 
  we 
expect for the work rate at that instant. I do not believe this has been comprehensively studied in healthy 
controls, and so my results may be the first to help confirm or refute this hypothesis. If the explanation is a delay 
in oxygen kinetics, as explained above, we would expect for healthy adults, with no delay to their oxygen 
kinetics, that these values should be unaffected or at least less affected by ramp intensity. This is not the case in 
my study, with a greater reduction in the slope in the healthy adults than the heart failure patients. Another 
explanation proposed for the higher values of the slope in longer, shallower protocols, is that alternative 
processes that add to oxygen consumption have time to become prominent. These processes include the use of 
muscle groups alongside the legs (such as arms); less efficient muscle fibre use as fatigue sets in, increased use 
of oxygen by the respiratory muscles; and the reconversion of lactate to glycogen within the liver which in the 
faster, steeper protocols “waits” until exercise finishes (Wasserman et al 2005). I know of no studies to prove 
these hypotheses, but they lead to two important assumptions which can be explored with the results of my 
study. Firstly it is difficult to explain how these effects would differ between patients with heart disease and 
healthy adults, i.e. the influence of protocol intensity on         slope is equal for all, and that seems 
probable given my results with the change in slope being of identical direction when altering ramp difficulty 
between the 2 studies. This is not the same as saying the slope is the same between patients with heart disease 
and healthy adults, only that the slope behaves similarly in both groups to a change in protocol. Secondly these 
hypotheses (and one explanation for the difference in slope between normal adults and those with CHF) is that 
the slope falls after the AT, most noticeably in patients with CHF as a greater proportion of work is performed 
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by anaerobic sources (and therefore does not require oxygen). As can be seen in Figure 5.5 when the slope is 
measured adding progressively more of the test in from the beginning of incremental exercise we do not see a 
clear deterioration in the slope in the latter stages (which would correspond to post-AT) in either CHF or healthy 
adults. They typically plateau with a rise in the slope in many COPD patients. Therefore the argument that the 
effect of protocol intensity on the         slope only appears after the AT appears incorrect based on my 
data. 
Choice of protocol is relevant because within research they are normally standardised so that all participants 
undergo the same ramp. In the reproducibility studies described earlier 10 used a standard protocol for all 
patients with no deviation. Only a single study (Skinner et al 1999) had an easier protocol for more limited 
patients, without deviation in protocol between test 1 and test 2. It is established practice (although this seems to 
be largely experiential rather than evidence-based) that to obtain optimal results for your patient an 
individualised protocol, aiming for maximal exercise within 8-12 minutes, should be employed (Balady et al 
2010), which only the Skinner et al study could claim to have done. The only study that appears to have 
definitively looked into the effect of test duration, did so on only 5 healthy adult males (Buchfuhrer et al 1983). 
My results suggest that should a policy exist for standardised protocols within a clinical institution or a research 
trial, then         slope may be affected but other variables should be largely unaffected. A different protocol 
when comparing two tests in the same patient should be interpreted with caution but aside from the         
slope should be comparable. 
 
5.5.5 Limitations 
Patients within this study were not blinded to the role of the 2 exercise tests. They were aware that test 1 was a 
familiarisation test and as such may have been inclined to perform to less maximal effort on this test. However 
the difference in peak      between the two tests is only 2.5%, a much smaller difference than that seen between 
test 1 and 2 in the study suggesting the need for a familiarisation test (Elborn et al 1990). Peak RER was, on 
average, identical between test 1 and 2, suggesting equal effort. Some patients had undergone previous CPX 
testing (largely treadmill) which may also have affected repeatability, especially if they were more common in 
one group (for example heart failure). However data was not collected as to patient familiarisation with the 
technique. 
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The decision to perform both tests on the same day or different days was not randomised. This may affect the 
validity of the statement that performing 2 tests on the same day does not change the test-retest reliability. 
Seven of the eight healthy volunteers were aged under 30; this small range may have affected reproducibility 
and ideally these results should be confirmed in a cohort of healthy adults with a broader age range. 
A criticism of this reproducibility is that all tests were performed only on a bicycle ergometer. As altering 
protocol had an effect, so too may changing ergometer affect reproducibility. It has previously been shown that 
cycle exercise is associated with a lower peak     ,  
 
        slope and     
 
  slope in patients with CHF 
compared with treadmill (Witte et al 2005). Another study comparing 3 treadmill protocols and a cycle protocol 
showed that the     at the AT was very reproducible between these four tests, but peak  
 
  was not (Piña et al 
1990). However a direct comparison of the reproducibility of variables between a treadmill and a bicycle CPX 
test is still lacking, but was just not possible within this study’s protocol. 
 
5.5.6 Conclusions 
Many variables obtained during CPX show excellent test-retest reliability. This study shows, for the first time, 
multiple values of reproducibility for many variables, and allows direct comparison between variables. Peak 
    , OUES, O2 pulse, peak circulatory power and the  
 
        ratio at nadir showed excellent test-retest 
reliability. Measures of the ventilatory threshold and the           slope showed good test-retest reliability. The 
          ratio at nadir was superior to the ratio at the AT, whilst OUES using foreshortened data was inferior to 
the full OUES.  
The difference in variables between two tests was largely unaffected, or only affected to a small degree by age, 
gender, weight, aetiology of disease, and inter-test interval. The protocol intensity chosen can affect certain 
variables, the         slope was the variable most affected by changes in ramp protocol. 
Peak      and  
 
   at the AT showed a significant familiarisation effect, however this was of small magnitude, 
and unlikely to be of clinical relevance. Most other gas analysis variables did not display this familiarisation 
effect. Overall there appears to be little necessity for a preliminary test in the majority of patients undergoing 
bicycle ergometry CPX testing. 
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6.0 The Observational Study 
  
192 
 
6.1 Abstract 
 
Cardiopulmonary exercise testing (CPX) has established its role in identifying a limiting pathophysiological 
state in patients with a variety of cardiorespiratory diseases. However it remains unclear if any variable can 
show specificity and sensitivity for cardiac over respiratory dysfunction. Certain variables such as the anaerobic 
threshold (AT) and oxygen uptake to work rate relationship (        slope) have been proposed to be specific 
for cardiac dysfunction, but the relative strengths of various variables for this purpose has not been tested. 
96 patients with chronic obstructive airways disease (COPD), chronic heart failure (CHF), severe mitral valve 
disease (MV) or combined COPD and CHF, were prospectively enrolled in an observational study and 
underwent CPX testing on a bicycle ergometer. Following a familiarisation test, each patient underwent a 
personalised second test aiming for maximal exercise after approximately 10 minutes. Multiple variables were 
measured from this second test. Although patients weren’t matched for exercise capacity, peak      was similar 
between the groups (mean 17.3 mL/min/kg COPD, 16.4 mL/min/kg CHF and 18.6 mL/min/kg MV). 
Breathing reserve (area under curve 0.912) and percent of predicted oxygen uptake efficiency slope (OUES) 
(AUC 0.877) had the greatest ability to discriminate between COPD and CHF on ROC curve analysis.      
   slope performed moderately (AUC 0.676), however the      at the AT was not significantly lower in the 
CHF patients and did not show any ability to discriminate (AUC 0.569 for AT as percent of predicted peak     ). 
Breathing reserve was confirmed as an excellent variable discriminating cardiac from respiratory disease. OUES 
had similar ability to discriminate and importantly abnormal values were found in the CHF and MV groups. 
Despite it being considered an important determinant of cardiac dysfunction, the AT could not discriminate in 
this typical clinical population. The         slope showed only moderate discriminant ability. 
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6.2 Introduction 
Cardiopulmonary exercise testing (CPX) is recommended for the identification of the key limiting organ in a 
patient presenting with exercise intolerance or dyspnoea (Balady et al 2010). 
Algorithms have been developed which allow the physician to determine limiting physiology using a handful of 
CPX variables (Neuberg et al 1988, Eschenbacher et al 1990, Milani et al 2004, Wasserman et al 4
th
 Edition 
2005). An example of one of these is shown below (Figure 6.1).
Most authors use an algorithm similar to the one displayed here, with peak      used to determine if patients are 
truly limited and the combination of anaerobic threshold and breathing reserve to thereafter determine cause. 
Eschenbacher et al added the ventilatory equivalent for CO2, a change in arterial oxygen saturations, ischaemic 
changes/symptoms and heart rate reserve (which is similar to the        slope I have measured in all) for a 
more comprehensive analysis. A breathing reserve cut-off of 30% and an anaerobic threshold cut-off of 40% of 
predicted peak      have typically been used to discriminate. It is difficult to validate these algorithms; even if 
you identify resting abnormalities in cardiac and/or respiratory function is it possible to be confident that these 
abnormalities alone limit exercise? Breathing reserve, measured at peak (Nery et al 1983) or at the anaerobic 
threshold (Medoff et al 1998) appears to have good ability to discriminate patients with known respiratory 
disease from healthy adults and those with heart disease. The former study also showed that the     at the 
anaerobic threshold was significantly lower in the cardiac (mitral valve disease) group when compared to a 
COPD and control group. However this was a small study and I have not seen the results replicated elsewhere. 
Whilst an algorithm (if validated) is an excellent approach to identify the limiting physiology in a patient with 
breathlessness or exercise intolerance, it is not useful in serial measurements of a single patient. Whilst 
anaerobic threshold may theoretically fall linearly with worsening disease severity the same cannot be said 
about the breathing reserve. Peak      may be the best way to track changes in a patient with a single disease to 
establish if they are deteriorating or perhaps improving after the initiation of therapy. Increasingly however, 
patients are presenting with multiple pathologies. In one study of heart failure clinic patients 40% had 
spirometry suggestive of COPD (Mascarenhas et al 2008). Therefore should we use peak      to detect changes 
over time? How can we be sure that a reduction in peak      reflects a worsening of cardiac and not respiratory 
function? 
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I aim within this chapter to show, in a prospective cohort of patients with COPD, heart failure, mitral valve 
disease and a mixture of the former 2 conditions, which variables show the best ability to discriminate broadly 
between respiratory and cardiac dysfunction. I propose that peak      will not show an ability, and will be 
similarly reduced in all groups; breathing reserve will show good ability to discriminate respiratory patients; and 
based on the work from the pilot data and other authors’ work, the OUES, the OUEP, the O2 pulse,         
slope and the     at the AT will show good ability to discriminate patients with cardiac disease. 
 
 
 
 
Figure 6.1: Flow Chart for the differential diagnosis of exertional dyspnoea. Neuberg et al. 
Cardiopulmonary exercise testing. The clinical value of gas exchange data. Arch Intern Med 1988; 
148(10):2221-6. Reproduced with permission. 
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6.3 Methods 
6.3.1 Patient recruitment 
This chapter is the central analysis of the principal Observational cohort recruited for the study. Therefore the 
recruitment details are explained in detail within the Methods Chapter alongside inclusion and exclusion criteria. 
Briefly patients from a respiratory clinic with COPD, patients with CHF either from a heart failure clinic or 
awaiting CRT implantation and patients with severe mitral valve disease awaiting surgical correction were 
recruited into this exercise study. Patients identified to have both COPD and CHF were not excluded but for 
much of the analyses performed within this chapter were analysed separately to those with only one diagnosis. 
Each patient underwent lung function tests with gas transfer measurements, total lung volumes and spirometry; 
an echocardiogram; and venous blood sampling including renal and liver biochemistry, full blood count and B-
type natriuretic peptide measurement (BNP). 
 
6.3.2 CPX analysis 
Each patient recruited undertook 2 bicycle ergometer CPX tests performed on a COSMED Quark CPET System 
(COSMED S.r.l. Rome, Italy). The first test, which all patients undertook on an identical 10W/minute ramp 
protocol, was for familiarisation purposes and was ignored in this primary analysis. The second test was 
personalised for each patient based on the length of time cycled on test 1 to achieve an incremental cycle time of 
around 10 minutes. Analysis was conducted on this second test. The identification and measurement of CPX 
variables was performed as per directions from within the Methods Chapter and will not be discussed again 
here. However following on from the identification of a new set of contemporary reference equations (Gläser et 
al 2010, Chapter 4) percent of predicted values for peak     , OUES and O2 pulse will be calculated using these 
equations shown below (Table 6.1). The      at the AT will be presented as a percent of the predicted peak  
 
   
using the SHIP reference equation for peak     . Circulatory power was calculated as the product of peak 
systolic blood pressure and peak       Whilst this data has also generated reference ranges for the  
         relationship,  
 
      slope and the     
 
  slope these variables do not behave in a typically linear 
manner, the magnitude of a percent of predicted value is not easily interpretable, and therefore these variables 
will just be displayed giving their raw values.          slope is displayed in 2 forms: slope 1 using data until the 
VCP; and slope 2 using data throughout exercise, in keeping with previous chapters. It was noticed that the 
         slope and ratio behaved differently between the groups, so I therefore hypothesised that the difference 
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between these 2 values may have some discriminatory power. This was calculated as          slope (data to VCP 
only) minus the          ratio at nadir.  
 
 Reference Equations for CPX variables 
Peak      M -69 + 1.48*Age + 14.02*Height + 7.44*Weight - 233.72*cs - 0.2256*Age
2
 
(mL/min) 
F -588 - 11.33*Age + 9.13*Height + 26.88*Weight - 0.12*Weight
2
 
O2 pulse M -0.7 - 0.044*Age + 0.064*Height + 0.086*Weight - 0.62*cs + 1.73*bb 
(mL/beat) 
F -3.7 - 0.004*Age + 0.056*Height + 0.075*Weight + 0.42*bb 
OUES M +907.7 - 11.51*Age + 5.67*Height + 8.62*Weight - 49.99*bb - 214.53*cs + 172.97*f 
 
F -182.4 - 8.89*Age + 10.12*Height + 10.51*Weight -117.65*bb -21.45*cs + 40.31*f 
 
Table 6.1: Reference ranges for peak      (mL/min), O2 pulse (mL/beat) and OUES (mL/min/10-fold 
increase in    ) for males (M) and females (F) based on the SHIP data. Age is measured in years; height in 
cm; weight in kg; cs (current smoker) = 0 for no, 1 for yes; bb (beta-blocker) = 0 for no, 1 for yes; f = FEV1 (L). 
 
6.3.3 Hypotheses 
I hypothesised that peak      would show no ability to discriminate between patients with cardiac or respiratory 
disease. Markers of lung function and cardiac function would influence peak     . Conversely variables 
including the OUES, the OUEP, the O2 pulse,         slope and the  
 
  at the AT, would all successfully 
discriminate these 2 disease categories, with high sensitivity and specificity for cardiac disease, and would 
therefore not be affected by markers of lung function. 
 
6.3.4 Statistical analysis 
Statistical analysis was performed using Stata version 11.1 for Windows (StataCorp LP, College Station, 
Texas). All patient characteristics and CPX variables were assessed for normal distribution using Shapiro-Wilk 
test. Because of multiple variables, and no a priori hypotheses regarding which variables may behave non-
normally, a Sidak correction was employed. For those variables showing a non-normal distribution only if 
logarithmic transformation significantly normalised distribution was this transformation used. For all other non-
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normal distributions the raw value was used in non-parametric analyses when possible. All values within tables 
are displayed as mean ± standard deviation for normally distributed data, and median (25
th
, 75
th
 percentiles-the 
interquartile range) for non-normally distributed data. 
To analyse for differences between groups, oneway analysis of variance (ANOVA) was used, with addition of 
the co-variates age, gender and weight. For between group differences in CPX variables three other co-variates 
were added to the model, beta-blocker use, eGFR and current smoking status, for which ex-smokers were 
classified with non-smokers. This distinction was made because cigarette smoke (principally carbon monoxide) 
can limit oxygen transport in haemoglobin; this is the effect I wish to analyse for as a confounder, and would 
therefore be inappropriate in ex-smokers. Although patients were encouraged to refrain from smoking prior to 
testing, carbon monoxide can remain in the blood for 48 hours, and we could not mandate smoking cessation for 
this length of time to all patients. For categorical variables the χ2 test was performed to assess for between group 
differences. For non-normally distributed variables the Kruskall-Wallis test was used in place of ANOVA. 
When comparing 2 continuous variables linear regression was performed. To assess for the influence of 
respiratory function on CPX variables a multivariate model including age, gender and weight was constructed. 
The primary analysis of this study is the ability of each variable to discriminate between COPD and cardiac 
disease. This was assessed using Receiver Operator Characteristic (ROC) curve analysis with area under curve 
(AUC) measurements. Comparison of the AUC values from key variables were analysed for significant 
differences to identify optimal variables. The groups tested against each other were: 1) all cardiac patients 
against COPD patients (excluding mixed disease); 2) CHF patients against COPD patients (excluding mixed 
disease); 3) CHF patients against COPD with patients identified by their primary diagnosis. The ROC model 
was constructed so that the AUC was always >0.50, however this does not identify direction of the 
discrimination i.e. whether higher or lower values predict cardiac disease or COPD. Therefore for some 
variables the AUC reflects ability to discriminate cardiac disease, and for others the ability to discriminate 
respiratory disease. However because the purpose of the study is not to identify a specific threshold for 
detection, merely to identify a variable which would appear to be relatively sensitive and specific for cardiac 
disease, this distinction is not relevant. 
A p value of <0.05 was considered significant throughout (with the exception of the Shapiro-Wilk test as 
described above).   
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6.4 Results 
6.4.1 Patient recruitment and characteristics 
257 patients were approached following identification as potentially appropriate for the study by members of 
their clinical team. 135 patients were either clearly inappropriate, declined, could not be further contacted, or 
met one or more of the exclusion criteria after detailed discussion. 122 patients agreed to be part of the study 
and appeared appropriate. Of these 122 a further 9 did not turn up to the original and repeated appointments; 7 
were either too unwell, had/were experiencing a recent decompensation or could not cycle; 1 patient had 
(unknown to him) being experiencing significant ventricular arrhythmias confirmed on CRT interrogation; 1 had 
an excessive BP response soon after testing began requiring immediate cessation of testing; 1 had completely 
normal spirometry (from the COPD group) so was not pursued, and a final patient could not tolerate the CPX 
mask.  
This left 102 patients that underwent the study protocol. 2 patients recruited near the beginning of the study had 
moderate to severe, asymptomatic, aortic stenosis, which was then dropped as an inclusion criteria.  2 patients 
with COPD were excluded because their spirometry failed to show respiratory limitation at rest significant 
enough for inclusion (although it was still abnormal). 1 patient with CRT was excluded due to recovery in left 
ventricular function following CRT (aetiology of left ventricular systolic dysfunction was alcoholic 
cardiomyopathy and the patient was now abstinent) and 1 patient with mitral valve disease was excluded 
because his MR was later deemed not of sufficient severity to require reparative surgery.  
3 patients did not have data from both a familiarisation and main test, but these 3 were still included in the final 
analysis (two patients underwent the full study protocol but did not have reliable data in the familiarisation test, 
and one patient did not wish to perform a second test or echocardiogram – his familiarisation test is used for the 
main analysis). 
 Of the final 96 patients (72 male), 43 were patients with CHF (14 undergoing CRT and 13 having undergone 
CRT), 26 with mitral valve disease and 27 with lung disease (25 showed obstructive physiology and 2 restrictive 
physiology but had a formal physician-made diagnosis of COPD). The patient characteristics of the total group 
and by disease category condition are shown in Table 6.2. 18 from 26 patients with mitral valve disease were 
symptomatic. 7 patients fulfilled criteria for inclusion in the mixed group. 4 of these patients had COPD as their 
primary diagnosis but 3 were known to have ischaemic heart disease and on echocardiography had 
abnormalities of left ventricular function, and a fourth had an elevated BNP and right atrial and ventricular 
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dilatation. 3 heart failure patients were known to have COPD. 5 further heart failure patients and 5 mitral valve 
patients had obstructive spirometry which met GOLD criteria category 2 but not higher. 2 were known to have 
long-standing asthma (not COPD) but none of the remaining patients had a formal secondary diagnosis or 
symptoms suggestive of COPD, and only 1 was a current smoker. Of these 10 patients 4 were reclassified with 
non-obstructive or mildly obstructive spirometry (GOLD category 1) on repeat spirometry, 2 had FEV1 values 
just below the 80% cut-off to distinguish between category 1 and 2, and 4 lay well within category 2. They were 
categorised within their principal disease category. Within the COPD category, 2 patients met the criteria for 
GOLD category 1 (mild), 12 patients met criteria for GOLD category 2 (moderate), 10 for category 3 (severe) 
and 3 for category 4 (very severe). 
Patient variables were assessed for a normal distribution. FVC and the FEV1:FVC ratio were the only major 
respiratory variables non-normally distributed. Echocardiographic variables were largely non-normally 
distributed, however they showed a bivariate distribution (which would be expected) and within each disease 
category the distribution was normal by Shapiro-Wilk testing; the FVC and FEV1:FVC ratio largely showed this 
pattern as well. LA volume was non-normally distributed throughout each group. BNP was non-normally 
distributed throughout the whole group and the individual groups. Therefore where necessary non-parametric 
tests were used but BNP and LA volume were the only variables logarithmically transformed. 
There were significantly more males in the CHF group, which also had a significantly greater BMI than the 
other 2 groups. Haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) were significantly lower in 
the CHF group, whilst BNP was significantly higher in the 2 cardiac groups compared to the COPD group. FVC 
was significantly lower in the COPD group compared to the others, but only significantly lower than the CHF 
group as a percent of predicted. FEV1 and percent of predicted FEV1, along with the FEV1:FVC ratio were 
significantly lower in the COPD group compared to both cardiac groups. All cardiac indices displayed in Table 
6.2 were significantly different between the CHF and COPD groups, and the CHF and mitral groups. LV 
diastolic volume (LVEDV) and LA volume were significantly larger in the mitral compared to the COPD group, 
but systolic volume (LVESV), ejection fraction (LVEF), fractional shortening (LVFS), RV S’ wave and TAPSE 
were similar. A significantly greater proportion of patients within the CHF group (34/40 patients), and a 
significantly smaller proportion within the COPD group (1/23 patients) regularly took beta-blockers. The use of 
beta-blockers did not significantly affect the results when added to any model of baseline characteristics. 
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 p between 
groups  
Mean ± SD/ 
Median (IQR) 
All 
Mean ± SD/ 
Median (IQR) 
COPD 
Mean ± SD/ 
Median (IQR)  
CHF 
Mean ± SD/ 
Median (IQR) 
MV 
Age (yrs) 0.32 65.0 ± 10.9 65.8 ± 9.8 66.6 ± 11.1 61.7 ± 11.3 
Male (n, %) 0.02 72, 75% 18, 66.7% 38, 88.4% 16, 61.5% 
Height (cm) 0.08 169.9 ± 9.9 166.5 ± 7.5 171.3 ± 9.2 171.2 ± 12.3 
Weight (kg) 0.03 77.3 ± 16.0 71.3 ± 16.4 82.7 ± 15.5 74.4 ± 13.8 
BMI (kg/m
2
) 0.01 26.6 ± 4.5 25.6 ± 4.9 28.1 ± 4.1 25.3 ± 4.0 
Diabetics (n, %) 0.06 10, 10.4% 1, 3.7% 8, 18.6% 1, 3.8% 
Current smokers (n, %) 0.09 12, 12.5% 5, 18.5% 7, 16.3% 0, 0% 
Hypertensive (n, %) 0.17 42, 43.8% 12, 44.4% 19, 44.2% 11, 42.3% 
Hb (g/dL) 0.02 14.0 ± 1.24 14.4 ± 1.17 13.8 ± 1.37 14.0 ± 1.03 
eGFR (mL/min/1.73m
2
) <0.01 77.8 ± 19.1 84.7 ± 19.6 70.6 ± 18.2 82.8 ± 16.4 
BNP (pg/mL) <0.001 85 (35, 195) 32.5 (13, 50) 118 (85, 286) 85 (43, 222) 
FVC (L) <0.01 3.26 (2.57, 3.91) 2.75 (2.29, 3.06) 3.59 (3.01, 4.31) 3.29 (2.75, 3.88) 
FVC (% predicted) 0.03 96.6 ± 22.9 87.3 ± 25.1 100.1 ± 18.0 100.5 ± 25.8 
FEV1 (L) <0.001 2.17 ± 0.90 1.28 ± 0.49 2.52 ± 0.73 2.50 ± 0.87 
FEV1 (% predicted) <0.001 78.2 ± 26.5 50.8 ± 19.6 89.7 ± 20.2 87.7 ± 21.4 
FEV1:FVC ratio (%) <0.001 66.9 (52.8, 74) 43.3 (35.8, 55.9) 71.1 (62.7, 77) 68.6 (65.1, 75.1) 
KCO (min
-1
) 0.002 1.16 ± 0.35 0.96 ± 0.40 1.20 ± 0.32 1.30 ± 0.29 
Ramp protocol (W/min) 0.05 11.3 ± 3.3 10.3 ± 2.8 11.3 ± 2.9 12.3 ± 4.0 
LVEDV (cm
3
) <0.001 1245 (89, 165) 72 (55, 92) 149 (112, 193) 125 (106, 147) 
LVESV (cm
3
) <0.001 56.5 (37.2, 99.8) 28.9 (19.7, 37.2) 99.9 (75.9, 145.3) 49 (38.5, 54.2) 
LVEF (%) <0.001 51.3 (33.8, 59.5) 59.5 (53.0, 64.5) 33.5 (30.8, 39.1) 58.4 (54.9, 65.7) 
LVFS (%) <0.001 23.2 (16.0, 29.8) 27.5 (23.3, 31.9) 15.2 (10.9, 18.8) 30.4 (25.6, 34.6) 
LA volume (cm
3
) <0.001 74.3 (52.2, 116.5) 43.0 (33.3, 63.8) 74.2 (56.4, 103.3) 135 (101, 170) 
TAPSE (mm) 0.001 21 ± 5 22 ± 4 19 ± 4 23 ± 5 
RV S’ wave (cm/s) <0.001 11.4 (9.4, 14) 12.5 (10.7, 15.6) 9.6 (8.7, 11.8) 12.8 (10.6, 16.6) 
 
Table 6.2: Patient characteristics. p values between groups by ANOVA with age and gender as co-
variates for continuous variables and χ2 analysis for categorical variables. Normally distributed data is 
presented as mean ± SD, with median (IQR) for non-normally distributed data. For abbreviations see text. 
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6.4.2 CPX results and influencing factors on exercise capacity 
Table 6.3 gives the mean values for the CPX variables overall and within each group. 8 patients in the COPD 
group, 1 in the CHF group and 1 in the mixed group did not reach anaerobic threshold, the variables recorded at 
the AT reflect only the patients reliably achieving the AT. On analysis of CPX variables, OUES/kg both 
measures of the          slope, all measures of the  
 
       ratio, resting heart rate, arterial oxygen saturations, 
breathing reserve at the AT and peak, and the        slope all showed a significantly non-normal distribution 
(p<0.0026 by Shapiro-Wilk test). All measures of the           relationship were made marginally more 
normally distributed by logarithmic transformation, but resting heart rate was the only variable which became 
significantly more normally distributed following logarithmic transformation and therefore transformed in this 
way for this analysis. 
Peak      (as the considered overall marker of exercise capacity) was assessed for the influence of certain patient 
factors. Creatinine and eGFR was related to peak     /kg (R
2
=0.05, p=0.03 and R
2
=0.08, p<0.01). Haemoglobin, 
sodium and bicarbonate did not relate to peak      as an absolute or weight adjusted value. BNP was related to 
both measures of peak      (R
2
=0.12, p=0.002 and R
2
=0.13, p=0.001 respectively). Atrial fibrillation compared 
with sinus rhythm did not significantly reduce peak      (p=0.90). No other rhythm abnormalities were found in 
the Observational study. 
 
6.4.3 The influence of the lungs on CPX variables 
As shown in the pilot data in Chapter 3 in a retrospective analysis of patients with heart failure, abnormal 
spirometry related to the peak     , loosely to the AT, and not to the  
 
       slope or OUES. The influence of 
FEV1 and percent of predicted FEV1 as continuous variables on CPX variables were therefore assessed using a 
regression model including age, gender, weight and eGFR (as these variables were significantly different 
between groups and affected peak     ) as co-variates on this prospective dataset. I also assessed for a relation 
between these CPX variables and the diffusional capacity of the lungs as measured by the transfer coefficient 
corrected for Hb (KCO (Hb)). Because this is a multivariate model I have not shown the R
2
 values, as these 
would pertain to the whole model rather than just the influence of FEV1 on the CPX variable. 
FEV1 and percent of predicted FEV1 related to peak      (p<0.02 for both), peak  
 
  /kg (p<0.005 for both), 
percent of predicted peak      (p<0.02), OUES (p<0.01), OUES/kg (p<0.005), percent predicted OUES 
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(p<0.001), OUEP (p<0.01),          slope measured throughout exercise (but not when measured until the VCP) 
(p<0.05) breathing reserve both at the AT (p<0.001) and at peak (p<0.001). The difference between the           
slope and           ratio related to the percent of predicted FEV1 only (p=0.02). It was interesting to see a 
relation between both          slope and OUES and FEV1; however these significant relationships were in the 
opposite direction to that expected, i.e. a rise in FEV1 related to lower OUES and higher          slope 
measures. For all measures of peak     , the OUEP and breathing reserve a fall in FEV1 led to a fall in these 
values. 
Peak      related to the KCO (Hb) (p<0.001), as did peak  
 
  /kg (p<0.001), percent predicted peak  
 
    
(p=0.001),      at the AT (p=0.03) (but not as a percent of predicted peak  
 
  ), OUEP (p<0.001), O2 pulse 
(p=0.01) and percent predicted O2 pulse (p=0.01),           slope until the VCP, (p=0.01) (but not measured 
throughout exercise),           ratio at the nadir (p<0.001) and AT (p<0.01), but not VCP, PETCO2 at the AT 
(p=0.003), circulatory power (p=0.006), and breathing reserve at peak (p=0.01) (but not at AT). For all of these 
variables, including the measures of          , a reduction in KCO related to a deterioration in the CPX variable 
(so therefore a rise in the measures of          ). 
 
6.4.4 Differences in variables between groups 
ANOVA (with age, gender and weight as co-variates) was performed to look for between group differences 
ignoring the 7 patients included in the mixed group. Figure 6.2 shows how each patient within each group and 
the within group means for the 3 diagnostic categories.          ratio at the VCP was not investigated because 
patients with COPD rarely reached this threshold. 
No measure of the peak      or the  
 
  at the AT was significantly different between the 3 groups (p>0.17 in all). 
OUES as an absolute value (p<0.001), adjusted for weight (p<0.001) and as percent predicted (p<0.001) was 
significantly different between groups with significantly lower values in the 2 cardiac groups compared to the 
COPD groups (but not different between the 2 cardiac groups). Foreshortened OUES measures were inferior to 
full data OUES (not shown in tables). OUEP and O2 pulse showed a borderline significant difference between 
the groups (p=0.02 and p=0.03 respectively). O2 pulse as a percent of predicted was not different between the 
groups. No measure of the          relationship was different between groups, except for the difference between 
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the slope and ratio (p=0.003) which was significantly lower in the cardiac groups. Heart rates at rest and peak 
exercise were significantly different between groups (p<0.001 both) with lower resting heart rates in the 2 
cardiac groups, significantly lower heart rate at peak in the CHF group compared to both, and significantly 
higher peak heart rate in the MV group. Both double product and peak circulatory power were significantly 
lower in the CHF group (p<0.001 both between groups) than the MV or COPD groups. Breathing reserve at the 
AT and at peak exercise, and the peak minute ventilation were also all different between groups (p<0.005 for 
all), with similar results for the 2 cardiac groups, and significantly lower values in the COPD group. The 
        slope was significantly lower in the CHF and MV groups (p=0.02), the     
 
  slope was 
significantly higher in the MV group (p=0.01) and the        intercept was significantly lower in both cardiac 
groups (0.002). Because measures of the          slope, breathing reserve, peak  
 
 ,         slope and 
       slope were non-normally distributed they were also assessed using the non-parametric Kruskall-Wallis 
test (no co-variates), with results the same as for ANOVA. The addition of the use of beta-blockers, eGFR and 
current smoking status to the model largely didn’t change the results with the exception of the O2 pulse which 
was no longer significantly different between groups after adjustment for beta-blocker use, and DP and 
circulatory power which were not significantly different between groups after adjustment for beta-blockers and 
smoking. Whilst beta-blocker use was related to peak heart rate, it did not affect the between categories 
difference.  
The absence of a reliably measurable AT was found in 7 patients with COPD (30.4%) and 1 patient with CHF 
(2.5%), and this may have affected the ability of the ANOVA to differentiate between groups; therefore for 
these 8 patients the peak     was also recorded as the  
 
  at the AT for a secondary analysis. This did not alter 
the results seen when analysing only patients who did achieve AT. 
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 All COPD (n=23) CHF (n=40) MV (n=26) Mixed (n=7) 
Peak      (mL/min) 1311.6 ± 376.8 1190.4 ± 316.5 1348.9 ± 348.0 1390.3 ± 460.6 1205.4 ± 322.6 
Peak      (mL/min/kg) 17.1 ± 4.3 17.3 ± 4.7 16.4 ± 3.6 18.6 ± 5.0 15.3 ± 2.8 
Peak      (% predicted) 71.5 ± 16.2 71.2 ± 18.2 70.2 ± 14.9 73.7 ± 16.7 68.8 ± 9.0 
AT (mL/min) 964.2 ± 248.3 885.3 ± 182.1 975.9 ± 212.5 979.5 ± 308.0 1019.0 ± 336.1 
AT (% of pred peak     ) 52.2 ± 12.5 53.0 ± 11.0 51.0 ± 13.3 52.6 ± 12.5 57.0 ± 11.1 
OUES * 1.67 ± 0.58 1.91 ± 0.56 1.57 ± 0.47 1.55 ± 0.65 1.87 ± 0.78 
OUES/kg * 20.9 (18.0, 25.3) 25.6 (21.4, 30.7) 19.4 (16.2, 22.2) 20.2 (17.2, 24.7) 21.2 (19.3, 32.1) 
OUEP * 33.1 ± 5.2 30.8 ± 5.5 33.3 ± 5.1 35.0 ± 4.2 32.7 ± 6.4 
O2 Pulse (mL/beat) * 11.1 ± 3.1 9.4 ± 2.0 12.5 ± 3.0 10.1 ± 3.2 13.4 ± 2.6 
         slope 1 34.3 (29.5, 38.1) 32.4 (27.2, 40.1) 34.8 (30.8, 38.1) 33.8 (29.1, 36.4) 34.7 (25.6, 39.8) 
         slope 2 35.4 (31.2, 40.0) 32.4 (29.2, 40.1) 36.4 (33.2, 39.0) 36.2 (33.0, 41.6) 34.7 (25.6, 39.8) 
         ratio nadir 32.5 (29.9, 38.1) 33.0 (29.7, 39.3) 32.8 (29.8, 36.6) 31.7 (30.2, 35.6) 35.9 (29.5, 41.7) 
         ratio at AT 34.5 (31.5, 38.4) 35.8 (30.9, 40.1) 34.5 (31.5, 39.0) 32.8 (31.7, 37.1) 35.8 (30.1, 37.4) 
RER at peak 1.08 ± 0.12 1.00 ± 0.13 1.11 ± 0.10 1.14 ± 0.11 1.00 ± 0.05 
PETCO2 at AT (mmHg) 35.4 ± 4.3 35.7 ± 4.5 35.2 ± 4.2 35.5 ± 3.9 36.3 ± 6.8 
HR at peak (bpm) * 124 ± 26 128 ± 18 114 ± 22 143 ± 26 98 ± 18 
DP (mmHg bpm) * 20356 ± 6552 23740 ± 5764 17566 ± 5029 23538 ± 6795 13839 ± 3485 
Circ power (mmHg mL/min)  * 216355 ± 84191 221155 ± 77057 208376 ± 68638 236728 ± 111159 171200 ± 58918 
Peak oxygen saturations (%) 94 (95, 98) 94 (91, 98) 98 (97, 99) 97 (96, 98) 94 (91, 96) 
BR at AT (%) * 68.8 (54.3, 76.3) 48.5 (43.6, 66.0) 72.3 (63.2, 77.4) 71.1 (63.3, 78.4) 38.0 (24.8, 59.3) 
BR (%) * 34.8 (16.8, 45.2) 11.1 (0.7, 28.0) 44.1 (34.7, 52.7) 39.8 (26.2, 45.3) 12.4 (-7.6, 38.1) 
        Slope * 9.0 (8.0, 9.9) 9.6 (9.2, 10.8) 8.7 (7.9, 9.8) 8.7 (7.6, 9.6) 9.5 (8.3, 9.7) 
       Slope * 0.044 (0.03, 0.06) 0.046 (0.04, 0.06) 0.038 (0.03, 0.05) 0.057 (0.04, 0.08) 0.036 (0.03, 0.04) 
Peak work rate (W) 92.8 ± 35.8 75.6 ± 32.2 95.7 ± 29.0 106.9 ± 44.3 79.9 ± 25.2 
Duration (mins:secs) 11:03 ± 1:54 10:11 ± 2:43 11:22 ± 1:27 11:26 ± 1:38 10:36 ± 1:07 
 
Table 6.3: CPX results for a number of principal variables for the whole cohort and then 
divided into disease categories; chronic obstructive pulmonary disease (COPD), chronic heart 
failure (CHF), mitral valve disease (MV) and mixed cardiac and respiratory abnormalities. 
Results are displayed as mean ± SD for normally distributed variables and median (25
th
, 75
th
 
percentiles) for non-normally distributed variables. * p<0.05 for difference between first 3 groups (see 
text for differences between which groups) 
 
205 
 
 
 
 
 
 
Figure 6.2: Dotplots for 9 CPX variables in patients with COPD, CHF, mitral valve disease (MV) 
and mixed disease. Each dot represents a single patient and mean values are represented by black lines.  
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6.4.5 ROC curve analysis 
Received Operator Characteristics (ROC) curve analysis was conducted on all the major variables to identify 
which had the ability to discriminate between a cardiac and respiratory diagnosis. The area under curve (AUC) 
for each variable was calculated for all cardiac patients against COPD patients (excluding mixed disease), CHF 
patients against COPD patients (excluding mixed disease) and CHF patients against COPD with patients 
identified by their primary diagnosis (Table 6.4). The AUC for each of the divisions of OUES (25-75, 0-50, 0-
70 and 0-90) were also calculated but, because they were all inferior to OUES using the full data, are not 
included in the table. The ROC model was constructed so that the AUC was always >0.50, however this does 
not identify direction of the discrimination i.e. whether higher or lower values predict cardiac disease or COPD. 
There were not sufficient measurements of the          slope at the VCP in the COPD group to construct an 
ROC curve. 
The close nature of the AUC for percent predicted peak      to 0.500 confirms that these groups are largely well 
matched in terms of exercise capacity. 
Variables with good AUC values to discriminate between COPD and cardiac disease included breathing reserve 
(AUC 0.899), breathing reserve at the AT (AUC 0.861), OUES/kg (AUC 0.822) and percent of predicted OUES 
(AUC 0.864). None of these values were significantly different from one another. For these variables the ability 
to discriminate improves marginally if only CHF patients were compared with COPD, and drops marginally if 
patients with mixed disease were also included under their primary diagnosis. The         slope had an 
intermediate AUC, but this was significantly worse than percent of predicted OUES. Measures of the     
     relationship did not reliably discriminate except for the difference between the slope and ratio at nadir. This 
value had an AUC of 0.761 between the 2 groups with positive measures (corresponding to ratios greater than 
slopes) predicting COPD, and negative values (corresponding to ratios less than slopes) predicting cardiac 
disease. The      at the AT as an absolute value and as a percentage of predicted peak  
 
   were not strong 
discriminators. 
The O2 pulse showed a reasonable ability to discriminate when comparing only CHF with COPD; however the 
highest values were seen in the CHF group and the differences disappear when displayed as a percentage of 
predicted. Double product was useful to discriminate between CHF and COPD but when mitral valve patients 
are introduced it significantly worsened. Reason for test cessation compared between fatigue/leg fatigue (n=50) 
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and breathlessness (n=22), ignoring patients stopping for both or alternative reasons (n=24), was not a strong 
discriminator (AUC 0.6691). 
A secondary analysis was performed re-classifying the 3 CHF and 1 MV patient with obstructive spirometry 
(but not known COPD) into the mixed group. All AUC values were within 2% (0.02) for the CHF versus COPD 
and cardiac versus COPD analyses. ROC curves for some of the key variables are shown in Figure 6.3. 
Accepting OUES and breathing reserve as the 2 best discriminators these variables were examined more closely. 
OUES had a good ability to discriminate between CHF and COPD (AUC 0.8772; 95% confidence intervals 
0.791, 0.963) when measured as a percentage of predicted. As a weight adjusted model the AUC was similar, 
but as an absolute value it was significantly worse, which may reflect the significant demographic differences 
between the groups. Lower values were predictive of CHF over COPD. Although the hypothesis of this study is 
not to generate a threshold, a percentage of predicted OUES of 89.3% gave a sensitivity of 78.3% with a 
specificity of 85% to identify CHF and correctly categorised 82.5% of patients (Figure 6.4). 
Breathing reserve had a slightly better, albeit not significant, ability to discriminate (AUC 0.9120; 95% 
confidence intervals 0.844, 0.980). In this case the lowest values were suggestive of COPD not CHF. A BR 
threshold of 33.6% gave a sensitivity of 80% with a specificity of 100% to identify COPD and correctly 
categorised 87.3% of patients (Figure 6.4). 
I looked to see if the combination of RER and BR at peak improved discrimination. The product of these 2 
variables showed a non-significant improvement in AUC for discriminating CHF from COPD (AUC=0.9283; 
95% confidence intervals 0.867, 0.989) and cardiac disease from COPD (AUC = 0.9177; 95% confidence 
intervals 0.862, 0.972) 
When patients were categorised based on the recommended algorithm (Figure 6.1) the results were as follows: 
15 from 23 with COPD were categorised as respiratory limitation, none were categorised as circulatory 
limitation; only 6 from 40 patients with CHF, and 2 from 26 with mitral valve disease, were categorised as 
circulatory limitation, the majority being categorised as normal, or poor effort/deconditioning; and none of the 7 
patients with significant cardiac and respiratory disease were categorised as mixed lesions. 
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  Cardiac vs COPD 
(excluding mixed) 
 CHF vs COPD 
(excluding mixed) 
 Cardiac vs COPD      
(by primary diagnosis) 
Peak      (mL/min)  0.6364  0.6370  0.6141 
Peak      (mL/min/kg)  0.5053  0.5554  0.5105 
Peak      (% predicted)  0.5204  0.5087  0.5030 
AT (mL/min)  0.6021  0.6239  0.5605 
AT (% of pred peak     )  0.5405  0.5692  0.5784 
OUES  0.6703  0.6625  0.6637 
OUES/kg  0.8221  0.8478  0.8084 
OUES (% predicted)  0.8656  0.8772  0.8642 
OUEP  0.6686  0.6272  0.6253 
O2 Pulse (mL/beat)  0.6902  0.7941  0.6678 
O2 Pulse (% predicted)  0.5007  0.5446  0.5070 
         slope 1  0.5903  0.6120  0.6001 
         slope 2  0.6644  0.6750  0.6702 
         ratio nadir  0.5191  0.5043  0.5056 
         ratio AT  0.5579  0.5419  0.5033 
         slope - ratio  0.7609  0.7750  0.7751 
RER at peak  0.7470  0.7337  0.7665 
PETCO2 at AT (mmHg)  0.5490  0.5526  0.6070 
HR at peak (bpm)  0.5224  0.6913  0.5172 
DP (mmHg bpm)  0.6784  0.7943  0.6388 
Circ power (mmHg mL/min)  0.5213  0.5534  0.5167 
Peak oxygen saturations (%)  0.7748  0.7962  0.7526 
Breathing reserve at AT (%)  0.8605  0.8752  0.8668 
Breathing reserve (%)  0.8986  0.9120  0.8991 
        Slope  0.7039  0.6761  0.6918 
       Slope  0.5321  0.6315  0.5169 
 
Table 6.4: Area under curve (AUC) for a number of CPX variables following 3 ROC curve 
analyses: patients with only heart failure or mitral valve disease versus COPD (n=89); patients 
with only heart failure versus COPD (n=63); and patients with cardiac disease versus COPD 
by primary diagnosis (mixed diseases allowed) (n=96). The AUC does not indicate the direction 
of the discrimination. 
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Figure 6.3: Receiver Operator Characteristic (ROC) curves to differentiate between COPD and 
CHF. Variables shown include peak      and OUES (as percent of predicted),  
 
   at the AT and the 
        slope,  
 
       slope and ratio at nadir, and the breathing reserve at the AT and peak 
exercise. In the top 2 graphs lower values of each variable discriminate CHF, whilst in the bottom 2 
graphs lower values discriminate COPD. At multiple cut-offs the sensitivity and specificity of each 
cut-off to predict one disease over the other is calculated. These are then plotted against each other as 
1-specificity on the x-axis, and sensitivity on the y-axis. The area under the curve defined by these 
points is calculated (AUC). A highly sensitive and specific variable will have an AUC close to 1. An 
AUC of 0.5 (the line of identity on each plot) will not discriminate. 
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Figure 6.4: Diagnostic capabilities of OUES and BR cut-offs. Using the optimal cut-offs identified for OUES 
(as a percent of predicted) and breathing reserve (%) from ROC curve analysis we can see how many patients 
would have their diagnosis of either COPD of CHF correctly identified by each variable. Numbers in red 
represent an incorrect diagnosis. 
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6.5 Discussion 
Cardiopulmonary exercise test variables are generally closely related to one another, but there exist specific 
differences between them which may mean certain variables are more useful in certain circumstances than 
others. Peak      is the most widely used and discussed exercise variable for patients, both with respiratory and 
cardiac diseases. I hypothesised that this would not have any ability to discriminate between the 2 disease 
categories and we can see with an AUC of approximately 0.500 that the null hypothesis is proved. This is an 
important proof of concept to have in place for further analysis. Peak      is known to be affected by both 
categories of disease, and the lack of a significant difference between groups in ANOVA and by ROC curve 
analysis means that the groups are potentially well matched in exercise capacity. This allows me to analyse 
further variables without concern that observed differences merely relate to the underlying group differences 
rather than pathophysiological differences. There existed a difference between groups in gender and weight; 
these can be corrected for in 2 ways, reference ranges and separate analyses by groups. I chose to correct 
variables that are affected by these variables (for example OUES, O2 pulse, peak     , AT) by the use of 
reference equations. This has been performed in the primary analyses. 
I find, to partially confirm my hypotheses, that OUES (when corrected as a percentage of predicted) had 
excellent discriminatory ability for CHF (and CHF plus MV disease) versus COPD. The other variables 
hypothesised to have strong discriminatory power performed less well. The         slope had reasonable 
capacity, and was in keeping with the expected direction of difference, i.e. lower values in the cardiac groups. 
The O2 pulse had highest values in the cardiac group which was in the opposite direction to the expected trend. 
This difference between groups was lost when O2 pulse was calculated as a percentage of predicted. It appears 
that the high use of beta-blockers is the principal contributing factor to this variable; slower heart rates at 
equivalent points of exercise necessitate a higher stroke volume or oxygen extraction at the muscle, reflected in 
a higher O2 pulse. The      at the AT (as a percent of predicted peak  
 
  ) and OUEP cannot discriminate, with 
lowest values in the latter associated with respiratory, not cardiac disease. Conceptually (and etymologically) 
the OUEP and OUES appear closely related, however they seem to behave very differently within this analysis. 
The breathing reserve, both at peak and at AT (the former non-significantly stronger than the latter) are very 
strong discriminators. Interestingly the long-standing proposed algorithm to differentiate patients with 
breathlessness performed badly. It could be argued that the presence of COPD or heart failure does not define 
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the lungs or heart as the limiting organ, but it does seem curious that so few patients (certainly within the CHF 
group) were classified in agreement with their objectively proven diagnoses.  
Because there are a number of variables that have performed differently than expected, some of them will now 
be discussed separately. 
 
6.5.1 Oxygen uptake efficiency slope 
The OUES was first described in 1996 by Baba et al. This group noticed that the relationship between oxygen 
uptake and minute ventilation did not conform to a linear relationship unless the minute ventilation was 
logarithmically transformed. Defined as the slope of this relationship, a unit increase in OUES represents a unit 
increase in      for a ten-fold increase in minute ventilation. It is considered effort independent and so is more 
reliable than the peak      in patients where non-cardiorespiratory disease curtails exercise prematurely, or 
where patients are not maximally exercised for safety reasons. From my analyses and previous work OUES 
appears to be relatively insusceptible to respiratory abnormalities. I am unaware of any previous work involving 
OUES in patients with primary respiratory disease. Hollenberg et al identified the first reference ranges for 
OUES in a group of older healthy adults and found that FEV1 and smoking status affected the OUES 
(Hollenberg et al 2000). However in that multivariate model used to identify an individual’s predicted OUES 
the contribution from FEV1 and smoking was small. For example in an average-sized male adult the reduction in 
predicted OUES caused by a reduction in FEV1 of 1L (a large change) is only 2.5%. Smoking contributed about 
10%. The FEV1 was a slightly more important contributor in the female reference ranges. Within the SHIP 
cohort I have shown that FEV1 was strongly related to OUES, but as a percent of predicted FEV1 the 
relationship was only weakly significant, suggesting that most of the influence comes from the impact of patient 
characteristics on both FEV1 and OUES (i.e. age, gender, height, weight). The relationship with smoking was 
weak and in opposite directions in males and females (Chapter 4). Within a population of patients with CHF I 
have shown a strong relationship between percentage of predicted FEV1 and peak     , but not OUES (Barron et 
al 2010, Chapter 3). Similar results were found in another study where the addition of respiratory disease to 
heart failure minimally, and non-significantly, reduced OUES (Marinov et al 2008).  
Within this observational study FEV1 relates to OUES but with an inverse relationship, i.e. lower FEV1 values 
related to higher OUES values. This likely represents an example of Simpson’s Paradox: a relationship noted 
individually in 2 or more groups can appear to reverse in direction when these groups are analysed together if 
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their group means are widely discrepant. In other words there may be a small positive relationship within each 
group (reduction in FEV1 leads to a small reduction in OUES) but because the mean OUES in the cardiac group 
is significantly lower than in the COPD group, and the FEV1 differences between groups lie in the opposite 
direction, when grouped together it looks like higher FEV1 values lead to lower OUES. Whilst I do not believe 
that the inverse relationship is real, this result does add further weight to the argument that OUES is largely 
resistant to abnormalities in lung function. OUES also did not relate to KCO (Hb), a marker of diffusion capacity 
of the lungs that is corrected for lung volume and haemoglobin concentration. 
However most important are the findings that OUES is significantly lower in the CHF and mitral valve groups 
despite similar exercise capacity (we would actually expect the mean OUES to be higher in the CHF group 
given the increased average weight and higher proportion of males) and on ROC curve analysis OUES, when 
corrected for weight or as a percentage of predicted value, was the strongest of the variables at identifying 
cardiac from respiratory disease where lower values predict cardiac abnormalities. Unlike breathing reserve, the 
only other variable with similar AUC values, its magnitude probably relates to exercise capacity (this hypothesis 
will be developed within Chapter 7), i.e. a reduction in OUES will mean a worsening of disease 
pathophysiology. Conceptually the same cannot be said for BR at peak, although the magnitude of BR at AT 
may be relevant if AT is unaffected by deteriorating respiratory disease. Why might OUES be largely resistant 
to abnormal lung function? Patients with heart failure typically have an abnormal peak      but may still 
ventilate to high levels. They spend a considerable portion of exercise where the     and      relationships are 
decoupled because of anaerobic metabolism, with greater ventilatory inefficiency. Hence the linear relationship 
is “flattened”. In contrast COPD patients behave more like healthy adults that just do not progress to maximal 
exercise. They spend less time in anaerobic zones and so the relationship between      and  
 
 , whilst still 
possibly abnormal, is more even throughout, leading to a more “normalised” OUES. This is only conjecture and 
is not examined specifically with the data I present here. 
 
6.5.2 Breathing reserve 
Multiple authors have suggested the use of breathing reserve as a discriminator of respiratory limitation 
(Eschenbacher et al 1990, Messner-Pellenc et al 1994, Medoff et al 1998, Milani et al 2004, Wasserman et al 
4
th
 Edition 2005). My analysis identified that a cut-off of 33.6% for the BR allowed for the greatest correct 
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classification of patients with a specificity of 100%; very close to the cut-off of 30% that has been suggested in 
previous studies. 
One of these previous authors suggested using the BR at the AT, as this was proposed to reduce the unwanted 
impact on diagnostic power if patients voluntarily cease exercise before their respiratory system is maximally 
stressed (Medoff et al 1998). I found good discriminatory power of the BR at the AT, although the BR at peak 
appeared to perform better. The optimal cut-off in my data for BR at the AT was 48.7% (results not shown), not 
dissimilar to their cut-off of 42%. However 40% of the patients within the Medoff study and 35% of my COPD 
patients did not achieve the anaerobic threshold, limiting the applicability of this variable within a general 
population of patients with cardiorespiratory disease. In contrast BR at peak and the OUES are measurable in 
all. 
Because RER was lower in the COPD group I investigated the role of the product of RER and BR. This showed 
a small, non-significant, improvement on BR at peak alone. Given the added complexity needed to record this 
variable this small improvement does not appear warranted. 
My results suggest that using the BR at peak is perfectly acceptable if you wish a single value to identify 
principal limiting physiology. The magnitude of the value appears to be largely meaningless when measuring 
severity of disease/exercise intolerance (this will be tested further in Chapter 7), so the use of the BR in serial 
studies may be limited.  
 
6.5.3 Anaerobic threshold 
It has long been believed that a reduced anaerobic threshold on CPX is pathognomonic for heart failure. This 
forms a central part of an established algorithm for the identification of the principal organ system limiting 
exercise (Milani et al 2004, Wasserman et al 4
th
 Edition 2005). Yet the evidence for this fact is scarce. In a 
study by Weber et al, a reduced      at the AT was found in patients with heart failure and related to functional 
limitation (Weber et al 1982). AT was found to be more sensitive than peak      at predicting prognosis in CHF 
(Gitt et al 2002). In a study by Nery et al, the      at the AT in a group of patients with mitral valve disease was 
lower than patients with COPD and healthy controls (Nery et al 1983); however the numbers were small with 
significant differences in gender and average age between groups. These studies alone appear to have laid the 
foundation of what has become a firmly held belief; that AT reflects cardiac function. A low AT has become 
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synonymous with “inadequate oxygen delivery” in the literature, but is this the case? There has been plenty of 
criticism of what the AT reflects and how it is measured (Hopker et al 2011), but if it really is the point when 
oxygen supply and demand diverge then does not the muscle have the central role in determining the AT? And 
muscular changes occur in COPD, CHF, sedentary behaviour and many other chronic diseases. Very few CPX 
studies performed on patients with COPD report the AT but in the study on the BR at the AT described above, 
Medoff et al showed that the     at the AT was the same in COPD and CHF patients with similar exercise 
capacities. Only the early study by Nery et al showed values in COPD similar to healthy controls. Therefore I 
suggest that the anaerobic threshold is critically determined by the muscle and any chronic process that impairs 
muscular function will reduce AT. Within this study the     at the AT (as a percentage of predicted peak  
 
  ) 
did not differ between groups and the AUC for its discriminant ability was very poor at 0.569. The use of 
absolute     at the AT was a better discriminator, but in the wrong direction, i.e. higher values in the CHF group. 
It may be that with early heart failure a reduction in cardiac output will lead to a reduction in     at the AT prior 
to the muscular maladaptation that occurs later, but given the very wide normal limits of AT, this would 
probably be difficult to detect. A potential limitation to my criticism of AT as discriminant is the range of values 
seen within my population. Only 14 patients (2 with COPD, 7 with CHF, 4 with MV disease and 1 with mixed 
disease) had a reduced AT as defined by the cut-off of 40% predicted peak     , and 28 with a value below 45%. 
Categorising by an AT above or below 40% did not help its ability to discriminate (AUC 0.456, results not 
shown). 
 
6.5.4 Other variables 
Similarly to the AT, the         slope has been regarded as a variable reflecting oxygen delivery, and 
therefore is believed to be reduced in patients with heart failure but not COPD (Hansen et al 1987). Hypotheses 
for the cause of the reduced slope include slow oxygen kinetics and increased utilisation of anaerobic sources of 
metabolism after the AT. In this seminal study by Hansen et al, (where they measured Δ    :ΔWR instead of the 
regression line of the slope), the value for patients with circulatory disease was 8.29, compared with 10.29 for 
the healthy controls. However, although they attempted to adjust the protocol for exercise capacity to ensure 
participants exercised for similar lengths of time, they do not show the average duration of exercise within each 
group, and 14/51 patients didn’t achieve 6 minutes; they did not reveal if similar findings were seen in the 
control group. As I have shown in Chapter 5, the         slope is heavily dependent on protocol with longer 
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protocols elevating the slope in healthy adults and patients with CHF and COPD. Therefore our study protocol 
is ideally designed to answer the hypothesis regarding the slope being a marker of impaired circulatory function, 
in that test 2 in all patients was specifically picked based on their own results from test 1 to lead to a 
standardised length of time undertaking incremental exercise (around 10 minutes). With this attempt at 
standardisation of time, patients with mitral valve disease and CHF had significantly lower         slopes 
(8.7) compared to COPD patients (9.6) although on average there was a trend to longer exercise times in the 
cardiac groups. The AUC was approximately 0.70 in the 3 analyses, so the slope appears to have moderate 
ability to discriminate. One of the key findings from Chapter 5 is that the         slope does not have 
excellent test-retest reliability and it would be unexpected for a variable that does not have good reproducibility 
to show a good ability to discriminate. Perhaps if methodology for the measurement of the slope alters to 
improve reproducibility this analysis could be rerun to see if this improves the ability of the slope to 
discriminate. 
The oxygen uptake efficiency plateau (OUEP) is a newly described variable that has shown similar prognostic 
power to OUES. However, unlike OUES, it didn’t appear to significantly discriminate between these groups 
(AUC 0.63-0.67) with mean OUEP lowest in the COPD group.  
The O2 pulse showed reasonable ability to discriminate, however the lowest values were paradoxically found in 
the COPD group, and once corrected using reference ranges any differences largely disappeared. It is believed 
that the O2 pulse reflects stroke volume and therefore in heart failure, a condition of reduced contractile ability 
of the heart (amongst other abnormalities), it should be lowest. This may have been appropriate in the pre-beta 
blockade era, but now most CHF patients are treated with beta blockers and the reduced heart rate leads to 
increased compensatory stroke volume (through increased ventricular filling time) or oxygen extraction, which 
will be reflected by an O2 pulse that normalises or may even become supranormal.  
It appears that neither the OUEP nor O2 pulse are ideally suited to discriminate. 
Measures of the          relationship have been shown to be abnormal in heart failure and COPD, and are strong 
prognostic markers, but their association with both conditions unsurprisingly means that within this study 
population they did not significantly differ between groups or have the ability to discriminate. There was an 
interesting observation that on average the slope was higher in the cardiac patients than the ratio at nadir, whilst 
in COPD patients the difference was in the opposite direction. When I created a variable of slope minus ratio at 
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nadir (using the slope measuring data pre-VCP as is convention) there was a significant difference between 
groups with a good ability to discriminate (AUC 0.76-0.78). Whilst this new variable may show some promise, 
the magnitude does not clearly relate to a specific pathophysiological abnormality and so may not add anything 
further to the variables already commonly used. Further work is necessary. 
The double product was significantly lower in the CHF group and this is reflected in its reasonable 
discriminatory power (AUC 0.79 for CHF vs COPD), however this was significantly reduced by the addition of 
mitral valve disease, suggesting it may not so much reflect the abnormal circulatory function as the increased 
numbers of anti-hypertensive agents used within the CHF group.  
Unsurprisingly RER at peak, peak heart rate and oxygen saturations were different between the groups, but did 
not add much over the other variables in terms of discriminatory ability. The        slope was lowest in the 
CHF group and highest in the mitral group. This U shaped relationship is to be expected. Patients with COPD 
behave reasonably typically, like healthy adults, but patients with circulatory abnormalities can behave in one of 
two ways; firstly there can be an excessive heart rate response to compensate for the reduced forward stroke 
volume; and secondly chronotropic incompetence (often due to beta blockers). Valve patients, who are less 
frequently prescribed beta blockers, would be expected to behave in the former manner as we largely see here, 
with CHF patients the latter. This bivariate effect limits the likelihood of this variable being useful; when mitral 
and CHF patients are considered together it had no discriminant ability, although for CHF alone it is better 
(AUC 0.63).  
Reason for stopping, when categorised into either breathlessness or fatigue, was not particularly discriminant. 
Given that this also hasn’t been shown to be prognostically powerful (Witte et al 2008) it argues against a need 
for the common approach of recording reason for test cessation. 
 
6.5.5 Clinical relevance 
My results suggest that whilst breathing reserve should retain its role at the heart of a decision-making tree into 
principal limiting physiology, the oxygen uptake at the AT is not sufficiently discriminant to add further 
information and should not be used in this capacity. Few typical heart failure patients fulfil the recommended 
AT cut-off of 40%. The OUES shows real promise; it is highly reproducible with a likely linear relationship to 
disease severity, hence I would propose that should a physician be attempting to track a patient’s “cardiac” 
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contribution to exercise intolerance this would be the best choice for a variable to follow. In a patient with 
coexistent respiratory and cardiac disease it could help differentiate between a decline in exercise capacity due 
to worsening cardiac versus respiratory pathology. 
 
6.5.6 Limitations 
The main limitation is the numbers of patients recruited. I had performed sample study calculations suggesting a 
requirement of 70 cardiac and 35 COPD patients; I was just short of both of those targets, however, perhaps 
because OUES had a greater AUC than anticipated, the results are highly significant. It will be interesting to see 
if this AUC is repeatable, and with 2 equally sized populations. This would ideally be performed by an 
independent study group.  
Secondly some of the patients within the study population, although proven to have either COPD or CHF, were 
not as symptomatic as expected, with a reasonable proportion achieving a reasonably normal peak      (17 
patients achieved 85% predicted peak      (18%), with 3 achieving 100% predicted). It would be interesting to 
see if these results could be replicated in a population of more severely affected patients, for example those 
awaiting heart or lung transplant. 
 
6.5.7 Conclusions 
OUES and breathing reserve are the best variables routinely measured on CPX at discriminating heart failure 
from COPD. These variables also have results largely unaltered by the addition of mitral valve pathology to the 
CHF group, and including patients with both pathologies under their principal diagnosis, unlike other variables. 
The anaerobic threshold does not discriminate CHF patients. The         slope shows an intermediate ability 
to discriminate, no other variable shows much promise. In a patient with heart failure and COPD, breathing 
reserve and OUES could be used to identify principal limiting physiology and for serial assessment of 
progression track the changes caused by each pathology separately. Further assessment of the role of these 
variables in patient with mixed disease is necessary. 
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7.0 Correlation of CPX variables to disease severity 
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7.1 Abstract 
 
Different cardiopulmonary exercise test (CPX) variables give us different information on the impact of 
cardiorespiratory disease on a patient. Some of these variables can be useful to distinguish limiting pathology, 
but it is unclear which variables most closely reflect disease severity.  
96 patients with COPD, CHF or mitral valve disease, recruited into the study had two CPX tests, an 
echocardiogram, full lung function tests and BNP measurement. Symptom status prior to exercise testing was 
established using the NYHA classification system. NYHA class, echocardiographic measures including ejection 
fraction, fractional shortening, s’ velocity, E:e’ ratio, left atrial volumes, TAPSE and right ventricular S’, and 
BNP were analysed against 24 CPX variables using ANOVA, interaction regression models and Spearman’s 
rank correlation. 
NYHA class related to a number of variables amongst the full patient population and to OUES, anaerobic 
threshold and         slope in cardiac patients alone. OUES, double product and the  
 
      slope 
correlated most closely to the echocardiographic variables. Most variables correlated to BNP within the full 
population and the cardiac patients when analysed alone, but not in the COPD patients; anaerobic threshold did 
not correlate to BNP. When the correlation of other variables against peak      (as the overall measure of 
exercise capacity) was tested almost none correlated in the COPD patients, and almost all correlated within the 
cardiac patients. Breathing reserve did not correlate to peak      within either group confirming its inability to 
reflect disease severity in either COPD or heart failure. 
OUES and the         slope appear to relate closely to disease and symptom severity in patients with heart 
failure and mitral valve disease, but not in patients with COPD. They may be ideally suited to the follow-up of 
patients with cardiac disease to specifically reflect disease severity and progression.  
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7.2 Introduction 
One of the key roles of CPX is to identify the principal limiting organ in a patient complaining of reduced 
exercise tolerance. I have shown in previous chapters how certain CPX variables are more discriminant of 
cardiac over respiratory disease (or vice versa). However the ability of a single exercise test to discriminate 
primary pathology limiting exercise is not the main concern. An algorithm approach (although not the 
recommended one) may well be sensitive and specific enough to identify principal limiting physiology, but 
where it fails to help is when a patient returns for a subsequent test to assess disease progression. For this 
physicians have largely used peak     , considered the endpoint of all disease processes on exercise capacity. 
Peak      is often used synonymously with exercise capacity. 
For many patients peak      will perform admirably when serial tests are required, but if, for whatever reason, 
peak      is not felt to be reflective of a patient’s disease progression it is unknown if other variables can 
perform in this role. An alternative variable would need to reflect both the disease severity and influence of the 
disease on exercise capacity.  
Within this chapter I explore the relationships between a number of the principal CPX variables and subjective 
and objective measures of disease severity, to see which variables would be appropriate to use in the serial 
testing of patients with a cardiac cause of exercise limitation.  
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7.3 Methods 
7.3.1 Patient recruitment 
This chapter involves only patients analysed within the Observational study (Chapter 6) and methodology for 
patient recruitment is described in detail within the Methods Chapter and Chapter 6. Each patient, prior to 
exercise test 1, was assessed for symptoms, and a symptom score based on NYHA classes 1-4 was assigned. 
Initially this was only performed for cardiac patients (as NYHA class has only been validated within cardiac 
patients) but was introduced for COPD patients after the first 7 patients had already completed the protocol. A 
symptom score validated for respiratory patients is the MRC breathlessness scale; this is a 1-5 scale and so was 
not adopted for this study because it could not be easily compared with a 1-4 scale for cardiac patients. Prior to 
exercise testing each patient also had venous bloods taken including B-Natriuretic Peptide (BNP). Based on 
previous analyses I have presented, it is clear that within my population BNP fits a skewed distribution that 
appears normally distributed following logarithmic transformation. Therefore this was performed for all patients 
BNP values. 
 
7.3.2 CPX analysis 
This is described in detail elsewhere. Briefly patients undertook 2 CPX bicycle ergometer tests. The first was a 
familiarisation test, with 3 minutes of rest, 3 minutes of unloaded cycling and then a 10W/min incremental 
protocol until symptoms limited further exercise and the test was stopped. Based on the results of this first test 
each patient had a second test with the same rest and unloaded sections, but with an incremental protocol 
designed to reach symptom limited maxima at approximately 10 minutes. All analysis was performed on the 
patients’ second tests. The following CPX variables were analysed within these analyses; peak     (mL/min), 
peak     (mL/min/kg), peak  
 
  (percent of predicted),  
 
  at the AT (mL/min),  
 
  at the AT (percent of 
predicted peak     ), OUES (L/min/10-fold increase in  
 
 ), OUES/kg, OUES (percent of predicted), OUEP, O2 
pulse (mL/beat), O2 pulse (percent of predicted),          slope until the VCP,  
 
       slope throughout full 
exercise,          ratio at nadir,  
 
       ratio at AT,  
 
       slope minus the  
 
       ratio at nadir, end-tidal 
partial pressure of CO2 (PETCO2), double product (DP), peak circulatory power, breathing reserve (BR) at the 
AT and peak exercise, peak minute ventilation,         slope and     
 
  slope. 
The percentages of predicted for peak      (and by extension  
 
   at the AT), OUES and O2 pulse use the 
reference equations described previously (Gläser et al 2010, Chapter 4). 
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7.3.3 Echocardiographic analysis 
All patients underwent an echocardiogram on the same day as exercise testing. I undertook each echo using the 
IE33 imaging system (Philips, Amsterdam, The Netherlands). Standard echocardiographic views were 
attempted in every patient and are explained in detail in the Methods Chapter. For this analysis only 7 measures 
were analysed. The first 3 were measures of systolic function and included: ejection fraction as measured by 
Simpson’s Biplane method (occasionally when views in only one plane were possible these single plane 
volumes alone were used); fractional shortening, using the left ventricular internal dimension at diastole and 
systole as measured in the parasternal long axis view at the mitral leaflet tips; and mean s’ velocity, this is the 
average of the mitral and lateral annular s wave velocities on tissue Doppler echocardiography (these represent 
the forward, systolic, movements). The next 2 were variables of diastolic function and included: left atrial 
volume (LAV) which was calculated using the area/length method; and the E:e’ ratio, where the ratio of the 
transmitral filling E wave to the mean of the mitral and lateral annular e wave velocities on tissue Doppler 
echocardiography (these represent the first backwards, or passive diastolic, movements). Finally I also measured 
two right ventricular variables:  the tricuspid annular plane systolic excursion (TAPSE) and right ventricular 
systolic (S’) wave on tissue Doppler imaging. Full techniques are described in the Methods Chapter. 
 
7.3.4 Hypotheses 
I hypothesised that an ideal variable of cardiac function would correlate to symptom severity in cardiac, but not 
COPD, patients; and correlate to objective measures of cardiac function (for example echocardiographic 
measurements of systolic and diastolic function) within cardiac, but not COPD, patients. I also hypothesised 
that, as peak      is the accepted measure of overall exercise capacity, an ideal variable will correlate with peak 
    . This correlation should be strong (r>0.50), but not close to 1, as this will show that almost no extra 
information is gained from adding this second variable to peak     .  
 
7.3.5 Statistical analysis 
Tests for normally distributed data have been performed on all CPX variables and BNP in previous chapters. 
Briefly BNP is skewed and appears normally distributed when logarithmically transformed; hence log 
transformed BNP will be used throughout. Similarly left atrial volume (LAV) is skewed and is normally 
distributed after logarithmic transformation and this will be used throughout. Whilst some of the CPX variables 
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are non-normally distributed (         slopes), they do not become normally distributed on logarithmic 
transformation so were analysed in their raw format and non-parametric tests used wherever necessary. 
NYHA class was analysed for its relation to CPX variables using oneway analysis of variance (ANOVA) within 
the whole patient population and by respiratory and cardiac groups. Spearman’s rank correlation (because some 
of the CPX variables are non-normally distributed) was used to analyse CPX variables for a correlation with 
echocardiographic measures of systolic function (ejection fraction, fractional shortening and mean s’), 
echocardiographic measures of diastolic function (LA volume and E:e’ ratio), echocardiographic measures of 
right ventricular function (TAPSE and RV S’) and BNP.  
Peak     , as an overall variable of exercise capacity, was correlated to the remaining CPX variables; also using 
Spearman’s rank correlation test. 
To analyse if the relationship between a CPX variable and the outcome variable (i.e. NYHA class, 
echocardiographic measures etc) is different in COPD compared with cardiac disease, a multivariate model was 
designed with the CPX variable and diagnosis as an interaction term. A statistically significant interaction term 
indicates that the CPX variable is significantly differently related to the outcome variable in cardiac versus 
respiratory patients. 
A p value of <0.05 is considered significant throughout.  
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7.4 Results 
7.4.1 Patient characteristics 
Details of recruitment numbers and dropout rates are reported in Chapter 6. This chapter reports on the same 96 
patients undertaking the Observational study. Briefly from 96 patients (72 male), 43 were patients with CHF (14 
undergoing CRT and 13 having undergone CRT), 26 with mitral valve disease requiring surgical correction and 
27 with lung disease (25 showed obstructive physiology and 2 restrictive physiology but had a formal physician-
made diagnosis of COPD). 18 from 26 patients with mitral valve disease were self-described as symptomatic. 7 
from 96 patients fulfilled criteria for inclusion in the mixed group. 4 of these patients had COPD as their 
primary diagnosis but 3 were known to have ischaemic heart disease and on echocardiography had 
abnormalities of left ventricular function, and a fourth had right atrial and ventricular dilatation with an elevated 
BNP. 3 heart failure patients were known to have COPD. 5 further heart failure patients and 5 mitral valve 
patients had obstructive spirometry which met GOLD criteria category 2 but not higher. 2 were known to have 
long-standing asthma (not COPD) but none of the remaining patients had a formal secondary diagnosis or 
symptoms suggestive of COPD, and only 1 was a current smoker. Of these 10 patients 4 were reclassified with 
non-obstructive or mildly obstructive spirometry (GOLD category 1) on repeat spirometry, 2 had FEV1 values 
just below the 80% cut-off to distinguish between category 1 and 2, and 4 lay well within category 2. They were 
categorised within their principal disease category. Within the COPD category, 2 patients met the criteria for 
GOLD category 1 (mild), 12 patients met criteria for GOLD category 2 (moderate), 10 for category 3 (severe) 
and 3 for category 4 (very severe). 
There were significantly more males in the CHF group; this group was also heavier, with a lower haemoglobin 
and estimated glomerular filtration rate (eGFR). 
 
7.4.2 Relation to symptom class 
The simplest way to describe a patient’s functional status is a symptom class. Within this study 65/66 patients 
with cardiac disease had an NYHA class recorded prior to exercise testing. For COPD patients the equivalent 
scoring system was performed on 16/23 patients for reasons described above. 
Symptom class was significantly related by ANOVA to peak      (F= 10.35, p<0.001), peak  
 
  /kg (F= 14.3, 
p<0.001) and percent predicted peak      (F= 9.67, p<0.001).  
 
  at the AT, OUEP, O2 pulse, variables of the 
         relationship, circulatory power, and peak  
 
  were also all highly significantly correlated to symptom 
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class (Table 7.1). OUES and the         slope were also significantly correlated, but with borderline p 
values. Measures of the AT and OUES (Figure 7.1), the         slope, and most variables of the  
 
        
relationship did not differ between groups of symptom class in patients with COPD, but they did in patients with 
CHF and MV disease. Breathing reserve at the AT, but not at peak, was related to symptom class in patients 
with COPD but not cardiac disease. 
 
7.4.3 Correlation with markers of cardiac dysfunction 
For a variable to be sensitive and specific for cardiac dysfunction it follows that it will correlate to objective 
markers of cardiac dysfunction; at least within the CHF and MV populations.CPX variables were analysed 
against echocardiographic variables and BNP.  
For markers of systolic function, ejection fraction (EF - measured by Simpson’s biplane method), fractional 
shortening (FS) and the mean of the mitral septal and lateral annular s’ velocities, correlations were performed 
against some of the principal CPX variables. Double product was highly correlated to all 3 measures (r=0.49, 
r=0.53, r=0.52 respectively, p<0.0001 for all). OUES as an absolute value, weight adjusted and percent of 
predicted was highly correlated to mean s’ velocity (r=0.40, r=0.41, r=0.34 respectively, p<0.0001 for all) and 
when adjusted for weight to fractional shortening (r=0.31, p=0.003). Peak      was highly correlated to mean s’ 
velocity only when weight adjusted (r=0.36, p<0.001) but not as a percent of predicted.  
As markers of diastolic function left atrial volume (LAV) and the ratio of transmitral E wave to mean mitral 
septal and lateral annular e’ velocities (E:e’ ratio) were calculated. Only OUES/kg (r= –0.39, p<0.001), percent 
of predicted OUES (r= –0.38, p<0.001) and the         slope (r= –0.36, p<0.001) correlated strongly with 
LAV, whereas OUES (as an absolute, weight adjusted and percent of predicted value) was highly correlated to 
the E:e’ ratio (r= –0.43, p=<0.001; r= –0.41, p<0.001; and r= –0.40, p<0.001 respectively) along with the  
        slope (r= –0.42, p<0.001). The relationship between E:e’ and s’ on OUES and peak  
 
   is shown in 
Figure 7.2. 
Measures of right ventricular function were also tested for correlation against some of the principal CPX 
variables. Peak     /kg (r=0.29, p=0.005),  
 
   at the AT (r=0.30, p=0.007), OUES (r=0.30, p=0.004),  
 
         
slope (r= -0.33, p=0.002) and ratio (r= -0.31, p=0.003), double product (r=0.41, p<0.001) and circulatory power 
(r=0.41, p<0.001) were all correlated to TAPSE.  
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  Full group  COPD group  Cardiac group 
  F p  F p  F p 
Peak      (mL/min)  10.35 <0.001  4.65 0.022  9.29 0.000 
Peak      (mL/min/kg)  14.30 <0.001  2.18 0.144  19.53 <0.001 
Peak      (% predicted)  9.67 <0.001  3.54 0.048  9.86 <0.001 
AT (mL/min)  8.80 <0.001  0.38 0.696  7.51 0.001 
AT (% of pred peak     )  4.01 0.022  0.08 0.925  3.91 0.025 
OUES   2.91 0.040  0.29 0.835  6.80 0.002 
OUES/kg  3.01 0.035  0.23 0.871  10.99 <0.001 
OUES (% predicted)  0.77 0.512  0.38 0.766  4.49 0.015 
OUEP  13.38 <0.001  4.69 0.022  10.32 <0.001 
O2 Pulse (mL/beat)  4.22 0.008  8.32 0.003  2.08 0.134 
O2 Pulse (% predicted)  4.92 0.004  4.83 0.020  4.33 0.018 
         slope 1  8.34 <0.001  0.75 0.545  11.58 <0.001 
         slope 2  3.53 0.018  0.25 0.863  4.80 0.012 
         ratio nadir  9.62 <0.001  2.52 0.107  8.47 <0.001 
         ratio AT  14.01 <0.001  5.81 0.024  7.31 0.001 
         slope - ratio  3.59 0.017  0.94 0.452  7.88 <0.001 
RER at peak  2.90 0.04  6.20 0.009  1.20 0.308 
PETCO2 at AT (mmHg)  13.1 <0.001  6.85 0.016  6.85 0.002 
DP (mmHg bpm)  2.12 0.104  0.64 0.607  3.29 0.044 
Circ power (mmHg mL/min) 7.59 <0.001  3.93 0.039  7.45 0.001 
BR at AT (%)  2.68 0.075  9.02 0.007  1.96 0.150 
BR (%)  1.49 0.222  1.65 0.230  0.08 0.919 
Peak     (L/min)  4.41 0.006  3.33 0.057  3.18 0.048 
        slope  3.14 0.049  0.46 0.639  7.88 <0.001 
       slope  0.26 0.852  0.31 0.818  0.72 0.491 
 
Table 7.1: Association (by ANOVA) between symptom class (I-IV) and CPX variables in 
the full group, patients with COPD, and patients with mitral valve disease and CHF.
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Figure 7.1: Change in 4 CPX variables with symptom class. Left hand plot shows values for the full population, the right hand plot 
shows pairs within each variable, COPD on the left and cardiac disease on the right. All variables are expressed as a percent of 
predicted. It can be seen that for peak     , O2 pulse and the  
 
   at the AT the trends in both disease categories are similar, whilst for 
OUES the directions are opposite between the two disease categories. 
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Figure 7.2: Correlation between tissue Doppler imaging, OUES and peak     . E:e’ ratio as a marker of diastolic 
function and mean s’ velocity as a marker of systolic function were correlated against 2 CPX variables, peak      and OUES 
(both as weight adjusted variables). It can be seen that the correlations with OUES are stronger than for peak     . 
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Peak     /kg (r=0.29, p=0.007),  
 
   at the AT (r=0.26, p=0.02), OUES/kg (r=0.38, p<0.001), double product 
(r=0.51, p<0.001) and circulatory power (r=0.44, p<0.001), but not the measures of the          relationship 
were correlated to the right ventricular S’ wave. 
On the interaction model double product was the only CPX variable influenced by disease category in its 
relation to the mean LV s’ velocity. There were no other significant interactions when assessing any of the 
principal CPX variables on E:e’ ratio, ejection fraction, fractional shortening, LAV, TAPSE or RV S’ wave. 
BNP was strongly correlated to a number of CPX variables within the whole group. Figure 7.3 shows the 
relationship between BNP and both OUES and peak     . Peak  
 
   as an absolute value (r= –0.32, p=0.003) and 
weight adjusted (r= –0.37, p<0.001), OUES as an absolute, weight adjusted and percent of predicted (r= –0.53, 
r= –0.57, r= –0.56 respectively, p<0.001 for all),          slope (r=0.48, p<0.001),  
 
       ratio at nadir (r=0.41, 
p<0.001) and at AT (r=0.42, p<0.001), double product (r= –0.56, p<0.001) and circulatory power (r= –0.49, 
p<0.001), breathing reserve at peak (r=0.33, p=0.002) and the         slope (r= –0.44, p<0.001) were all 
strongly correlated with BNP. Almost all variables had a significant interaction term; on further analysis the 
presence of COPD significantly reduced the correlation between CPX variables and BNP so that none were 
significantly correlated, whilst the same correlation in the cardiac patients was largely improved or remained the 
same, with the exception of breathing reserve at peak which was not correlated to BNP in either group 
independently. 
 
7.4.4 Correlation with peak      
Almost all principal CPX variables correlated to peak      (as weight adjusted and percent predicted) (Table 
7.2). Within the full population of patients only the          slope-ratio difference, breathing reserve and the  
       slope did not correlate strongly with peak  
 
  /kg or percent predicted peak  
 
   (p<0.002 for all).  
On the interaction model all measures of OUES and peak     were the only variables that showed a significant 
interaction with disease category on their correlation with peak     . The correlation between OUES and peak 
     was significantly stronger in the cardiac patients (OUES/kg vs peak  
 
  /kg r=0.84, p<0.0001; percent 
predicted OUES vs percent predicted peak      r=0.71, p<0.0001) than the COPD patients (OUES/kg vs peak 
    /kg r=0.50, p=0.02; percent predicted OUES vs percent predicted peak  
 
   r=0.20, p=0.36) (Figure 7.4). 
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Figure 7.3: Correlation between log BNP and both OUES and peak      (both as weight adjusted variables). It can be seen 
that the correlation between log BNP and OUES is stronger than for peak     . 
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Figure 7.4: Scatter plot of percent of predicted OUES against percent of predicted peak     . Plot 1 shows all COPD (red) and cardiac patients 
(blue). Plot 2 shows only COPD patients with a weaker correlation coefficient. Plot 3 shows only cardiac patients with a stronger correlation coefficient. 
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  Peak      (mL/min/kg)  Peak  
 
   (% predicted) 
  r p  r p 
AT (mL/min)  0.596 <0.001  0.529 <0.001 
AT (% of pred peak     ) 
 0.670 <0.001  0.806 <0.001 
OUES   0.511 <0.001  0.370 <0.001 
OUES/kg  0.666 <0.001  0.442 <0.001 
OUES (% predicted)  0.392 <0.001  0.447 <0.001 
OUEP  0.550 <0.001  0.473 <0.001 
O2 Pulse (mL/beat) 
 0.400 <0.001  0.404 <0.001 
O2 Pulse (% predicted) 
 0.554 <0.001  0.671 <0.001 
         slope 1 
 -0.500 <0.001  -0.441 <0.001 
         slope 2 
 -0.399 <0.001  -0.368 <0.001 
         ratio nadir 
 -0.548 <0.001  -0.521 <0.001 
         ratio AT 
 -0.469 <0.001  -0.381 <0.001 
         slope - ratio 
 0.241 0.018  0.090 0.384 
PETCO2 at AT (mmHg) 
 0.467 <0.001  0.408 <0.001 
DP (mmHg bpm)  0.461 <0.001  0.369 <0.001 
Circulatory power  0.681 <0.001  0.591 <0.001 
BR at AT (%)  0.031 0.780  -0.168 0.123 
Breathing reserve (%)  -0.100 0.335  -0.146 0.156 
Peak     (L/min) 
 0.536 <0.001  0.383 <0.001 
        slope 
 0.458 <0.001  0.313 0.002 
       slope 
 0.026 0.805  -0.079 0.452 
 
 
Table 7.2: Correlation between peak      and other CPX variables. Correlation coefficients 
and p values were calculated for peak      (mL/min/kg) and percent of predicted peak  
 
  . 
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7.5 Discussion 
The purpose of this thesis is to establish which CPX variable should be used, if your patient has both cardiac and 
respiratory disease, to monitor the cardiac impact on exercise capacity. Previous chapters have explored the 
ability of certain variables to discriminate better than others, and future chapters will investigate the change in 
variables following cardiac interventions. 
But an important criterion for a variable to be truly reflective of cardiac dysfunction is that it varies predictably 
with disease severity, or at least does so within a population of patients with cardiac disease, whilst remaining 
unrelated to disease severity in patients with other disease processes, for example respiratory disease. 
Therefore within this chapter I have shown which variables are reflective of subjective measures of disease 
severity such as symptom status, and objective measures of disease severity such as echocardiographic variables 
and BNP, as well as the correlation between CPX variables and peak     , which I use as a surrogate for overall 
exercise capacity. Finally I have analysed which CPX variables vary in their relation to these markers of disease 
severity by disease category. 
 
7.5.1 NYHA classification 
Symptom status, commonly described in heart failure patients using the New York Heart Association (NYHA) 
class, is a simple test but suffers from poor reproducibility (Goldman et al 1981, Raphael et al 2007). I have 
used it here because it requires almost no extra time or effort to record and in large populations allows us to 
view trends adequately despite this poor reproducibility. It is known to correlate poorly to ejection fraction yet 
moderately to peak      (Van den Broek 1992), although generally offers little extra information beyond peak 
     to aid in heart failure prognosis (Likoff et al 1987, Cohn et al 1993). Within this study peak  
 
  , OUEP and 
the          ratio were amongst the variables that best reflected symptom status regardless of disease category. 
The variables that changed significantly when divided by disease category were the      at the AT, OUES, 
         slope and the  
 
      slope (which all became strongly correlated in the cardiac group and non-
correlated in the COPD group), and the breathing reserve at AT (which became strongly correlated in the COPD 
group and remained non-correlated in the cardiac group).  
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7.5.2 Objective measures of respiratory and cardiac dysfunction 
Thereafter I have used more objective measures of disease severity. Markers of respiratory severity were 
discussed in Chapter 6, where peak     , the OUEP, O2 pulse and breathing reserve all showed a significant 
relation to FEV1 and KCO as measures of respiratory severity, and in the appropriate direction, i.e. worsening 
respiratory function related to a worsening of the CPX variable. 
When we consider objective measures of cardiac dysfunction we typically think about systolic function. 
However it has long been established that echocardiographic indices of systolic dysfunction, namely ejection 
fraction, correlate poorly to exercise capacity (Franciosa et al 1981, Szlachcic et al 1985, Cohn et al 1988, Van 
den Broek et al 1992). However in a single study OUES correlated closely with ejection fraction in a group of 
patients with heart failure and reduced ejection fraction (Straburzyńska-Migaj et al 2010). Another problem is 
that patients with heart failure may have a normal ejection fraction; this group of patients, previously labelled as 
diastolic heart failure, would show an even poorer relationship between EF and objective exercise capacity. I 
limited the recruitment of heart failure patients to those with reduced ejection fractions, however heterogeneous 
abnormalities of cardiac function will still exist that make systolic dysfunction much more complex than just a 
reduced ejection fraction (for example impaired relaxation, valvular dysfunction, elevated pulmonary venous 
pressure). Unsurprisingly most CPX variables within my analysis did not correlate to ejection fraction, both 
across the whole group and when limited to CHF patients alone (results not shown). A more recently described 
marker of systolic function is the annular longitudinal velocities of systolic wall motion on tissue Doppler 
imaging. This has previously been shown to correlate more closely to peak      than ejection fraction does 
(Witte et al 2004), and within my analysis peak     /kg, all measures of the OUES, double product and 
circulatory power all correlated closely with this marker; interestingly the correlation coefficients for OUES 
were higher than for peak     . OUES also strongly correlated with left atrial volume and E:e’ as markers of 
diastolic function, as did the         slope.  
OUES and peak      both had similar correlations with TAPSE, whilst variables of the  
 
       relationship, DP 
and circulatory power were the most significantly correlated. DP and circulatory power were also very strongly 
correlated to the RV S’ wave, with OUES showing a stronger correlation than peak     . In contrast to TAPSE, 
measures of the          relationship did not correlate strongly with this measure of RV function. It has 
previously been shown that the          relationship related independently on multivariate analysis to TAPSE 
but not left ventricular abnormalities in patients with severe heart failure; both were strong predictors of death or 
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heart transplantation (Methvin et al 2011). On these analyses TAPSE overall correlates more closely with CPX 
variables than ejection fraction or fractional shortening do. This probably reflects the compliant right ventricle’s 
response to the constant burden of elevated pulmonary pressures secondary to left ventricular dysfunction. 
Whilst we see heterogeneous responses within the left ventricle, meaning that no single marker of “impairment” 
will strongly correlate to other global markers of heart failure, the right ventricular response is more uniform 
with dilatation and systolic impairment. 
BNP measured from venous blood sampling reflects raised intra-cardiac pressures, and is typically elevated in 
patients with heart failure. It has been previously shown to correlate closely with OUES (Straburzyńska-Migaj 
et al 2010) and peak      (Williams et al 2004). My results largely agree with these studies; OUES, peak  
 
  , all 
measures of the          relationship, DP and circulatory power and  
 
      slope all closely correlate with 
BNP across the full study group. However when dividing by disease category these close correlations are lost in 
patients with COPD, and maintained within the cardiac population.  
 
7.5.3 Correlation between peak       and other cardiopulmonary exercise variables 
Finally I analysed the relationship between CPX variables; and the effect of disease aetiology on these 
relationships. Rather than analysing 15-20 variables against one another I chose peak     , because this probably 
best reflects a patient’s overall exercise capacity. For any variable to be able to be considered “Ideal” it should 
correlate to peak     . This relationship should be strong but not 100% (as otherwise it would not add further 
information to peak     ). Alternatively the variable could have a correlation close to 100% with peak  
 
   in 
cardiac patients, but little or no correlation in respiratory disease, although this would be highly unlikely to 
occur physiologically. Importantly breathing reserve, both at peak and AT did not correlate to peak     . This is 
the most discrepant of variables but this lack of a relationship with peak      suggests that the magnitude of BR 
is not useful in predicting disease severity; it can only really act by determining if the lungs limit exercise 
through a threshold (for example 30% at peak) but the value generated gives us no further information, and 
probably has no relevance in serial tests. It is possible that the normal BR values seen in cardiac patients obscure 
a potential relationship with disease severity in COPD patients, however the correlation with peak      was not 
significant even when only COPD patients were considered. Almost all other CPX variables I have listed, with 
the exception of the        slope, correlated to peak  
 
  . For the various measures of the  
 
       relationship 
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it was, as expected, an inverse correlation. Disease category affects the relationship between OUES and peak 
    , but not most of the remaining CPX variables. Importantly OUES is much more closely correlated to peak 
     within the cardiac patients. 
 
7.5.4 Variables relating to disease severity 
Overall certain variables appear to display the necessary properties that would be consistent with reflecting 
disease severity. OUES reflected symptom scores in patients with cardiac disease, but not COPD, correlated 
closely with tissue Doppler measurements of  left ventricular systolic and diastolic function, LA volume, right 
ventricular systolic function and BNP, did not relate to resting spirometry and diffusion capacity, and reflected 
exercise capacity (as measured by peak     ) in cardiac but not respiratory patients. The  
 
      slope also 
related to NYHA class in cardiac patients, was correlated to diastolic although not systolic markers of cardiac 
dysfunction, and closely correlated with BNP. Within the cardiac patients it was closely correlated to peak 
    /kg and percent of predicted peak  
 
  . Similarly to the OUES, the  
 
        slope improved as FEV1 
worsened, however unlike OUES a decline in KCO was reflected by a rise (worsening) of the slope. All measures 
of the          relationship showed a strong correlation with peak  
 
   (it is an inverse correlation but this would 
be expected given that a worsening slope rises, not falls) and a strong positive correlation with BNP in the 
cardiac group.          slope did not correlate strongly with any of the echocardiographic variables except 
TAPSE, but did strongly correlate to symptom score within the cardiac group. The          ratio behaved 
slightly differently in that when measured at the AT it also appeared to correlate to symptom score within the 
COPD group, and the ratio at nadir correlated to peak      within the COPD population. DP and circulatory 
power correlated to RV systolic function and BNP; DP also correlated with LV systolic function and circulatory 
power with symptom class. The OUEP and O2 pulse correlated to peak      and to symptom score in both groups 
and so do not appear specifically related to symptom severity in heart failure. Breathing reserve at the AT 
correlated with symptom status in the COPD group, but not to peak     . BR at peak exercise was correlated to 
BNP and ejection fraction in the full group of patients, however this was an inverse relationship, i.e. higher 
breathing reserves were correlated to higher BNP levels and reduced EF, suggesting another example of 
Simpson’s paradox due to the conflicting nature of the two diseases on the 2 variables being correlated. This 
hypothesis seems likely as BR at peak was not correlated to EF or BNP when analysed within respiratory and 
cardiac disease separately. 
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7.5.5 Limitations 
The non-specific use of NYHA class in this study could be criticised. Firstly it is for use in heart failure, not 
COPD, but I have applied the same scoring system for my COPD patients. That was because the MRC dyspnoea 
score, although validated in COPD patients, runs on an ordinal scale from 1-5, so would statistically be very 
difficult to compare to a scale running from 1-4. The symptoms that help physicians categorise a heart failure 
patient with the NYHA classification are just as appropriate for a respiratory cause of breathlessness. Therefore 
I elected to use it for all patients; this decision was unfortunately made after the first few COPD patients had 
undergone the study protocol. A concern about NYHA class is the difficulty distinguishing between class II and 
III; confusion between these two classes leads to most of the poor reproducibility in this classification system. 
Within this analysis 82% of patients were within class II or III, which may restrict the classification system’s 
ability within my analyses. 
Within chapter 6 I analyse the relationship between FEV1 and CPX variables using multivariate regression. 
Within this chapter I use correlation with echocardiographic variables. That choice was made because regression 
implies direction and causation. It is conceptually likely that the obstructive abnormalities of respiration found 
in COPD patients cause the reduced exercise capacity and symptoms (although I accept COPD is far more 
complex than just obstructive spirometry). However abnormalities on echocardiography and BNP, for example, 
are features of heart failure, the same as exercise intolerance. Therefore there is no direction or causation and 
correlation is appropriate. The variables correlated against CPX variables, NYHA class, echocardiographic 
abnormalities and BNP, are largely unaffected by age, gender and weight, thus removing the need for a 
multivariate model. 
 
7.5.6 Conclusion 
OUES and then the         slope appear to closely reflect disease severity, as measured by multiple 
variables, in cardiac, but not respiratory, patients. Other variables perform less well, and some such as the peak 
    , OUEP and O2 pulse, probably reflect disease severity in both conditions. The breathing reserve, whilst a 
good discriminator, does not reflect disease severity of cardiac or respiratory disease.  
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8.0 The Interventional Study – The Mitral Valve 
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8.1 Abstract 
 
Certain cardiopulmonary exercise test (CPX) variables appear to show discriminant properties in identifying 
cardiac limitation. If these variables are specific for cardiac function then they should show rapid improvements 
following restoration of normal cardiac function following mitral valve surgery for severe mitral regurgitation or 
stenosis. Non-specific variables may deteriorate initially due to the long process of postoperative recovery and 
the impact of the surgery on the lungs. Minimally invasive mitral repair should show greater improvements in 
all CPX variables when compared to open repair. However these hypotheses have never been investigated. 
21 patients (16 males, 5 females) with severe mitral regurgitation (n=20) or stenosis (n=1), were recruited prior 
to surgery. They underwent CPX testing on a bicycle ergometer. Following a familiarisation test, each patient 
underwent a personalised second test aiming for maximal exercise after approximately 10 minutes. This test was 
repeated approximately 2 months after surgery and again 6 months after surgery in 9 patients. Postoperative 
changes at 2 months were noted in FEV1 and total lung capacity. Transfer coefficient significantly deteriorated 
postoperatively in patients undergoing open repair, but not in those undergoing minimally invasive surgery. 
Despite symptomatic improvement peak      was reduced at 2 months, and similar to baseline at 6 months when 
compared to baseline.     at the AT was reduced to a greater degree postoperatively than other variables and was 
not back to baseline at 6 months. OUES showed a borderline reduction at 2 months. Measures of the     
     relationship all showed non-significant trends to early (2 months) and sustained (6 months) improvement. 
Operation type, residual regurgitation and alterations to medication did not affect the degree of change in the 
majority of CPX variables. 
Following mitral valve repair/replacement many variables take time to recover. Peak      and  
 
  at the AT 
deteriorated significantly after surgery, OUES less so. Measures of the relationship between minute ventilation 
and CO2 elimination showed a trend to early and sustained improvements. 
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8.2 Introduction 
In previous chapters I have shown that certain variables appear to have increased sensitivity and specificity to 
detect abnormal cardiac physiology over others; importantly whilst remaining relatively resilient to abnormal 
respiratory function. OUES stands out as a variable with excellent reproducibility, excellent discriminant ability 
and with minimal correlation to abnormal spirometry. However, as defined within the aims of the study, an ideal 
variable will also appropriately reflect changes to a patient’s cardiac function. 
This is a difficult criterion to investigate. It is not ethically acceptable to perform interventions on patients or 
healthy controls which may lead to permanent reductions in their cardiac function. It may be possible to perform 
acute, reversible interventions on specific populations of heart failure patients; this has been tested using 
patients with left ventricular assist devices with a transient reduction in pump speed (Jakovljevic et al 2010, 
Noor et al 2012). Ethically it is easier to perform studies on patients undergoing interventions to improve 
cardiac function; there are also common examples of this performed regularly in clinical practice. 
Mitral valve reparative surgery is one such intervention. It is a relatively good model of an intervention that 
should acutely and persistently improve cardiac output and intra-cardiac pressures. Generally it is associated (so 
long as surgery is performed at an appropriate time) with good left ventricular function so recovery can be 
anticipated to be near absolute. Patients are often younger, in the degenerative form (where repair is commonly 
attempted) it is often an isolated disease and, because unwanted risk factors such as smoking and hypertension 
are not causative, typically patients will have no predisposition to coronary artery disease or respiratory 
abnormalities. Patients with mitral valve disease may be relatively asymptomatic (Messika-Zeitoun et al 2006), 
but even these patients can show improvements in their exercise capacity from surgery (Madaric et al 2007). 
However there are limitations to this model, such as it doesn’t truly isolate improvements to the circulatory 
system without impacting on other organs, and despite amelioration of the regurgitation or stenosis of the mitral 
valve potentially permanent microscopic changes to the left ventricle and pulmonary vasculature may have 
occurred along with macroscopic abnormalities of the left atrium which predispose to atrial arrhythmias. The 
procedure may impact on other organs because the operation requires significant chest trauma (typically a 
midline sternotomy), and time on cardiopulmonary bypass and mechanical ventilation, which can all affect the 
lungs. Medium and long-term changes in respiratory function have been shown following coronary artery 
bypass surgery (Staton et al 2005) and heart transplantation (Ewert et al 1999).  
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Recovery time back to normal activity is considerable in patients undergoing mitral valve surgery and this, 
alongside reduced calorific intake (Nizami et al 1990), may lead to significant skeletal muscle loss. As 
discussed previously the muscle and heart have a complex interaction, and it is possible that gains to cardiac 
function could be offset by muscular changes associated with a post-surgical recovery state. This would delay 
the time taken to observe a benefit in exercise capacity. Therefore newer techniques, including minimally 
invasive mitral valve repair, are potentially better models as thoracic wall trauma is minimised, and overall 
recovery time is reduced potentially leading to less skeletal muscle atrophy. 
Surgical correction of mitral valve disease has been shown to lead to rapid improvement of exercise capacity 
(Madaric et al 2007), although this response doesn’t appear uniform with significant time taken in other studies 
(Le Tourneau et al 2000, Kim et al 2004). In the former study improvements were seen at 4 months, however all 
patients had undergone minimally invasive surgery unlike the latter two studies. 
No studies of CPX testing before or after surgical intervention measured more than a few variables. No 
statistical tests were used to compare if certain variables were affected to a greater or lesser extent.  
Therefore I aim to show, in patients undergoing mitral valve surgery, whether CPX variables are differentially 
affected and to establish if surgical factors, including the use of minimally invasive surgery, can influence the 
change in these variables postoperatively. 
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8.3 Methods 
8.3.1 Patient recruitment 
 Patients were recruited from Imperial College Healthcare NHS Trust (ICHNT) whilst awaiting surgical 
correction of severe mitral valve disease. They had all seen one of two surgeons who routinely performed mitral 
valve repairs and replacements at ICHNT and were involved in this research study. Potential patients were 
identified by a member of the cardiology or surgical team, and the patient was contacted asking them to be 
involved in the study. The decision for surgery was made by the patients’ own clinical teams; neither myself nor 
the results of this study influenced the decision to operate. Patients with either mitral regurgitation or stenosis 
were recruited, however I preferentially aimed to recruit patients undergoing repair, as this may be more 
physiological than a replacement valve. One of the two surgeons involved also performed some repairs via a 
minimally invasive access route (right minithoracotomy, typically through the 3
rd
 or 4
th
 intercostal space). 
 
8.3.2 Patient testing preoperatively 
Once patients were identified and consented, they underwent full lung function tests, a transthoracic 
echocardiogram, venous blood tests and 2 cardiopulmonary exercise tests; these are considered the baseline 
tests. The full description of these tests can be found within the Methods Chapter. The first test was for 
familiarisation and to identify the optimal protocol for each patient to achieve similar duration of exercise in all 
(approximately 10 minutes of incremental exercise). The results of this first CPX test were not considered. The 
results of the second test, performed at least 2 hours after the first test to allow for muscular recovery, were 
performed on the patient’s optimal protocol and were retained for analysis. 
CPX tests were performed using a bicycle ergometer (Ergoline, GmbH, Bitz, Baden-Württemberg, Germany) on 
a COSMED Quark CPET System (COSMED S.r.l. Rome, Italy). The identification and measurement of CPX 
variables was performed as per directions from within the Methods Chapter and will not be discussed again 
here. However following on from the identification of a new set of contemporary reference equations (Gläser et 
al 2010, Chapter 4) percent of predicted values for peak     , OUES and O2 pulse were calculated using these 
SHIP equations described previously. The     at the AT will be presented as a percent of the predicted peak  
 
   
using the SHIP reference equation for peak     . All other variables will just be displayed giving their raw 
values. The          slope is displayed in 2 forms: slope 1 using data until the VCP; and slope 2 using data 
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throughout exercise, in keeping with previous chapters, the          slope minus ratio difference was also 
calculated for each patient as per previous chapters.  
 
8.3.3 Patient testing postoperatively 
There was no involvement from myself during the perioperative and immediate postoperative period. 
Patients were contacted over a month after their operation to gauge recovery and arrange follow-up. After 
discussion with the two surgeons involved it was agreed that 6 weeks should allow for enough recovery to make 
exercise testing safe; this was the minimum time from operation to follow-up for the study. On arrival patients 
underwent venous blood sampling, transthoracic echocardiography and full lung function testing, in the same 
manner as preoperatively. They each then underwent a single CPX test on the same protocol as the main test 
from the preoperative testing (i.e. not the familiarisation test).  
Patients were then re-contacted at 5 months to arrange a further CPX test (on an identical protocol to the 
previous 2) at 6 months following surgery. Other tests were not repeated at this point, only CPX. 
 
8.3.4 Echocardiography 
Whilst transthoracic echocardiography is covered in detail within the Methods Chapter, there are specific 
measurements made for the mitral valve patients that warrant special mention. Wherever possible, quantitative 
measurements of regurgitant severity were attempted. This typically involves the use of the Proximal Isovelocity 
Surface Area (PISA) method, first described over 20 years ago (Recusani et al 1991). Full methodology for how 
I performed PISA is described in the Methods Chapter but briefly a hemisphere of colour Doppler on the 
ventricular aspect of the mitral valve leaflet tips occurs during systole in patients with MR. The size can be 
manipulated by altering the aliasing velocity in the direction towards regurgitant flow. Once a reasonable sized 
hemisphere is noted the radius of this hemisphere is measured, and recorded alongside the aliasing velocity. 
Continuous wave Doppler across the mitral valve generates a velocity-time integral (VTI) and peak velocity. 
These measurements allow for calculation of a regurgitant volume and effective orifice area of regurgitation 
(EROA). If forward stroke volume is known regurgitant fraction can also be calculated.  
A semi-quantitative method of MR assessment is jet: left atrial area ratio. In the apical 4 chamber view, 
following optimisation of gain and depth settings, the frame is paused where the largest regurgitant jet area can 
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be seen. The area of the jet within the left atrium is measured (excluding the PISA on the ventricular aspect of 
the valve and any flow in the pulmonary veins) alongside the area of the left atrium; the ratio of these 2 areas is 
then calculated. 
 
8.3.5 Hypotheses 
I hypothesised that at 2 months we would see either no improvement or a deterioration in variables of exercise 
testing, but at 6 months we would see values superior to preoperative levels. I hypothesised that variables that 
are more reflective of cardiac function (based on the results of preceding chapters), for example OUES, would 
show a lesser reduction at 2 months compared with more non-specific variables, for example peak     , which 
would be more negatively affected by the total body adaptations post-surgery (such as prolonged, enforced rest 
and recovery, reduced nutritional intake etc). I also hypothesised that the process of surgery would lead to some 
changes in respiratory function and that these would correlate to the reduction in exercise capacity at 2 months 
in non-specific variables, but not cardio-specific variables such as OUES. 
 
8.3.6 Statistical analysis 
Variables of gas analysis and lung function have previously been assessed for normal distribution. Normally 
distributed variables are displayed as mean ± standard deviation; non-normally distributed variables as median 
(25
th
, 75
th
 percentiles). For preoperative versus postoperative changes of linear variables paired t-tests were 
used, unless the variable was non-normally distributed, in which case a Wilcoxon rank test was employed. For 
graphical representation of the change between baseline and 2 and 6 months each variable was standardised 
using the z-score method (z-score = change/standard deviation of variables within population). On these plots a 
leftward shift represents a worsening of a variable, regardless of whether this is an increase or decrease in the 
magnitude of the variable. Because z-scores standardise each variable these scores were directly compared, 
paired t-tests were employed to compare each variable against one another to see if there was a significant 
difference in the change between tests. 
I analysed potential confounders for their influence on the change in a variable in 2 ways. Firstly patients were 
grouped by type of surgery (repair, minimally invasive repair, valve replacement), access site (sternotomy or 
thoracotomy), severity of residual regurgitation (none/trivial, mild, moderate, severe), surgeon, rhythm at 
baseline and rhythm postoperatively, and alterations in medications grouped by an increase, decrease or no 
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change in rate-control drugs and an increase, decrease or no change in anti-hypertensive medication. Each of 
these sets of groups were analysed against the change in each variable (the deltas) using an ANOVA model and 
confirmed using an interaction mixed linear model (interaction between change in variable and potential 
confounder). 
Secondly for the continuous variables such as change in lung function, and length of time from surgery to 
follow-up, a multivariate regression model was employed. Change in FEV1, and either change in DLCO or KCO 
(Hb) were used as measures of a change in lung function. The influence on the change in each CPX variable was 
assessed using this multivariate model. 
A p value <0.05 was considered significant throughout.  
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8.4 Results 
8.4.1 Patient recruitment and characteristics 
26 patients were recruited with mitral valve disease requiring surgical correction. Of these 26, 1 died 
perioperatively, 1 had a postoperative stroke and 1 suffered multiple medical co-morbidities making follow-up 
impractical. A further 2 patients had delays to surgery (awaiting dental work) so that they still had not received 
the surgery by this analysis. 
The study group was therefore on 21 patients (mean age 63.1 ± 9.3 years; 16 males, 5 females). All of these 21 
patients had follow-up at approximately 2 months (median 61 days, IQR 53-71 days), with a further 9 having a 
second follow-up at approximately 6 months (median 211 days, IQR 188-233 days). Patient and surgical 
characteristics are shown in Table 8.1. Patient 5 was the only patient undergoing surgery for mitral stenosis; the 
others were all for mitral regurgitation. Patient 21 was the only patient with diabetes mellitus (Type 2). 
Preoperatively, on transthoracic echocardiography, mean ejection fraction was 61.1 ± 9.6 %, 12 patients had an 
ejection fraction <60%, no patients had an ejection fraction ≤ 30 %. Left ventricular diastolic dimension was 
55.5 ± 4.9 mm, systolic dimension was 37.7 ± 6.1 mm and left atrial volume was 150 ± 79 cm
3
. Only 2 patients 
had a left ventricular systolic dimension ≥ 45 mm. Whilst all patients had echocardiography with internal 
dimension measurements, not all patients were able to have quantitative analysis of their mitral regurgitation 
severity, due to eccentric jets. All patients had previously undergone transoesophageal echocardiography; it was 
this test, rather than transthoracic echocardiography, that had ultimately made the decision for surgery. On 17 
patients however I was able to make PISA measurements of their MR severity; effective orifice area (EROA) 
was 0.38 (0.27, 0.89) cm
2
; regurgitant fraction was 51.4 (35.1, 67.0) %; and regurgitant volume was 58.5 (37.1, 
108.1) mL. Mean jet area: left atrial area ratio was 42.7 ± 15.9 %.The patient with mitral stenosis had a mitral 
valve area of 0.99 cm
2
 by pressure half time, and a mean transmitral pressure gradient of 11.3 mmHg.  
12 patients underwent a traditional repair with midline sternotomy, 4 patients underwent repair via a minimally 
invasive approach, 3 patients underwent a valve replacement with a tissue valve, and 2 with a tilting disk metal 
valve. Largely they were uncomplicated, although one needed a repeat procedure 2 days after his first operation, 
and another patient had significant haemolysis requiring repeat transfusions, and eventually a repeat operation.  
The postoperative study haemoglobin for this patient was 6.6 g/dL; in all other patients it was 11.2 g/dL or 
higher. The results will be considered for the full group of 21, but then also with this single patient excluded, 
because of the potential influence of anaemia on exercise capacity. 
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Patient 
 
Gender 
 
Age 
(yrs) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m
2
) 
NYHA 
class 
Smoking 
status 
Baseline 
rhythm 
Peak      (% 
predicted) 
Protocol 
(W/min) 
Procedure 
performed 
Rhythm 
post-op 
MR grade 
post-op Significant complications 
1 M 50 188 91 25.7 2 Never SR 76.8 20 Repair SR 1  
2 M 52 174 72 23.6 1 Never SR 87.0 20 Repair (MI) SR 0  
3 F 63 158 88 35.3 3 Ex-smoker SR 98.6 12 Repair SR 0  
4 M 63 175 82 26.8 2 Never AF 64.2 12 Repair AF 2  
5 F 76 161 47 18.1 2 Never AF 75.0 8 Tissue valve AF 0  
6 M 76 163 67 25.2 1 Never SR 76.0 10 Repair SR 3 Requiring transfusions 
7 M 66 170 62 21.5 2 Ex-smoker AF 52.1 10 Tissue valve AF 0  
8 M 63 187 90 25.7 1 Never AF 77.3 15 Tissue valve AF 1  
9 M 76 185 100 29.1 2 Ex-smoker AF 77.9 12 Repair (MI) AF 1  
10 M 50 193 85 22.8 3 Never SR 27.9 15 Repair Flutter 0  
11 M 59 188 81 22.9 2 Ex-smoker SR 86.6 20 Repair SR 0  
12 M 58 188 91 25.7 2 Ex-smoker AF 69.0 15 Tilting disk SR 0  
13 M 65 182 78 23.5 1 Never SR 71.2 12 Repair (MI) SR 1  
14 M 69 172 62 21 2 Never SR 73.9 15 Repair SR 2  
15 M 44 175 85 27.8 2 Ex-smoker SR 74.9 15 Repair SR 0  
16 M 73 167 77 27.6 1 Never SR 84.9 12 Repair (MI) SR 1  
17 F 68 157 64 26 3 Ex-smoker AF 65.5 8 Repair AF 0 Recurrent chest infections 
18 F 54 171 60 20.5 1 Ex-smoker SR 101.3 15 Repair SR 0  
19 F 71 164 71 26.4 1 Ex-smoker SR 97.4 10 Repair SR 0  
20 M 68 160 61 23.8 3 Ex-smoker SR 71.2 8 Repair SR 0  
21 M 62 169 77 26.9 2 Never AF 61.9 12 Tilting disk AF 0 Repeat surgery 2days later 
 
Table 8.1: Patient baseline and operative characteristics. 21 patients had undergone mitral valve surgery for severe regurgitation (n=20) or stenosis (n=1). NYHA=New 
York Heart Association; SR=sinus rhythm; AF=atrial fibrillation; MI=minimally invasive; MR=mitral regurgitation. 
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8.4.2 Impact of surgery on respiratory function 
All patients underwent full lung function testing on recruitment prior to surgery, and then again after surgery on 
the same day as the 2 month CPX was performed. The pre and post results for some of the important lung 
function variables can be seen in Table 8.2. FEV1 as an absolute value and percent predicted deteriorated 
postoperatively (-0.15 L and -5.9 % respectively). The FVC deteriorated to a similar extent (-0.23 L and -7.1 % 
respectively), and the FEV1:FVC ratio was not significantly altered. Total lung capacity significantly 
deteriorated by quite a large volume (-0.66 L and -11.1 %), and the measures of diffusion capacity all went 
down (corrected for predicted values, haemoglobin and for alveolar volume – the transfer coefficient). Although 
the numbers are small for patients undergoing minimally invasive surgery (n=4) they did not have a 
significantly reduced diffusion capacity unlike patients undergoing open repair (n=12) (ΔKCO (Hb) = -0.02 in 
minimally invasive patients, p=0.72; -0.16 in open repair patients, p=0.002). 
 
8.4.3 Other changes postoperatively and echocardiographic findings 
There was a significant fall in haemoglobin postoperatively (mean change -1.5 g/dL, p<0.001), which was still 
significant even after exclusion of the single patient with haemolysis (mean change -1.3 g/dL, p<0.001). There 
were no significant changes in creatinine, eGFR, sodium, bicarbonate or BNP. 
1 patient was graded to have severe residual regurgitation following the operation. This was the same patient 
who had haemolysis and soon after he underwent a repeat operation. 2 patients had the appearances of moderate 
mitral regurgitation postoperatively, but no patients had restrictive opening of the mitral valve. There was a 
significant reduction in left ventricular diastolic dimension (-7.1 mm, p<0.001) and diastolic volume (-27.8 cm
3
, 
p=0.001), but not systolic dimension (-1.4 mm, p=0.28) or volume (+1.9 cm
3
, p=0.67). Ejection fraction but not 
left atrial volume fell significantly (-9.9 %, p<0.001, -21.4 cm
3
, p=0.13 respectively). 
1 patient reverted to sinus rhythm from their preoperative rhythm of AF, whilst another changed from sinus 
rhythm to atrial flutter. All other patients retained the rhythm of their baseline tests. 
Largely symptoms were non-significantly improved at 2 months with an average NYHA class 1.9 ± 0.7 
preoperatively and 1.6 ± 0.7 postoperatively, with 10 not changing class, 8 improving and 3 worsening. 
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Lung function variable 
Preoperative 
(mean ± sd) 
Postoperative 
(mean ± sd) 
p value 
FEV1 (L) 2.49 ± 0.70 2.34 ± 0.75 0.07 
FEV1 (% predicted) 85 ± 20 79 ± 20 0.02 
FVC (L) 3.63 ± 1.00 3.40 ± 1.04 0.03 
FVC (% predicted) 99 ± 24 92 ± 23 0.01 
FEV1:FVC ratio 69 ± 10 69 ± 10 0.82 
PEF 7.77 ± 1.96 7.41 ± 2.28 0.15 
TLC 5.92 ± 1.67 5.26 ± 1.57 <0.01 
RV 2.19 ± 0.92 1.94 ± 0.54 0.09 
FRC 3.35 ± 0.99 3.10 ± 0.76 0.08 
DLCO 6.90 ± 2.07 5.94 ± 2.05 <0.01 
DLCO (% predicted) 77 ± 16 66 ± 16 <0.01 
DLCO (Hb) 7.08 ± 2.18 6.23 ± 1.99 <0.01 
KCO 1.29 ± 0.23 1.17 ± 0.26 <0.01 
KCO (% predicted) 94 ± 16 86 ± 18 <0.01 
KCO (Hb) 1.32 ± 0.24 1.23 ± 0.24 0.01 
VA 5.39 ± 1.43 5.13 ± 1.38 0.07 
 
Table 8.2: Comparison of lung function variables before and after mitral surgery. FEV1 = forced 
expiratory volume in 1 second; FVC = forced vital capacity; PEF = peak expiratory flow; TLC = total lung 
capacity; RV = residual volume; FRC = function residual capacity; DLCO = Diffusing capacity of the lung for 
carbon monoxide; Hb = haemoglobin; KCO = transfer coefficient; VA = alveolar volume. 
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8.4.4 Change in CPX variables at 2 months 
All 21 patients had a CPX performed postoperatively at approximately 2 months (median 61 days, IQR 53-71 
days); although in two patients they did not have their CPX test until at least 4 months had passed (Table 8.3). 
Generally CPX variables worsened when comparing with preoperative values (Figure 8.1).     at the AT 
(p<0.001), peak      (p≤0.001 all measures), double product and circulatory power were the most significantly 
reduced. Peak      was reduced by a mean value of 2.1 mL/min/kg, or 9 % predicted. OUES showed a small, but 
significant, drop between the 2 tests (-0.14, p=0.047; -6.3% predicted, p=0.04) but not when adjusted for weight 
(p=0.10). The OUEP (p=0.01) and peak minute ventilation (p=0.004), but not breathing reserve, were also 
significantly lower on test 2. Mean peak watts attained was lower during the second test (106 W vs 115 W); 
when combined with the reduction in peak      this led to a non-significantly lower  
 
      slope (-0.66, 
p=0.065). The O2 pulse did not change.          slope throughout exercise and until the VCP, and the  
 
        
ratio at nadir and AT all showed a non-significant trend to lower, improved values at the second test. The 
       slope was significantly flatter on the second test (p=0.02 by Wilcoxon rank test). 
Following the removal of the single patient with severe postoperative mitral regurgitation and severe anaemia 
the majority of the results did not significantly alter. However OUES and percent of predicted OUES were no 
longer significantly different between the 2 tests (-0.12, p=0.08; -5.4% predicted, p=0.07 respectively). The 
         slope throughout the whole test became significantly lower than baseline after the removal of that single 
patient (-3.3, p=0.04 by Wilcoxon rank test). 
The z-scores of certain variables were compared against one another. Peak      (mL/min/kg) showed a 
significantly smaller reduction between baseline and 2 months than     at the AT (p=0.025). However peak  
 
   
showed a significantly greater deterioration at 2 months when compared to OUES (p=0.002), the O2 pulse 
(p<0.01),          slope (p=0.0001) and ratio (p<0.001). 
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 Baseline test (n=21) Δ at 2 month test 
(n=21) 
Δ at 6 month test    
(n=9) 
Peak      (mL/min) 1472  ±  425 -175  ±  202* 1  ±  254‡ 
Peak      (mL/min/kg) 19.4  ±  4.5 -2.1  ±  2.5* 0.2  ±  3.1‡ 
Peak      (% predicted) 74.8  ±  16.3 -9.0  ±  9.5* 0.4  ±  10.1‡ 
AT (mL/min) 1022  ±  287 -173  ±  153* -81  ±  282‡ 
AT (% of pred peak     ) 52.3  ±  12 -9.3  ±  7.2* -2.6  ±  10.9‡ 
OUES 1.65  ±  0.64 -0.14  ±  0.30* -0.02  ±  0.52 
OUES/kg 21.7  ±  7.3 -1.5  ±  3.9 0.26  ±  6.43 
OUES (% predicted) 76.7  ±  23.8 -6.3  ±  13.1* 0.8  ±  21.4 
OUEP 35.4  ±  4.1 -1.8  ±  3.02* 0.73  ±  4.22 
O2 Pulse (mL/beat) 10.8  ±  3.0 0.22  ±  2.46 0.44  ±  1.24 
O2 Pulse (% predicted) 76.5  ±  20.0 0.9  ±  17.7 4.0  ±  8.1 
         slope 1 33 (28.3, 36.1) -0.82  ±  6.47 -3.87  ±  12.12 
         slope 2 35.9 (32.4, 39.9) -2.49  ±  8.09 -5.60  ±  12.16 
         ratio nadir 31.5 (29.9, 34.2) -0.41  ±  4.1 -2.32  ±  5.99‡ 
         ratio AT 32.6 (31, 36.8) -0.24  ±  3.9 -1.66  ±  6.13‡ 
          slope - ratio -0.4 (-1.9, 1) 0.4  ±  3.54 1.55  ±  6.46 
RER at peak 1.15  ±  0.11 0.06  ±  0.11* 0.04  ±  0.11 
PetCO2 at AT (mmHg) 36  ±  3.9 0.48  ±  3.37 2.11  ±  4.78‡ 
HR at peak (bpm) 143  ±  26 -19  ±  26* 0  ±  33‡ 
DP (mmHg bpm) 23699  ±  7151 -3978  ±  6904* -827  ±  6302‡ 
Peak circulatory power 251789  ±  111271 -42280  ±  73837* -13393  ±  70314‡ 
Peak oxygen saturations (%) 97 (96, 98) -0.63  ±  3.61 1.13  ±  2.17 
Breathing reserve at AT (%) 69.3 (63.3, 77.9) 1.26  ±  5.59 0.32  ±  8.31 
Breathing reserve (%) 36.9 (26.2, 42.3) 1.11  ±  15.1 -5.16  ±  22.3 
Minute ventilation (L/min) 63.9  ±  16.8 -7.08  ±  10.05* -1.15 ± 14.6 
        slope 8.7 (8.2, 9.6) -0.66  ±  1.55 0.02  ±  1.37 
Peak work rate (W) 115  ±  41 -9  ±  17* 2  ±  15‡ 
        slope 0.055 (0.043, 0.070) -0.015  ±  0.024* -0.011  ±  0.022 
 
Table 8.3: CPX variables preoperatively and at an average of 2 and 6 months 
postoperatively in patients undergoing mitral valve surgery for severe mitral 
regurgitation (n=20) or stenosis (n=1). * p<0.05 baseline vs 2 months; † p<0.05 
baseline vs 6 months; ‡ p<0.05 2 months vs 6 months 
253 
 
 
 
 
 
Figure 8.1: Change in 12 variables between a preoperative CPX and a CPX performed, on 
average, 2 months postoperatively. The change has been converted in a z-score to allow for 
comparison between variables. A deviation to the left indicates a worsening of the variable (so 
for the          slope the positive score indicates a decrease in magnitude). 
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8.4.5 Change in CPX variables at 6 months 
9 patients came back for a 6 month CPX test. Table 8.3 shows the difference in the major variables between 
baseline and this 6 month time point. No variables were significantly different from baseline (Figure 8.2), 
however there remains a trend to an improvement in the           slope, which was first noted at 2 months. 
It is interesting to see, although the numbers are too small to achieve statistical significance, that the     at the 
AT remained markedly reduced compared to other variables. The near zero difference in peak      suggests 
exercise capacity was back to preoperative levels. When 6 month tests were compared to 2 months, peak      
had significantly improved but     at the AT, OUES, OUEP and O2 pulse did not change.  
 
       ratio at nadir 
and AT had significantly decreased whilst the PETCO2 at the AT had significantly increased. Peak heart rate, 
double product and circulatory power were significantly higher at 6 months than 2 months. A higher work rate 
was achieved but the         slope was not significantly altered. 
 
8.4.6 Influencing factors on postoperative CPX variables 
Surgical factors were assessed for their influence on CPX variables. Valve replacements had a significantly 
greater drop in OUEP compared to valve repairs (p=0.008). Minimally invasive surgery (n=4) did not 
significantly alter any results when compared with open repair and replacement. Ignoring the single patient with 
grade 3 residual MR, the presence of grade 1 or 2 regurgitation did not alter CPX variables significantly. Two 
surgeons operated, with no significant differences their results. Looking more closely at the patients with 
minimal access surgery, they actually displayed the largest decline in peak      (-223mL/min, -10.5%, compared 
with -188mL/min, -10.2% for open repair, and -105mL/min, -4.9% for replacement) although they did have the 
highest exercise capacity at baseline, so perhaps would expect to show the largest absolute difference. 
 
  
255 
 
 
 
 
 
Figure 8.2: Change in 12 variables between a preoperative CPX and a CPX performed, on 
average, 6 months postoperatively. The change has been converted in a z-score to allow for 
comparison between variables. A deviation to the left indicates a worsening of the variable (so 
for the           slope the positive score indicates a decrease in magnitude). 
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Only 2 patients had a change in rhythm between the 2 tests, one from sinus to atrial flutter, and one from atrial 
fibrillation to sinus. Analysing from baseline rhythm patients in AF had a borderline significantly smaller drop 
in OUES/kg and percent of predicted OUES, with a significantly greater deterioration in OUEP. However the 
patients with AF at recruitment had lower OUES values at baseline so a smaller decline after intervention would 
be expected. When assessing the impact of medication, I analysed for the addition of rate-control, no change to 
rate control and a reduction in rate-control medication. Unsurprisingly the postoperative changes in double 
product and peak heart rate varied to different degrees in these 3 groups. Patients with a reduction in rate-control 
showed a borderline smaller decline in OUES/kg than the other two groups (p=0.048); no other variables 
showed a significant influence from rate-control medications. When patients were grouped into more, less or the 
same amount of antihypertensive medication, in none of the variables was the change between tests affected. 
A regression model including the change in FEV1, DLCO and the length of time from surgery to testing showed 
significant relationships between the change in DLCO and peak     ,  
 
   at the AT, OUES,  
 
       slope and 
ratio, and PETCO2 at the AT. However after correction for haemoglobin and alveolar volume, the KCO (Hb) was 
not significantly related to the change in any CPX variables. The change in FEV1 was related to the change in 
the OUEP,           ratio and the breathing reserve at peak. Length of time from operation to first follow-up 
CPX did not significantly affect the change in CPX variables. 
 
8.4.7 Changes in patients with reduced exercise capacity 
5 of the 21 patients had a normal exercise capacity preoperatively as defined by a peak      ≥ 85% predicted. I 
considered the group with reduced preoperative exercise capacity separately. In these remaining 16, peak      
was reduced at 2 months by 146 ± 213 mL/min, 1.6 ± 2.6 mL/min/kg and 7.5% ± 10.3 (p<0.03 for all), which 
were all non-significantly smaller reductions than seen across the full group. OUES, OUES/kg and percent 
predicted OUES were all non-significantly reduced at 2 months compared with baseline in these 16 patients (-
0.11, p=0.23; -0.95/kg, p=0.40; -4.4%, p=0.24 respectively), a smaller change than that seen across the full 
cohort. Double product, circulatory power, peak work rate and        slope also displayed non-significantly 
smaller reductions at 2 months in patients with reduced exercise capacity compared to those within normal 
exercise capacity.  
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8.5 Discussion 
 I have shown that 2 months following mitral valve surgery for severe regurgitation or stenosis, there were large, 
significant declines in peak     , anaerobic threshold, double product and circulatory power. There are 
significantly smaller reductions in OUES, which are almost non-significant from baseline. The ventilatory 
equivalents for CO2 show an early and persistent, albeit non-significant, improvement following surgery. At 6 
months most changes, with the principal exception of the     at the AT, have returned to close to the baseline 
values. At this time point     at the AT has a z-score of approximately -0.3, that is 0.3 standard deviations (of 
AT within the whole population) worse than baseline, although this does not reach significance. The           
slope is almost +0.5 z-scores, but with each variable, the presence of only 9 patients so far returned for 6 month 
follow-up makes statistical significance difficult to obtain. It is also interesting to see that minimally invasive 
surgery does not show an improvement in exercise capacity, although there are suggestions that lung function 
may be improved. 
 
8.5.1 Reductions in exercise capacity pre- and postoperatively 
Organic mitral regurgitation is known to limit exercise capacity, but even in the presence of severe regurgitation 
it is not uncommon for patients to have preserved exercise tolerance (Messika-Zeitoun et al 2006). Conversely 
patients who believe themselves to be asymptomatic are often limited in exercise capacity compared with 
matched controls (Olaf et al 2012). 7 patients within my analysis were self-described as asymptomatic (NYHA 
class 1) whilst only 5 had a peak     > 85%, and only 3 patients met both these criteria (i.e. were both self-
described as asymptomatic and had a near normal peak     ). A reduction in exercise capacity in mitral 
regurgitation is important as it is associated with increased clinical events such as death, heart failure and atrial 
arrhythmias (Messika-Zeitoun et al 2006), and also predicts a worse symptom class a year after surgery (Kim et 
al 2003). It would be expected that exercise capacity should improve following surgical correction of mitral 
regurgitation; however previous studies have shown vastly different results. A single study has shown 
significant improvements in peak      four months after minimally invasive mitral valve repair for regurgitation 
(Madaric et al 2007); interestingly improvements were most marked in the least symptomatic patients. In 
contrast two studies have shown no change in exercise capacity following open surgery. One study of patients 
undergoing open repair showed no overall difference in peak      at one year, with a decline if residual 
regurgitation persisted (Kim et al 2004). Another study, in which 40% of patients underwent replacement and 
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60% repair, showed no improvement in peak      after an average of 7 months (Le Tourneau et al 2000). It is 
difficult to know if the different modes of surgical correction, or underlying patient characteristics lead to such 
dramatically different results. Madaric et al did not recruit any patients with AF; either this or the minimally 
invasive nature of the surgery could explain the differences found. Whilst it is not the purpose of my study to 
detail the change in exercise capacity, purely to look at how various CPX variables behave differently, it’s 
interesting to note that my results show more similarities with the latter studies, rather than the former. At 2 
months, albeit much earlier than the Madaric et al study, I show a significant deterioration in most variables. At 
6 months they have returned to baseline and no better, although small numbers at this time point make it 
difficult to draw firm conclusions. Also in contrast to the Madaric et al study I find that it is probably the most 
symptomatic patients in my study who benefit the most. Could the differences be explained by their universal 
adoption of minimally invasive repair? Unfortunately it is impossible to draw any conclusions from my 
minimally invasive patients, as they number only 4. 
What is interesting is that despite subjective opinion that symptoms are improved (0.3 improvement in NYHA 
class), objective measures of maximal exercise capacity do not agree. 
 
8.5.2 Changes in CPX variables 
It is to be expected that different variables will behave differently following surgery as they are all influenced to 
different degrees from the numerous processes that go on before, during and after surgery, such as improvement 
in cardiac function, potential deterioration in lung function from cardio-pulmonary bypass and mechanical 
ventilation, and the reduction in muscle bulk and power associated with a prolonged period of recovery. 
Madaric et al showed improvements in peak      and O2 pulse, but not the AT. There have been a handful of 
studies following balloon valvuloplasty for mitral stenosis that have similarly shown a smaller improvement in 
the AT when compared to the improvement noted in the peak      (Douard et al 1997, Meurin et al 2005). 
Meanwhile Wright et al showed a reasonable improvement in both peak      (+2.5 mL/min/kg) and  
 
  
     slope (-4.5), although only the former reached statistical significance, with no mention of the AT (Wright et 
al 2003).  
Evidence that the muscle plays a strong role in the delay of improvement in CPX variables comes from work by 
Yasu et al, who showed that despite an immediate improvement in symptoms following balloon valvuloplasty 
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for mitral stenosis it took a month until peak      improved. These prolonged improvements were closely 
correlated to muscular changes on magnetic resonance spectroscopy of the forearm, including intracellular pH 
on exercise and phosphocreatine recovery (Yasu et al 1996). In the study by Meurin et al an early exercise 
rehabilitation program following valve repair led to an increase in peak      (+22%) and a smaller increase in the 
AT (+16%) when compared before and after the program. However there was no control group, no tests 
performed before surgery, and tests were done on average at 3 and then 6 weeks postoperatively. This is a very 
early period postoperatively and we would expect to see large changes between these two time points; at 3 
weeks patients have only recently become fully ambulant again, compared with 6 weeks when their leg muscles 
have had a much longer time to recover strength and bulk. When Douard et al compared two groups after 
balloon valvuloplasty, one following routine care, and the other undergoing an exercise rehabilitation program, 
the latter showed significant increases in peak      and work rate achieved (Douard et al 1997). AT non-
significantly increased in the exercise program group by 17%, with only a 1% improvement in the control 
group;          slope was significantly decreased in both groups but to a greater extent in the exercise regime 
group.  
The valvuloplasty model is relatively unique in that it can immediately rectify some of the abnormal physiology 
associated with mitral valve disease without the long recovery time seen with an open repair or replacement. 
Despite immediate restoration of valvular function (mean gradient fell from 12.7 to 3.4 in the control arm of the 
Douard et al study) anaerobic threshold appears unchanged at 3 months unless exercise rehabilitation occurred. 
It seems that AT may lag behind other variables, perhaps because it reflects muscular adaptations which take 
time, and I see similar results in my study, with AT being the most negatively affected variable at both 2 and 6 
months. I have used a z-score method to allow comparison between variables (change in each variable between 
tests is normalised for the standard deviation of that variable) and peak     , AT, DP and circulatory power have 
the largest negative change at 2 months. However most of these appear to recover by 6 months -although total 
patient numbers are too small to draw statistically significant conclusions - with the exception of AT, which 
although not significant shows a trend to a continued deterioration from baseline.  
OUES behaves in an interesting manner. It does not improve immediately postoperatively, but neither does it 
show the significant declines noted with peak     , AT and some of the other variables. Surprisingly changes 
postoperatively were less marked in patients with atrial fibrillation than in those in sinus rhythm. 
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8.5.3           relationship 
The main group of variables which appear to show an early and persistent benefit are variables of the             
         relationship. This may help us to explain the patients’ symptomatic improvement. In their day-to-day 
lives patients don’t typically stress themselves maximally, and may not reach their anaerobic threshold whilst 
only undertaking activities of daily living, so a decline in peak      may go unnoticed. In contrast improved 
ventilatory efficiency means that work of breathing for any level of activity will be reduced, and this may be 
noted as an improvement in symptoms by the patient. Why does the          relationship improve? This 
relationship is largely felt to reflect 2 major components in a heart failure patient; abnormal ventilation: 
perfusion matching; and primary hyperventilation possibly driven from the ergoreflex. In mitral valve disease 
high left atrial pressures drive abnormal pulmonary vasoregulation leading to ventilation: perfusion mismatch, 
this could potentially be reversed soon after amelioration of the valve lesion. Although there are medium-term 
reductions in lung function, as I show with a reduction in KCO and FEV1 postoperatively, because the lungs 
capacity for diffusion of carbon dioxide is far greater than for oxygen (Wagner et al 1971) it is possible that 
these reductions do not affect the          relationship, whilst variables involving oxygen uptake may be more 
affected. However there was no correlation between the change in KCO postoperatively and the change in CPX 
variables which would argue against this explanation. It is possible that in a group of patients with only mildly 
symptomatic mitral valve disease the abnormal physiology of the heart failure syndrome has, as yet, not 
intervened, hence the contribution to an abnormal          relationship from the ergoreflex is minimal. 
Therefore muscular adaptations after surgery (which take time) are not necessary to improve the coupling of 
CO2 elimination to ventilation which is solely affected by ventilation: perfusion mismatch. 
 
8.5.4 Effect of surgery on lung function 
Although not part of this study’s aims, it is interesting to note how lung function is affected by cardiac surgery. 
There have been a number of studies on lung function following heart transplantation (Ewert et al 1999, Ewert 
et al 2000) and in patients undergoing coronary artery bypass graft (CABG) surgery, although there is little data 
beyond the first few days postoperatively (Staton et al 2005). I am unaware of any studies specifically looking at 
the long-term effects to the lungs from mitral valve surgery. This differs from heart transplant recipients in that 
patients are normally less symptomatic, with fewer abnormalities of resting lung function preoperatively. Heart 
transplantation therefore possibly represents the extreme end of the spectrum. Conversely CABG surgery is 
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often performed on patients with structurally normal hearts, and operative time can be shorter in duration when 
compared to mitral valve repair. Therefore we may expect long-term abnormalities in lung function following 
mitral surgery to lie somewhere between CABG surgery and heart transplantation. I have shown an 8% 
reduction in KCO and 11% reduction in DLCO, which at 2 months are smaller reductions than noted in patients 
comparing before with 6 and 12 months after heart transplantation (Ewert et al 1999). I also show small but 
significant changes in FEV1 (-6% predicted) and FVC (-7% predicted) but not the ratio of these 2 values, 
suggesting that there has been the addition of a small restrictive, but not obstructive, insult to the lungs. 
Although the numbers are small there was a 7-fold smaller reduction in KCO for my patients undergoing 
minimally invasive rather than open repair. Larger studies will be necessary to decide if this is significant.  
 
8.5.5 Limitations 
Unfortunately total numbers of patients are small, especially when trying to look for differences between 
surgical techniques and looking for differences at 6 months. 
There are many confounding influences that we cannot account for. Postoperative recovery times, rehabilitation 
routines, nutrition etc will all vary between patients and may influence results but are not easily quantifiable. 
For calculation of breathing reserve the spirometry performed preoperatively was used for the baseline test, and 
the spirometry performed postoperatively (at 2 months) was used for both the 2 month and 6 month test. It is 
possible that spirometry could have improved between these 2 time points; this would therefore have led to an 
underestimation of breathing reserve at the 6 month mark. It was, however, unfortunately not practical to repeat 
full lung function tests a third time. 
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8.5.6 Conclusions 
Two months following mitral valve surgery peak      is depressed compared with preoperative measures. By 6 
months peak      has returned to baseline.  
 
  at the AT shows significantly greater deterioration at 2 months 
compared with peak     . In contrast OUES shows a small deterioration at 2 months, which is also back to 
baseline at 6 months. At 2 months this small decline in OUES is significantly smaller than the decline in peak 
     and  
 
  at the AT. Markers of the  
 
       relationship show no such deterioration at 2 months, with a trend 
to large improvements at 6 months. OUES and          slope or ratio may be good variables to assess the 
changes in cardiac function. It does not appear that the increased influence of lung abnormalities on peak      
accounts for its greater decline at 2 months when compared to OUES and           slope and ratio, so it is 
possible that these other variables are less affected by the peripheral changes associated with a postoperative 
state than peak     . 
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9.0 The Interventional Study – Cardiac 
Resynchronisation Therapy 
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9.1 Abstract 
 
Cardiac resynchronisation therapy (CRT) has been shown to improve prognosis and exercise capacity in patients 
with heart failure. Given that certain cardiopulmonary exercise test (CPX) variables appear to be more specific 
for cardiac function than others, these should show rapid improvements following CRT. Non-specific variables 
should improve to a lesser degree because they also require improvements within other organs. Conversely the 
sudden reduction in cardiac function, via the transient switching off of CRT, should reduce all variables equally 
as the heart becomes centrally limiting. I will investigate these hypotheses. 
10 patients with heart failure were recruited prior to CRT implantation (pre-post study), and a further 13 with 
existing CRT (on-off study). They underwent CPX testing on a bicycle ergometer. Following a familiarisation 
test, each patient in the pre-post study underwent a personalised second test aiming for maximal exercise after 
approximately 10 minutes. This test was repeated approximately 2 months after CRT implantation. Patients in 
the on-off study underwent two identical, personalised tests in a random order, one with CRT active and one 
deactivated. QRS duration was on average 24.3 ms shorter with CRT. 
The          ratio, PETCO2 at the AT and respiratory frequency improved after implantation. The change in these 
variables,           slope and OUES were all better than the change in peak  
 
   which non-significantly 
deteriorated post-implant. 
When CRT was transiently switched off there were no changes to any variables. When all patients were 
considered together the act of resynchronisation only significantly affected the         slope, reducing it by 
0.64. 
CRT was not associated with an improvement in exercise capacity as measured by peak     . There was a 
dissociation between various variables with ventilatory equivalents and slopes for       and OUES responding 
more positively to CRT than peak      did. I propose that this may be because peak  
 
   requires full body 
adaptations post-CRT which take longer to manifest.  
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9.2 Introduction 
Cardiac resynchronisation therapy (CRT) has been shown to improve symptoms, exercise capacity and reduce 
hospitalisations (Cazeau et al 2001, Abraham et al 2002, Cleland et al 2005). 
Improvements in exercise capacity seem consistent throughout the published literature. Cazeau et al showed a 
significant average improvement in peak      of 8% following 3 months of CRT (Cazeau et al 2001). Larger 
changes in peak      were noted in other studies; including a 28% increase at 3-6 months (Chwyczko et al 2008), 
26% in a study of a single left ventricular lead (no right ventricular lead) after 12 months (Blanc et al 2004), and 
a 17% improvement in another study (Madaric et al 2007). In patients with pre-existing CRT, significant 
reductions in exercise capacity have been noted when removing the CRT component transiently (Salukhe et al 
2008, Laveneziana et al 2009). 
In most of these studies only peak      was measured, although Chwyczko et al showed improvements in the 
anaerobic threshold, O2 pulse and          slope; Laveneziana et al showed significant improvements in the O2 
pulse,         slope, respiratory frequency and ventilatory equivalents when CRT was “on”. Another study 
showed significant increases in OUES in responders to CRT (Berger et al 2011). However what none of these 
studies have done is to compare the response of different variables. 
To prove my overall hypothesis that an ideal variable of cardiovascular function on CPX exists, it should 
reliably and consistently improve following an intervention to the heart designed to improve cardiac function. 
CRT supplies us with an excellent model, because cardiac output should improve and procedural recovery is 
minimal. Therefore any muscular maladaptation that occurs in mitral surgery patients owing to the long 
recovery time, should not occur in CRT patients. Because certain variables, such as the anaerobic threshold and 
peak     , may be more reflective of total body physiology, these may not improve as significantly following 
CRT implantation (because further changes are required within the body to improve them) compared with more 
specific variables. Variables more specific for the heart, such as OUES, would show improvements independent 
of the changes to maximal exercise capacity.  
Conversely the sudden impairment of cardiac function through an intervention would affect all variables equally 
as the heart becomes the “lowest common denominator”. It is unethical to perform an intervention causing 
lasting cardiac impairment, however the transient deactivation of CRT by switching to an alternative pacing 
mode, has been shown, in the studies by Salukhe et al and Laveneziana et al, to be safe and result in sudden and 
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significant reductions in exercise capacity. Similar experiments have been conducted on patients with a left 
ventricular assist device for severe heart failure, where a reduction in pump speed (consistent with a decline in 
circulatory support) led to an immediate decline in peak      (Jakovljevic et al 2010, Noor et al 2012). 
I aim, through the investigation of CPX testing, both before and, on average, 2 months after CRT implantation 
(pre-post study) as well as in patients with pre-existing CRT in 2 states, CRT-on and CRT-off (on-off study), 
how different variables behave, and how they relate to the overall improvement in exercise capacity.  
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9.3 Methods 
9.3.1 Patient Recruitment 
 Patients were recruited for the pre-post study from Imperial College Healthcare NHS Trust (ICHNT) whilst 
awaiting the implantation of a cardiac resynchronisation therapy pacemaker. The indication for this had to 
include left ventricular systolic impairment with a broad QRS duration on ECG (>120 milliseconds). The 
decision for CRT had been made by one of the heart failure or electrophysiology physicians at ICHNT. 
Separately patients with pre-existing CRT were recruited for the on-off study. These were either patients at 
ICHNT or the Royal Brompton and Harefield NHS Foundation Trust. The patients from the latter organisation 
had been approached by their pacing team to take part in research studies into CRT optimisation at ICHNT; I 
approached them after their acceptance. Patients with pre-existing CRT from my institution were either recruited 
from the aforementioned optimisation studies, the pacing clinic or heart failure clinics. The presence or absence 
of a defibrillator component to the pacemaker did not affect recruitment (i.e. the patient could have CRT-P or 
CRT-D). 
 
9.3.2 Patient testing 
Once patients were identified and consented for the pre-post study, they underwent full lung function tests, a 
transthoracic echocardiogram, venous blood tests and 2 cardiopulmonary exercise tests; these are considered the 
baseline tests. The full description of these tests can be found within the Methods Chapter. The first test was for 
familiarisation and to identify the optimal protocol for each patient to achieve similar duration of exercise in all 
(approximately 10 minutes of incremental exercise). The results of this first CPX test were not considered. The 
results of the second test, performed at least 2 hours after the first test to allow for muscular recovery, were 
performed on the patient’s optimal protocol and were recorded for analysis. 
CPX tests were performed using a bicycle ergometer (Ergoline, GmbH, Bitz, Baden-Württemberg, Germany) on 
a COSMED Quark CPET System (COSMED S.r.l. Rome, Italy). The identification and measurement of CPX 
variables was performed as per directions from within the Methods Chapter and will not be discussed again 
here. However following on from the identification of a new set of contemporary reference equations (Gläser et 
al 2010, Chapter 4) percent of predicted values for peak     , OUES and O2 pulse were calculated using these 
SHIP equations described previously. The     at the AT will be presented as a percent of the predicted peak  
 
   
using the SHIP reference equation for peak     . All other variables will just be displayed giving their raw 
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values.          slope is displayed in 2 forms: slope 1 using data until the VCP; and slope 2 using data 
throughout exercise, in keeping with previous chapters, the          slope minus ratio difference was also 
calculated for each patient as per previous chapters.  
Patients were contacted over a month after their CRT implantation to gauge recovery and arrange follow-up. It 
was agreed that 4 weeks should allow for enough recovery to make exercise testing safe, this was the minimum 
time from procedure to follow-up for the study. On arrival patients underwent venous blood sampling and a 
single CPX test on the same protocol as the main test from the preoperative testing (i.e. not the familiarisation 
test).  
Patients within the on-off study had 3 CPX tests; the familiarisation test, one test on their optimal protocol with 
the CRT switched off, and one test on their optimal protocol with the CRT on. No more than 2 tests were 
performed on a single day, so this study required 2 visits. The order of the second and third tests was random. 
Typically these 2 tests were performed on the same day so differed from the other parts of the Observational 
study. Patients in the on-off study also had baseline full lung function tests, venous bloods and 
echocardiography. For CRT-on, the device was allowed to work at the pre-specified settings by the patients’ 
clinical teams. Upper tracking rates and defibrillator (if appropriate) thresholds were recorded to allow me to 
stop exercise if necessary in the event of inappropriately high heart rates during exercise. For CRT-off the 
patients’ devices were interrogated for an underlying rhythm (i.e. not pacing dependent). If they had a stable 
underlying rhythm (all patients) then the patients had their pacemaker set to DDI-40, so that they would resume 
pacing in the event of bradycardia, but would otherwise remain intrinsic. It was decided that in the absence of a 
stable intrinsic rhythm the patients would have the left ventricular lead component deactivated so that they only 
paced with their right ventricular lead; this would accentuate dyssynchrony. These changes to the patients’ 
pacemakers were made a few minutes prior to this CPX test, and returned back to normal immediately after. The 
patient underwent a “sham” turning off of their CRT for the CRT-on test so that they remained blinded to the 
order of tests. This was not possible for myself or the other operator as we had to, for safety, watch the ECG 
during exercise. 
QRS durations whilst unpaced (pre-implant or CRT-off) and paced (post-implant and CRT-on) were measured 
using Iconico screen calipers (Iconico, New York, USA) on digitised ECG recordings at rest. 
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9.3.3 Hypotheses 
I hypothesised that because CRT was a procedure requiring minimal recovery (and therefore minimal risk of 
loss of muscle bulk) we would not see a reduction in exercise capacity between pre-implantation and post-
implantation. I hypothesised that we would see a small improvement in exercise capacity because the short time 
between implantation and retesting meant that muscular adaptations would be minimal. However cardiac 
specific variables (as based on previous chapters) such as OUES would show greater improvements because 
they may be more independent of the muscles’ impact on exercise.  
Conversely the on-off experiment would show a similar drop in all variables because the muscles would not 
have had time to deteriorate from just a few minutes of dyssynchrony and so all variables would only be 
influenced by the change in cardiac output. 
 
9.3.4 Statistical analysis 
Variables of gas analysis and lung function have previously been assessed for normal distribution. Normally 
distributed variables are displayed as mean ± standard deviation; non-normally distributed variables as median 
(25
th
, 75
th
 percentiles). For pre-implant versus post-implant changes of continuous variables paired t-tests were 
used, unless the variable was non-normally distributed, in which case a Wilcoxon signed rank test was 
employed. For graphical representation of the change in each variable it was standardised using the z-score 
method (z-score = change/standard deviation of variables within population). On these plots a leftward shift 
represents a worsening of a variable, regardless of whether this is an increase or decrease in the magnitude of 
the variable. Because z-scores standardise each variable these scores could be directly compared, paired t-tests 
were employed to compare each variable against one another to see if there was a significant difference in the 
change between tests. 
Unpaired t-tests were performed between the 2 study groups. Where variables were non-parametric, the 
Kruskall-Wallis test was performed. Linear regression was employed to look for relations between continuous 
variables. 
A p value <0.05 was considered significant throughout.  
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9.4 Results 
9.4.1 Patient recruitment and characteristics 
17 patients awaiting CRT implantation were recruited. 2 of these patients did not have a left ventricular lead 
implanted or switched on. 2 patients had problems with lead displacement, so did not have a prolonged period of 
biventricular pacing. 2 patients did not return for follow-up, and 1 patient had his procedure delayed multiple 
times and still had not undergone CRT prior to this analysis, leaving only 10 patients. 
15 patients who had previously undergone CRT were assessed comparing the on-off state. 1 patient with 
alcoholic cardiomyopathy and long-standing CRT was found on echocardiogram to have near normal systolic 
function. He was abstinent from alcohol and in the CRT-off state his QRS duration was noted to be narrow 
(<120ms). He was hence excluded from all analyses. A further patient did not attend his second visit. He had 
already undertaken 2 tests (familiarisation plus CRT-on) so his data was retained within the reproducibility and 
Observational studies but not within the Interventional study. This left 13 patients for the CRT on-off study.  
For the 10 patients tested before and after implantation (mean age 66.9 ± 10.4 years) the average time to testing 
was 52 days (IQR 42-69 days), however there were 2 patients as significant outliers due to unavoidable delays 
(returned 154 and 160 days post-implantation). For the 13 patients with pre-existing CRT (mean age 67.8 ± 8.5 
years), 11 undertook both tests on the same day (therefore both on a different day to the familiarisation test), 1 
patient undertook both tests within 4 weeks and 1 patient undertook both tests within 5 weeks. Order was 
randomised for each patient; 8 undertook CRT-off first, 5 CRT-on first. Of the 2 patients performing the 2 tests 
on different days the order was different. Details of the 23 patients are shown in Table 9.1. The first 10 patients 
are from the pre-post study, the last 13 from the on-off study. Patient 1 was in atrial fibrillation; all other 
patients were in sinus rhythm. Patients 3 and 21 had type 2 diabetes mellitus. On echocardiography only ejection 
fraction from the principal variables differed between these two study groups (30.8 ± 7.2 % pre-post study; 40.9 
± 9.2 % on-off study, p=0.01 between studies). One patient within the CRT on-off study group had reasonable 
systolic function, however they had a broad QRS duration on CRT-off so were retained within the study. Mean 
left ventricular internal dimension in diastole was 55 ± 8 mm, left ventricular diastolic volume   165 ± 59 cm
3
, 
left ventricular systolic volume 107 ± 47 cm
3
, fractional shortening 16.6 ± 7.7 %, left atrial volume 86 ± 35 cm
3
 
and TAPSE 18.8 ± 4.5 mm. 
Mean QRS duration was 169 ± 21 milliseconds pre-implant and 176 ± 34 milliseconds in the second group 
when in the off-state. 
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Patient 
 
Gender 
 
Age 
(yrs) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m
2
) 
NYHA 
class 
Smoking 
status 
FEV1 (% 
predicted) 
Peak      (% 
predicted) 
Protocol 
(W/min) 
Order 
of tests 
Indication for implant Time from 
implant (yrs) 
1 M 81 170 83 28.6 3 Ex-smoker 81 54.5 6 
 
IHD  
2 F 63 157 61 24.7 1 Never 121 85.5 10 
 
DCM  
3 F 60 149 74 33.3 2 Never 111 64.6 8 
 
DCM  
4 M 80 175 80 26.1 2 Current 96 94.2 10 
 
DCM  
5 M 78 178 85 26.8 2 Never 89 80.7 12 
 
DCM  
6 M 63 190 119 33 3 Ex-smoker 91 56.3 15 
 
IHD  
7 M 72 173 109 36.4 2 Ex-smoker 120 90.8 12 
 
IHD  
8 M 64 167 82 29.6 2 Ex-smoker 86 58.8 10 
 
IHD  
9 M 50 183 79 23.6 2 Current 90 48.7 12 IHD  
10 M 58 172 87 29.4 1 Ex-smoker 90 76.9 15 
 
DCM  
11 M 73 174 82 27.1 2 Never 109 54.0 10 off-on IHD 2 
12 M 71 177 67 21.4 3 Never 59 37.5 10 on-off DCM 3 
13 M 84 159 63 24.9 1 Ex-smoker 130 98.7 10 on-off IHD and heart block 2 
14 M 66 173 78 26.1 2 Ex-smoker 33 63.5 12 off-on DCM 4 
15 F 62 162 82 31.2 2 Never 103 73.1 10 on-off DCM 3 
16 M 69 175 70 22.9 2 Ex-smoker 81 69.2 12 off-on IHD, AoV disease 5 
17 M 53 179 116 36.2 3 Ex-smoker 87 52.7 8 on-off IHD 2 
18 M 66 165 85 31.2 2 Never 76 89.3 10 off-on DCM 4 
19 M 55 173 93 31.1 1 Never 88 74.2 15 off-on DCM 7 
20 M 77 168 65 23 2 Never 69 66.3 8 off-on CHB, pacing induced LVSD 7 
21 M 67 183 122 36.4 2 Ex-smoker 79 65.7 15 on-off DCM 1 
22 M 74 186 112 32.4 2 Never 84 85.0 15 off-on IHD 5 
23 M 64 172 79 26.7 2 Current 68 66.0 12 off-on IHD, AVR 8 
 
Table 9.1: Patient baseline characteristics. Patients 1-10 were recruited prior to CRT implantation; patients 11-23 had longstanding CRT and were tested 
with CRT on vs off. AoV = aortic valve disease, CHB = complete heart block, AVR = aortic valve replacement, LVSD = LV systolic dysfunction
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9.4.2 Changes between pre- and post-implantation 
There were no significant changes in haemoglobin, creatinine, eGFR, sodium, bicarbonate or BNP between pre-
implantation and post-implantation. 8 patients described themselves as having responded to CRT, 1 other was 
unsure, whilst 1 patient felt there had been no change and had had repeated chest infections post-implant. There 
was a non-significant reduction in NYHA class (mean change – 0.20, p=0.17). 2 patients, despite both taking 
2.5mg of Bisoprolol, exceeded the upper tracking rate of the pacemaker and assumed an intrinsic rhythm 
towards the end of exercise. Heart rates did not closely approach the defibrillator thresholds and neither intrinsic 
rhythm led to a deterioration in symptoms, so exercise was not halted. The potential impact of the intrinsic 
rhythm is shown in Figure 9.1.  
2 patients had an increase in beta-blocker dose, and 1 patient a decrease. 
Mean change in QRS duration when comparing post-implant or the on-state, with pre-implant or the off-state 
was a 24.3 millisecond reduction with CRT (range -33 to 74 milliseconds). 
 
9.4.3 Comparing the 2 groups 
There were no differences in age, height, weight, BMI, smoking status, and beta-blocker use at baseline between 
those undergoing CRT and those in the on-off study. Other baseline variables compared include similar BNP 
values (p=0.56) and NYHA class (p=0.90). 
CPX tests from patients recruited into the on-off study were compared with those in the pre- post-implant study; 
results are shown in Table 9.2. At baseline/CRT-off the only significant differences between the groups were a 
         slope two 10.9 higher in the pre-implant group (p=0.03 by t-test, p=0.03 by Kruskall-Wallis),  
 
        
ratio at the AT 7.1 higher in the pre-implant group (p=0.02 by t-test, p=0.05 by Kruskall-Wallis), an end-tidal 
CO2 at the AT 4.9 mmHg lower in the pre-implant group (p=0.01), minute ventilation 16.7 L/min higher in the 
pre-implant group (p=0.03 by t-test), and a 7 breaths per minute higher respiratory frequency in the pre-implant 
group (p=0.02).  
  
  
 
 
Figure 9.1: Sparkline plots of the change of      over time for the 10 patients post-
implantation. The top two patients breached the upper tracking rate on their CRT 
devices, and assumed an intrinsic rhythm; this is denoted by the black arrowhead. It can 
be seen that in these two patients      reaches a plateau and may start to fall whereas this 
phenomenon is not noted in the other eight patients who remained in a paced rhythm 
throughout. 
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  Pre-Post Study  On-Off Study 
  Baseline test Δ at 2 month test  CRT-off Δ for CRT-on 
Peak      (mL/min)  1334 ± 340 -109 ± 198  1348  ±  357 29  ±  118 
Peak      (mL/min/kg)  15.6 ± 3.1 -1.02 ± 1.94  15.8  ±  3.1 0.41  ±  1.47 
Peak      (% predicted)  71 ± 16 -4.4 ± 10.1  69  ±  16 1.2  ±  5.7 
AT (mL/min)  973 ± 229 -71 ± 151  993  ±  223 0  ±  101 
AT (% of pred peak     )  52.9 ± 13.9 -3.1 ± 7.8  51.2  ±  12.4 -0.4  ±  6 
OUES  1.40 ± 0.44 -0.02 ± 0.28  1.74  ±  0.58 -0.08  ±  0.2 
OUES/kg  16.5 ± 4.7 -0.07 ± 3.27  20.4  ±  5.8 -0.77  ±  2.52 
OUES (% predicted)  66 ± 18 0.1 ± 14.1  81  ±  25 -3.4  ±  9.6 
OUEP  31.2 ± 4.8 -0.3 ± 2.93  34.1  ±  4.7 -0.49  ±  3.55 
O2 Pulse (mL/beat)  12.2 ± 3 -0.16 ± 1.4  14.1  ±  3.1 -0.02  ±  1.1 
O2 Pulse (% predicted)  80 ± 19 -2.3 ± 11.9  89  ±  20 -0.3  ±  7.4 
         slope 1  37.9 (33.1, 48.9) -3.1 ± 6.7  33.2 (30.7, 38.1) 0.7  ±  3.3 
         slope 2 *  37.9 (35.4, 58.6) -3.6 ± 7.6  34.1 (30.9, 39.3) 1.3  ±  4.4 
         ratio nadir  33.7 (32.1, 39.4) -0.7 ± 2.6  31.2 (29.8, 33.7) 0.5  ±  2.4 
         ratio AT *†  37.7 (33.6, 44.5) -2.7 ± 3.3  34.4 (30.4, 37.7) 0.6  ±  1.9 
         slope - ratio  -3.4 (-9, -0.5) 2.3 ± 5.4  -1.9 (-3.7, 0.1) -0.2  ±  2.5 
RER at peak  1.14 ± 0.1 0.04 ± 0.11  1.1  ±  0.08 0  ±  0.07 
PETCO2 at AT (mmHg) *†  31.5 ± 4.6 3 ± 3.4  36.4  ±  3.6 -0.8  ±  1.7 
HR at peak (bpm) *†  120 ± 26 -11 ± 8  100  ±  17 2  ±  6 
DP (mmHg bpm)  18693 ± 6008 -1684 ± 3636  15281  ±  3761 414  ±  1483 
Peak circulatory power  212741 ± 92111 -20964 ± 57858  204463  ±  56878 5445  ±  19759 
Peak O2 saturations (%)  98.5 (96, 100) -1 ± 4.5  98 (97, 100) 0.3  ±  2.4 
BR at AT (%) †  68.9 (66.7, 72.3) 5 ± 5.8  70.8 (63.2, 74) -0.5  ±  3.7 
Breathing reserve (%)  38.4 (26.5, 42.9) 8.2 ± 13.4  45.1 (34.7, 50.4) -3.9  ±  11 
        slope †  9.5 (8.4, 9.8) -1.19 ± 1.05  9.2 (8.1, 10.4) -0.22  ±  1.12 
Peak work rate (W)  100 ± 26 -4 ± 19.1  92  ±  22 2.9  ±  5.3 
       slope  0.043 (0.04, 0.06) 0.007 ± 0.008  0.032 (0.03, 0.04) -0.002  ±  0.012 
 
Table 9.2: CPX results for the pre- and post-implant patients, and the CRT on-off patients. Pre-
implant (column 2) and CRT-off (column 4) are considered the two baseline states, the results of post-
implant (column 3) and CRT-on (column 5) are displayed as a change (Δ) from the baseline states. * p 
<0.05 baseline pre-post study vs on-off study  † p <0.05 baseline vs 2 months pre-post study  ‡ p <0.05 on 
versus off. 
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9.4.4 CPX results – The pre-post study 
10 patients underwent two identical CPX tests, one prior to implantation of CRT and a second an average of 52 
days (IQR 42-69 days) after. On average there was a non-significant reduction in peak      of 1.02 mL/min/kg, 
or 4.4% of predicted.     at the AT showed a similar, non-significant, reduction of 3.1%. OUES showed trivial, 
non-significant differences between tests (-0.02 kg
-1
, +0.7% predicted). There were suggestions that ventilatory 
control in heart failure was improved by CRT. All measures of the          relationship improved, although only 
the          ratio at the AT showed statistically significant improvements post-implant (p=0.03). The PETCO2 at 
the AT was 3 mmHg higher post-implant (p=0.02), with a reduction in respiratory frequency (-4.6 breaths per 
minute, p=0.03). Breathing reserve was significantly improved by +5% at the AT and non-significantly by +8% 
at peak (p=0.02 and p=0.09 respectively). Heart rate was significantly lower at rest and peak (p=0.01 and 
p=0.002 respectively). The         slope was significantly lower (worse) post-implant with the value falling 
in 8 of the 10 patients (p=0.001). There were no significant differences in duration, peak work rate or peak RER. 
Figure 9.2 shows the change in a few principal variables. 
When the change in each of the major variables was compared to the change in peak      (standardised by z-
scores) the change in OUES (p=0.005), OUES/kg (p=0.02), percent of predicted OUES (p=0.02),          slope 
(p=0.03) and ratio at nadir (p=0.04), and PETCO2 at the AT (p=0.005) were all better than for peak     . 
 
9.4.5 CPX results – The on-off study 
All patients had an intrinsic rhythm capable of sustaining exercise, therefore all patients within this part of the 
study were set to DDI-40, and none of them required RV pacing during their CRT-off test. 
There were no significant differences between patients when tested with their intrinsic rhythm (CRT-off) versus 
full biventricular pacing (CRT-on) (Figure 9.3). Importantly there were no significant differences between the 
groups in resting (66 bpm CRT-off versus 65 bpm CRT-on, p=0.77) and peak heart rates (100 bpm CRT-off 
versus 103 bpm CRT-on, p=0.18) and the        slope (0.038 CRT-off versus 0.036 CRT-on, p=0.62), 
suggesting that any contribution from rate-responsive pacing was not significant. When the change in each of 
the major variables was compared to the change in peak      (standardised by z-scores) there were no significant 
differences within the on-off group. 
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When all the patients from both studies were considered together only the         slope was significantly 
different with an average reduction of 0.64 (p=0.02) between pre-implant/off-CRT and post-implant/on-CRT. 
Only the         slope’s z-score was significantly different from peak  
 
   when both groups’ results were 
considered together. 
The change in variables between on-off and pre-post were significantly different for peak      (p<0.05),  
 
  
     slope throughout exercise (p=0.03 by Kruskall-Wallis),  
 
       ratio at the AT (p=0.01 by Kruskall-
Wallis), PETCO2 at the AT (p=0.003), breathing reserve at the AT and peak (p=0.01 and p=0.03 respectively) 
and         slope (p<0.05).  
Because 6 patients finished the tests with breathing reserves <30% (i.e. could be considered to have a 
component of respiratory limitation) the analyses were rerun without these patients, with no change in results. 
Change in the QRS duration in the patients following implantation or after switching CRT on related only to the 
change in O2 pulse and         slope between the 2 tests and to no other variables. Both of these 
relationships were negative, i.e. the greater the improvement in QRS the less the improvement in O2 pulse and 
greater deterioration in         slope. Baseline (pre-implant or CRT-off) QRS duration did not relate to 
exercise capacity. 
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Figure 9.2: Change in 13 variables between a pre-implant CPX and a CPX performed on 
average 2 months post-implant. The change has been converted in a z-score for comparison 
between variables. A deviation to the left indicates a worsening of the variable following 
implantation (so for the          slope a positive score indicates a decrease in magnitude). 
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Figure 9.3: Change in 13 variables between a CPX performed with CRT enabled and 
another with CRT disabled. The change has been converted in a z-score for comparison 
between variables. A deviation to the left indicates a worsening of the variable with CRT 
enabled (so for the          slope a negative score indicates an increase in magnitude). 
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9.5 Discussion 
Cardiac resynchronisation therapy for patients with heart failure does not appear to significantly improve 
exercise capacity within my cohort of patients receiving CRT. If it does, it requires longer than 2 months for 
these improvements to be noticeable. If improvements in exercise capacity will occur and were not identified 
during this time frame, this action does not appear to be significantly influenced by the acute haemodynamic 
improvements associated with the act of resynchronisation, given we see no early improvements, and removing 
it (by switching LV pacing off) does not affect exercise capacity. The state of resynchronisation may, without 
affecting peak exercise capacity, exert beneficial effects on ventilatory efficiency. 
 
9.5.1 Changes in ventilation 
Despite the numbers being small there are strong trends to improvements in all measures of the           
relationship following implantation of CRT. There are also significant increases in PETCO2 at the AT and 
reductions in respiratory frequency. Minute ventilation at anaerobic threshold and peak exercise are reduced to a 
greater amount on average than oxygen uptake at these points, suggesting less ventilation is required to perform 
a similar amount of work; this may explain the improvement in subjective symptoms of exercise intolerance 
following implantation. It has long been established that patients with heart failure have elevated ventilatory 
equivalents, often wrongly referred to as ventilatory efficiency. Historically an elevated minute ventilation to 
carbon dioxide ratio was believed to be caused principally by an increase in ventilation: perfusion mismatch, 
hence it was considered to be synonymous with ventilatory inefficiency (Wasserman et al 1997). However more 
recently it has been proven that a large contribution to the elevated ratio of ventilation to carbon dioxide 
excretion is caused by a reduced arterial CO2 set-point (Wensel et al 2004). Increased ventilation is required to 
maintain arterial carbon dioxide levels lower than average. It has become clear that the muscle is central to this 
pathophysiological state; ergoreceptors within the muscle, sensitive to hydrogen ions, drive ventilation (Scott et 
al 2002). It may be that although peripheral lactate levels are not elevated, lactate contained within the muscle’s 
local environment triggers the ergoreflex. Typically patients with heart failure display a flattened end-tidal CO2 
profile during incremental exercise; they do not show the rise from baseline to a plateau around anaerobic 
metabolism before the fall due to worsening systemic acidosis. End-tidal CO2 is reflective of arterial CO2 levels, 
although it becomes less closely correlated to arterial levels the more abnormal a patient’s physiology is. I have 
shown that, even in this small population of patients, a significant rise in end-tidal CO2 at the anaerobic 
threshold occurs after CRT. Whilst we cannot infer mechanistic conclusions from these results, they may 
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suggest a reduction in the ergoreflex with a resetting of the CO2 set-point at a level closer to that seen in healthy 
adults. 
It is interesting to note that in the mitral intervention study very similar results were seen, with small but 
noticeable improvements in the ventilatory equivalents for carbon dioxide early after intervention. 
Whilst the ventilatory equivalent measures for carbon dioxide show improvement the same cannot be said for 
oxygen. The oxygen uptake efficiency plateau (OUEP) is conceptually similar to the          ratio at the nadir, 
only as an inverse relationship (Sun et al 2012). It is a recent addition to the panoply of CPX variables, although 
its own inverse, the         ratio, has been around for much longer. It has been postulated as a marker of 
cardiovascular fitness, and within the seminal papers describing its use was measured as the highest total 90 
second continuous average during exercise. This “plateau” typically happens around the anaerobic threshold; in 
fact it is almost identical to averages of the OUE at the AT (Sun et al 2012). I believe the authors used a 90 
second average to minimise the influence from cycles of oscillatory breathing which may be up to 90 seconds in 
duration. There are significant physiological differences with how the body manages oxygen and carbon 
dioxide; whilst it is easily to alter arterial carbon dioxide levels through adjusting ventilatory patterns, this is less 
possible with oxygen. Should improvements in the          relationship stem principally from improvements to 
ventilation: perfusion matching we would expect to see similar improvements (albeit a rise in OUEP 
corresponds to a fall in          ) in OUEP. We do not, in either CRT patients or in those post mitral valve 
repair. This lack of similarity between these two conceptually similar groups of variables perhaps more than any 
other result in this study shows the variability in the body’s response to improving cardiac haemodynamics.  
 
9.5.2 Lack of improvement in exercise capacity 
Both arms of this study failed to show an improvement in exercise capacity despite the pre-post study observing 
a subjective improvement in symptoms. These findings do not agree with published trials. Cazeau et al, in one 
of the early studies into CRT performed a cross-over design of 3 months of active CRT pacing, and 3 months 
inactive (Cazeau et al 2001). Overall there was a significant 8% improvement at the end of the periods of 
pacing, however it appeared that this benefit was greater for those who had the inactive state first (+1.6 
mL/min/kg compared to +0.6 mL/min/kg). This would suggest that following a period of CRT, benefits are 
exerted that are independent of the act of acute resynchronisation; in this respect the results are comparable to 
mine. Other studies have shown a 28% increase in peak      at 3-6 months post-implant compared to pre-implant 
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(Chwyczko et al 2008), a 26% increase in peak      in a study examining the benefit of a single left ventricular 
lead (no right ventricular lead) after 12 months (Blanc et al 2004) and a 17% improvement in peak      in a 
study that showed benefits to exercise capacity correlated to the degree of improvement in mitral regurgitation 
(Madaric et al 2007). Only the former of these 3 studies commented on other CPX variables, showing large 
improvements in the          slope and ratio at the AT. Berger et al showed a significant improvement in OUES 
in responders to CRT therapy, but no change in non-responders. However many of the variables of severity in 
the responder group were worse than the non-responders at baseline, for example peak     , and it may be that 
this is an example that patients with greater severity of disease benefit more (Berger et al 2011). It was 
interesting to see that OUES predicted response to CRT better than peak      and  
 
       slope (which non-
significantly improved in both groups); this may be further evidence for the ability of OUES to have increased 
specificity for cardiac impairment. Salukhe et al showed a significant mean increase of 1.6 mL/min/kg in 
patients when their device was switched from AAI mode to full CRT (i.e. a similar experiment to our on-off 
study) (Salukhe et al 2008). In a further study looking at the on-off state of CRT there were significant 
improvements in the on-state seen in peak     , O2 pulse,  
 
      slope and ventilatory equivalents 
(Laveneziana et al 2009). Respiratory frequency was significantly reduced with CRT on, which is similar to the 
results seen in my pre-post study group, although this was not replicated in my on-off study. 
It is difficult to understand why I see such different results from the above studies. My sample size calculations 
were based on the results from these studies, so it looks like I am seeing a completely different effect rather than 
an underpowered study. It may be my study population differs significantly from those studied before. Certainly 
a few of my patients display signs of respiratory limitation (BR <30%) but the results with these patients 
removed do not change. Two patients went into an intrinsic rhythm during exercise (went above the upper 
tracking rate of CRT), with the resultant effect that final peak      appeared to underestimate the apparent trend 
that      was on prior to this; however this still resulted in similar peak  
 
  s to pre-implant, not an effect large 
enough to alter the full group analysis. The ejection fraction within my pre-post cohort does not appear to differ 
largely from these previous studies. The QRS benefit seen within my patients from CRT is only 24 ms, perhaps 
these patients do not have a sufficient degree of correctable dyssynchrony. 15 of the 23 patients had a baseline 
OUES value below the threshold identified by Berger et al to be highly specific and sensitive for the detection 
of response to CRT. Interestingly both patients pre-implant with an OUES above this threshold self-described as 
responders. Perhaps a sensitive indicator that I have a group of patients that has not responded is the change in 
BNP between baseline and post-implant (+64pg/mL, p=0.71). The CARE-HF study showed large improvements 
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in N-terminal pro-BNP values at 3 months and at 18 months (over 50% reduction at this time point) in the CRT 
group (Fruhwald et al 2007). Significantly smaller improvements were seen in the control arm, suggesting a 
component of the improvement may have come from the intensification of medical therapy. This is still vastly 
different from my non-significant increase in BNP post-implant. 
 
9.5.3 Differences between variables 
Because of very small changes in all variables between the on-state and off-state (Figure 9.3) it is unsurprising 
that there are no significantly better or worse z-scores of change than peak     . These results are also seen for 
all 23 patients together. However from the pre-post study we see that the z-score of change for all measures of 
OUES,           slope, breathing reserve, and the PETCO2 at the AT improved to a significantly greater degree 
(or deteriorated to a significantly lesser degree) than peak     . This is further support for the hypothesis that 
these variables are distinct from peak     , and give us information beyond maximal exercise capacity. As 
suggested in previous chapters, interventional improvements in cardiac function will not improve maximal 
exercise capacity and anaerobic threshold without rehabilitation. That is not routinely offered to the recipients of 
CRT. The potential to improve exercise capacity through the medium of exercise rehabilitation may be limited 
by cardiac function; by improving cardiac function you raise the ceiling of what’s possible, but without work to 
improve muscular strength and endurance, ultimately gains won’t occur. The improvements seen in OUES and 
         slope compared to peak  
 
   may give us hints that improved exercise capacity is possible. 
 
9.5.4 Limitations 
Post-implant echocardiograms were not performed. I did not feel that an echocardiogram at this time point 
would add further information. 2 months is a short time period to expect reverse remodelling within the 
ventricle; any improvements in ejection fraction at this time point would be through the visual phenomenon of a 
resynchronised ventricle, not a true improvement in muscular contraction and systolic function. It could be 
criticised that the EF of the on-off group was higher than the pre-post group, however, again, because the 
echocardiogram in the on-off group was performed in the on-state, we would expect higher EFs because the act 
of resynchronisation improves how we visually assess EF. It is known that for any given EF the presence of 
interventricular mechanical delay (IVMD) improves prognosis and the greater the IVMD the lower the mortality 
(Richardson et al 2007, Cleland et al 2008). This is because dyssynchrony itself does not reflect reduced systolic 
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function of the individual myocytes. For any given EF with no IVMD there will be a greater burden of myocyte 
damage than in an equivalent ventricle with the same EF and significant IVMD. Therefore I do not believe that 
the higher EFs seen in my on-off group represent a set of patients with less severe heart failure than the pre-post 
group. Similar NYHA class and BNP values between my 2 groups supports that.  
Final numbers for analysis were lower than anticipated. Sample size calculations required 44 patients within the 
mitral and CRT studies combined; this has been achieved, however it was disappointing that from 17 patients 
recruited prior to implantation only 10 returned at 2 months. This illustrates some of the difficulties in 
performing research on patients undergoing procedures for clinical purposes. 
 
9.5.5 Conclusions 
CRT implantation in a small group of patients did not improve exercise capacity. Transient deactivation of CRT 
in patients with long-term devices in situ did not improve exercise capacity. The model of on-off did not show 
any significant differences between variables, however the pre-post study did show variability in the response of 
different CPX variables. 
Measures of ventilatory control, namely the          relationship, end-tidal CO2 at the AT and respiratory 
frequency all improved following implantation. The change from baseline in these variables and the OUES was 
significantly better than the change from baseline in peak     . These variables may better reflect the improved 
haemodynamics following CRT implantation than peak     , which requires concurrent enhancements in other 
organ systems (namely the muscle) to show improvements. 
  
284 
 
10.0 Synthesis 
  
285 
 
10.1 Overview 
Diagnosis and prognosis are two of the key roles for cardiopulmonary exercise testing. Furthermore changes in 
objective exercise capacity as measured by CPX are felt to reflect disease progression or improvement following 
intervention. Yet it has never been reliably proven that CPX can distinguish the cause of a patient with exercise 
limitation via the algorithms published, and the reasons for the different prognostic powers of different variables 
on exercise testing has never been explained. Peak      is the ubiquitous variable measured during a test and is 
well known to specialists within exercise physiology and beyond. But whilst it is an excellent variable to 
describe overall exercise capacity, its universality limits its use in many patients where multiple medical 
conditions coexist. In a young adult with dilated cardiomyopathy alone it will be an excellent marker for 
prognosis and therefore decision making on heart transplantation (Mancini et al 1991), but in a typical older 
patient with cardiac, and respiratory disease, can we be sure that abnormalities and changes over time in peak 
     relate only to the heart? It was the aim of this thesis to identify if a variable exists that will be specific and 
sensitive to cardiovascular changes, limiting the influence from a common co-morbidity in cardiac patients that 
also severely limits exercise, respiratory disease. 
4 criteria for an ideal variable were investigated: the ability to discriminate the two disease states; good 
reproducibility; appropriately alters with interventions to the heart; and finally relates to disease severity in 
cardiac, but not respiratory, disease. 
I recruited patients with COPD, chronic heart failure and severe mitral valve disease, and measured objective 
variables of cardiac and respiratory function in all and then compared CPX tests in all as the Observational 
study. All patients underwent two baseline tests, to optimise individual testing conditions and to allow for 
comparison of the reproducibility of the various variables. Most of the patients recruited with CHF or mitral 
valve disease were undergoing a clinical intervention (CRT or valve repair) with the intention of improving the 
heart. These patients comprised the Interventional study, in which I compared the response of individual CPX 
variables to improvements in cardiac physiology. 
Whilst many variables were examined throughout the thesis for comprehensiveness, only a small number were 
considered likely candidates. Amongst them was the      at the anaerobic threshold (AT), measures of                      
the          relationship, the O2 pulse, the oxygen uptake efficiency plateau (OUEP), interactions between 
breathing reserve and RER, circulatory power, and measures of oxygen uptake kinetics; which included the 
oxygen uptake efficiency slope (OUES), oxygen uptake - work rate (         slope and the heart rate - 
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oxygen uptake (       ) slope. I will go through many of these variables to describe their strengths and 
weaknesses. 
 
10.2 Respiratory exchange ratio and breathing reserve 
I will discuss these 2 variables together. The breathing reserve (BR) is a well established variable used to 
identify patients with respiratory limitation; a value < 30% has been suggested as a suitable cut-off 
(Eschenbacher et al 1990, Messner-Pellenc et al 1994, Milani et al 2004). It is typically calculated using the 
patient’s FEV1, measured during spirometry, and the maximum minute ventilation at peak exercise. As such it is 
reliant on data obtained both during exercise and before. Spirometry is dependent on technique and effort and so 
FEV1 and therefore the BR, could easily be underestimated. This would have the effect of identifying a greater 
proportion of patients as respiratory limited. Another problem is that patients with heart failure commonly have 
abnormalities of spirometry; combined with the greater ventilatory requirements of exercise as seen with 
elevated ventilatory equivalents, means that heart failure patients may appear to have a degree of ventilatory 
limitation rather than respiratory disease per se. Patients with significant respiratory limitation typically stop 
exercise when the mechanical act of ventilation becomes discomforting. This can occur even though oxygen 
delivery to the exercising muscles may be normal and anaerobic metabolism has not occurred. Therefore the 
respiratory exchange ratio (RER) is typically lower in patients with COPD than CHF. 
I have shown that both BR and RER display a good ability to discriminate patients with cardiovascular disease 
from COPD. BR measured at peak exercise was slightly superior to BR measured at the anaerobic threshold; 
both were significantly superior to the RER and although there was a slight improvement in the AUC with the 
addition of RER to BR, it was a non-significant improvement. BR at peak exercise was overall the best variable 
at discriminating patients with COPD from patients with CHF. However the aim of the thesis is to identify an 
ideal variable for cardiovascular dysfunction. For BR and RER patients with CHF and mitral valve disease 
behave more like healthy adults, with COPD patients behaving differently. Therefore these variables 
discriminate COPD from CHF or normal adults. BR could still be useful for the management of respiratory 
patients, so long as it correlates well with markers of disease severity. Symptom score correlated reasonably 
well with BR at the AT, but not at peak exercise. Importantly the 2 measures of the BR were amongst only a 
small handful of variables that did not correlate to peak     . BR at AT and peak had excellent test-retest 
reliability as measured by ICC. It is unsurprising that BR at peak had a poor coefficient of variation, as this is a 
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measure that performs poorly when a variable can assume negative values. The reproducibility of BR was not 
affected by age, gender, BMI, disease category, time interval between tests or a change in ramp protocol.  
Overall RER appears to add nothing beyond BR. The product of the two behaves similarly to BR alone, and is 
more complex. BR may be beneficial in identifying patients with respiratory limitation, and it is reproducible, 
but its magnitude adds nothing in terms of identifying severity of disease or symptom status. For patients with 
CHF it is unlikely it will be a useful variable in serial testing. 
 
10.3 Oxygen uptake efficiency slope 
The oxygen uptake efficiency slope (OUES) has been shown to be superior when predicting prognosis in 
patients with heart failure than both peak      and the  
 
       slope (Davies et al 2006). Pilot data from this 
thesis showed that OUES is much less sensitive to respiratory abnormalities than peak      or the  
 
  at the AT. 
Population data from over 1200 healthy adults also confirms that OUES is less affected by a number of lung 
function variables than peak     , although more so than the  
 
   at the AT. Using predictive equations for FEV1, 
correcting for age, gender and height, removed almost all of the relationship between FEV1 and OUES. 
However there still remained a small relation and it was necessary to take this into consideration in the 
predictive equations generated from this population. In results similar to the pilot data, within the Observational 
cohort of 96 patients with CHF, mitral valve disease and COPD, OUES was actually inversely related to FEV1, 
so that a worsening in FEV1 led to an improvement in OUES; almost certainly however this is just a statistical 
anomaly due to the combined analysis of two discordant groups, cardiac and respiratory disease. Within this 
analysis the OUES interestingly did not relate to the KCO, despite KCO being affected by heart failure as well as 
primary lung disease. Within the analysis absolute OUES was different between the groups, but this difference 
was more noticeable when adjusted for weight or as a percent of predicted. This was because there were 
significantly more males, and heavier individuals in the CHF group. OUES/kg and as a percent of predicted 
showed excellent discriminatory ability between CHF and COPD, second only to BR. What was also interesting 
was that the addition of the mitral patients, on average the group with the best exercise capacity, did not 
measurably reduce the area-under-curve on ROC curve analysis. A surprising result from the reproducibility 
study was that markers at peak exercise (peak      and the O2 pulse) had the best test-retest reliability as 
measured by ICC, better than measurements of slopes which we would imagine would be superior. However 
whilst the ICC and CoV for OUES was not as strong as for peak      and the O2 pulse, they were still very good, 
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and importantly there was not a significant mean difference in OUES between test 1 to 2, unlike peak     , i.e. 
there was no learning effect, and change in protocol intensity did not affect reproducibility. This may make it a 
more useful variable to serially measure in patients who are naive to exercise testing on their first visit. A slight 
weakness of OUES is that it appears to be less reproducible in heavier individuals and in those with COPD and 
CHF compared to mitral valve disease. However in all these groups the ICC was still >0.88. There remains no 
evidence for the comparison of OUES on treadmill versus bicycle ergometer testing, which until studied may 
restrict the applicability of these results to bicycle tests. 
Perhaps disappointingly OUES did not appear to be affected much in either direction following interventions on 
the heart. The reduction at 2 months post-mitral valve surgery was less than for peak     and the  
 
  at the AT, 
which it could be argued reflects a lesser effect from the peripheral effects of recovery from major surgery on 
this variable. Interestingly the reduction in OUES was of a smaller, now non-significant, magnitude when 
patients with good preoperative exercise capacity were excluded, which perhaps indicates that in patients where 
their cardiac disease does not significantly limit their OUES it can still be affected by external components 
(surgical recovery), but in those where cardiac function is the driver to an abnormal OUES, the improvement to 
the heart allows for early improvements in the OUES. However at 6 months, when we would expect recovery to 
be complete and patients to have values better than those preoperatively, the OUES was unchanged from the 
baseline test. The results in patients undergoing CRT were very similar, with small, non-significant changes in 
OUES, although again OUES showed less deterioration than peak     and the  
 
  at the AT. It is difficult to 
understand why any variables worsened as CRT is a procedure unlikely to require recovery, muscular changes 
should therefore be minimal, and any cardiovascular changes should only be positive. In patients where the CRT 
was transiently turned off there were no real changes in any variables, at odds with previous work which had 
shown significant improvements in peak        a similar style of study. OUES had been shown to predict 
response to CRT, although my results would not support that. 
Finally OUES does appear to be a good measure of disease severity. As shown above it doesn’t strongly relate 
to respiratory dysfunction, but correlates well to peak     , especially in patients with heart failure. Similarly it 
correlates to symptom scores in patients with heart failure but unlike other major variables has an inverse 
relationship in patients with COPD. Tissue Doppler measures of systolic and diastolic function as well as right 
ventricular function, correlated better with OUES than peak     and almost all other variables, whilst B-
natriuretic peptide, a highly objective measure of heart failure severity correlated strongly with OUES. 
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Overall therefore OUES is a reproducible, easily measured variable that correlates closely to disease and 
symptom severity in patients with cardiac disease but not respiratory disease, and appears to discriminate 
patients with cardiovascular limitation from respiratory limitation better than almost any other. Ideally it should 
be either weight adjusted or corrected using predictive equations. I believe it is the single best, and therefore 
ideal, variable identified through this thesis. In a heart failure patient with respiratory co-morbidities the serial 
measurement of OUES allows a way to isolate the contribution to exercise limitation from the heart. 
 
10.4 Oxygen uptake at the anaerobic threshold 
It has long been believed that this variable best discriminates these two common disease states. Patients with 
respiratory limitation are believed to have relatively normal ATs, the problem is that their lungs either stop them 
reaching it, or do so shortly after. In contrast the AT is reached early in patients with cardiovascular limitation. 
A threshold of 40% of a patient’s predicted peak       has been described as a useful discriminant. 
Within my Observational group, the     at the AT was a poor discriminator between cardiac and respiratory 
disease and only 14 from 96 patients (2 with COPD) had a value below the suggested threshold of 40%. The      
at the AT appears to be affected to a greater degree postoperatively than any other variable, with a large 
deterioration at 2 months that is still to return to baseline at 6 months. It, like many other variables, was 
unaffected by the implantation of CRT. It did relate strongly to symptom score in CHF patients but not COPD, 
but was less closely correlated than other variables to BNP, and was not correlated to echocardiographic 
variables of systolic and diastolic function. It was not as reproducible as peak      or the OUES when comparing 
the 2 tests performed by each patient, and showed a potential learning effect with a statistically significant 
systematic increase from test 1 to test 2, especially noted if the two tests were performed on the same day. It did 
however show almost excellent reproducibility amongst healthy adults. 
I believe the     at the AT is principally a index of the muscle. Any chronic disease can, and will reduce it. It is 
known that endurance athletes see greater improvements in the     at the AT over peak  
 
   with training. 
Postoperatively following an operation with a considerable recovery time, mitral valve surgery, this variable is 
the most adversely affected. My results show no ability to discriminate and the accepted algorithms for 
distinguishing limiting physiology, within which the     at the AT is so central, should be reconsidered. 
 
290 
 
10.5 Oxygen uptake to work rate slope 
The oxygen uptake to work rate (       ) slope, another measure of oxygen uptake kinetics with similarities 
to the OUES, has been suggested to be a marker of oxygen delivery and utilisation, with significant reductions 
in patients with cardiovascular disease. One of its perceived strengths is that the value shows very little 
variability in healthy adults, with minimal influence from age, gender and body size. My results from the SHIP 
data agree with the marginal influence of these variables on the slope, however in older adults there was an 
increased spread of values. A criticism of a seminal study into the specificity of a decrease in the slope for CHF 
was that these patients appeared to have shorter exercise durations than the controls; as I and others have shown, 
this would lead to a reduction in the slope independent of the patient’s physiology. My data goes some way to 
confirming their conclusion however, irrespective of test duration; in my Observational cohort this slope was a 
reasonable discriminator between CHF and COPD with similar exercise durations between the groups. The 
        slope wasn’t strongly related to respiratory variables, and unlike many other variables its ability to 
discriminate was strengthened by the inclusion of mitral valve patients to the CHF cohort, suggesting it reflects 
cardiac physiology more specifically than just heart failure physiology. However it is poorly reproducible, and 
its magnitude can be heavily influenced by the intensity of the protocol used. Following intervention on the 
mitral valve there is an early deterioration, with a return to baseline levels, performing similarly to many of the 
other variables. When CRT is implanted the        slope is the only principal variable that is reduced, 
despite an overall improvement in the patients’ symptom status. At baseline it does correlate to symptom score 
and markers of diastolic function. It is strongly correlated, although not as strongly as OUES, to BNP. 
Overall it shows reasonable ability to discriminate but its other limitations, namely its poor reproducibility, 
make it an unsuitable candidate for the ideal variable. It must also be remembered that it can only be measured 
using bicycle ergometry. 
 
10.6 O2 Pulse and the heart rate to oxygen uptake slope 
Oxygen uptake is equal to the product of cardiac output and arterial-venous oxygen difference. Cardiac output is 
the product of stroke volume and heart rate, so     divided by heart rate measures the product of stroke volume 
and arterial-venous oxygen difference. It is therefore taken as a surrogate for stroke volume, and so is expected 
to be reduced in patients with cardiac limitation. My results from the Observational study show the O2 pulse was 
highest in the CHF patients and lowest in COPD, although these differences were no longer significant when a 
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percentage of predicted is calculated and  it shows no ability to discriminate. The likely explanation for the 
higher absolute O2 pulse in the CHF group is the use of rate-limiting drugs, principally beta-blockers, as 
following correction for the use of beta-blockers the between groups differences were no longer present. A 
reduction in heart rate would allow increased diastolic filling which should therefore lead to increased stroke 
volumes (Starling’s law).  
The O2 pulse correlated to symptom score as well in COPD as CHF patients, and to peak     , although it did not 
correlate to BNP or echocardiographic variables. It has excellent reproducibility. Following mitral valve surgery 
it was non-significantly improved with no changes in patients undergoing CRT. It is possible that the non-
significant changes after mitral surgery reflect a slight improvement in forward stroke volume with a reduction 
in the regurgitant fraction; peak heart rate at 6 months was unchanged and a reduction or increase in rate-
limiting drugs did not affect the change in O2 pulse in this group. 
A limitation to the O2 pulse is that submaximal effort will reduce its magnitude; the         slope minimises 
this limitation because it measures a slope of the heart rate relationship to     , rather than just the ratio at peak. 
It appears to be largely independent of respiratory abnormalities, both in health and disease, but is less 
reproducible than many other variables. It does not appear to correlate to most markers of disease or symptom 
severity, and importantly behaves differently between the two cardiac groups. It was significantly lower in the 
CHF patients and higher in the mitral valve disease patients, with the COPD patients in the middle. This 
bivariate distribution severely limits is ability to diagnose and monitor cardiac disease. The AUC on ROC curve 
analysis for all cardiac patients is very poor (0.53) and only moderate if mitral valve patients are excluded 
(0.63). It goes down after mitral surgery, which in a similar manner to the non-significant rise in O2 pulse, may 
reflect the increase in forward stroke volume and reduced dependency on heart rate.  
These two variables each have specific uses and strengths, but unfortunately do not appear to fulfil the necessary 
criteria for an ideal variable. 
 
10.7 Ventilatory equivalents 
There are a number of ways to measure the ventilatory response, typically the relationship of minute ventilation 
to carbon dioxide elimination, either as the regression slope throughout exercise or as instantaneous ratios at 
predetermined times such as the AT, is used. All measures are generally reproducible, with coefficients of 
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variation showing better reproducibility than intraclass correlation coefficients. Their test-retest reliabilities are 
worse in females and heavier individuals. They do not show a significant difference in mean values between 
tests i.e. no systematic bias or learning effect. However the          slope and  
 
       ratio do not show a strong 
ability to discriminate between the different aetiologies of disease, the principal criterion required by this study. 
These variables may be useful in determining an effect of intervention above and beyond all others however. 
They correlate to BNP and symptom status, and in both the CRT implantation and mitral studies showed strong 
trends towards improvement. It is difficult to reconcile the lack of benefit noted in many variables despite 
subjective suggestion of symptom improvement; these variables may give us an explanation. They represent the 
ventilatory work required to perform a certain degree of external work, improvements will lead to an improved 
sensation of breathlessness during exercise. This is what is of most importance to patients, not their peak 
exercise capacity. Improvements in cardiac physiology may lead to peripheral changes to the autonomic system, 
neurohormonal interactions and the ergoreflex which all reduce the peripheral drive to ventilation. There may 
also be improvements in ventilation to perfusion matching within the lungs, due to better blood flow 
distribution. These physiological adaptations reduce the drive to ventilation, yielding improved symptoms. 
What I don’t think my results answer is which of the variables is superior. Ratios appear to have greater 
reproducibility but were less discriminant. The slope shows greater improvement after intervention, perhaps 
because it is influenced from ventilatory control during aerobic and importantly anaerobic metabolism, the latter 
where improvements in physiology may have the greatest bearing. Measuring the slope throughout exercise 
rather than the traditional approach of censoring data at the ventilatory compensation point, showed greater 
differences after intervention but given that very few patients went significantly past the VCP the significance of 
these results is difficult to assess. I still feel conceptually that stopping at the VCP is physiologically correct; 
however within this thesis the evidence for differences noted using both methods are at least presented. 
Rather than making CO2 elimination the focus, we could look at the relationship between oxygen uptake and 
ventilation. Recently a variable called the oxygen uptake efficiency plateau has been described (OUEP) which is 
the highest 90 second average of the ratio of      to  
 
 . It was a highly reproducible variable but, unlike the 
         variables within my analysis, worse values were found in the COPD group, not the CHF. It showed 
moderate discriminant ability, but again to detect COPD, not CHF. It also behaved differently than the           
variables after interventions, with early deteriorations noted. Although conceptually similar variables, these 
results show the difference in how ventilation interacts with oxygen uptake or carbon dioxide elimination.  
293 
 
Overall these variables, mainly those involving the          relationship, may be able to provide information in 
patients undergoing interventions, but the lack of discriminant ability between COPD and CHF does not make 
them good candidates at tracking changes specific to cardiac function over time. 
 
10.8 Double product and circulatory power 
These two variables are derived from systolic blood pressure (SBP) at peak exercise. DP is the product of heart 
rate and SBP, whilst circulatory power is the product of SBP and peak     . DP was an excellent discriminator of 
CHF and COPD, but this was significantly reduced after the addition of mitral valve patients. This may just 
reflect the greater burden of heart rate and blood pressure reducing drugs taken by the CHF group compared to 
the other groups. Circulatory power showed poor ability to discriminate. Surprisingly given the accepted poor 
reproducibility of manually measured blood pressure and the difficulties measuring it during exertion, both these 
variables showed good test-retest reliability. DP correlated to systolic function on echocardiography, whilst both 
correlated to BNP. Unsurprisingly circulatory power correlated to peak     , as it is calculated using peak  
 
    
DP also correlated quite strongly to peak     . On the Interventional studies they showed similar results to peak 
    with early deteriorations after mitral surgery that had not fully resolved by 6 months, with non-significant 
reductions after CRT implantation.  
The poor discriminant ability of these variables, especially circulatory power, unfortunately make them poor 
candidates for an ideal variable of cardiac function. 
 
10.9 Limitations 
Limitations of each separate study are shown within each Chapter.  
A major limitation is my assumption that principal disease categorisation also equals limiting physiology. Left 
ventricular impairment is not always symptomatic and may be an almost incidental finding. This is even more 
likely following CRT therapy when reverse remodelling may lead to long-term improvements in cardiac 
function. However I have wherever possible tried to take this into account, by looking separately at patients with 
reduced exercise capacity and removing from the cardiac group those with low breathing reserves. The study 
design with prospective echocardiography, BNP measurement and full lung function allows for patients to be 
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grouped differently than their prevailing diagnosis. However it is entirely possible that their known diagnosis 
biases my later judgement on whether they belong within that category or another. 
Ideally these studies would be replicated in patients with new diagnoses of heart failure or COPD, prior to 
medical involvement. The testing of patients with long-standing diagnoses will influence the results in a number 
of ways, principally with the prescription of medications. There were naturally large differences in the numbers 
and types of medications between groups; these will certainly affect variables that are heart rate and blood 
pressure derived, and may affect other variables in ways we cannot determine. A diagnosis of heart disease is 
likely to lead to sedentary behaviour as this is often wrongly believed to be safer than regular exercise. It is 
difficult to ascertain how patients’ previous and current experience with exercise would differ between groups, 
although it is not in doubt that it will significantly affect almost all variables on exercise testing. 
It could be argued that because I was aware the groups the patients were in I could somehow bias the exercise 
tests. However the protocols for performing the tests and calculating results were predefined. Only the AT and 
VCP were subjectively identified. I performed the test analysis remote to the test, patient details were also 
anonymised, to minimise the chance that I would understand which disease category the patient belonged to 
whilst measuring, and therefore inadvertently biasing my positioning of either of these thresholds. 
It can be argued that my research group has a vested interest in OUES based on previous work they have 
published showing its prognostic superiority over the          slope and peak  
 
  . It would be interesting for 
these results, certainly of the Observational study using ROC curve analysis, to be replicated by an independent 
study group. 
Finally I have shown how variables change following interventions to the heart, but not to interventions to the 
lungs. An ideal cardiac variable would show no difference between 2 tests performed with different lung 
function, whilst other variables would change. A respiratory Interventional study was attempted; patients with 
COPD requiring tiotropium, a long-acting anticholinergic agent, had this and other long-acting inhalers withheld 
for 72 hours prior to a repeat CPX test, and then another test the following day after reinstitution of the inhalers. 
Unfortunately the first two patients became markedly breathless during the 72 hour period and the study was 
halted. 
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10.10 Conclusions 
Breathing reserve appears to discriminate patients with COPD better than any other variable. However its 
magnitude has no value beyond being used as a threshold for discrimination. Measures of the           
relationship were not discriminant but may reflect improvements in cardiac physiology following cardiac 
interventions. OUES, a highly reproducible variable, shows excellent ability to discriminate CHF from COPD, 
with a strong relationship to markers of disease and symptom severity in cardiovascular, but not respiratory, 
disease. It appears to be affected to a lesser degree by the peripheral changes brought about through recovery 
post-surgery than other variables. In a patient with concomitant cardiac and respiratory disease, the OUES is a 
variable that appears to specifically reflect the burden of disease from the heart alone. 
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12.0 Appendix 1 – Data analysis within Excel2007/2010 
12.1 Identification of AT and slopes 
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12.2 Measurement of OUES and foreshortened OUES 
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12.3 Measurement of          slope up to the VCP and post-VCP 
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13.0 - Appendix 2 
13.1 Participant Information Leaflet – Valve disease 
 
Identifying an Ideal Cardiopulmonary Exercise Test Parameter 
        Chief Investigator: Dr Roland Wensel 
 
What is the purpose of the study? 
We want to learn how best to use a test called a Cardiopulmonary Exercise Test. This is a stress test 
involving cycling on an exercise bicycle, or walking on a treadmill, whilst doctors measure your breaths. We 
want to know how people with different diseases of the heart and lungs have different readings on this test 
to decide how best to treat patients with a range of heart and lung conditions. 
Why have I been chosen? 
You can take part in our research as you are awaiting valvular surgery. 
It is not compulsory to take part and even if you initially agree to can withdraw at any time. Your usual 
treatment and follow up will not be affected should you chose not to take part. Participation is entirely 
voluntary. 
What happens if I chose to take part? 
You will meet with one of the research team to arrange suitable times for you to come for the studies, on this 
initial meeting blood tests will be taken from a vein in your arm which will be about 10-20ml (2-4 teaspoons). 
We will then arrange for you to come for the lung function tests, echocardiography studies and exercise 
tests. 
The echocardiography studies take up to 1 hour. We will ask you to lie on a bed and we will attach several 
pieces of equipment including ECG leads. We will take images of your heart using an echo scanner. During 
the same visit we will arrange for you to have lung function testing which will also take about 1 hour. This 
involves controlled breathing into a machine under the instruction of a professional to record the ability of 
your lungs. 
You will also undergo exercise testing on multiple visits (between 2 and 4, before and after surgery). This 
will involve cycling on an exercise bicycle with a mouthpiece in. This records your breathing and the amount 
of oxygen or carbon dioxide you breathe in and out. You are also attached to an ECG machine and have 
regular blood pressure readings. You will be expected to cycle until you are unable to continue. The bicycle 
will get progressively harder to cycle. We aim for the length of time for you to be cycling to be 10-15 
minutes, total time will be less than 1 hour. You decide when you have cycled enough and you are unable to 
continue, the test stops when you stop cycling. 
Expenses and Payments 
Any travel and costs for meals will be reimbursed up to an amount of £50 per person and will vary based on 
individual expenses. 
What are the side effects of taking part? 
There are no drugs or invasive tests. We will require blood tests during your first visit, and rarely once more 
after then. Some people find having echocardiography uncomfortable. If this is the case we will take breaks 
and / or stop as required. 
Occasionally, the blood pressure monitor can cause tingling on the finger. This goes away when removed. 
A cardiopulmonary exercise test is tiring, and it is expected that you will be out of breath at the end. We will 
allow you plenty of time for recovery, and supply you with drinks and food as you need. The mouthpiece 
causes some dribbling, we will cover your clothes with an apron if required. 
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What if something goes wrong? 
We will take every care in the course of this study, and the risk involved is minimal. 
Imperial College London holds insurance policies which apply to this study.  If you experience serious and 
enduring harm or injury as a result of taking part in this study, you may be eligible to claim compensation 
without having to prove that Imperial College is at fault.  This does not affect your legal rights to seek 
compensation. 
If you are harmed due to someone’s negligence, then you may have grounds for a legal action.  Regardless 
of this, if you wish to complain, or have any concerns about any aspect of the way you have been treated 
during the course of this study then you should immediately inform the Investigator, Dr Anthony Barron 
(07932 648274) or Dr Roland Wensel.  The normal National Health Service complaint mechanisms are also 
available to you.  If you are still not satisfied with the response, you may contact the Imperial AHSC Joint 
Research Office, Imperial College London, St Mary’s Hospital, 41 Praed Street, Paddington, London, W2 
1NY (02033126484).  
What are the benefits? 
The research may not benefit you directly. However, we will have improved knowledge regarding the best 
possible use of this test for the future management of patients with a variety of heart conditions. This may 
impact on who and when patients undergo procedures and operations to the heart. This may prevent 
unnecessary treatments. 
Will my taking part in this study be kept confidential? 
Data collected about you will be entered on to a computer, in an anonymous format and any information 
taken from this investigation that can be identified will remain confidential. 
If you agree, we would contact your GP to inform them you are participating and will provide them with 
information regarding the study. 
At times during the study professional bodies (for example the NHS Research and Development team or 
Imperial College) may wish to audit our data to ensure that the study is being carried out appropriately. Any 
non-essential information regarding your involvement will not be shown. These auditors will be appropriate 
professionally trained individuals and all information will be kept confidential. Our research is in collaboration 
with experts in Germany, they will be given access to the results of your tests, but again your personal 
details will be kept anonymous. 
What happens once the research stops? 
The results may be presented at meetings and published so that it can be used to help treatment of other 
patients with heart failure, lung disease, arrhythmias and valve disease. 
Your participation will be kept strictly confidential. 
Should you wish to receive information regarding the outcomes of the study, this can be sent to you at the 
conclusion of the study. 
Who has reviewed the study? 
This study has been reviewed by the South East London Research Ethics Committee. 
If you have any further questions please do not hesitate to contact: 
Dr Anthony Barron on 07932 648274 
 
Thank you for taking the time to consider participating in this 
study. 
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13.2 Participant Information Leaflet - COPD 
 
Identifying an Ideal Cardiopulmonary Exercise Test Parameter 
        Chief Investigator: Dr Roland Wensel 
 
What is the purpose of the study? 
We want to learn how best to use a test called a Cardiopulmonary Exercise Test. This is a stress test 
involving cycling on an exercise bicycle, or walking on a treadmill, whilst doctors measure your breaths. We 
want to know how people with different diseases of the heart and lungs have different readings on this test 
to decide how best to treat patients with a range of heart and lung conditions. 
Why have I been chosen? 
You can take part in our research as you have COPD/lung disease. 
It is not compulsory to take part and even if you initially agree to can withdraw at any time. Your usual 
treatment and follow up will not be affected should you chose not to take part. Participation is entirely 
voluntary. 
What happens if I chose to take part? 
You will meet with one of the research team to arrange suitable times for you to come for the studies, on this 
initial meeting blood tests will be taken from a vein in your arm which will be about 10-20ml (2-4 teaspoons). 
We will then arrange for you to come for the lung function tests, echocardiography studies and exercise 
tests. 
The echocardiography studies take up to 1 hour. We will ask you to lie on a bed and we will attach several 
pieces of equipment including ECG leads. We will take images of your heart using an echo scanner. During 
the same visit we will arrange for you to have lung function testing which will also take about 1 hour. This 
involves controlled breathing into a machine under the instruction of a professional to record the ability of 
your lungs. 
You will also undergo exercise testing on multiple visits (usually 2). This will involve cycling on an exercise 
bicycle with a mouthpiece in. This records your breathing and the amount of oxygen or carbon dioxide you 
breathe in and out. You are also attached to an ECG machine and have regular blood pressure readings. 
You will be expected to cycle until you are unable to continue. The bicycle will get progressively harder to 
cycle. We aim for the length of time for you to be cycling to be 10-15 minutes, total time will be less than 1 
hour. You decide when you have cycled enough and you are unable to continue, the test stops when you 
stop cycling. 
Expenses and Payments 
Any travel and costs for meals will be reimbursed up to an amount of £50 per person and will vary based on 
individual expenses. 
What are the side effects of taking part? 
There are no drugs or invasive tests. We will require blood tests during your first visit, and rarely once more 
after then. Some people find having echocardiography uncomfortable. If this is the case we will take breaks 
and / or stop as required. 
Occasionally, the blood pressure monitor can cause tingling on the finger. This goes away when removed. 
A cardiopulmonary exercise test is tiring, and it is expected that you will be out of breath at the end. We will 
allow you plenty of time for recovery, and supply you with drinks and food as you need. The mouthpiece 
causes some dribbling, we will cover your clothes with an apron if required. 
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What if something goes wrong? 
We will take every care in the course of this study, and the risk involved is minimal. 
Imperial College London holds insurance policies which apply to this study.  If you experience serious and 
enduring harm or injury as a result of taking part in this study, you may be eligible to claim compensation 
without having to prove that Imperial College is at fault.  This does not affect your legal rights to seek 
compensation. 
 
If you are harmed due to someone’s negligence, then you may have grounds for a legal action.  Regardless 
of this, if you wish to complain, or have any concerns about any aspect of the way you have been treated 
during the course of this study then you should immediately inform the Investigator, Dr Anthony Barron 
(07932 648274) or Dr Roland Wensel.  The normal National Health Service complaint mechanisms are also 
available to you.  If you are still not satisfied with the response, you may contact the Imperial AHSC Joint 
Research Office, Imperial College London, St Mary’s Hospital, 41 Praed Street, Paddington, London, W2 
1NY (02033126484).  
What are the benefits? 
The research may not benefit you directly. However, we will have improved knowledge regarding the best 
possible use of this test for the future management of patients with a variety of heart conditions. This may 
impact on who and when patients undergo procedures and operations to the heart. This may prevent 
unnecessary treatments. 
Will my taking part in this study be kept confidential? 
Data collected about you will be entered on to a computer, in an anonymous format and any information 
taken from this investigation that can be identified will remain confidential. 
If you agree, we would contact your GP to inform them you are participating and will provide them with 
information regarding the study. 
At times during the study professional bodies (for example the NHS Research and Development team or 
Imperial College) may wish to audit our data to ensure that the study is being carried out appropriately. Any 
non-essential information regarding your involvement will not be shown. These auditors will be appropriate 
professionally trained individuals and all information will be kept confidential. Our research is in collaboration 
with experts in Germany, they will be given access to the results of your tests, but again your personal 
details will be kept anonymous. 
What happens once the research stops? 
The results may be presented at meetings and published so that it can be used to help treatment of other 
patients with heart failure, lung disease, arrhythmias and valve disease. 
Your participation will be kept strictly confidential. 
Should you wish to receive information regarding the outcomes of the study, this can be sent to you at the 
conclusion of the study. 
Who has reviewed the study? 
This study has been reviewed by the South East London Research Ethics Committee. 
If you have any further questions please do not hesitate to contact: 
Dr Anthony Barron on 07932 648274 
 
Thank you for taking the time to consider participating in this 
study. 
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13.3 Consent form 
 
 
Imperial College Healthcare NHS Trust 
International Centre for Circulatory Health, 
59-61 North Wharf Road, 
London 
W2 1LA 
 
Direct Dial: 020 7594 1093 
 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
Title of Project:  Identifying an Ideal Cardiopulmonary Exercise Test Parameter 
            Chief Investigator: Dr Roland Wensel 
 
 
Name of Researcher:  Dr Anthony Barron                                      Please tick box
  
 
 
    
1. I confirm that I have read and understand the information sheet version 1 and 
  
dated 01/03/2010 for the above study. I have had the opportunity to consider the  
information, ask questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason and without my medical care or legal rights being affected. 
 
 
3. I understand that relevant sections of any of my medical notes and data collected during   
the study, may be looked at by responsible individuals from Imperial College Healthcare  
NHS Trust, Imperial College and Regulatory bodies, where it is relevant to my 
taking part in this research. I give permission for these individuals to have 
access to my records.  
 
 
4. I understand the risks and benefits of the study and have had any questions answered. I     
 am aware of who to contact should I have any further queries. 
 
 
5. I agree to my GP being informed of my participation in the study.  
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6. I agree to my personal data being stored safely for a total of 10 years after  
 completion of the study and for further contact and invitation to future studies (at my  
 discretion for inclusion at this time) only by the host institution (Imperial College and  
 Imperial College Healthcare NHS Trust). Otherwise it will be destroyed at the end of the  
 3 years. 
 
 
7. The compensation arrangements have been discussed with me.  
 
 
8. I agree to take part in the above study.    
 
 
 
 
_____________________ ________________ ____________________ 
Name of Patient  Date Signature 
 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher   Date  Signature 
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13.4 Research Ethics Committee acceptance 
South East London REC 5 
South London REC Office (5) 
Ranken House 
Queen Elizabeth Hospital 
Stadium Road 
Woolwich 
London 
SE18 4QH 
 
Tel: 0208 8366740 
Fax: 0208 8364862  
 
19 August 2010 
 
Dr Roland Wensel 
Consultant Cardiologist 
International Centre for 
Circulatory Health, Imperial College 
59 North Wharf Road, London 
W2 1LA 
 
 
Dear Dr Wensel 
 
Study title: Identifying the Ideal Parameter of the Cardiopulmonary Exercise Test 
to Distinguish Between the Cardiovascular and Respiratory 
Components of Functional Limitation and to detect Relevant 
Physiological Changes in Function 
REC reference: 10/H0805/36 
Protocol number: N/A 
Amendment number: 1 
Amendment date: 05 August 2010 
 
The above amendment was reviewed at the meeting of the Sub-Committee held on 17 August 2010 by the Sub-
Committee in correspondence.  
 
Ethical opinion 
 
Favourable opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on 
the basis described in the notice of amendment form and supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date    
Notice of Substantial Amendment (non-CTIMPs)  1  05 August 2010    
Covering Letter    05 August 2010    
IRAS project filter questions  2.2      
  
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached sheet. 
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R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the relevant NHS care 
organisation of this amendment and check whether it affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
10/H0805/36:     Please quote this number on all 
correspondence 
 
Yours sincerely 
 
 
 
 Esther Richman 
Committee Co-ordinator 
 
E-mail: estherrichman@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the review 
 
Copy to: Lucy Parker, Imperial College 
 
 
South East London REC 5 
 
Attendance at Sub-Committee of the REC meeting on 22 August 2010 
 
 
name Profession position 
Carol Jones Management Consultant Chair 
Niall MacCrae Health service 
researcher 
Vice-chair 
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13.5 Permission for use of figure 
 
September 10, 2007 
Anthony Barron 
Journal Name Year Citation Item(s) used 
Arch Intern Med 1988 148:2221-2226 Figure 
Intended Material will be used in a paper on cardiopulmonary exercise testing. 
Permission Granted: 
Thank you for your interest in JAMA, Archives and AM News. Rights granted herein are 
non-exclusive and limited to one time only reproduction as specified in this request, in 
printed format in the English Language. Your credit line must include the name of the 
publication, issue date, volume and page number, as well as “Copyright © (Year of 
Publication), American Medical Association. All Rights reserved.” 
Best wishes, 
Rhonda Bailey Brown 
Permission Assistant 
Publishing Operations 
AMA 
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